ZA200702100B - Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient - Google Patents
Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient Download PDFInfo
- Publication number
- ZA200702100B ZA200702100B ZA200702100A ZA200702100A ZA200702100B ZA 200702100 B ZA200702100 B ZA 200702100B ZA 200702100 A ZA200702100 A ZA 200702100A ZA 200702100 A ZA200702100 A ZA 200702100A ZA 200702100 B ZA200702100 B ZA 200702100B
- Authority
- ZA
- South Africa
- Prior art keywords
- amino
- methyl
- phenyl
- carbonyl
- piperidinyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 27
- 239000004480 active ingredient Substances 0.000 title description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 283
- 150000001875 compounds Chemical class 0.000 claims description 256
- -1 butyl {1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]- 4-piperidinyl }amino Chemical group 0.000 claims description 240
- 125000001424 substituent group Chemical group 0.000 claims description 199
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 133
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 108
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 88
- 125000000623 heterocyclic group Chemical group 0.000 claims description 72
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 68
- 150000002430 hydrocarbons Chemical group 0.000 claims description 67
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 63
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 55
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 45
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 43
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 42
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 42
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 29
- 150000001204 N-oxides Chemical class 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 229940002612 prodrug Drugs 0.000 claims description 28
- 239000000651 prodrug Substances 0.000 claims description 28
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 27
- USJUUYYGHABIBU-UHFFFAOYSA-N methanesulfonamide;hydrochloride Chemical compound Cl.CS(N)(=O)=O USJUUYYGHABIBU-UHFFFAOYSA-N 0.000 claims description 27
- 239000012453 solvate Substances 0.000 claims description 27
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 26
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 26
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 22
- 125000003277 amino group Chemical group 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 19
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 16
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 15
- 210000000056 organ Anatomy 0.000 claims description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 14
- 239000005557 antagonist Substances 0.000 claims description 13
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 125000002837 carbocyclic group Chemical group 0.000 claims description 12
- 238000002054 transplantation Methods 0.000 claims description 12
- 208000030507 AIDS Diseases 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 10
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 10
- 208000026278 immune system disease Diseases 0.000 claims description 10
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 9
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 9
- 125000003386 piperidinyl group Chemical group 0.000 claims description 9
- 150000003536 tetrazoles Chemical class 0.000 claims description 9
- 150000003852 triazoles Chemical class 0.000 claims description 9
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 8
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 8
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 8
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 8
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 8
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 8
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 8
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 7
- 239000003018 immunosuppressive agent Substances 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 7
- 125000006850 spacer group Chemical group 0.000 claims description 7
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 claims description 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 6
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 6
- FKBANLNERKCVRY-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)-2-methoxyphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 FKBANLNERKCVRY-UHFFFAOYSA-N 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims description 5
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 5
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 5
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 5
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 5
- 150000003180 prostaglandins Chemical class 0.000 claims description 5
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 claims description 5
- GIAUMNTVDYPZCW-UHFFFAOYSA-N 2-fluoro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]benzamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(C(F)=CC=2)C(N)=O)C=2C=CC=CC=2)CC1 GIAUMNTVDYPZCW-UHFFFAOYSA-N 0.000 claims description 4
- VMDHUQBKTHIOHZ-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(ethylsulfonylamino)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide Chemical compound C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(=O)(=O)CC)C=C1 VMDHUQBKTHIOHZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims description 4
- 229940124790 IL-6 inhibitor Drugs 0.000 claims description 4
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 claims description 4
- 229940123950 Prostaglandin synthase inhibitor Drugs 0.000 claims description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 4
- 108700012920 TNF Proteins 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 239000003042 chondroprotective agent Substances 0.000 claims description 4
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims description 4
- 229940079919 digestives enzyme preparation Drugs 0.000 claims description 4
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 4
- 229940124524 integrase inhibitor Drugs 0.000 claims description 4
- 239000002850 integrase inhibitor Substances 0.000 claims description 4
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims description 4
- 229940126170 metalloproteinase inhibitor Drugs 0.000 claims description 4
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims description 4
- 229930004006 tropane Natural products 0.000 claims description 4
- NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1r,2s)-2-[[(3s)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 claims description 3
- GUPFWVGOGOKCJS-UHFFFAOYSA-N 2-chloro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]-n-methylbenzamide Chemical compound C1=C(Cl)C(C(=O)NC)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C=2C=CC=CC=2)=C1 GUPFWVGOGOKCJS-UHFFFAOYSA-N 0.000 claims description 3
- KYJNBDOPVYCEKT-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 KYJNBDOPVYCEKT-UHFFFAOYSA-N 0.000 claims description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims description 3
- OTKXZNHWMHGDSA-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(methanesulfonamido)-2-methylphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2-chloro-4-fluorobenzamide Chemical compound C=1C(C(N)=O)=C(Cl)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1C OTKXZNHWMHGDSA-UHFFFAOYSA-N 0.000 claims description 3
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 3
- 229940126669 CCR4 antagonist Drugs 0.000 claims description 3
- 229940126692 CXCR3 antagonist Drugs 0.000 claims description 3
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 3
- 125000003725 azepanyl group Chemical group 0.000 claims description 3
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 claims description 3
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims description 3
- 239000002559 chemokine receptor antagonist Substances 0.000 claims description 3
- 229940125777 fusion inhibitor Drugs 0.000 claims description 3
- WYVBISCFCHREDA-UHFFFAOYSA-N n-cycloheptyl-6,7-dimethoxy-2-(4-piperidin-1-ylpiperidin-1-yl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC(N2CCC(CC2)N2CCCCC2)=NC=1NC1CCCCCC1 WYVBISCFCHREDA-UHFFFAOYSA-N 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- NLPGRHWAWHGTSS-UHFFFAOYSA-N 2-fluoro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)NC)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C=2C=CC=CC=2)=C1 NLPGRHWAWHGTSS-UHFFFAOYSA-N 0.000 claims description 2
- NKSNSHRSLJZYOC-UHFFFAOYSA-N 2-fluoro-n-methyl-5-[[[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(=CC=4)S(C)(=O)=O)=CC=3)CC2)C=2C=CC=CC=2)=C1 NKSNSHRSLJZYOC-UHFFFAOYSA-N 0.000 claims description 2
- IIIGSLVYZUIUOC-UHFFFAOYSA-N 5-[[butyl-[1-[[4-(4-methylsulfonylphenoxy)phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide Chemical compound C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(S(C)(=O)=O)C=C1 IIIGSLVYZUIUOC-UHFFFAOYSA-N 0.000 claims description 2
- QQEZPZWMUMGGSO-UHFFFAOYSA-N 5-[[butyl-[1-[[4-[4-(methanesulfonamido)-2-methylphenoxy]phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1C QQEZPZWMUMGGSO-UHFFFAOYSA-N 0.000 claims description 2
- FDIBLJOUTGXEDY-UHFFFAOYSA-N 5-[[butyl-[1-[[4-[4-(methylsulfamoyl)phenoxy]phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide Chemical compound C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(S(=O)(=O)NC)C=C1 FDIBLJOUTGXEDY-UHFFFAOYSA-N 0.000 claims description 2
- DVWPGOGCIDVKRF-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(2-methoxyethylcarbamoyl)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide Chemical compound C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(C(=O)NCCOC)C=C1 DVWPGOGCIDVKRF-UHFFFAOYSA-N 0.000 claims description 2
- ISQSEMWJBZWLBJ-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(methanesulfonamido)phenoxy]-2-methylpyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C(=N1)C)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 ISQSEMWJBZWLBJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims description 2
- 229940123650 Interferon gamma agonist Drugs 0.000 claims description 2
- 101000935814 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Periplasmic beta-glucosidase Proteins 0.000 claims description 2
- 229940123155 T cell inhibitor Drugs 0.000 claims description 2
- REQPQFUJGGOFQL-UHFFFAOYSA-N dimethylcarbamothioyl n,n-dimethylcarbamodithioate Chemical compound CN(C)C(=S)SC(=S)N(C)C REQPQFUJGGOFQL-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- NTQVMOJYIOBYQO-UHFFFAOYSA-N n-[2-fluoro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]phenyl]acetamide Chemical compound C1=C(F)C(NC(=O)C)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C=2C=CC=CC=2)=C1 NTQVMOJYIOBYQO-UHFFFAOYSA-N 0.000 claims description 2
- LMLLKSUVNANHLI-UHFFFAOYSA-N n-[4-[5-[[4-[n-[(4-fluorophenyl)carbamoyl]anilino]piperidin-1-yl]methyl]pyridin-2-yl]oxyphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 LMLLKSUVNANHLI-UHFFFAOYSA-N 0.000 claims description 2
- NKMRRWSZFRJZLZ-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(methanesulfonamido)phenoxy]-2-methylpyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide Chemical compound C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C(=N1)C)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 NKMRRWSZFRJZLZ-UHFFFAOYSA-N 0.000 claims 2
- ZHDBOVUYYGNAKZ-UHFFFAOYSA-N 1-(3-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-3-(6-methylpyridin-3-yl)urea;dihydrochloride Chemical compound Cl.Cl.C1=NC(C)=CC=C1NC(=O)N(C=1C=C(F)C=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(NS(C)(=O)=O)=CC=3)=CC=2)CC1 ZHDBOVUYYGNAKZ-UHFFFAOYSA-N 0.000 claims 1
- LDYHUZXWMIBFIK-UHFFFAOYSA-N 1-(3-fluorophenyl)-3-(6-methylpyridin-3-yl)-1-[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]urea Chemical compound C1=NC(C)=CC=C1NC(=O)N(C=1C=C(F)C=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(=CC=3)S(C)(=O)=O)=CC=2)CC1 LDYHUZXWMIBFIK-UHFFFAOYSA-N 0.000 claims 1
- GNHMDGSGNMIXOU-UHFFFAOYSA-N 1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-3-(4-methylphenyl)-1-phenylurea Chemical compound C1=CC(C)=CC=C1NC(=O)N(C=1C=CC=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(NS(C)(=O)=O)=CC=3)=CC=2)CC1 GNHMDGSGNMIXOU-UHFFFAOYSA-N 0.000 claims 1
- BYYQNDRRGNKYAN-UHFFFAOYSA-N 2-[4-[[4-[n-[(3-acetamido-4-fluorophenyl)carbamoyl]anilino]piperidin-1-yl]methyl]phenoxy]-5-(methanesulfonamido)benzamide Chemical compound C1=C(F)C(NC(=O)C)=CC(NC(=O)N(C2CCN(CC=3C=CC(OC=4C(=CC(NS(C)(=O)=O)=CC=4)C(N)=O)=CC=3)CC2)C=2C=CC=CC=2)=C1 BYYQNDRRGNKYAN-UHFFFAOYSA-N 0.000 claims 1
- LTJRAZRRTQFJFH-UHFFFAOYSA-N n-[4-[5-[[4-[n-[(4-fluorophenyl)carbamoyl]anilino]piperidin-1-yl]methyl]pyridin-2-yl]oxyphenyl]acetamide;hydrochloride Chemical compound Cl.C1=CC(NC(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 LTJRAZRRTQFJFH-UHFFFAOYSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 843
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 528
- 238000004809 thin layer chromatography Methods 0.000 description 272
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 204
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- 210000004027 cell Anatomy 0.000 description 56
- 238000000034 method Methods 0.000 description 51
- 239000000243 solution Substances 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000003960 organic solvent Substances 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 19
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 19
- 125000006239 protecting group Chemical group 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
- 125000005843 halogen group Chemical group 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 238000010511 deprotection reaction Methods 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 102000009410 Chemokine receptor Human genes 0.000 description 13
- 108050000299 Chemokine receptor Proteins 0.000 description 13
- SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 description 13
- 239000000460 chlorine Substances 0.000 description 13
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 13
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 239000004215 Carbon black (E152) Substances 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 229930195733 hydrocarbon Natural products 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 11
- 102000019034 Chemokines Human genes 0.000 description 11
- 108010012236 Chemokines Proteins 0.000 description 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 11
- 230000012292 cell migration Effects 0.000 description 11
- 229910052801 chlorine Inorganic materials 0.000 description 11
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 11
- 125000001624 naphthyl group Chemical group 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 10
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 125000003710 aryl alkyl group Chemical group 0.000 description 10
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 10
- 229910052794 bromium Inorganic materials 0.000 description 10
- 239000011737 fluorine Substances 0.000 description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 10
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 10
- 230000003449 preventive effect Effects 0.000 description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 9
- 208000031886 HIV Infections Diseases 0.000 description 9
- 208000037357 HIV infectious disease Diseases 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 125000003396 thiol group Chemical group [H]S* 0.000 description 9
- 108010055166 Chemokine CCL5 Proteins 0.000 description 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 7
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 7
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 7
- 150000001266 acyl halides Chemical class 0.000 description 7
- 230000000172 allergic effect Effects 0.000 description 7
- 230000003042 antagnostic effect Effects 0.000 description 7
- 208000010668 atopic eczema Diseases 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 125000001153 fluoro group Chemical group F* 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 5
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 229930189065 blasticidin Natural products 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 5
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 5
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- RXBYRTSOWREATF-UHFFFAOYSA-N 1,2,3,4-tetrahydroacridine Chemical compound C1=CC=C2C=C(CCCC3)C3=NC2=C1 RXBYRTSOWREATF-UHFFFAOYSA-N 0.000 description 4
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 4
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 4
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 4
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 206010010741 Conjunctivitis Diseases 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 208000024780 Urticaria Diseases 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 4
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- DTHHUAXKOMWYBI-UHFFFAOYSA-N oxadiazolidine Chemical compound C1CONN1 DTHHUAXKOMWYBI-UHFFFAOYSA-N 0.000 description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 4
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 238000006268 reductive amination reaction Methods 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 4
- OQJVXNHMUWQQEW-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazine Chemical compound C1CNC=CN1 OQJVXNHMUWQQEW-UHFFFAOYSA-N 0.000 description 3
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 3
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 3
- SCEIUGQQBYRBPP-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-azepine Chemical compound C1CCC=CNC1 SCEIUGQQBYRBPP-UHFFFAOYSA-N 0.000 description 3
- YYVKQFQZKSLYFN-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-diazepine Chemical compound C1CNNC=CC1 YYVKQFQZKSLYFN-UHFFFAOYSA-N 0.000 description 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 3
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 3
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 3
- LSBDFXRDZJMBSC-UHFFFAOYSA-N Amide-Phenylacetic acid Natural products NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 201000002909 Aspergillosis Diseases 0.000 description 3
- 208000036641 Aspergillus infections Diseases 0.000 description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 108010041397 CD4 Antigens Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 3
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 229960001830 amprenavir Drugs 0.000 description 3
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 3
- 229960005207 auranofin Drugs 0.000 description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 3
- 239000012964 benzotriazole Substances 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000004696 coordination complex Chemical class 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 3
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 3
- 229960002656 didanosine Drugs 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229960002390 flurbiprofen Drugs 0.000 description 3
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000003677 hemocyte Anatomy 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 3
- 229960002702 piroxicam Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 3
- 229960001852 saquinavir Drugs 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- KHVCOYGKHDJPBZ-WDCZJNDASA-N tetrahydrooxazine Chemical compound OC[C@H]1ONC[C@@H](O)[C@@H]1O KHVCOYGKHDJPBZ-WDCZJNDASA-N 0.000 description 3
- PGAZQSBUJDVGIX-UHFFFAOYSA-N thiazepane Chemical compound C1CCNSCC1 PGAZQSBUJDVGIX-UHFFFAOYSA-N 0.000 description 3
- AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical compound C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 description 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 229960000523 zalcitabine Drugs 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
- CNPVJJQCETWNEU-CYFREDJKSA-N (4,6-dimethyl-5-pyrimidinyl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]methanone Chemical compound N([C@@H](COC)C=1C=CC(=CC=1)C(F)(F)F)([C@H](C1)C)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)N=CN=C1C CNPVJJQCETWNEU-CYFREDJKSA-N 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- IXTPCSZJZAKJTO-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a,9,9a,10,10a-tetradecahydroacridine Chemical compound N1C2CCCCC2CC2C1CCCC2 IXTPCSZJZAKJTO-UHFFFAOYSA-N 0.000 description 2
- PIHAUZGWAXLKCA-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydro-1,8-naphthyridine Chemical compound N1CCCC2CCCNC21 PIHAUZGWAXLKCA-UHFFFAOYSA-N 0.000 description 2
- VKJHANNFFHMLBB-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydrocinnoline Chemical compound N1NCCC2CCCCC21 VKJHANNFFHMLBB-UHFFFAOYSA-N 0.000 description 2
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 2
- AEBKORRYDYKJLT-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydrophthalazine Chemical compound C1NNCC2CCCCC21 AEBKORRYDYKJLT-UHFFFAOYSA-N 0.000 description 2
- HZNXIPDYYIWDNM-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinazoline Chemical compound N1CNCC2CCCCC21 HZNXIPDYYIWDNM-UHFFFAOYSA-N 0.000 description 2
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 2
- MDEXMBGPIZUUBI-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoxaline Chemical compound N1CCNC2CCCCC21 MDEXMBGPIZUUBI-UHFFFAOYSA-N 0.000 description 2
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 2
- WXRSSOIHEAVYLL-UHFFFAOYSA-N 1,2,3,4-tetrahydrocinnoline Chemical compound C1=CC=C2NNCCC2=C1 WXRSSOIHEAVYLL-UHFFFAOYSA-N 0.000 description 2
- STIWEDICJHIFJT-UHFFFAOYSA-N 1,2,3,4-tetrahydrophthalazine Chemical compound C1=CC=C2CNNCC2=C1 STIWEDICJHIFJT-UHFFFAOYSA-N 0.000 description 2
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 description 2
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 2
- PKORYTIUMAOPED-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinazoline Chemical compound C1=CC=C2NCNCC2=C1 PKORYTIUMAOPED-UHFFFAOYSA-N 0.000 description 2
- HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical compound C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 description 2
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- UUZJJNBYJDFQHL-UHFFFAOYSA-N 1,2,3-triazolidine Chemical compound C1CNNN1 UUZJJNBYJDFQHL-UHFFFAOYSA-N 0.000 description 2
- AGSHYIAAUGKFEA-UHFFFAOYSA-N 1,2,5-oxadiazolidine Chemical compound C1CNON1 AGSHYIAAUGKFEA-UHFFFAOYSA-N 0.000 description 2
- XEYKWYIXHMEQGM-UHFFFAOYSA-N 1,2-dihydro-1,8-naphthyridine Chemical compound C1=CC=C2C=CCNC2=N1 XEYKWYIXHMEQGM-UHFFFAOYSA-N 0.000 description 2
- UXJHQQLYKUVLIE-UHFFFAOYSA-N 1,2-dihydroacridine Chemical compound C1=CC=C2N=C(C=CCC3)C3=CC2=C1 UXJHQQLYKUVLIE-UHFFFAOYSA-N 0.000 description 2
- QRDNXAYNXUKMOO-UHFFFAOYSA-N 1,2-dihydrocinnoline Chemical compound C1=CC=C2C=CNNC2=C1 QRDNXAYNXUKMOO-UHFFFAOYSA-N 0.000 description 2
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 2
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical compound N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 description 2
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 2
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 2
- XXBQLHATYQHJQC-UHFFFAOYSA-N 1,2-dihydroquinoxaline Chemical compound C1=CC=C2N=CCNC2=C1 XXBQLHATYQHJQC-UHFFFAOYSA-N 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- ITMZITCVFGCDRS-UHFFFAOYSA-N 1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1,3-di(thiophen-3-yl)urea Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC2=CSC=C2)C2=CSC=C2)CC1 ITMZITCVFGCDRS-UHFFFAOYSA-N 0.000 description 2
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- MHVSMFDBVMPRGT-UHFFFAOYSA-N 1-methoxyethanamine Chemical compound COC(C)N MHVSMFDBVMPRGT-UHFFFAOYSA-N 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 2
- OGHHATWOTABYKY-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1,3-benzothiazole Chemical compound C1CCCC2SCNC21 OGHHATWOTABYKY-UHFFFAOYSA-N 0.000 description 2
- XLRZZUUFKAXBGZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1,3-benzoxazole Chemical compound C1CCCC2OCNC21 XLRZZUUFKAXBGZ-UHFFFAOYSA-N 0.000 description 2
- MDNGXAFGRWQHNZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-benzimidazole Chemical compound C1CCCC2NCNC21 MDNGXAFGRWQHNZ-UHFFFAOYSA-N 0.000 description 2
- LVJPACZOEKXFAY-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indazole Chemical compound C1CCCC2CNNC21 LVJPACZOEKXFAY-UHFFFAOYSA-N 0.000 description 2
- SBVSDAFTZIVQEI-UHFFFAOYSA-N 2,3,4,4a,4b,5,6,7,8,8a,9,9a-dodecahydro-1h-carbazole Chemical compound C1CCCC2C3CCCCC3NC21 SBVSDAFTZIVQEI-UHFFFAOYSA-N 0.000 description 2
- UDMSIVPAVKUOKF-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,2-benzoxazepine Chemical compound C1CCNOC2=CC=CC=C21 UDMSIVPAVKUOKF-UHFFFAOYSA-N 0.000 description 2
- QEYQSYAGLRIYBE-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1,2-benzodiazepine Chemical compound C1CCNNC2=CC=CC=C21 QEYQSYAGLRIYBE-UHFFFAOYSA-N 0.000 description 2
- MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 description 2
- GLCYMVDVOVIDBB-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxadiazepine Chemical compound C1CC=CONN1 GLCYMVDVOVIDBB-UHFFFAOYSA-N 0.000 description 2
- ABQOPHYTASMWLA-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxazepine Chemical compound C1CNOC=CC1 ABQOPHYTASMWLA-UHFFFAOYSA-N 0.000 description 2
- WHUAPUGLAGYTQS-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiadiazepine Chemical compound C1CC=CSNN1 WHUAPUGLAGYTQS-UHFFFAOYSA-N 0.000 description 2
- IFPKIMVCYSSDDJ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiazepine Chemical compound C1CNSC=CC1 IFPKIMVCYSSDDJ-UHFFFAOYSA-N 0.000 description 2
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 description 2
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 2
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 2
- HRCMXYXVAWHBTH-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazole Chemical compound C1=CC=C2OCNC2=C1 HRCMXYXVAWHBTH-UHFFFAOYSA-N 0.000 description 2
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 2
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 2
- ZWWWYOKRVNYQHF-UHFFFAOYSA-N 2,3-dihydro-1h-1,2-benzodiazepine Chemical compound C1=CCNNC2=CC=CC=C21 ZWWWYOKRVNYQHF-UHFFFAOYSA-N 0.000 description 2
- BEWVAZNECYSPMT-UHFFFAOYSA-N 2,3-dihydro-1h-azepine Chemical compound C1CC=CC=CN1 BEWVAZNECYSPMT-UHFFFAOYSA-N 0.000 description 2
- QHYXWSXPPUTDRA-UHFFFAOYSA-N 2,3-dihydro-1h-diazepine Chemical compound C1NNC=CC=C1 QHYXWSXPPUTDRA-UHFFFAOYSA-N 0.000 description 2
- QDKGOMZIPXGDDJ-UHFFFAOYSA-N 2,3-dihydro-1h-indazole Chemical compound C1=CC=C2CNNC2=C1 QDKGOMZIPXGDDJ-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- IZEOXCXHDBQQAP-UHFFFAOYSA-N 2,3-dihydrothiazepine Chemical compound C1NSC=CC=C1 IZEOXCXHDBQQAP-UHFFFAOYSA-N 0.000 description 2
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 description 2
- ZECQLHQEHJJSAN-UHFFFAOYSA-N 2,9-dihydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCC=C2 ZECQLHQEHJJSAN-UHFFFAOYSA-N 0.000 description 2
- ODTSWCWTGDEKDL-UHFFFAOYSA-N 2-[4-[[4-[n-[[4-fluoro-3-(methanesulfonamido)phenyl]carbamoyl]anilino]piperidin-1-yl]methyl]phenoxy]-5-(methanesulfonamido)benzamide Chemical compound NC(=O)C1=CC(NS(=O)(=O)C)=CC=C1OC(C=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(NS(C)(=O)=O)C(F)=CC=2)C=2C=CC=CC=2)CC1 ODTSWCWTGDEKDL-UHFFFAOYSA-N 0.000 description 2
- CMKRLDUSUOXRQP-UHFFFAOYSA-N 2-[5-[[4-[3-fluoro-n-[(6-methylpyridin-3-yl)carbamoyl]anilino]piperidin-1-yl]methyl]pyridin-2-yl]oxy-5-(methanesulfonamido)-n-methylbenzamide Chemical compound CNC(=O)C1=CC(NS(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=NC(C)=CC=2)C=2C=C(F)C=CC=2)CC1 CMKRLDUSUOXRQP-UHFFFAOYSA-N 0.000 description 2
- LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- IDUSJBBWEKNWAK-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzothiazine Chemical compound C1=CC=C2SNCCC2=C1 IDUSJBBWEKNWAK-UHFFFAOYSA-N 0.000 description 2
- BGDOLELXXPTPFX-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzoxazine Chemical compound C1=CC=C2ONCCC2=C1 BGDOLELXXPTPFX-UHFFFAOYSA-N 0.000 description 2
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 2
- NDTSIDOTKVWMRI-UHFFFAOYSA-N 3,4-dihydro-2h-pyrazino[2,3-b][1,4]oxazine Chemical compound C1=CN=C2NCCOC2=N1 NDTSIDOTKVWMRI-UHFFFAOYSA-N 0.000 description 2
- NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical compound C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 description 2
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 2
- GWNOTCOIYUNTQP-FQLXRVMXSA-N 4-[4-[[(3r)-1-butyl-3-[(r)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid Chemical compound N([C@@H](C(=O)N1CCCC)[C@H](O)C2CCCCC2)C(=O)C1(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(C(O)=O)C=C1 GWNOTCOIYUNTQP-FQLXRVMXSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 2
- 101000919359 Homo sapiens Cytochrome P450 2C9 Proteins 0.000 description 2
- 101000745711 Homo sapiens Cytochrome P450 3A4 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 2
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N Seratrodast Chemical compound O=C1C(C)=C(C)C(=O)C(C(CCCCCC(O)=O)C=2C=CC=CC=2)=C1C ZBVKEHDGYSLCCC-UHFFFAOYSA-N 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 108010069102 Thromboxane-A synthase Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 229960004748 abacavir Drugs 0.000 description 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 2
- CWRYPZZKDGJXCA-UHFFFAOYSA-N acenaphthene Chemical compound C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 description 2
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 2
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940125716 antipyretic agent Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- BIDUPMYXGFNAEJ-APGVDKLISA-N astromicin Chemical compound O[C@@H]1[C@H](N(C)C(=O)CN)[C@@H](OC)[C@@H](O)[C@H](N)[C@H]1O[C@@H]1[C@H](N)CC[C@@H]([C@H](C)N)O1 BIDUPMYXGFNAEJ-APGVDKLISA-N 0.000 description 2
- 229950004074 astromicin Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- UDSRUCAJZSIRHZ-UHFFFAOYSA-N benzamide dihydrochloride Chemical compound Cl.Cl.NC(=O)C1=CC=CC=C1.NC(=O)C1=CC=CC=C1 UDSRUCAJZSIRHZ-UHFFFAOYSA-N 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- MXMZCLLIUQEKSN-UHFFFAOYSA-N benzimidazoline Chemical compound C1=CC=C2NCNC2=C1 MXMZCLLIUQEKSN-UHFFFAOYSA-N 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- YQXCVAGCMNFUMQ-UHFFFAOYSA-N capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229950000726 cefetamet pivoxil Drugs 0.000 description 2
- DASYMCLQENWCJG-XUKDPADISA-N cefetamet pivoxil Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DASYMCLQENWCJG-XUKDPADISA-N 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- KSPYMJJKQMWWNB-UHFFFAOYSA-N cipamfylline Chemical compound O=C1N(CC2CC2)C(=O)C=2NC(N)=NC=2N1CC1CC1 KSPYMJJKQMWWNB-UHFFFAOYSA-N 0.000 description 2
- 229950002405 cipamfylline Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 229960005319 delavirdine Drugs 0.000 description 2
- 229960003657 dexamethasone acetate Drugs 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229960003804 efavirenz Drugs 0.000 description 2
- 239000003602 elastase inhibitor Substances 0.000 description 2
- 229960000366 emtricitabine Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 2
- RSOJSFYJLQADDM-UHFFFAOYSA-N ethanesulfonamide Chemical compound [CH2]CS(N)(=O)=O RSOJSFYJLQADDM-UHFFFAOYSA-N 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 102000048369 human CYP2C9 Human genes 0.000 description 2
- 102000044284 human CYP3A4 Human genes 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 229960001936 indinavir Drugs 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 2
- 229960002373 loxoprofen Drugs 0.000 description 2
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- NPGREARFJMFTDF-UHFFFAOYSA-N n-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)N=C1C(Cl)=CN(O)C=C1Cl NPGREARFJMFTDF-UHFFFAOYSA-N 0.000 description 2
- 229960000884 nelfinavir Drugs 0.000 description 2
- 229960000689 nevirapine Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- OTLYTKRAADUASA-UHFFFAOYSA-N oxadiazepane Chemical compound C1CCONNC1 OTLYTKRAADUASA-UHFFFAOYSA-N 0.000 description 2
- XCRJTRCPEJKXLR-UHFFFAOYSA-N oxadiazinane Chemical compound C1CNNOC1 XCRJTRCPEJKXLR-UHFFFAOYSA-N 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229950000688 phenothiazine Drugs 0.000 description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229960003101 pranoprofen Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229960000825 proglumetacin Drugs 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229960003090 seratrodast Drugs 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960001203 stavudine Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 description 2
- RWXZKKKYLRFREK-UHFFFAOYSA-N thiadiazepane Chemical compound C1CCSNNC1 RWXZKKKYLRFREK-UHFFFAOYSA-N 0.000 description 2
- TVQOEGVBMRCMFR-UHFFFAOYSA-N thiadiazinane Chemical compound C1CNNSC1 TVQOEGVBMRCMFR-UHFFFAOYSA-N 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- 229960000707 tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 125000006000 trichloroethyl group Chemical group 0.000 description 2
- 125000000165 tricyclic carbocycle group Chemical group 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229950004227 zaltoprofen Drugs 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- SFZVXTJDDOYGIS-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)-methylazanium;chloride Chemical compound Cl.CNC(CS)C(O)=O SFZVXTJDDOYGIS-UHFFFAOYSA-N 0.000 description 1
- IOVGROKTTNBUGK-SJKOYZFVSA-N (1S,2R)-ritodrine Chemical compound N([C@H](C)[C@@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJKOYZFVSA-N 0.000 description 1
- UHSXRTHJCJGEKG-UQKRIMTDSA-N (1s)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-6,7-diol;chloride Chemical compound Cl.COC1=C(OC)C(OC)=CC(C[C@H]2C3=CC(O)=C(O)C=C3CCN2)=C1 UHSXRTHJCJGEKG-UQKRIMTDSA-N 0.000 description 1
- RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical compound C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 description 1
- BWRBVBFLFQKBPT-UHFFFAOYSA-N (2-nitrophenyl)methanol Chemical compound OCC1=CC=CC=C1[N+]([O-])=O BWRBVBFLFQKBPT-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- PNILZVBINXNWHW-FHWLQOOXSA-N (2s)-1-[(2s)-2-[(4-methoxybenzoyl)amino]-3-methylbutanoyl]-n-[(3s)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]pyrrolidine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)N[C@@H](C(C)C)C(=O)N1[C@H](C(=O)N[C@@H](C(C)C)C(=O)C(F)(F)F)CCC1 PNILZVBINXNWHW-FHWLQOOXSA-N 0.000 description 1
- KRDCGZGYWRCHNN-NAWJVIAPSA-N (2s)-2-(6-methoxynaphthalen-2-yl)propanoic acid;piperazine Chemical compound C1CNCCN1.C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21.C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 KRDCGZGYWRCHNN-NAWJVIAPSA-N 0.000 description 1
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- NDNKNUMSTIMSHQ-URZKGLGPSA-N (3ar,6s,6as)-4-methylsulfonyl-1-[(e)-4-piperidin-1-ylbut-2-enoyl]-6-propan-2-yl-3,3a,6,6a-tetrahydro-2h-pyrrolo[3,2-b]pyrrol-5-one Chemical compound C([C@@H]1[C@@H]2[C@@H](C(N1S(C)(=O)=O)=O)C(C)C)CN2C(=O)\C=C\CN1CCCCC1 NDNKNUMSTIMSHQ-URZKGLGPSA-N 0.000 description 1
- QNQBPPQLRODXET-AIMHRHHOSA-N (3e,5s)-3-[[(1s,2r,4as,6r,8ar)-1,6-dimethyl-2-[(e)-prop-1-enyl]-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl]-hydroxymethylidene]-5-(hydroxymethyl)-1-methylpyrrolidine-2,4-dione Chemical compound O/C([C@@]1(C)[C@@H]2CC[C@@H](C)C[C@H]2C=C[C@H]1/C=C/C)=C1\C(=O)[C@H](CO)N(C)C1=O QNQBPPQLRODXET-AIMHRHHOSA-N 0.000 description 1
- MYZDPUZXMFCPMU-LRIWMWCYSA-N (6r,8s,9r,10s,11s,13s,14s,17r)-2-bromo-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1C(Br)=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@@H](F)C2=C1 MYZDPUZXMFCPMU-LRIWMWCYSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 1
- FWLKKPKZQYVAFR-LVEZLNDCSA-N (e)-but-2-enedioic acid;1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 FWLKKPKZQYVAFR-LVEZLNDCSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- NLSBKPYEIDTJNH-SKXZHHINSA-N (ne)-n-[2-[3-[3-[1-[(2e)-2-hydroxyiminoethyl]pyridin-1-ium-3-yl]oxypropoxy]pyridin-1-ium-1-yl]ethylidene]hydroxylamine;diiodide Chemical compound [I-].[I-].O\N=C\C[N+]1=CC=CC(OCCCOC=2C=[N+](C\C=N\O)C=CC=2)=C1 NLSBKPYEIDTJNH-SKXZHHINSA-N 0.000 description 1
- GXINKQQWHLIBJA-UCIBKFKQSA-N (z)-but-2-enedioic acid;(4,6-dimethylpyrimidin-5-yl)-[4-[(3s)-4-[(1r)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone Chemical compound OC(=O)\C=C/C(O)=O.N([C@@H](COC)C=1C=CC(=CC=1)C(F)(F)F)([C@H](C1)C)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)N=CN=C1C GXINKQQWHLIBJA-UCIBKFKQSA-N 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- ODJQFZXHKPCJMD-UHFFFAOYSA-N 1,2,3,3a,4,5,6,7,8,8a-decahydroazulene Chemical compound C1CCCCC2CCCC21 ODJQFZXHKPCJMD-UHFFFAOYSA-N 0.000 description 1
- XTDNMGZRUWMVLT-UHFFFAOYSA-N 1,2,3,4,4a,5a,6,7,8,9,9a,9b-dodecahydrodibenzofuran Chemical compound C1CCCC2C3CCCCC3OC21 XTDNMGZRUWMVLT-UHFFFAOYSA-N 0.000 description 1
- XMJFSCXZDZSDJS-UHFFFAOYSA-N 1,2,3,4,4a,5a,6,7,8,9,9a,9b-dodecahydrodibenzothiophene Chemical compound C1CCCC2C3CCCCC3SC21 XMJFSCXZDZSDJS-UHFFFAOYSA-N 0.000 description 1
- LOWDSHXWDYULHF-UHFFFAOYSA-N 1,2,3,4,5,5a,6,7,8,9,10,10a-dodecahydroheptalene Chemical compound C1CCCCC2CCCCCC21 LOWDSHXWDYULHF-UHFFFAOYSA-N 0.000 description 1
- LREHXNMBUBVFHA-UHFFFAOYSA-N 1,2,3,4-tetrahydrodibenzofuran Chemical compound O1C2=CC=CC=C2C2=C1CCCC2 LREHXNMBUBVFHA-UHFFFAOYSA-N 0.000 description 1
- JCLPOPNXITXHOR-UHFFFAOYSA-N 1,2,3,4-tetrahydrodibenzothiophene Chemical compound S1C2=CC=CC=C2C2=C1CCCC2 JCLPOPNXITXHOR-UHFFFAOYSA-N 0.000 description 1
- KAOYLRLQZXRRBD-UHFFFAOYSA-N 1,2,3-benzothiadiazepine Chemical compound S1N=NC=CC2=CC=CC=C12 KAOYLRLQZXRRBD-UHFFFAOYSA-N 0.000 description 1
- DMTVEFFTCXZRHY-UHFFFAOYSA-N 1,2,3-benzoxadiazepine Chemical compound O1N=NC=CC2=CC=CC=C12 DMTVEFFTCXZRHY-UHFFFAOYSA-N 0.000 description 1
- DPHVWRMZSWGLLA-UHFFFAOYSA-N 1,2-benzodithiine Chemical compound C1=CC=C2C=CSSC2=C1 DPHVWRMZSWGLLA-UHFFFAOYSA-N 0.000 description 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 1
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical compound O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- AYMOVGCUZMUZSI-UHFFFAOYSA-N 1,2-dihydrodibenzothiophene Chemical compound S1C2=CC=CC=C2C2=C1C=CCC2 AYMOVGCUZMUZSI-UHFFFAOYSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- PXGILEVFPBXLEB-UHFFFAOYSA-N 1,2-dimethyl-3-propan-2-ylazulene Chemical compound C1=CC=CC=C2C(C(C)C)=C(C)C(C)=C21 PXGILEVFPBXLEB-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- HGQBCKVFVUCIML-UHFFFAOYSA-N 1,3,3a,4,5,6,7,7a-octahydro-2-benzofuran Chemical compound C1CCCC2COCC21 HGQBCKVFVUCIML-UHFFFAOYSA-N 0.000 description 1
- SJXUGVWKLLOJDR-UHFFFAOYSA-N 1,3,3a,4,5,6,7,7a-octahydro-2-benzothiophene Chemical compound C1CCCC2CSCC21 SJXUGVWKLLOJDR-UHFFFAOYSA-N 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- ABDDOHWBDSUNPS-UHFFFAOYSA-N 1-(3,5-dimethyl-1,2-oxazol-4-yl)-3-(4-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]urea;hydrochloride Chemical compound Cl.CC1=NOC(C)=C1N(C(=O)NC=1C=CC(F)=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(NS(C)(=O)=O)=CC=3)=CC=2)CC1 ABDDOHWBDSUNPS-UHFFFAOYSA-N 0.000 description 1
- JKLKXNLHRWDYPV-UHFFFAOYSA-N 1-(3-fluorophenyl)-1-[1-[[6-(2-methoxy-4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-3-(6-methylpyridin-3-yl)urea;dihydrochloride Chemical compound Cl.Cl.COC1=CC(S(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=NC(C)=CC=2)C=2C=C(F)C=CC=2)CC1 JKLKXNLHRWDYPV-UHFFFAOYSA-N 0.000 description 1
- CNXYXHZSMQCTQB-UHFFFAOYSA-N 1-(3-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-3-(6-methylpyridin-3-yl)urea Chemical compound C1=NC(C)=CC=C1NC(=O)N(C=1C=C(F)C=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(NS(C)(=O)=O)=CC=3)=CC=2)CC1 CNXYXHZSMQCTQB-UHFFFAOYSA-N 0.000 description 1
- RREANTZUJYPAMD-UHFFFAOYSA-N 1-(3-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenyl]pyridin-3-yl]methyl]piperidin-4-yl]-3-(6-methylpyridin-3-yl)urea Chemical compound C1=NC(C)=CC=C1NC(=O)N(C=1C=C(F)C=CC=1)C1CCN(CC=2C=NC(=CC=2)C=2C=CC(NS(C)(=O)=O)=CC=2)CC1 RREANTZUJYPAMD-UHFFFAOYSA-N 0.000 description 1
- DLXLTQHPFAEDMQ-UHFFFAOYSA-N 1-(3-fluorophenyl)-3-(4-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]urea;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=C(F)C=CC=2)CC1 DLXLTQHPFAEDMQ-UHFFFAOYSA-N 0.000 description 1
- CMNLXACSNNEJTC-UHFFFAOYSA-N 1-(3-fluorophenyl)-3-(6-methylpyridin-3-yl)-1-[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]urea;dihydrochloride Chemical compound Cl.Cl.C1=NC(C)=CC=C1NC(=O)N(C=1C=C(F)C=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(=CC=3)S(C)(=O)=O)=CC=2)CC1 CMNLXACSNNEJTC-UHFFFAOYSA-N 0.000 description 1
- WPUYOLGSBCULMZ-UHFFFAOYSA-N 1-(3-fluorophenyl)-3-(6-methylpyridin-3-yl)-1-[1-[[6-(4-propan-2-ylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]urea Chemical compound C1=CC(S(=O)(=O)C(C)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=NC(C)=CC=2)C=2C=C(F)C=CC=2)CC1 WPUYOLGSBCULMZ-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- RLQJVJNOGXWIEM-MHZLTWQESA-N 1-[(3s)-1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]pyrrolidin-3-yl]-3-(6-methylpyridin-3-yl)-1-phenylurea Chemical compound C1=NC(C)=CC=C1NC(=O)N(C=1C=CC=CC=1)[C@@H]1CN(CC=2C=NC(OC=3C=CC(NS(C)(=O)=O)=CC=3)=CC=2)CC1 RLQJVJNOGXWIEM-MHZLTWQESA-N 0.000 description 1
- LMPFRZZMXDMMFZ-UHFFFAOYSA-N 1-[1-[[3,5-dimethyl-1-[4-(2-morpholin-4-ylethylsulfamoyl)phenyl]pyrazol-4-yl]methyl]piperidin-4-yl]-3-(4-fluorophenyl)-1-phenylurea;trihydrochloride Chemical compound Cl.Cl.Cl.CC1=NN(C=2C=CC(=CC=2)S(=O)(=O)NCCN2CCOCC2)C(C)=C1CN(CC1)CCC1N(C=1C=CC=CC=1)C(=O)NC1=CC=C(F)C=C1 LMPFRZZMXDMMFZ-UHFFFAOYSA-N 0.000 description 1
- HNOUZLIPBZPQSF-UHFFFAOYSA-N 1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]-3-(oxan-4-yl)-1-phenylurea;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(C=C1)=CC=C1CN1CCC(N(C(=O)NC2CCOCC2)C=2C=CC=CC=2)CC1 HNOUZLIPBZPQSF-UHFFFAOYSA-N 0.000 description 1
- GXOFTAYZGUMSGY-UHFFFAOYSA-N 1-[1-[[6-(4-ethylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-1-(3-fluorophenyl)-3-(6-methylpyridin-3-yl)urea Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=NC(C)=CC=2)C=2C=C(F)C=CC=2)CC1 GXOFTAYZGUMSGY-UHFFFAOYSA-N 0.000 description 1
- ALDUYZYOJFSKHY-UHFFFAOYSA-N 1-[1-[[6-[4-(methanesulfonamido)-2-methylphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-3-(6-methylpyridin-3-yl)-1-phenylurea;dihydrochloride Chemical compound Cl.Cl.C1=NC(C)=CC=C1NC(=O)N(C=1C=CC=CC=1)C1CCN(CC=2C=NC(OC=3C(=CC(NS(C)(=O)=O)=CC=3)C)=CC=2)CC1 ALDUYZYOJFSKHY-UHFFFAOYSA-N 0.000 description 1
- URCZERRPFSXOIY-UHFFFAOYSA-N 1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1,3-di(thiophen-3-yl)urea;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC2=CSC=C2)C2=CSC=C2)CC1 URCZERRPFSXOIY-UHFFFAOYSA-N 0.000 description 1
- ZCOCNHVCQTVFBD-UHFFFAOYSA-N 1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenyl-3-thiophen-3-ylurea;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC2=CSC=C2)C=2C=CC=CC=2)CC1 ZCOCNHVCQTVFBD-UHFFFAOYSA-N 0.000 description 1
- AEXWUIXIQDCYBG-UHFFFAOYSA-N 1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(N)=O)C=2C=CC=CC=2)CC1 AEXWUIXIQDCYBG-UHFFFAOYSA-N 0.000 description 1
- HCCKUMPKGVGCHT-UHFFFAOYSA-N 1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-3-(2-methoxyphenyl)-1-phenylurea;hydrochloride Chemical compound Cl.COC1=CC=CC=C1NC(=O)N(C=1C=CC=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(NS(C)(=O)=O)=CC=3)=CC=2)CC1 HCCKUMPKGVGCHT-UHFFFAOYSA-N 0.000 description 1
- XWZWQANKFUHWIF-UHFFFAOYSA-N 1-[1-[[6-[4-(methanesulfonamido)phenyl]pyridin-3-yl]methyl]piperidin-4-yl]-3-(6-methylpyridin-3-yl)-1-phenylurea Chemical compound C1=NC(C)=CC=C1NC(=O)N(C=1C=CC=CC=1)C1CCN(CC=2C=NC(=CC=2)C=2C=CC(NS(C)(=O)=O)=CC=2)CC1 XWZWQANKFUHWIF-UHFFFAOYSA-N 0.000 description 1
- ASSJTMUEFHUKMJ-UHFFFAOYSA-N 1-acetyl-n-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-n-(3-chloro-4-methylphenyl)piperidine-4-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(=O)N(C=1C=C(Cl)C(C)=CC=1)CCCN1CCC(CC=2C=CC(=CC=2)C(N)=O)CC1 ASSJTMUEFHUKMJ-UHFFFAOYSA-N 0.000 description 1
- NIGNBCLEMMGDQP-UHFFFAOYSA-N 1-benzothiepine Chemical compound S1C=CC=CC2=CC=CC=C12 NIGNBCLEMMGDQP-UHFFFAOYSA-N 0.000 description 1
- LWZYUACNWRVDDJ-UHFFFAOYSA-N 1-benzoxepine Chemical compound O1C=CC=CC2=CC=CC=C12 LWZYUACNWRVDDJ-UHFFFAOYSA-N 0.000 description 1
- NQBWUADIAJGJEY-UHFFFAOYSA-N 1-butyl-1-[1-[[6-[2-chloro-4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-3-(1-methylpyrazol-4-yl)urea;dihydrochloride Chemical compound Cl.Cl.C1=NN(C)C=C1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1Cl NQBWUADIAJGJEY-UHFFFAOYSA-N 0.000 description 1
- JVGSCWRAAXOMEU-UHFFFAOYSA-N 1-butyl-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-3-(1-methylpyrazol-4-yl)urea;dihydrochloride Chemical compound Cl.Cl.C1=NN(C)C=C1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 JVGSCWRAAXOMEU-UHFFFAOYSA-N 0.000 description 1
- GUXCNFXDDIZBDD-UHFFFAOYSA-N 1-butyl-3-(2,4-difluorophenyl)-1-[1-[[4-(4-morpholin-4-ylsulfonylphenoxy)phenyl]methyl]piperidin-4-yl]urea;hydrochloride Chemical compound Cl.C=1C=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC(C=C1)=CC=C1S(=O)(=O)N1CCOCC1 GUXCNFXDDIZBDD-UHFFFAOYSA-N 0.000 description 1
- WHHKCABIVAWFHP-UHFFFAOYSA-N 1-butyl-3-(2,4-difluorophenyl)-1-[1-[[4-[4-(2-methoxyethylsulfamoyl)phenoxy]phenyl]methyl]piperidin-4-yl]urea;hydrochloride Chemical compound Cl.C=1C=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(S(=O)(=O)NCCOC)C=C1 WHHKCABIVAWFHP-UHFFFAOYSA-N 0.000 description 1
- KBZSKDRIDIPYTJ-UHFFFAOYSA-N 1-butyl-3-(2,4-difluorophenyl)-1-[1-[[4-[4-(methanesulfonamido)-2-methoxyphenoxy]phenyl]methyl]piperidin-4-yl]urea;hydrochloride Chemical compound Cl.C=1C=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1OC KBZSKDRIDIPYTJ-UHFFFAOYSA-N 0.000 description 1
- GGRGQBQNMMLYQU-UHFFFAOYSA-N 1-butyl-3-(2,4-difluorophenyl)-1-[1-[[4-[4-(methylsulfamoyl)phenoxy]phenyl]methyl]piperidin-4-yl]urea;hydrochloride Chemical compound Cl.C=1C=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(S(=O)(=O)NC)C=C1 GGRGQBQNMMLYQU-UHFFFAOYSA-N 0.000 description 1
- GMKHIJNBLRLXAO-UHFFFAOYSA-N 1-butyl-3-(2,4-difluorophenyl)-1-[1-[[4-[4-(oxan-4-ylsulfamoyl)phenoxy]phenyl]methyl]piperidin-4-yl]urea;hydrochloride Chemical compound Cl.C=1C=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC(C=C1)=CC=C1S(=O)(=O)NC1CCOCC1 GMKHIJNBLRLXAO-UHFFFAOYSA-N 0.000 description 1
- NSAAPXJLPNSSMI-UHFFFAOYSA-N 1-butyl-3-(2,4-difluorophenyl)-1-[1-[[4-[4-[2-(dimethylamino)ethylsulfamoyl]phenoxy]phenyl]methyl]piperidin-4-yl]urea;dihydrochloride Chemical compound Cl.Cl.C=1C=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(S(=O)(=O)NCCN(C)C)C=C1 NSAAPXJLPNSSMI-UHFFFAOYSA-N 0.000 description 1
- IFXYHVWJKVEQPW-UHFFFAOYSA-N 1-butyl-3-(2,4-difluorophenyl)-1-piperidin-4-ylurea;hydrochloride Chemical compound Cl.C=1C=C(F)C=C(F)C=1NC(=O)N(CCCC)C1CCNCC1 IFXYHVWJKVEQPW-UHFFFAOYSA-N 0.000 description 1
- NXJFXXHNLHZQCR-UHFFFAOYSA-N 1-butyl-3-(4-cyano-2,5-difluorophenyl)-1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]urea;hydrochloride Chemical compound Cl.C=1C(F)=C(C#N)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 NXJFXXHNLHZQCR-UHFFFAOYSA-N 0.000 description 1
- WMYBGVDLINTIQR-UHFFFAOYSA-N 1-butyl-3-[1-(2-hydroxyethyl)pyrazol-4-yl]-1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]urea;dihydrochloride Chemical compound Cl.Cl.C1=NN(CCO)C=C1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 WMYBGVDLINTIQR-UHFFFAOYSA-N 0.000 description 1
- VTVSULVXMCMOCM-UHFFFAOYSA-N 1-butyl-3-[2,4-difluoro-5-(hydroxymethyl)phenyl]-1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]urea;hydrochloride Chemical compound Cl.C=1C(CO)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 VTVSULVXMCMOCM-UHFFFAOYSA-N 0.000 description 1
- QHCGYZDMERREKY-UHFFFAOYSA-N 1-butyl-3-[2,4-difluoro-5-(morpholine-4-carbonyl)phenyl]-1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]urea;hydrochloride Chemical compound Cl.C=1C(C(=O)N2CCOCC2)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 QHCGYZDMERREKY-UHFFFAOYSA-N 0.000 description 1
- OQZBAQXTXNIPRA-UHFFFAOYSA-N 1-pyridin-4-ylpiperazine Chemical class C1CNCCN1C1=CC=NC=C1 OQZBAQXTXNIPRA-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- DNZWAKVIOXCEHH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1-benzofuran Chemical compound C1CCCC2OCCC21 DNZWAKVIOXCEHH-UHFFFAOYSA-N 0.000 description 1
- NZOBCFVNZQYCCZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1-benzothiophene Chemical compound C1CCCC2SCCC21 NZOBCFVNZQYCCZ-UHFFFAOYSA-N 0.000 description 1
- SOHIYESEPVZKHS-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxepine Chemical compound C1CCC=COC1 SOHIYESEPVZKHS-UHFFFAOYSA-N 0.000 description 1
- VRKPANGTGANDRQ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiepine Chemical compound C1CCC=CSC1 VRKPANGTGANDRQ-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- RIUSCLBEBIOIRP-UHFFFAOYSA-N 2,3-dihydro-1,2-benzoxazepine Chemical compound C1=CCNOC2=CC=CC=C21 RIUSCLBEBIOIRP-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- WSSWXGZEJNNFSN-UHFFFAOYSA-N 2,3-dihydro-1h-1-benzazepine Chemical compound N1CCC=CC2=CC=CC=C21 WSSWXGZEJNNFSN-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- HNENEALJPWJWJY-UHFFFAOYSA-N 2,4-difluoro-1-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C(F)=C1 HNENEALJPWJWJY-UHFFFAOYSA-N 0.000 description 1
- DCOZDCZNKXIMBE-UHFFFAOYSA-N 2,4-difluoro-5-[[[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-pentylcarbamoyl]amino]benzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(S(C)(=O)=O)C=C1 DCOZDCZNKXIMBE-UHFFFAOYSA-N 0.000 description 1
- LJBYIKJZZQLLMJ-UHFFFAOYSA-N 2,4-difluoro-5-[[[1-[[6-[4-(methanesulfonamido)-2-methylphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-pentylcarbamoyl]amino]-n-methylbenzamide;hydrochloride Chemical compound Cl.C=1C(C(=O)NC)=C(F)C=C(F)C=1NC(=O)N(CCCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1C LJBYIKJZZQLLMJ-UHFFFAOYSA-N 0.000 description 1
- OPFDDHMHPCNWTI-UHFFFAOYSA-N 2,4-difluoro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-pentylcarbamoyl]amino]-n-methylbenzamide;hydrochloride Chemical compound Cl.C=1C(C(=O)NC)=C(F)C=C(F)C=1NC(=O)N(CCCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 OPFDDHMHPCNWTI-UHFFFAOYSA-N 0.000 description 1
- OYGLEGGINLFPHN-UHFFFAOYSA-N 2,4-difluoro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-pentylcarbamoyl]amino]benzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 OYGLEGGINLFPHN-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- BGTOFVPAJHAPMR-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylguanidine Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=N)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 BGTOFVPAJHAPMR-UHFFFAOYSA-N 0.000 description 1
- YSIHYROEMJSOAS-UHFFFAOYSA-N 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-n-[1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]acetamide Chemical compound N=1N=C(C(C)(C)C)OC=1C(=O)C(C(C)C)NC(=O)CN(C(C(N)=CN=1)=O)C=1C1=CC=CC=C1 YSIHYROEMJSOAS-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- CCOHTTDZVJUFBM-UHFFFAOYSA-N 2-[2,4-difluoro-5-[[[1-[[6-[4-(methanesulfonamido)-2-methylphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-pentylcarbamoyl]amino]phenyl]acetamide;hydrochloride Chemical compound Cl.C=1C(CC(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1C CCOHTTDZVJUFBM-UHFFFAOYSA-N 0.000 description 1
- AEIOJVGBPVJOLC-BTJKTKAUSA-N 2-[2-(4-benzhydrylpiperazin-1-yl)ethoxy]benzoic acid;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)C1=CC=CC=C1OCCN1CCN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 AEIOJVGBPVJOLC-BTJKTKAUSA-N 0.000 description 1
- DHQQXRRWRZFGDW-WBAXXEDZSA-N 2-[3-[2-[[(2s)-3-methyl-1-oxo-1-[(2s)-2-[[(3s)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]carbamoyl]pyrrolidin-1-yl]butan-2-yl]amino]-2-oxoethyl]-2-oxoimidazolidin-1-yl]acetic acid Chemical compound N([C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)C(F)(F)F)C(=O)CN1CCN(CC(O)=O)C1=O DHQQXRRWRZFGDW-WBAXXEDZSA-N 0.000 description 1
- KKXPBQQLKHBRDA-DJJJIMSYSA-N 2-[4-[2-[[(1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenoxy]acetic acid Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(OCC(O)=O)C=C1 KKXPBQQLKHBRDA-DJJJIMSYSA-N 0.000 description 1
- VLJFHMPHASLRQU-UHFFFAOYSA-N 2-[4-[[4-[butyl-[(5-carbamoyl-2,4-difluorophenyl)carbamoyl]amino]piperidin-1-yl]methyl]phenoxy]-5-(methanesulfonamido)benzoic acid;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1C(O)=O VLJFHMPHASLRQU-UHFFFAOYSA-N 0.000 description 1
- WQHYJUSJSIUNRT-UHFFFAOYSA-N 2-[4-[[4-[n-[(3-acetamido-4-fluorophenyl)carbamoyl]anilino]piperidin-1-yl]methyl]phenoxy]-5-(methanesulfonamido)benzamide;hydrochloride Chemical compound Cl.C1=C(F)C(NC(=O)C)=CC(NC(=O)N(C2CCN(CC=3C=CC(OC=4C(=CC(NS(C)(=O)=O)=CC=4)C(N)=O)=CC=3)CC2)C=2C=CC=CC=2)=C1 WQHYJUSJSIUNRT-UHFFFAOYSA-N 0.000 description 1
- UPDDCWCCPSQPIG-UHFFFAOYSA-N 2-[4-[[4-[n-[(4-fluorophenyl)carbamoyl]anilino]piperidin-1-yl]methyl]phenoxy]-5-(methanesulfonamido)benzamide;hydrochloride Chemical compound Cl.NC(=O)C1=CC(NS(=O)(=O)C)=CC=C1OC(C=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 UPDDCWCCPSQPIG-UHFFFAOYSA-N 0.000 description 1
- OVAIWLPAZSSCJJ-UHFFFAOYSA-N 2-[4-[[4-[n-[[4-fluoro-3-(methanesulfonamido)phenyl]carbamoyl]anilino]piperidin-1-yl]methyl]phenoxy]-5-(methanesulfonamido)benzamide;hydrochloride Chemical compound Cl.NC(=O)C1=CC(NS(=O)(=O)C)=CC=C1OC(C=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(NS(C)(=O)=O)C(F)=CC=2)C=2C=CC=CC=2)CC1 OVAIWLPAZSSCJJ-UHFFFAOYSA-N 0.000 description 1
- VXYDHPDQMSVQCU-UHFFFAOYSA-N 2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)piperidin-1-yl]-n-hydroxyacetamide Chemical compound COC1=CC=C(C2(CCN(CC(=O)NO)CC2)C#N)C=C1OC1CCCC1 VXYDHPDQMSVQCU-UHFFFAOYSA-N 0.000 description 1
- AZMUABSDMOKXQJ-UHFFFAOYSA-N 2-[5-[[butyl-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorophenyl]acetamide;hydrochloride Chemical compound Cl.C=1C(CC(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 AZMUABSDMOKXQJ-UHFFFAOYSA-N 0.000 description 1
- UNXUDTFKLOZFMV-UHFFFAOYSA-N 2-[5-[[butyl-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorophenyl]acetamide Chemical compound C=1C(CC(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 UNXUDTFKLOZFMV-UHFFFAOYSA-N 0.000 description 1
- WTBRUSNNZKWTMI-UHFFFAOYSA-N 2-[6-[3-(4-benzhydryloxypiperidin-1-yl)propylamino]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoic acid Chemical compound C1=CC2=NC(C(C)(C(O)=O)C)=CN2N=C1NCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 WTBRUSNNZKWTMI-UHFFFAOYSA-N 0.000 description 1
- SBUFZXRNKJQHLD-CQSZACIVSA-N 2-[N-[(2R)-1-(1H-imidazol-5-yl)propan-2-yl]-C-phenylcarbonimidoyl]phenol Chemical compound C([C@@H](C)N=C(C=1C=CC=CC=1)C=1C(=CC=CC=1)O)C1=CNC=N1 SBUFZXRNKJQHLD-CQSZACIVSA-N 0.000 description 1
- VPCOODFYDJWLHD-YMZXMBPUSA-N 2-[[(7s)-7-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-n,n-dimethylacetamide;sulfuric acid Chemical compound OS(O)(=O)=O.C1([C@@H](O)CN[C@H]2CCC3=CC=C(C=C3C2)OCC(=O)N(C)C)=CC=C(O)C(CCO)=C1.C1([C@@H](O)CN[C@H]2CCC3=CC=C(C=C3C2)OCC(=O)N(C)C)=CC=C(O)C(CCO)=C1 VPCOODFYDJWLHD-YMZXMBPUSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- FFUZWBFUJZNMHW-UHFFFAOYSA-N 2-chloro-5-[[[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]benzamide;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(C=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(C(Cl)=CC=2)C(N)=O)C=2C=CC=CC=2)CC1 FFUZWBFUJZNMHW-UHFFFAOYSA-N 0.000 description 1
- NWBJCFCDKPVXQL-UHFFFAOYSA-N 2-chloro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]-n-methylbenzamide;hydrochloride Chemical compound Cl.C1=C(Cl)C(C(=O)NC)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C=2C=CC=CC=2)=C1 NWBJCFCDKPVXQL-UHFFFAOYSA-N 0.000 description 1
- JOLCVLLFRQEOJX-UHFFFAOYSA-N 2-chloro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]benzoic acid;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(C(Cl)=CC=2)C(O)=O)C=2C=CC=CC=2)CC1 JOLCVLLFRQEOJX-UHFFFAOYSA-N 0.000 description 1
- UVDDVUAKKMJVKH-SANMLTNESA-N 2-fluoro-5-[[(3-fluorophenyl)-[(3s)-1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]pyrrolidin-3-yl]carbamoyl]amino]-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)NC)=CC(NC(=O)N([C@@H]2CN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C=2C=C(F)C=CC=2)=C1 UVDDVUAKKMJVKH-SANMLTNESA-N 0.000 description 1
- UKRTYYLJXMVYRX-UHFFFAOYSA-N 2-fluoro-5-[[(3-fluorophenyl)-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-n-methylbenzamide;hydrochloride Chemical compound Cl.C1=C(F)C(C(=O)NC)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C=2C=C(F)C=CC=2)=C1 UKRTYYLJXMVYRX-UHFFFAOYSA-N 0.000 description 1
- QOOGTLMDNXPZJB-UHFFFAOYSA-N 2-fluoro-5-[[[1-[[6-(2-methoxy-4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]benzamide;hydrochloride Chemical compound Cl.COC1=CC(S(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(C(F)=CC=2)C(N)=O)C=2C=CC=CC=2)CC1 QOOGTLMDNXPZJB-UHFFFAOYSA-N 0.000 description 1
- NAGLDSIOFDCLRX-UHFFFAOYSA-N 2-fluoro-5-[[[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]benzamide;hydrochloride Chemical compound Cl.C1=CC(S(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(C(F)=CC=2)C(N)=O)C=2C=CC=CC=2)CC1 NAGLDSIOFDCLRX-UHFFFAOYSA-N 0.000 description 1
- ZZEPRNRARBVJCE-UHFFFAOYSA-N 2-fluoro-5-[[[1-[[6-[4-(methanesulfonamido)-2-methoxyphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]benzamide;hydrochloride Chemical compound Cl.COC1=CC(NS(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(C(F)=CC=2)C(N)=O)C=2C=CC=CC=2)CC1 ZZEPRNRARBVJCE-UHFFFAOYSA-N 0.000 description 1
- QISFMSIQYCAECQ-UHFFFAOYSA-N 2-fluoro-5-[[[1-[[6-[4-(methanesulfonamido)-2-methylphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]benzamide Chemical compound CC1=CC(NS(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(C(F)=CC=2)C(N)=O)C=2C=CC=CC=2)CC1 QISFMSIQYCAECQ-UHFFFAOYSA-N 0.000 description 1
- NATNDMOUAIKCON-UHFFFAOYSA-N 2-fluoro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]azetidin-3-yl]-phenylcarbamoyl]amino]-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)NC)=CC(NC(=O)N(C2CN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)C2)C=2C=CC=CC=2)=C1 NATNDMOUAIKCON-UHFFFAOYSA-N 0.000 description 1
- XKVHFSIPVCAILU-UHFFFAOYSA-N 2-fluoro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-(3-methylphenyl)carbamoyl]amino]benzamide Chemical compound CC1=CC=CC(N(C2CCN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C(=O)NC=2C=C(C(F)=CC=2)C(N)=O)=C1 XKVHFSIPVCAILU-UHFFFAOYSA-N 0.000 description 1
- RGAXKEPQKSRKQA-UHFFFAOYSA-N 2-fluoro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]-n-methylbenzamide;hydrochloride Chemical compound Cl.C1=C(F)C(C(=O)NC)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C=2C=CC=CC=2)=C1 RGAXKEPQKSRKQA-UHFFFAOYSA-N 0.000 description 1
- PBRMXVDRJVQCHE-UHFFFAOYSA-N 2-fluoro-n-methyl-5-[[[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]benzamide;hydrochloride Chemical compound Cl.C1=C(F)C(C(=O)NC)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(=CC=4)S(C)(=O)=O)=CC=3)CC2)C=2C=CC=CC=2)=C1 PBRMXVDRJVQCHE-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- FSUYMKXZLQOFQY-UHFFFAOYSA-N 3,4-dihydro-1,2-benzodithiine Chemical compound C1=CC=C2SSCCC2=C1 FSUYMKXZLQOFQY-UHFFFAOYSA-N 0.000 description 1
- NTOIMCSZPGZTND-UHFFFAOYSA-N 3,4-dihydro-1,2-benzoxathiine Chemical compound C1=CC=C2OSCCC2=C1 NTOIMCSZPGZTND-UHFFFAOYSA-N 0.000 description 1
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 description 1
- KYANRFNCNXMGKK-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-1-[1-[[6-(2-methyl-4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea;hydrochloride Chemical compound Cl.CC1=CC(S(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C(=CC(F)=CC=2)F)C=2C=CC=CC=2)CC1 KYANRFNCNXMGKK-UHFFFAOYSA-N 0.000 description 1
- MVTRUEWLCXMLQT-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)-2-methoxyphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C(=CC(F)=CC=2)F)C=2C=CC=CC=2)CC1 MVTRUEWLCXMLQT-UHFFFAOYSA-N 0.000 description 1
- LAOROLNDGSJOEB-UHFFFAOYSA-N 3-(2-chlorophenothiazin-10-yl)-n,n-dimethylpropan-1-amine;4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one;n-(4-ethoxyphenyl)acetamide;1,3,7-trimethylpurine-2,6-dione Chemical compound CCOC1=CC=C(NC(C)=O)C=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1.C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 LAOROLNDGSJOEB-UHFFFAOYSA-N 0.000 description 1
- OYGAHLZJQMBKJI-UHFFFAOYSA-N 3-(2-chlorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C(=CC=CC=2)Cl)C=2C=CC=CC=2)CC1 OYGAHLZJQMBKJI-UHFFFAOYSA-N 0.000 description 1
- LMJIBKHIMKQQFC-UHFFFAOYSA-N 3-(2-hydroxybutyl)-1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]-1-phenylurea;hydrochloride Chemical compound Cl.C=1C=CC=CC=1N(C(=O)NCC(O)CC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 LMJIBKHIMKQQFC-UHFFFAOYSA-N 0.000 description 1
- MZSXRLOBRQCGBC-UHFFFAOYSA-N 3-(3-chlorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(Cl)C=CC=2)C=2C=CC=CC=2)CC1 MZSXRLOBRQCGBC-UHFFFAOYSA-N 0.000 description 1
- KIKYTGJYTRGKIY-UHFFFAOYSA-N 3-(3-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(F)C=CC=2)C=2C=CC=CC=2)CC1 KIKYTGJYTRGKIY-UHFFFAOYSA-N 0.000 description 1
- SXOZITBZVJZWFN-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea;hydrochloride Chemical compound Cl.C1=CC(S(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(Cl)=CC=2)C=2C=CC=CC=2)CC1 SXOZITBZVJZWFN-UHFFFAOYSA-N 0.000 description 1
- HXOKTEHARXAGDD-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(Cl)=CC=2)C=2C=CC=CC=2)CC1 HXOKTEHARXAGDD-UHFFFAOYSA-N 0.000 description 1
- NBLKWGIRRHWRJT-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]-1-(3-methylsulfanylphenyl)urea;hydrochloride Chemical compound Cl.CSC1=CC=CC(N(C2CCN(CC=3C=CC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C(=O)NC=2C=CC(F)=CC=2)=C1 NBLKWGIRRHWRJT-UHFFFAOYSA-N 0.000 description 1
- CQPGDPLPXYPWSL-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]-1-(3-methylsulfinylphenyl)urea;hydrochloride Chemical compound Cl.CS(=O)C1=CC=CC(N(C2CCN(CC=3C=CC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C(=O)NC=2C=CC(F)=CC=2)=C1 CQPGDPLPXYPWSL-UHFFFAOYSA-N 0.000 description 1
- YGMMQIWAFHVYLH-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]-1-(3-methylsulfonylphenyl)urea;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(C=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=C(C=CC=2)S(C)(=O)=O)CC1 YGMMQIWAFHVYLH-UHFFFAOYSA-N 0.000 description 1
- AMQNNPFQIGALIP-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]-1-(4-methylsulfanylphenyl)urea;hydrochloride Chemical compound Cl.C1=CC(SC)=CC=C1N(C(=O)NC=1C=CC(F)=CC=1)C1CCN(CC=2C=CC(OC=3C=CC(NS(C)(=O)=O)=CC=3)=CC=2)CC1 AMQNNPFQIGALIP-UHFFFAOYSA-N 0.000 description 1
- RVIMAQICZQECFX-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[5-[4-(methanesulfonamido)phenoxy]pyrazin-2-yl]methyl]piperidin-4-yl]-1-phenylurea;dihydrochloride Chemical compound Cl.Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CN=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 RVIMAQICZQECFX-UHFFFAOYSA-N 0.000 description 1
- ZXPDZJRNBALZCP-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[6-(2-methoxy-4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea;hydrochloride Chemical compound Cl.COC1=CC(S(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 ZXPDZJRNBALZCP-UHFFFAOYSA-N 0.000 description 1
- SZWPMHQOTUSOSM-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[6-(2-methyl-4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea;hydrochloride Chemical compound Cl.CC1=CC(S(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 SZWPMHQOTUSOSM-UHFFFAOYSA-N 0.000 description 1
- ZXUHGALZZRDCPM-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-1-thiophen-3-ylurea;hydrochloride Chemical compound Cl.C1=CC(S(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C2=CSC=C2)CC1 ZXUHGALZZRDCPM-UHFFFAOYSA-N 0.000 description 1
- JDPDYPIBJNMZBC-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)-2-methoxyphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea;hydrochloride Chemical compound Cl.COC1=CC(NS(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 JDPDYPIBJNMZBC-UHFFFAOYSA-N 0.000 description 1
- ZGSKQSAKUITKSL-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-(2-methoxyphenyl)urea;hydrochloride Chemical compound Cl.COC1=CC=CC=C1N(C(=O)NC=1C=CC(F)=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(NS(C)(=O)=O)=CC=3)=CC=2)CC1 ZGSKQSAKUITKSL-UHFFFAOYSA-N 0.000 description 1
- NZTMTRGRDKISEH-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-(4-methoxyphenyl)urea Chemical compound C1=CC(OC)=CC=C1N(C(=O)NC=1C=CC(F)=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(NS(C)(=O)=O)=CC=3)=CC=2)CC1 NZTMTRGRDKISEH-UHFFFAOYSA-N 0.000 description 1
- DKULUHYAQFGCLM-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 DKULUHYAQFGCLM-UHFFFAOYSA-N 0.000 description 1
- WSSPSSWLBOZBLL-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 WSSPSSWLBOZBLL-UHFFFAOYSA-N 0.000 description 1
- DFLOZGJRSQOOFI-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[1-[[6-[4-(morpholine-4-carbonyl)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1NC(=O)N(C=1C=CC=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(=CC=3)C(=O)N3CCOCC3)=CC=2)CC1 DFLOZGJRSQOOFI-UHFFFAOYSA-N 0.000 description 1
- KTFFBDKMEDRCPE-UHFFFAOYSA-N 3-(6-ethylpyridin-3-yl)-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea Chemical compound C1=NC(CC)=CC=C1NC(=O)N(C=1C=CC=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(NS(C)(=O)=O)=CC=3)=CC=2)CC1 KTFFBDKMEDRCPE-UHFFFAOYSA-N 0.000 description 1
- MISVZQUDCXSRJS-UHFFFAOYSA-N 3-(6-methylpyridin-3-yl)-1-[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea;dihydrochloride Chemical compound Cl.Cl.C1=NC(C)=CC=C1NC(=O)N(C=1C=CC=CC=1)C1CCN(CC=2C=NC(OC=3C=CC(=CC=3)S(C)(=O)=O)=CC=2)CC1 MISVZQUDCXSRJS-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- PCUSDXIOJGANHD-UHFFFAOYSA-N 3-[4-fluoro-3-(methanesulfonamido)phenyl]-1-[1-[[6-(2-methoxy-4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea;hydrochloride Chemical compound Cl.COC1=CC(S(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(NS(C)(=O)=O)C(F)=CC=2)C=2C=CC=CC=2)CC1 PCUSDXIOJGANHD-UHFFFAOYSA-N 0.000 description 1
- NIGJBFYLGNVDLG-UHFFFAOYSA-N 3-[4-fluoro-3-(methanesulfonamido)phenyl]-1-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-1-phenylurea;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(NS(C)(=O)=O)C(F)=CC=2)C=2C=CC=CC=2)CC1 NIGJBFYLGNVDLG-UHFFFAOYSA-N 0.000 description 1
- ULMFXAMQUGLVGA-LJQANCHMSA-N 3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-n-[(2r)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide Chemical compound C=1C=C(CC=2C3=CC(=CC=C3N(C)C=2)C(=O)NC[C@H](C)CC(F)(F)F)C(OC)=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C ULMFXAMQUGLVGA-LJQANCHMSA-N 0.000 description 1
- RJHSPMVMUUJTNI-UHFFFAOYSA-N 3-[[[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]benzamide;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1OC(C=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(C=CC=2)C(N)=O)C=2C=CC=CC=2)CC1 RJHSPMVMUUJTNI-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 1
- WHGMHGPIJZTKTI-UHFFFAOYSA-N 3h-1,2-benzodithiole Chemical compound C1=CC=C2CSSC2=C1 WHGMHGPIJZTKTI-UHFFFAOYSA-N 0.000 description 1
- GPYDBWWOYRNOBL-UHFFFAOYSA-N 4,5-dihydro-3h-1,2-benzodioxepine Chemical compound C1CCOOC2=CC=CC=C21 GPYDBWWOYRNOBL-UHFFFAOYSA-N 0.000 description 1
- VXEBMQZDPONDFB-UHFFFAOYSA-N 4-(2h-tetrazol-5-yl)-n-[4-(2h-tetrazol-5-yl)phenyl]benzamide Chemical compound C=1C=C(C2=NNN=N2)C=CC=1C(=O)NC(C=C1)=CC=C1C=1N=NNN=1 VXEBMQZDPONDFB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RBJGIMKYMMAXBZ-UHFFFAOYSA-N 4-[4-[[4-[butyl-[(5-carbamoyl-2,4-difluorophenyl)carbamoyl]amino]piperidin-1-yl]methyl]phenoxy]-3-methoxybenzoic acid;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(C(O)=O)C=C1OC RBJGIMKYMMAXBZ-UHFFFAOYSA-N 0.000 description 1
- LQGJPVMVVNUVRM-UHFFFAOYSA-N 4-[4-[[4-[butyl-[(5-carbamoyl-2,4-difluorophenyl)carbamoyl]amino]piperidin-1-yl]methyl]phenoxy]benzoic acid;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(C(O)=O)C=C1 LQGJPVMVVNUVRM-UHFFFAOYSA-N 0.000 description 1
- LQYZZDNOQOYPQM-UHFFFAOYSA-N 4-[4-[[4-[n-[(4-fluorophenyl)carbamoyl]anilino]piperidin-1-yl]methyl]phenoxy]benzoic acid;hydrochloride Chemical compound Cl.C1=CC(C(=O)O)=CC=C1OC(C=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 LQYZZDNOQOYPQM-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- MLHXGCDCLMMKQQ-UHFFFAOYSA-N 4-chloro-5-[[[1-[[6-(2,6-dimethyl-4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-pentylcarbamoyl]amino]-2-fluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(Cl)C=1NC(=O)N(CCCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=C(C)C=C(S(C)(=O)=O)C=C1C MLHXGCDCLMMKQQ-UHFFFAOYSA-N 0.000 description 1
- HJVXSEXZLPDAPP-UHFFFAOYSA-N 4-fluoro-n-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-n-phenylbenzamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)C=2C=CC(F)=CC=2)C=2C=CC=CC=2)CC1 HJVXSEXZLPDAPP-UHFFFAOYSA-N 0.000 description 1
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- AOWAWZJZQLDMIZ-UHFFFAOYSA-N 5-(methanesulfonamido)-2-[5-[[4-[n-[(6-methylpyridin-3-yl)carbamoyl]anilino]piperidin-1-yl]methyl]pyridin-2-yl]oxybenzamide Chemical compound C1=NC(C)=CC=C1NC(=O)N(C=1C=CC=CC=1)C1CCN(CC=2C=NC(OC=3C(=CC(NS(C)(=O)=O)=CC=3)C(N)=O)=CC=2)CC1 AOWAWZJZQLDMIZ-UHFFFAOYSA-N 0.000 description 1
- JOPSSWGWLCLPPF-RUDMXATFSA-N 5-[2-(2-carboxyethyl)-3-[(e)-6-(4-methoxyphenyl)hex-5-enoxy]phenoxy]pentanoic acid Chemical compound C1=CC(OC)=CC=C1\C=C\CCCCOC1=CC=CC(OCCCCC(O)=O)=C1CCC(O)=O JOPSSWGWLCLPPF-RUDMXATFSA-N 0.000 description 1
- UWBCUFCKCOTUTF-UHFFFAOYSA-N 5-[4-[[4-[butyl-[(5-carbamoyl-2,4-difluorophenyl)carbamoyl]amino]piperidin-1-yl]methyl]phenoxy]-2-(methanesulfonamido)benzoic acid;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C(C(O)=O)=C1 UWBCUFCKCOTUTF-UHFFFAOYSA-N 0.000 description 1
- VMVCUYDSYRPZIN-AREMUKBSSA-N 5-[[[(3r)-1-[[6-[4-(ethylsulfonylamino)phenoxy]pyridin-3-yl]methyl]pyrrolidin-3-yl]-phenylcarbamoyl]amino]-2-fluorobenzamide Chemical compound C1=CC(NS(=O)(=O)CC)=CC=C1OC(N=C1)=CC=C1CN1C[C@H](N(C(=O)NC=2C=C(C(F)=CC=2)C(N)=O)C=2C=CC=CC=2)CC1 VMVCUYDSYRPZIN-AREMUKBSSA-N 0.000 description 1
- OMFPIMJAOPRUTN-UHFFFAOYSA-N 5-[[[1-[[6-[2-chloro-4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-pentylcarbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1Cl OMFPIMJAOPRUTN-UHFFFAOYSA-N 0.000 description 1
- OSOVZNWKJADSDO-UHFFFAOYSA-N 5-[[[1-[[6-[4-(ethylsulfonylamino)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-pentylcarbamoyl]amino]-2,4-difluoro-n-methylbenzamide;hydrochloride Chemical compound Cl.C=1C(C(=O)NC)=C(F)C=C(F)C=1NC(=O)N(CCCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(=O)(=O)CC)C=C1 OSOVZNWKJADSDO-UHFFFAOYSA-N 0.000 description 1
- XWXNZQQKGGOCHB-UHFFFAOYSA-N 5-[[[1-[[6-[4-(ethylsulfonylamino)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-pentylcarbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(=O)(=O)CC)C=C1 XWXNZQQKGGOCHB-UHFFFAOYSA-N 0.000 description 1
- JFUAPLRRSFDNNP-UHFFFAOYSA-N 5-[[but-2-ynyl-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CC#CC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 JFUAPLRRSFDNNP-UHFFFAOYSA-N 0.000 description 1
- QXTBCPZNTYIQNT-UHFFFAOYSA-N 5-[[butyl-[1-[[1-[4-(methanesulfonamido)phenyl]-3,5-dimethylpyrazol-4-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;dihydrochloride Chemical compound Cl.Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(=C1C)C(C)=NN1C1=CC=C(NS(C)(=O)=O)C=C1 QXTBCPZNTYIQNT-UHFFFAOYSA-N 0.000 description 1
- SEOQFDIWWCUUBN-UHFFFAOYSA-N 5-[[butyl-[1-[[4-(4-carbamoylphenoxy)phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(C(N)=O)C=C1 SEOQFDIWWCUUBN-UHFFFAOYSA-N 0.000 description 1
- WEMVXMNZLBBCHL-UHFFFAOYSA-N 5-[[butyl-[1-[[4-(4-sulfamoylphenoxy)phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(S(N)(=O)=O)C=C1 WEMVXMNZLBBCHL-UHFFFAOYSA-N 0.000 description 1
- QJOXDBOAKWRNOD-UHFFFAOYSA-N 5-[[butyl-[1-[[4-[2-methoxy-4-(morpholine-4-carbonyl)phenoxy]phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC(C(=C1)OC)=CC=C1C(=O)N1CCOCC1 QJOXDBOAKWRNOD-UHFFFAOYSA-N 0.000 description 1
- QRRCRBWQURRBNQ-UHFFFAOYSA-N 5-[[butyl-[1-[[4-[4-(dimethylsulfamoyl)phenoxy]phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(S(=O)(=O)N(C)C)C=C1 QRRCRBWQURRBNQ-UHFFFAOYSA-N 0.000 description 1
- OFBPSTCFSZUZNY-UHFFFAOYSA-N 5-[[butyl-[1-[[4-[4-(methanesulfonamido)-2-methylphenoxy]phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide Chemical compound C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1C OFBPSTCFSZUZNY-UHFFFAOYSA-N 0.000 description 1
- BVUISFYVQKYUCG-UHFFFAOYSA-N 5-[[butyl-[1-[[4-[4-(methanesulfonamido)-3-methoxyphenoxy]phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C(OC)=C1 BVUISFYVQKYUCG-UHFFFAOYSA-N 0.000 description 1
- DIABAJRATOTUEA-UHFFFAOYSA-N 5-[[butyl-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluoro-n-methylbenzamide;hydrochloride Chemical compound Cl.C=1C(C(=O)NC)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 DIABAJRATOTUEA-UHFFFAOYSA-N 0.000 description 1
- NEGJTJVIVVPQBS-UHFFFAOYSA-N 5-[[butyl-[1-[[4-[4-(morpholine-4-carbonyl)phenoxy]phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC(C=C1)=CC=C1C(=O)N1CCOCC1 NEGJTJVIVVPQBS-UHFFFAOYSA-N 0.000 description 1
- RCEGCUCVROHDKU-UHFFFAOYSA-N 5-[[butyl-[1-[[4-[4-[methyl(methylsulfonyl)amino]phenoxy]phenyl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(N(C)S(C)(=O)=O)C=C1 RCEGCUCVROHDKU-UHFFFAOYSA-N 0.000 description 1
- PVNNUNBGLHQREE-UHFFFAOYSA-N 5-[[butyl-[1-[[5-[4-(methanesulfonamido)phenoxy]pyrazin-2-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;dihydrochloride Chemical compound Cl.Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(N=C1)=CN=C1OC1=CC=C(NS(C)(=O)=O)C=C1 PVNNUNBGLHQREE-UHFFFAOYSA-N 0.000 description 1
- PLHPUNZERQKKQY-UHFFFAOYSA-N 5-[[butyl-[1-[[6-(2,6-dimethyl-4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-4-chloro-2-fluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(Cl)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=C(C)C=C(S(C)(=O)=O)C=C1C PLHPUNZERQKKQY-UHFFFAOYSA-N 0.000 description 1
- GUKPROVKOWQDSV-UHFFFAOYSA-N 5-[[butyl-[1-[[6-(2-chloro-4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-4-chloro-2-fluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(Cl)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(S(C)(=O)=O)C=C1Cl GUKPROVKOWQDSV-UHFFFAOYSA-N 0.000 description 1
- QSWLLRQLUKZQAA-UHFFFAOYSA-N 5-[[butyl-[1-[[6-(4-carbamoylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(C(N)=O)C=C1 QSWLLRQLUKZQAA-UHFFFAOYSA-N 0.000 description 1
- DMDLBSSMYQMOCB-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[2-chloro-4-(ethylsulfonylamino)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(=O)(=O)CC)C=C1Cl DMDLBSSMYQMOCB-UHFFFAOYSA-N 0.000 description 1
- AAZVKYGEGQKQHR-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[2-chloro-4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluoro-n-methylbenzamide;hydrochloride Chemical compound Cl.C=1C(C(=O)NC)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1Cl AAZVKYGEGQKQHR-UHFFFAOYSA-N 0.000 description 1
- GNQAVLWHYRBSOK-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(2-methoxyethylcarbamoyl)-2-methylphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(C(=O)NCCOC)C=C1C GNQAVLWHYRBSOK-UHFFFAOYSA-N 0.000 description 1
- FKWIKMIKBYLUFZ-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(dimethylcarbamoyl)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(C(=O)N(C)C)C=C1 FKWIKMIKBYLUFZ-UHFFFAOYSA-N 0.000 description 1
- XZXMHRRWNJHLDP-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(ethylsulfonylamino)-2-methylphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(=O)(=O)CC)C=C1C XZXMHRRWNJHLDP-UHFFFAOYSA-N 0.000 description 1
- XNXODMIZNBEXEF-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(ethylsulfonylamino)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluoro-n-methylbenzamide;hydrochloride Chemical compound Cl.C=1C(C(=O)NC)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(=O)(=O)CC)C=C1 XNXODMIZNBEXEF-UHFFFAOYSA-N 0.000 description 1
- ZKHZRTRNEQMZTN-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(ethylsulfonylamino)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2-chloro-4-fluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(Cl)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(=O)(=O)CC)C=C1 ZKHZRTRNEQMZTN-UHFFFAOYSA-N 0.000 description 1
- UMFSQIRCUJVZOP-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(methanesulfonamido)-2-methylphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluoro-n-methylbenzamide;hydrochloride Chemical compound Cl.C=1C(C(=O)NC)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1C UMFSQIRCUJVZOP-UHFFFAOYSA-N 0.000 description 1
- KQHOTJUYZIZOFD-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(methanesulfonamido)-2-methylphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1C KQHOTJUYZIZOFD-UHFFFAOYSA-N 0.000 description 1
- AFSGCZKBXSDLOH-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluoro-n-methylbenzamide;hydrochloride Chemical compound Cl.C=1C(C(=O)NC)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 AFSGCZKBXSDLOH-UHFFFAOYSA-N 0.000 description 1
- KIZJMECOQMPZIA-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide Chemical compound C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 KIZJMECOQMPZIA-UHFFFAOYSA-N 0.000 description 1
- XPVHFZDFTPGQBX-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 XPVHFZDFTPGQBX-UHFFFAOYSA-N 0.000 description 1
- XGZVPDULQNQRLM-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(methylcarbamoyl)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC1=CC=C(C(=O)NC)C=C1 XGZVPDULQNQRLM-UHFFFAOYSA-N 0.000 description 1
- YGTPSCOSWVQXCJ-UHFFFAOYSA-N 5-[[butyl-[1-[[6-[4-(morpholine-4-carbonyl)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]-2,4-difluorobenzamide;hydrochloride Chemical compound Cl.C=1C(C(N)=O)=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=N1)=CC=C1OC(C=C1)=CC=C1C(=O)N1CCOCC1 YGTPSCOSWVQXCJ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- AWRLZJJDHWCYKN-UHFFFAOYSA-N 5-bromo-2-ethoxy-3-nitropyridine Chemical compound CCOC1=NC=C(Br)C=C1[N+]([O-])=O AWRLZJJDHWCYKN-UHFFFAOYSA-N 0.000 description 1
- SRTBBLNAKMLZTN-UHFFFAOYSA-N 6-amino-2,3-dichlorobenzoic acid Chemical compound NC1=CC=C(Cl)C(Cl)=C1C(O)=O SRTBBLNAKMLZTN-UHFFFAOYSA-N 0.000 description 1
- SIDLHXXVIBTSJZ-UHFFFAOYSA-N 7-phenylmethoxyquinoline Chemical compound C=1C=C2C=CC=NC2=CC=1OCC1=CC=CC=C1 SIDLHXXVIBTSJZ-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- WVLHHLRVNDMIAR-IBGZPJMESA-N AMD 070 Chemical compound C1CCC2=CC=CN=C2[C@H]1N(CCCCN)CC1=NC2=CC=CC=C2N1 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 description 1
- MROJXXOCABQVEF-UHFFFAOYSA-N Actarit Chemical compound CC(=O)NC1=CC=C(CC(O)=O)C=C1 MROJXXOCABQVEF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100023245 Asparagine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036845 C-C motif chemokine 22 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- DRSFVGQMPYTGJY-GNSLJVCWSA-N Deprodone propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DRSFVGQMPYTGJY-GNSLJVCWSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- URJQOOISAKEBKW-UHFFFAOYSA-N Emorfazone Chemical compound C1=NN(C)C(=O)C(OCC)=C1N1CCOCC1 URJQOOISAKEBKW-UHFFFAOYSA-N 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Chemical group 0.000 description 1
- APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- WLHKPDQFOBROCS-UHFFFAOYSA-N Gossypetin 3-methyl ether Chemical compound O1C2=C(O)C(O)=CC(O)=C2C(=O)C(OC)=C1C1=CC=C(O)C(O)=C1 WLHKPDQFOBROCS-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000624939 Homo sapiens Asparagine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- QPJBONAWFAURGB-UHFFFAOYSA-L Lobenzarit disodium Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1NC1=CC(Cl)=CC=C1C([O-])=O QPJBONAWFAURGB-UHFFFAOYSA-L 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MMCDXJOMPMIKGP-UHFFFAOYSA-N Mabuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 MMCDXJOMPMIKGP-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- DJEIHHYCDCTAAH-UHFFFAOYSA-N Mofezolac (TN) Chemical compound C1=CC(OC)=CC=C1C1=NOC(CC(O)=O)=C1C1=CC=C(OC)C=C1 DJEIHHYCDCTAAH-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- WMOBXBMOUMTNTL-UHFFFAOYSA-N N-[6-(4-formylphenoxy)pyridin-3-yl]methanesulfonamide [4-(5-nitropyridin-2-yl)oxyphenyl]methanol Chemical compound [N+](=O)([O-])C=1C=CC(=NC1)OC1=CC=C(C=C1)CO.C(=O)C1=CC=C(OC2=CC=C(C=N2)NS(=O)(=O)C)C=C1 WMOBXBMOUMTNTL-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000004107 Penicillin G sodium Substances 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102100026476 Prostacyclin receptor Human genes 0.000 description 1
- 101710170814 Prostacyclin receptor Proteins 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102000000471 Prostaglandin F receptors Human genes 0.000 description 1
- 108050008995 Prostaglandin F receptors Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical compound N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NFQIAEMCQGTTIR-UHFFFAOYSA-N Repirinast Chemical compound C12=CC=C(C)C(C)=C2NC(=O)C2=C1OC(C(=O)OCCC(C)C)=CC2=O NFQIAEMCQGTTIR-UHFFFAOYSA-N 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- 229920002536 Scavenger resin Polymers 0.000 description 1
- 101100473189 Schizosaccharomyces pombe (strain 972 / ATCC 24843) rpn1 gene Proteins 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- XQTARQNQIVVBRX-UHFFFAOYSA-N Tazanolast Chemical compound CCCCOC(=O)C(=O)NC1=CC=CC(C2=NNN=N2)=C1 XQTARQNQIVVBRX-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- KPWYNAGOBXLMSE-UHFFFAOYSA-N Tipelukast Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1SCCCOC1=CC=C(C(C)=O)C(OCCCC(O)=O)=C1CCC KPWYNAGOBXLMSE-UHFFFAOYSA-N 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- RSLNRVYIRDVHLY-UHFFFAOYSA-N Tulobuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC=CC=C1Cl RSLNRVYIRDVHLY-UHFFFAOYSA-N 0.000 description 1
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- VGXACJMXDYPFDB-SXMMONRFSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] (2s)-2-(hydroxymethyl)-4-[(r)-methylsulfinyl]-2-phenylbutanoate Chemical compound C1([C@@](CO)(C(=O)O[C@@H]2C3CCN(CC3)C2)CC[S@](=O)C)=CC=CC=C1 VGXACJMXDYPFDB-SXMMONRFSA-N 0.000 description 1
- RYVJQEZJUFRANT-UHFFFAOYSA-N [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 RYVJQEZJUFRANT-UHFFFAOYSA-N 0.000 description 1
- ZGDKVKUWTCGYOA-URGPHPNLSA-N [4-[4-[(z)-c-(4-bromophenyl)-n-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone Chemical compound C=1C=C(Br)C=CC=1C(=N/OCC)\C(CC1)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)C=C[N+]([O-])=C1C ZGDKVKUWTCGYOA-URGPHPNLSA-N 0.000 description 1
- DMEPDNFRHUGNPT-UHFFFAOYSA-N [5-(diethylamino)-2-methylpent-3-yn-2-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C=1C=CC=CC=1C(O)(C(=O)OC(C)(C)C#CCN(CC)CC)C1CCCCC1 DMEPDNFRHUGNPT-UHFFFAOYSA-N 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- MGVGMXLGOKTYKP-ZFOBEOMCSA-N acetic acid;(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 MGVGMXLGOKTYKP-ZFOBEOMCSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229950003218 actarit Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- SQKMCUVJZBDQDL-UHFFFAOYSA-K aluminum;2-(2,3-dimethylanilino)benzoate Chemical compound [Al+3].CC1=CC=CC(NC=2C(=CC=CC=2)C([O-])=O)=C1C.CC1=CC=CC(NC=2C(=CC=CC=2)C([O-])=O)=C1C.CC1=CC=CC(NC=2C(=CC=CC=2)C([O-])=O)=C1C SQKMCUVJZBDQDL-UHFFFAOYSA-K 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 108010074587 aminooxypentane-RANTES Proteins 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- UQNCVOXEVRELFR-UHFFFAOYSA-N aminopropylone Chemical compound O=C1C(NC(=O)C(N(C)C)C)=C(C)N(C)N1C1=CC=CC=C1 UQNCVOXEVRELFR-UHFFFAOYSA-N 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229950002999 andolast Drugs 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003705 anilinocarbonyl group Chemical group O=C([*])N([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229940092117 atgam Drugs 0.000 description 1
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 1
- 229960004335 azelastine hydrochloride Drugs 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 1
- 229960002071 bepotastine Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- VIQRCOQXIHFJND-UHFFFAOYSA-N bicyclo[2.2.2]oct-2-ene Chemical compound C1CC2CCC1C=C2 VIQRCOQXIHFJND-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960002335 bromhexine hydrochloride Drugs 0.000 description 1
- 229960004272 bucillamine Drugs 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- JAXFKSJFRIXGQJ-DMIDHIQXSA-L calcium;(z)-7-[(1r,2s,3s,4s)-3-(benzenesulfonamido)-2-bicyclo[2.2.1]heptanyl]hept-5-enoate;tetrahydrate Chemical compound O.O.O.O.[Ca+2].N([C@H]1[C@H]2CC[C@H](C2)[C@@H]1C\C=C/CCCC(=O)[O-])S(=O)(=O)C1=CC=CC=C1.N([C@H]1[C@H]2CC[C@H](C2)[C@@H]1C\C=C/CCCC(=O)[O-])S(=O)(=O)C1=CC=CC=C1 JAXFKSJFRIXGQJ-DMIDHIQXSA-L 0.000 description 1
- CHRHZFQUDFAQEQ-UHFFFAOYSA-L calcium;2-hydroxyacetate Chemical compound [Ca+2].OCC([O-])=O.OCC([O-])=O CHRHZFQUDFAQEQ-UHFFFAOYSA-L 0.000 description 1
- 229950008230 capravirine Drugs 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- 229960000534 cefuroxime sodium Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- GPUVGQIASQNZET-CCEZHUSRSA-N cinnoxicam Chemical compound C=1C=CC=CC=1/C=C/C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 GPUVGQIASQNZET-CCEZHUSRSA-N 0.000 description 1
- 229960001399 clenbuterol hydrochloride Drugs 0.000 description 1
- OPXKTCUYRHXSBK-UHFFFAOYSA-N clenbuterol hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 OPXKTCUYRHXSBK-UHFFFAOYSA-N 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940088900 crixivan Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- LMGZGXSXHCMSAA-UHFFFAOYSA-N cyclodecane Chemical compound C1CCCCCCCCC1 LMGZGXSXHCMSAA-UHFFFAOYSA-N 0.000 description 1
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical compound C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- GPTJTTCOVDDHER-UHFFFAOYSA-N cyclononane Chemical compound C1CCCCCCCC1 GPTJTTCOVDDHER-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
- 239000004913 cyclooctene Substances 0.000 description 1
- SRONXYPFSAKOGH-UHFFFAOYSA-N cyclopentadecane Chemical compound C1CCCCCCCCCCCCCC1 SRONXYPFSAKOGH-UHFFFAOYSA-N 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- KATXJJSCAPBIOB-UHFFFAOYSA-N cyclotetradecane Chemical compound C1CCCCCCCCCCCCC1 KATXJJSCAPBIOB-UHFFFAOYSA-N 0.000 description 1
- UEVXKGPJXXDGCX-UHFFFAOYSA-N cyclotridecane Chemical compound C1CCCCCCCCCCCC1 UEVXKGPJXXDGCX-UHFFFAOYSA-N 0.000 description 1
- KYTNZWVKKKJXFS-UHFFFAOYSA-N cycloundecane Chemical compound C1CCCCCCCCCC1 KYTNZWVKKKJXFS-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- MTZXHKAPOZYPCQ-NHVFNMKISA-N d05511 Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1.OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO MTZXHKAPOZYPCQ-NHVFNMKISA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- CIWBQSYVNNPZIQ-PKWREOPISA-N dexamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-PKWREOPISA-N 0.000 description 1
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 1
- 229950000812 dexamethasone palmitate Drugs 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 229950006825 dexamethasone valerate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 1
- 229960003970 diflucortolone valerate Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- JGKVKXPDDVRUKC-UHFFFAOYSA-N dimethothiazine mesylate Chemical compound CS(O)(=O)=O.C1=C(S(=O)(=O)N(C)C)C=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 JGKVKXPDDVRUKC-UHFFFAOYSA-N 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- AYXBAIULRDEVAS-UHFFFAOYSA-N dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7h-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium;iodide Chemical compound [I-].C1=CC(C)=CC=C1C1=CC=C(CCCC(=C2)C(=O)NC=3C=CC(C[N+](C)(C)C4CCOCC4)=CC=3)C2=C1 AYXBAIULRDEVAS-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960000409 dopexamine hydrochloride Drugs 0.000 description 1
- 229960004483 doxofylline Drugs 0.000 description 1
- HWXIGFIVGWUZAO-UHFFFAOYSA-N doxofylline Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1OCCO1 HWXIGFIVGWUZAO-UHFFFAOYSA-N 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229960000325 emedastine Drugs 0.000 description 1
- 229950010243 emorfazone Drugs 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229960002548 epinastine hydrochloride Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229950003801 epirizole Drugs 0.000 description 1
- 229940072253 epivir Drugs 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- QNQBPPQLRODXET-UHFFFAOYSA-N equisetin Natural products CC=CC1C=CC2CC(C)CCC2C1(C)C(O)=C1C(=O)C(CO)N(C)C1=O QNQBPPQLRODXET-UHFFFAOYSA-N 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- VYNSZADTVZXEJF-UHFFFAOYSA-N ethanesulfonamide dihydrochloride Chemical compound Cl.Cl.C(C)S(=O)(=O)N VYNSZADTVZXEJF-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 229940061262 ethyl cysteine hydrochloride Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- SBVYURPQULDJTI-UHFFFAOYSA-N ethyl n-[amino-[4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]phenyl]methylidene]carbamate Chemical compound C1=CC(C(=N)NC(=O)OCC)=CC=C1OCC1=CC=CC(COC=2C=CC(=CC=2)C(C)(C)C=2C=CC(O)=CC=2)=C1 SBVYURPQULDJTI-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 229960005341 fenoprofen calcium Drugs 0.000 description 1
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
- 229960001037 fenoterol hydrobromide Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960003240 floctafenine Drugs 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 229940042902 flumethasone pivalate Drugs 0.000 description 1
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960001321 flunoxaprofen Drugs 0.000 description 1
- ARPYQKTVRGFPIS-VIFPVBQESA-N flunoxaprofen Chemical compound N=1C2=CC([C@@H](C(O)=O)C)=CC=C2OC=1C1=CC=C(F)C=C1 ARPYQKTVRGFPIS-VIFPVBQESA-N 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- FNUZASGZEHGWQM-RJRMRWARSA-M flutropium bromide Chemical compound C[N@+](CCF)([C@H](CC1)C2)[C@@H]1C[C@H]2OC(C(C1=CC=CC=C1)(C1=CC=CC=C1)O)=O.[Br-] FNUZASGZEHGWQM-RJRMRWARSA-M 0.000 description 1
- 229950008319 flutropium bromide Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960000193 formoterol fumarate Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940059346 glucosaminoglycan polysulfate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- POOYFSLWYLDQMD-UHFFFAOYSA-N heptacalcium;zinc Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Zn+2] POOYFSLWYLDQMD-UHFFFAOYSA-N 0.000 description 1
- DDTGNKBZWQHIEH-UHFFFAOYSA-N heptalene Chemical compound C1=CC=CC=C2C=CC=CC=C21 DDTGNKBZWQHIEH-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 1
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940088976 invirase Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940112586 kaletra Drugs 0.000 description 1
- LGYTZKPVOAIUKX-UHFFFAOYSA-N kebuzone Chemical compound O=C1C(CCC(=O)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 LGYTZKPVOAIUKX-UHFFFAOYSA-N 0.000 description 1
- 229960000194 kebuzone Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000002664 langerhans' cell Anatomy 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- AVMZBERNWNNCTN-UHFFFAOYSA-N methanesulfonamide trihydrochloride Chemical compound Cl.Cl.Cl.CS(N)(=O)=O AVMZBERNWNNCTN-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- UQDGCRLPGXSTAN-UHFFFAOYSA-N methyl 2-[4-[4-[[4-[butyl-[(2,4-difluorophenyl)carbamoyl]amino]piperidin-1-yl]methyl]phenoxy]-n-methylsulfonylanilino]acetate;hydrochloride Chemical compound Cl.C=1C=C(F)C=C(F)C=1NC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(N(CC(=O)OC)S(C)(=O)=O)C=C1 UQDGCRLPGXSTAN-UHFFFAOYSA-N 0.000 description 1
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- LZULAZTXJLWELL-UHFFFAOYSA-N methyl hex-5-ynoate Chemical compound COC(=O)CCCC#C LZULAZTXJLWELL-UHFFFAOYSA-N 0.000 description 1
- ZYLBZJKJNAYAFU-AVGNSLFASA-N methyl n-[(2s)-3-methyl-1-oxo-1-[(2s)-2-[[(3s)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]carbamoyl]pyrrolidin-1-yl]butan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)C(F)(F)F ZYLBZJKJNAYAFU-AVGNSLFASA-N 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- PSCNNGGPKIBAHB-WFVOKNHCSA-N methylprednisolone 21-suleptanic acid ester Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS(O)(=O)=O)CC[C@H]21 PSCNNGGPKIBAHB-WFVOKNHCSA-N 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- 229950010796 methylprednisolone suleptanate Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 229960000429 mofezolac Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UYMDKKVILQGGBT-ZTOMLWHTSA-N n-[(2s)-5-(diaminomethylideneamino)-1-[[(1s)-1-naphthalen-1-ylethyl]amino]-1-oxopentan-2-yl]-4-[(pyridin-2-ylmethylamino)methyl]benzamide Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C=1C2=CC=CC=C2C=CC=1)C(=O)C(C=C1)=CC=C1CNCC1=CC=CC=N1 UYMDKKVILQGGBT-ZTOMLWHTSA-N 0.000 description 1
- DUVNVYNHZUZLQN-UHFFFAOYSA-N n-[2-[5-[[4-[3-fluoro-n-[(6-methylpyridin-3-yl)carbamoyl]anilino]piperidin-1-yl]methyl]pyridin-2-yl]oxy-5-methylsulfonylphenyl]acetamide Chemical compound CC(=O)NC1=CC(S(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=NC(C)=CC=2)C=2C=C(F)C=CC=2)CC1 DUVNVYNHZUZLQN-UHFFFAOYSA-N 0.000 description 1
- GJEXDWIWZUCVTR-UHFFFAOYSA-N n-[2-chloro-5-[[[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=C(Cl)C(NC(=O)C)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(=CC=4)S(C)(=O)=O)=CC=3)CC2)C=2C=CC=CC=2)=C1 GJEXDWIWZUCVTR-UHFFFAOYSA-N 0.000 description 1
- JQGXLJAFZAUGSY-UHFFFAOYSA-N n-[2-chloro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=C(Cl)C(NC(=O)C)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C=2C=CC=CC=2)=C1 JQGXLJAFZAUGSY-UHFFFAOYSA-N 0.000 description 1
- NBPPLGOKGFSABF-UHFFFAOYSA-N n-[2-fluoro-5-[[(3-fluorophenyl)-[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]carbamoyl]amino]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=C(F)C(NC(=O)C)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C=2C=C(F)C=CC=2)=C1 NBPPLGOKGFSABF-UHFFFAOYSA-N 0.000 description 1
- HCPJVSYCVRIORW-UHFFFAOYSA-N n-[2-fluoro-5-[[[1-[[6-(4-methylsulfonylphenoxy)pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=C(F)C(NC(=O)C)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(=CC=4)S(C)(=O)=O)=CC=3)CC2)C=2C=CC=CC=2)=C1 HCPJVSYCVRIORW-UHFFFAOYSA-N 0.000 description 1
- SQAHEZCUXQYMEV-UHFFFAOYSA-N n-[2-fluoro-5-[[[1-[[6-[4-(methanesulfonamido)-2-methoxyphenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]phenyl]acetamide;hydrochloride Chemical compound Cl.COC1=CC(NS(C)(=O)=O)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(NC(C)=O)C(F)=CC=2)C=2C=CC=CC=2)CC1 SQAHEZCUXQYMEV-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- MSXTUBJFNBZPGC-UHFFFAOYSA-N n-[4-oxo-2-(2h-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide;hydrate Chemical compound O.C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC1=CC=CC(C(C=2)=O)=C1OC=2C=1N=NNN=1.C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC1=CC=CC(C(C=2)=O)=C1OC=2C=1N=NNN=1 MSXTUBJFNBZPGC-UHFFFAOYSA-N 0.000 description 1
- KKYDJZZLWKYDOV-UHFFFAOYSA-N n-[5-[[[1-[[6-[2-chloro-4-(ethylsulfonylamino)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-(3-fluorophenyl)carbamoyl]amino]-2-fluorophenyl]acetamide Chemical compound ClC1=CC(NS(=O)(=O)CC)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(NC(C)=O)C(F)=CC=2)C=2C=C(F)C=CC=2)CC1 KKYDJZZLWKYDOV-UHFFFAOYSA-N 0.000 description 1
- CPHFBWIPQIFODP-UHFFFAOYSA-N n-[5-[[[1-[[6-[4-(ethylsulfonylamino)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-(3-fluorophenyl)carbamoyl]amino]-2-fluorophenyl]acetamide Chemical compound C1=CC(NS(=O)(=O)CC)=CC=C1OC(N=C1)=CC=C1CN1CCC(N(C(=O)NC=2C=C(NC(C)=O)C(F)=CC=2)C=2C=C(F)C=CC=2)CC1 CPHFBWIPQIFODP-UHFFFAOYSA-N 0.000 description 1
- RBCZIKPUOVFXEU-UHFFFAOYSA-N n-butyl-2-(2,4-difluorophenyl)-n-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]acetamide;hydrochloride Chemical compound Cl.C=1C=C(F)C=C(F)C=1CC(=O)N(CCCC)C(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 RBCZIKPUOVFXEU-UHFFFAOYSA-N 0.000 description 1
- WWYFCCPOFXBGSN-UHFFFAOYSA-N n-ethyl-2-fluoro-5-[[[1-[[6-[4-(methanesulfonamido)phenoxy]pyridin-3-yl]methyl]piperidin-4-yl]-phenylcarbamoyl]amino]benzamide Chemical compound C1=C(F)C(C(=O)NCC)=CC(NC(=O)N(C2CCN(CC=3C=NC(OC=4C=CC(NS(C)(=O)=O)=CC=4)=CC=3)CC2)C=2C=CC=CC=2)=C1 WWYFCCPOFXBGSN-UHFFFAOYSA-N 0.000 description 1
- VGJDSNZOPPZCTB-UHFFFAOYSA-N n-methyl-2-(4-nitrophenyl)ethanamine;hydrochloride Chemical compound Cl.CNCCC1=CC=C([N+]([O-])=O)C=C1 VGJDSNZOPPZCTB-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005185 naphthylcarbonyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 229960004832 netilmicin sulfate Drugs 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 229940072250 norvir Drugs 0.000 description 1
- 229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- NIEHEMAZEULEKB-UHFFFAOYSA-N ortho-ethylanisole Natural products CCC1=CC=CC=C1OC NIEHEMAZEULEKB-UHFFFAOYSA-N 0.000 description 1
- RYDICHIKLKVOEJ-UHFFFAOYSA-N oxadiazepine Chemical compound O1C=CC=CN=N1 RYDICHIKLKVOEJ-UHFFFAOYSA-N 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 1
- 229960002698 oxatomide Drugs 0.000 description 1
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- SHZKQBHERIJWAO-AATRIKPKSA-N ozagrel Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1CN1C=NC=C1 SHZKQBHERIJWAO-AATRIKPKSA-N 0.000 description 1
- 229950003837 ozagrel Drugs 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960000865 paramethasone acetate Drugs 0.000 description 1
- DXHYQIJBUNRPJT-UHFFFAOYSA-N parsalmide Chemical compound CCCCNC(=O)C1=CC(N)=CC=C1OCC#C DXHYQIJBUNRPJT-UHFFFAOYSA-N 0.000 description 1
- 229950001060 parsalmide Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019369 penicillin G sodium Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- XDJOIMJURHQYDW-UHFFFAOYSA-N phenalene Chemical compound C1=CC(CC=C2)=C3C2=CC=CC3=C1 XDJOIMJURHQYDW-UHFFFAOYSA-N 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical class NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229960001369 piroxicam cinnamate Drugs 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
- 229960002169 plerixafor Drugs 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- ZUFQCVZBBNZMKD-UHFFFAOYSA-M potassium 2-ethylhexanoate Chemical compound [K+].CCCCC(CC)C([O-])=O ZUFQCVZBBNZMKD-UHFFFAOYSA-M 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- 229960002176 prednisolone sodium succinate Drugs 0.000 description 1
- FKKAEMQFOIDZNY-CODXZCKSSA-M prednisolone sodium succinate Chemical compound [Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 FKKAEMQFOIDZNY-CODXZCKSSA-M 0.000 description 1
- 229960004259 prednisolone tebutate Drugs 0.000 description 1
- DGYSDXLCLKPUBR-SLPNHVECSA-N prednisolone valerate acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O DGYSDXLCLKPUBR-SLPNHVECSA-N 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 229960002789 procaterol hydrochloride Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- PTXGHCGBYMQQIG-UHFFFAOYSA-N proglumetacin Chemical compound C=1C=CC=CC=1C(=O)NC(C(=O)N(CCC)CCC)CCC(=O)OCCCN(CC1)CCN1CCOC(=O)CC(C1=CC(OC)=CC=C11)=C(C)N1C(=O)C1=CC=C(Cl)C=C1 PTXGHCGBYMQQIG-UHFFFAOYSA-N 0.000 description 1
- MKFWBVKQDGNXDW-SPIKMXEPSA-N proglumetacin dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(=O)NC(C(=O)N(CCC)CCC)CCC(=O)OCCCN(CC1)CCN1CCOC(=O)CC(C1=CC(OC)=CC=C11)=C(C)N1C(=O)C1=CC=C(Cl)C=C1 MKFWBVKQDGNXDW-SPIKMXEPSA-N 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229950004496 ramatroban Drugs 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 229950009147 repirinast Drugs 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 229940063627 rescriptor Drugs 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 229950000915 revatropate Drugs 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- 229960000720 ritodrine hydrochloride Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- MKTVMEMIKNBVHI-UHFFFAOYSA-N s-[1-oxo-1-[(2-oxothiolan-3-yl)amino]propan-2-yl] thiophene-2-carbothioate Chemical compound C1CSC(=O)C1NC(=O)C(C)SC(=O)C1=CC=CS1 MKTVMEMIKNBVHI-UHFFFAOYSA-N 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229950000112 serrapeptase Drugs 0.000 description 1
- 108010038132 serratiopeptidase Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IMOLVSPMDGCLMB-UHFFFAOYSA-N simetride Chemical compound COC1=CC(CCC)=CC=C1OCC(=O)N1CCN(C(=O)COC=2C(=CC(CCC)=CC=2)OC)CC1 IMOLVSPMDGCLMB-UHFFFAOYSA-N 0.000 description 1
- 229950007670 simetride Drugs 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 229960001435 sisomicin sulfate Drugs 0.000 description 1
- BTGNGJJLZOIYID-UHFFFAOYSA-N sivelestat Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)NCC(O)=O BTGNGJJLZOIYID-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- BGXXYHIWOXFRLF-UHFFFAOYSA-M sodium;2-(imidazol-1-ylmethyl)-4,5-dihydro-1-benzothiophene-6-carboxylate Chemical compound [Na+].C=1C=2CCC(C(=O)[O-])=CC=2SC=1CN1C=CN=C1 BGXXYHIWOXFRLF-UHFFFAOYSA-M 0.000 description 1
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 1
- QIBQVFYOTMPEIP-UHFFFAOYSA-M sodium;3-[4-[(4-chlorophenyl)sulfonylamino]butyl]-6-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].C=1C(S([O-])(=O)=O)=C2C=CC(C(C)C)=CC=C2C=1CCCCNS(=O)(=O)C1=CC=C(Cl)C=C1 QIBQVFYOTMPEIP-UHFFFAOYSA-M 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- PHICBFWUYUCFKS-UHFFFAOYSA-N spiro[4.4]nonane Chemical compound C1CCCC21CCCC2 PHICBFWUYUCFKS-UHFFFAOYSA-N 0.000 description 1
- NECLQTPQJZSWOE-UHFFFAOYSA-N spiro[5.5]undecane Chemical compound C1CCCCC21CCCCC2 NECLQTPQJZSWOE-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960004533 streptodornase Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 229950011082 suplatast tosilate Drugs 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940054565 sustiva Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229950011558 tazanolast Drugs 0.000 description 1
- BESDYXOPYOAWRZ-UHFFFAOYSA-N temacrazine Chemical compound C12=C3C(=O)C4=CC=CC=C4N1N=NC2=CC=C3NCCCN(CC1)CCN1CCCNC1=CC=C2N=NN3C4=CC=CC=C4C(=O)C1=C32 BESDYXOPYOAWRZ-UHFFFAOYSA-N 0.000 description 1
- 229950000334 temiverine Drugs 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UOLYEXHXUXXJAO-UHFFFAOYSA-N tert-butyl 4-(butylamino)piperidine-1-carboxylate Chemical compound CCCCNC1CCN(C(=O)OC(C)(C)C)CC1 UOLYEXHXUXXJAO-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- BXVYJQULAWJPSR-UHFFFAOYSA-N thiadiazepine Chemical compound S1C=CC=CN=N1 BXVYJQULAWJPSR-UHFFFAOYSA-N 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- BISQTCXKVNCDDA-UHFFFAOYSA-N thiepine Chemical compound S1C=CC=CC=C1 BISQTCXKVNCDDA-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 229940107955 thymoglobulin Drugs 0.000 description 1
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 1
- 229950010302 tiaramide Drugs 0.000 description 1
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 1
- PFENFDGYVLAFBR-UHFFFAOYSA-N tinoridine Chemical compound C1CC=2C(C(=O)OCC)=C(N)SC=2CN1CC1=CC=CC=C1 PFENFDGYVLAFBR-UHFFFAOYSA-N 0.000 description 1
- 229950010298 tinoridine Drugs 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- PCFIPYFVXDCWBW-UHFFFAOYSA-N tricyclo[3.3.1.03,7]nonane Chemical compound C1C(C2)C3CC2CC1C3 PCFIPYFVXDCWBW-UHFFFAOYSA-N 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229960004846 tulobuterol hydrochloride Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229950010121 ufenamate Drugs 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940023080 viracept Drugs 0.000 description 1
- 229940098802 viramune Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- 229940087450 zerit Drugs 0.000 description 1
- 229940052255 ziagen Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
® Bo2007/ uv. v0
NITROGENOUS HETEROCYCLIC DERIVATIVE AND
MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT
The present invention relates to a nitrogen-containing heterocyclic derivative which is useful as medicament and a drug containing the same as the active ingredient.
Explaining in more detail about the present invention, it relates to 9) a compound represented by formula (I)
SOYCROT
X
(wherein all symbols have the same meanings as described hereinafter.), a salts thereof, an
N-oxide thereof or a solvate thereof, or prodrugs thereof, 2) treatment and/or prevention for CCR5-related diseases comprising compounds represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or prodrugs thereof, as an active ingredient, and 3) a process for the preparation thereof
Chemokine is known as an endogeneous basic protein having leukocyte ~~ chemotactic and activating abilities and strong heparin-binding abilities. At present, it is considered that chemokine is related to not only the control of infiltration of specific leukocyte at the time of inflammations and immune responses but also the development and homing of lymphocyte under physiological conditions and migration of hemocyte precursor cells and somatic cells.
Differentiation, proliferation and cell death of hemocytes are controlled by various types of cytokine. In the living body, inflammations are found topically and differentiation, maturation and the like of lymphocytes are carried out at certain specified sites. That is, various necessary cells migrate into certain specified sites and accumulate therein to cause a series of inflammations and immune responses. Accordingly, migration of cells is also an indispensable phenomenon in addition to differentiation, proliferation and death of cells.
Migration of hemocytes in the living body starts firstly in the development stage by the shift of hematopoiesis started in the AGM region into permanent
3 ~ a hematopoiesis in bone marrow via fetal liver. Furthermore, precursor cells of T cells and thymus dendritic cells migrate from the fetal liver into the bone marrow and then into the thymus gland and cytodifferentiate under thymus environment. The T cell which received clone selection migrates into secondary lymphoid tissues and takes part in an immune response in the periphery. The Langerhans cell of the skin activated and differentiated by capturing an antigen migrates into the T cell region of a topical lymph node and activates naive T cell therein as a dendritic cell. The memory T cell performs its homing again into the lymph node via lymphatic and blood vessels. Also, B cell, T cell in the intestinal epithelium, y8 T cell, NKT cell and dendritic cell migrate from bone marrow without passing through the thymus gland and differentiate to take part in an immune response.
Chemokine deeply takes part in the migration of such various cells.
Chemokine receptors are greatly related to the control of inflammation and immune responses through a mechanism in which they are expressed at certain specified periods in variously specific cells and the effector cells are accumulated in a region where chemokine is produced. :
For example, it is reported an investigation in animal models such as CCR5- knockout mouse suggesting that CCRS as a chemokine receptor plays a significant role in rejection in organ transplantation or autoimmune disease, etc. (77 ransplantation, Vol.72(7), 1199-1205 (2001); Diabetes, Vol.51(8), 2489-2495 (2002); Journal of Virology, Vol. 77(1), 191-198 (2003); Journal of Immunology, Vol.164(12), 6303-6312 (2000)). It is also reported which make a comparison a risk of developing several diseases and a length of the survival of the transplanted graft, etc. between a human having inactive CCR and a human i having wild-type one (Ref The Lancet, Vol.357, 1758-1761 (2001); Arthritis &
Rheumatism, Vol.42(5), 989-992 (1999); The Lancet, Vol.354, 1264-1265 (1999);
European Journal of Immunogenetics, Vol.29(6) 525-528 (2002)). It is suggested that
CCRS is related to several diseases, but they make no reference to the effect of drugs which antagonizes CCR in their reports.
At present, immunosuppressive treatment for diseases in transplantation area is provided. That is, a calcineurin inhibitor such as cyclosporin or tacrolimus (FKS506) is used mainly with various type of an immunosuppressant agent, for example, a TOR (target of rapamycin) inhibitor such as sirolimus (rapamycin), a non-specific antiphlogistic such as corticosteroids, an antiproliferative drug such as azathioprine, mycophenolate mofetil, etc.
But, it frequently causes a chronic rejection or a severe side effect, so it is desired a useful novel immunosuppressant agent which prolongs a length of the survival of the transplanted graft and reduces the side effects in comparison with existing drugs.
An antiinflammatory drug or a drug which modulates immune function such as nonsteroidal antiinflammatory drug (NSAIDs) which have an inhibitory activity against
® ® co9007/02100 cyclooxygenase (COX), disease modifying anti-rheumatic drug (DMARDs), steroids, ec. is used for treatment for autoimmune disease or allergic diseases. The more effective a drug 1s, the severer a side effect caused by it is, and it is suggested that the treatment with these drugs is not an underlying remedy for the disease, but a mere symptomatic treatment.
At the same time, acquired immunodeficiency syndrome (hereinafter referred to as "AIDS") which is induced by human immunodeficiency virus (hereinafter referred to as "HIV") is one of the diseases of which their therapeutic methods are most earnestly desired in recent years. Once infection with HIV is completed in a CD4-positive cell which is a principal target cell, HIV repeats its proliferation in the body of the patient and, sooner or later, completely destroys T cell which takes charge of the immunological function. During this process, the immunological function is gradually reduced to cause fever, diarrhea, lymph node enlargement and the like various immunodeficiency conditions which are apt to cause complications with pneumocystis carinii pneumonia and the like various opportunistic infections. Such conditions are the onset of AIDS, and it is well known that they induce and worsen Kaposi sarcoma and the like malignant tumors.
As the recent preventive and/or therapeutic methods for AIDS, attempts have been made to, e.g., (1) inhibit growth of HIV by the administration of a reverse transcriptase inhibitor or a protease inhibitor and (2) prevent or alleviate opportunistic infections by the administration of a drug having immunopotentiation activity.
Helper T cells which take charge of the central of immune system are mainly infected with HIV. It is known since 1985 that HIV uses the membrane protein CD4 expressing on the membrane of T cells in the infection (Cell, 52, 631 (1985)). The CD4 molecule is composed of 433 amino acid residues, and its expression can be found in } macrophages, some B cells, vascular endothelial cells, Langerhans' cells in skin tissues, dendritic cells in lymphoid tissues, glia cells of the central nervous system and the like, in addition to the mature helper T cells. However, since it has been revealed that the infection with HIV is not completed by the CD4 molecule alone, a possibility has been suggested on the presence of factors other than the CD4 molecule, which are related to the infection of cells with HIV.
CCRS, which is a receptor of RANTES, MIP-1a and MIP-18, is also used at the time of the infection with a macrophage tropic (RS) HIV (Science, 272, 1955 (1996)).
Accordingly, substances which can compete with CCRS for HIV, or which can bind to HIV virus thus causing the virus unable to bind to CCRS, could become HIV infection inhibitors.
It is also reported a possibility that the CCRS5 is used in the infection with
Respiratory Syncytial Virus (hereinafter referred to as "RSV"). _3-
a ~ ° eo 5.007077 07
It is reported that CCRS are expressed in arteriosclerotic plaque, so it is considered that chemokine receptor modulators are also useful in treating cardiovascular diseases.
Based on the above, it is considered that chemokine (for example, RANTES, MIP-la, MIP-1B, etc.) receptors, especially CCRS are deeply related to the inflammation, immunological diseases, infectious diseases (infection with HIV, infection with RSV, etc), and cardiovascular diseases. For example, it is considered that they are related to various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, erc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, erc.), Immunosuppression, psoriasis, multiple sclerosis, ezc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc), allergic diseases (atopic dermatitis,
I5 urticaria, allergic bronchoplumonary aspergillosis, allergic eosinophilic gastroenteritis, efc.), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, efc.), acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes mellitus, cancer metastasis and the like.
It is reported that the aminopiperidine derivatives represented by formula (2) “TL
NR @ 2 A RE
RZ
(wherein R'? is hydrogen atom or C1-12 alkyl, R* and R* are each independently hydrogen atom or C1-12 alkyl, X* is nitrogen atom or oxygen atom, AZ is “f “=
NR or REIN
R>¢ RZ (wherein R* is hydrogen atom, C1-12 alkyl, C3-8 cycloalkyl, aryl, substituted aryl, aryl-
C(=0)- or aryl-CH(OH)-, R** is hydrogen, C1-12 alkyl, C1-4 alkoxy, halogen or COR, R%% is hydrogen, C1-12 alkyl or substituted C1-4 alkyl. With the proviso that the definition of
@® ° sr 90077 v= V0
T.9007/02108 each symbol is an excerpt partially.) are useful as inhibitors of the chemokine receptors (ref. specification of W002/079186).
It is described that the sulfonic acid compounds represented by formula (W)
SOH 0 (Rew
RO x? IL 7 | ®RMa W) (RY) yw N ( Jaw (Row (wherein XV is -O-, -S-, -CH;- or -NR®-, YV is C6-10 aryl or C2-9 heteroaryl, R'Y is selected from the group consisting of: H-, HO-, halo-, C1-8 alkyl- optionally substituted with 1-3 fluorine atoms, efc., R>” and R*V is selected from the group consisting of: H-, oxo, C1-8 alkyl- optionally substituted with 1-3 fluorine atoms, efc., R*Y is selected from the group consisting of: H-, HO-, halo-, NC-, etc, R’Y is C1-8 alkyl, aW is 0-5, bW is 0-2, c¢W is 0-2, and dW is 0-4. With the proviso that the definition of each symbol is an excerpt partially.), pharmacological acceptable salts thereof and prodrugs thereof are selective antagonists of CCR1 (ref. specification of W002/102787).
Moreover, 1-(4-pyridyl)-piperazine derivatives are described as CCRS antagonists (ref. specification of US6,391,865).
On the other hand, it is reported that triazaspiro[S.5Jundecane derivatives, quaternary ammonium salts thereof or N-oxides thereof, or pharmacologically acceptable salts thereof regulate the effect of chemokine/chemokine receptor, so they are used for prevention and/or treatment of various inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases (allergic bronchopulmonary aspergillosis or allergic eosinophilic gastroenteritis efc.), nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, psoriasis, rhinitis, conjunctivitis, ischemic reperfusion disorder, multiple sclerosis, ulcerative colitis, acute respiratory distress syndrome, cytotoxic shock, diabetes, autoimmune disease, in transplanted organ rejection reactions, immunosuppression, cancer metastasis and acquired immune deficiency syndrome (ref. specification of WO01/40227).
It is described that the compounds represented by formula (M) 0
PIS M
DYN vo Nn (M)
RM R2M _-
® ® (wherein mM and nM, which are the same or different, is each zero or the integer 1 or 2,
All’™ is a covalent bond or a straight or branched C1-6 alkylene chain, R'™ and R?™™ which are the same or different, is each a hydrogen atom or a straight or branched C1-6 alkyl group, DM is an optionally substituted aromatic or heteroaromatic ring group, EM is an optionally substituted C7-10 cycloalkyl, C7-10 cycloalkenyl or C7-10 polycycloaliphatic group.) are modulators of CXCR3 (ref. specification of W003/070242).
The compound which has the antagonistic activity against CCRS is useful in preventing and/or treating CCRS-related diseases. Therefore it is desired that safety
CCRS antagonists are developed.
In order to find a compound which specifically binds chemokine receptor, especially CCRS, and has the antagonistic activity against it, the present inventors have conducted intensive studies and found, as a result, that the objects can be accomplished by the compound represented by formula (I), and thus the present invention has been accomplished.
The present invention relates to 1. a compound represented by formula (I)
ANORCET
X wherein R' represents (1) -N(R'*)SO,-R'E, (2) -SO,NR'°R'®, (3) -COOR'E, (4) -OR™, (5) -S(0)mR', (6) -CONR'MR", (7) -NR* CORY, or (8) cyano, wherein m is 0, 1 or 2; R'" R'® RC R' RE RF R! R™ RY R' and R" each independently represents a hydrogen atom, a hydrocarbon group which may have a substituent(s), or a 3- to 15-membered heterocyclic group which may have a substituent(s), and wherein R'C and
R'P or R'™ and RY may form a nitrogen-containing heterocyclic group which may have a substituent(s) together with a nitrogen atom to which they bind;
X and Y each independently represents a bond or a spacer containing 1 to 3 atoms as a main chain; ring A and ring B, which are the same or different, each represents a 3- to 15- membered carbocyclic group or heterocyclic group which may have a substituent(s); ring D is a 3- to 15-membered nitrogen-containing heterocyclic group which may have a substituent(s);
R? is (1) a hydrogen atom, (2) a hydrocarbon group which may have a substituent(s), (3) a cyano group, (4) a hydroxy group which may be protected, (5) an
® ® amino group which may have a substituent(s), (6) an oxo group, (7) a 3- to 15-membered heterocyclic group which may have a substituent(s) or (8) =N-OR®, wherein R® represents a hydrogen atom or C1-4 alkyl, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof’ 2 the compound according to the above-described 1, wherein X and Y are each independently a bond or a divalent group comprising a combination of one or two unit(s) selected from (1) -CR'R®-, (2) -NR’-, (3) -CO-, (4) -O-, (5) -S-, (6) -SO-, (7) -SO,- and (8) -C(=N-OR')-, wherein R7 and R® each independently represents a hydrogen atom, C1-4 alkyl, -OR' or phenyl, R’ represents a hydrogen atom, C1-4 alkyl, or phenyl; R'® and R'! each independently represents a hydrogen atom or C1-4 alkyl; 3. the compound according to the above-described 2, wherein X is a bond, -O- or -CH,-; 4. the compound according to the above-described 2, wherein Y is C1-2 alkylene; 5. the compound according to the above-described 1, wherein ring D is a 5- to 10- membered nitrogen-containing heterocyclic group which may have a substituent(s); 6. the compound according to the above-described 5, wherein ring D is a tropane, pyrrolidine, piperidine or azepane ring which may have a substituent(s); 7. the compound according to the above-described 6, wherein ring D is a piperidine ring which may have a substituent(s); 8. the compound according to the above-described 1, wherein ring A and ring B, which are the same or different, are each a 5- or 6-membered aromatic ring group which may have a substituent(s), 9. the compound according to the above-described 1, wherein R? is 0 “\ IL R53 nN
R31 R2 wherein the arrow represents a binding position to ring D, R®, R*? and R® each independently represents (1) a hydrogen atom, (2) a hydrocarbon group which may have a substituent(s), (3) a 3- to 15-membered heterocyclic group which may have a substituent(s), (4) a C1-4 alkoxy group which may have a substituent(s), (5) a phenoxy group which may have a substituent(s) or (6) a benzyloxy group which may have a substituent(s); 10. the compound according to the above-described 1, wherein R? is
® @® 0
SA gs
RS wherein the arrow represents a binding position to ring D, R*! and R* each independently represents (1) a hydrogen atom, (2) a hydrocarbon group which may have a substituent(s), (3) a 3-to 15-membered heterocyclic group which may have a substituent(s), 4)acCl-4 alkoxy group which may have a substituent(s), (5) a phenoxy group which may have a substituent(s) or (6) a benzyloxy group which may have a substituent(s); 11. the compound according to the above-described 1, which is represented by formula (Ib) 53
X e RE
R31 R52 wherein all symbols have the same meanings as those described in the above-described 1 and 9; 12. the compound according to the above-described 9, wherein the hydrocarbon group which may have a substituent(s) or the 3- to 15-membered heterocyclic group which may have a substituent(s) represented by R’' is an aromatic ring group which may have a substituent(s); 13. the compound according to the above-described 12, wherein the aromatic ring group which may have a substituent(s) is a benzene, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, or thiadiazole ring; 14. the compound according to the above-described 12, which is represented by formulae (Ie), (If), (Ig), or (Ih)
®
CNOA. x NRE Ge)
R56 R52 0), 0
X EN Re
R56 R52 , 0, (3 x NARS 09 or
R56 R52
X EN R53 : RSS R52 wherein symbol “NN represents f3-configuration and symbol “a represents o- configuration, B-configuration or the mixture of them; R® is aromatic ring group which may have a substituent(s); other symbols have the same meanings as those described in the above-described 1 and 9; 15. the compound according to the above-described 1, wherein the hydrocarbon group which may have a substituent(s) represented by R* is C1-15 alkyl; 16. the compound according to the above-described 15, which is selected from the group consisting of (DH 5-({[butyl(1-{ 4-[4-(methylsulfonyl)phenoxy]benzyl }-4- piperidinyl)amino]carbonyl }amino)-2,4-difluorobenzamide, (2) S-[({butyl[1-({ 6-[4~(methylsulfonyl)phenoxy]-3 -pyridinyl} methyl)-4- piperidinylJamino}carbonyl)amino)-2,4-difluorobenzamide, 1s (3) 5-({[butyl(1-{[6-(4-{ [(2-methoxyethyl)amino]carbonyl }phenoxy)-3- pyridinyl]methyl}-4-piperidinyl)amino]carbonyl }amino)-2,4-difluorobenzamide, 4) 5-{[(butyl{ 1-[(6-{4-[(ethylsulfonyl)amino]phenoxy}-3 -pyridinyl)methyl]-4- piperidinyl}amino)carbonyl]amino}-2,4-difluorobenzamide, (5) 5-{[(butyl{1 -[(6-{2-methyl-4-[(methylsulfonyl)amino]phenoxy} -3- pyridinyl)methyl]-4-piperidinyl }amino)carbonyl]amino }-2-chloro-4-fluorobenzamide, (6) 2-(5-{[(butyl { 1-[(6-{ 4-[(methylsulfonyl)amino]phenoxy} -3-pyridinyl)methyl]- 4-piperidinyl }amino)carbonyl]amino }-2,4-difluorophenyl)acetamide, @) S-[({butyl[1-(4-{4-[(methylsulfonyl)amino phenoxy }benzyl)-4- piperidinylJamino }carbonyl)amino]-2,4-difluoro-N-methylbenzamide,
® ® (8) 5-{[(butyl{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl}amino)carbonyl]amino}-2,4-difluorobenzamide, and (9) 5-[({butyl[1-(4-{4-[(methylamino)sulfonyl]phenoxy } benzyl)-4- piperidinyl]amino }carbonyl)amino]-2,4-difluorobenzamide;
17. the compound according to the above-described 12, wherein the aromatic ring group represented by R*! is a mono- carbocyclic group or mono- heterocyclic group which have aromaticity;
18. the compound according to the above-described 17, which is selected from the group consisting of
(1) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]oxy } -3-methoxyphenyl)methanesulfonamide, (2) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide, 3) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl } (3-thienyl)amino]}-1-
piperidinyl } methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide, 4) N-[4-({5-[(4-{3-thienyl[(3-thienylamino)carbonyl]amino}-1- piperidinyl)methyl]-2-pyridinyl} oxy)phenyl]methanesulfonamide, (5) 2-fluoro-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyi]-4-piperidinyl } (phenyl)amino]carbonyl }amino)benzamide,
(6) N-{4-[4-({4-[{[(4-fluorophenyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl } methyl)-3,5-dimethyl-1H-pyrazol- 1-yl]Jphenyl } methanesulfonamide, ©) 4-[4-({4-[{[(4-fluorophenyl)amino]carbony! }(phenyl)amino]-1- piperidinyl } methy!)-3,5-dimethyl-1H-pyrazol-1-yl]-N-{2-(4- morpholinyl)ethyl]benzenesulfonamide,
(8) N-(4-{[5-({4-[{[(2,4-difluorophenyl)amino]carbonyl}(3-thienyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide, ©) 2-chloro-N-methyl-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl} (phenyl)amino]carbonyl }amino)benzamide, (10) N-(4-{[5-({4-[({[4-chloro-3-(4-
morpholinylcarbonyl)phenyl]amino }carbonyl)(phenyl)amino]- 1-piperidiny!} methyl)-2- pyridinyl]oxy } phenyl)methanesulfonamide, 8) 2-fluoro-5-{[((3-fluorophenyl){ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl}-4-piperidinyl }amino)carbonyl]amino }benzamide, (12) N-(3-fluorophenyl)-N'-(6-methyl-3-pyridinyl)-N-[1-({6-[4-
(methylsulfonyl)phenoxy]-3-pyridinyl} methyl)-4-piperidinyljurea, (13) 2-[4-({4-[[({4-fluoro-3- [(methylsulfonyl)amino]phenyl} amino)carbonyl](phenyl)amino]-1- piperidinyl }methyl)phenoxy]-5-[(methylsulfonyl)amino]benzamide,
® ® (14) 2-fluoro-N-methyl-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl } (phenyl)amino]carbonyl }amino)benzamide, (15) 2-fluoro-N-methyl-5-({[[1-({ 6-[4-(methylsulfonyl)phenoxy]-3- pyridinyl }methyl)-4-piperidinyl](phenyl)amino]carbonyl }amino)benzamide, (16) 2-[4-({4-[({[3 -(acetylamino)-4-fluorophenyl]Jamino} carbonyl)(phenyl)amino]- 1-piperidinyl} methyl)phenoxy]-5 -[(methylsulfonyl)amino]benzamide, (17) N-(4-{[5-({4-[{[(6-methyI-3 -pyridinyl)amino]carbonyl} (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyljoxy} phenyl)methanesulfonamid, (18) N-[2-fluoro-5-({[{1-[(6- {4-[(methylsulfonyl)amino]phenoxy }-3- pyridinyl)methyl]-4-piperidinyl }(phenyl)amino]carbonyl} amino)phenyl]acetamide, (19) N-{4-[(5-{[4-((3-fluorophenyl){[(6-methy]-3- pyridinyl)amino]carbonyl }amino)-1 -piperidinyl]methyl}-2- pyridinyl)oxy]phenyl} methanesulfonamide, and (20) N'-(4-fluorophenyl)-N-[1-({ 6-[4-(methylsulfonyl)phenoxy]pyridin-3- yl}methyl)piperidin-4-yl]-N-phenylurea; 19. the compound according to the above-described 11, which is selected from a group the group consisting of* §)) 2-fluoro-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl } (phenyl)amino]carbonyl }amino)benzamide, (2) N-(4-{[5-({4-[{[(6-methyl-3 -pyridinyl)amino carbonyl }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyljoxy} phenyl)methanesulfonamide, 3) N-[2-fluoro-5-({[{1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl}-4-piperidinyl } (phenyl)amino]carbonyl }amino)phenyl]acetamide, and
CG) N-{4-[(5-{[4-((3-fluorophenyl) {[(6-methyl-3- pyridinyl)amino]carbonyl}amino)-1-piperidinyl}Jmethyl } -2- pyridinyl)oxy]pheny! } methanesulfonamide: 20. the compound according to the above-described 11, which is selected from the group consisting of’ (1) 5-[({butyl[ 1-(4-{2-methyl-4-[(methylsulfonyl)amino phenoxy }benzyl)-4- piperidinylJamino} carbonyl)amino]-2,4-difluorobenzamide, 2) N-(4-{[5-({4-[{ [(2,4-difluorophenyf)amino]carbony!} (phenyl)amino]- 1- piperidinyl} methyl)-2-pyridinyl Joxy }-3-methoxyphenyl)methanesulfonamide, 3) N-(4-{[5-({4-[{ [(4-methylphenyl)amino]carbony!} (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy} phenyl)methanesulfonamide, 4) N-(4-{[5-({4-[{ [(4-chlorophenyl)amino]carbonyl} (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy} phenyl)methanesulfonamide, and (5) N-(4-{[5-({4-[{[(4-fluoropheny!)amino]carbonyl }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy } phenyl)acetamide;
® ® 21. the compound according to the above-described 1, which is selected from the group consisting of: (1 2-fluoro-5-({[{ 1-[(6- {4-[(methylsulfonyl)amino phenoxy }-3- pyridinyl)methyl]-4-piperidinyl } (phenyl)amino]carbonyl}amino)benzamide, 5) N-(4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbonyl} (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide dihydrochloride, (3) N-[2-fluoro-5-({[{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl} (phenyl)amino carbonyl }amino)phenyl]acetamide hydrochloride, 4) N-{4-[(5-{[4-((3-fluorophenyl){[(6-methy]-3- pyridinyl)amino]carbonyl }amino)-1-piperidinyl]methyl}-2- pyridinyl)oxy]phenyl}methanesulfonamide dihydrochloride, 5) 5-[({butyl[1-(4-{2-methyl-4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyl]amino} carbonyl)amino]-2,4-difluorobenzamide hydrochloride, (6) N-(4-{ [5-({4-[{[(2,4-difluorophenyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy }-3-methoxyphenyl)methanesulfonamide hydrochloride, ©) N-(4-{[5-({4-[{{(4-methylphenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide, (8) N-(4-{[5-({4-[{[(4-chlorophenyl)amino]carbonyl}(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide, and ©) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl}methyl)-2-pyridinyl}oxy } phenyl)acetamide hydrochloride: 22. a pharmaceutical composition, which comprises the compound according to the above-described 1, a salt thereof an N-oxide thereof, a solvate thereof, or a prodrug thereof; 23. the pharmaceutical composition according to the above-described 22, which is a chemokine receptor antagonist; 24. the pharmaceutical composition according to the above-described 23, which is a CCRS5 antagonist; 25. the pharmaceutical composition according to the above-described 24, which is an agent for treatment and/or prevention for a CCR5-related disease; 26. the pharmaceutical composition according to the above-described 25, wherein the CCRS-related disease is infectious diseases, immunological diseases, inflammatory diseases and/or cardiovascular diseases; 27. the pharmaceutical composition according to the above-described 26, wherein the CCRS-related disease is infection with human immunodeficiency virus, acquired
S12 -
® ® immunodeficiency syndrome, infection with Respiratory Syncytial Virus, rejection in organ transplantation, multiple sclerosis, inflammatory bowel disease, and/or asthma; 28. the pharmaceutical composition according to the above-described 26, wherein the immunological diseases is rejection in organ transplantation; 29. the pharmaceutical composition according to the above-described 22, which is an agent for prevention and/or treatment for infectious diseases, immunological diseases, inflammatory diseases and/or cardiovascular diseases; 30. a medicament comprising a combination of the compound represented by formula (IT) according to the above-described 1, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof, and one or more agent(s) selected from a reverse transcriptase inhibitor, a protease inhibitor, an integrase inhibitor, a CCR2 antagonist, a
CCR3 antagonist, a CCR4 antagonist, a CCRS antagonist, a CXCR3 antagonist, a CXCR4 antagonist, a fusion inhibitor, an antibody against a surface antigen of HIV, and a vaccine of HIV; 31 a medicament comprising a combination of the compound represented by formula (I) according to the above-described 1, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof, and one or more agent(s) selected from an immunosuppressant agent, a nonsteroidal antiinflammatory drug, a disease modifying anti- rheumatic drug, steroids, an antiinflammatory enzyme preparations, a chondroprotective agents, a T-cell inhibitor, a TNFa inhibitor, a prostaglandin synthase inhibitor, an IL-1 inhibitor, an IL-6 inhibitor, an interferon gamma agonist, prostaglandins, a phosphodiesterase inhibitor, and a metalloproteinase inhibitor; 32. a method for preventing or treating a CCRS-related disease in a mammal, which comprises administering to a mammal an effective amount of a compound represented by formula (I) according to the above-described 1, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof: 33. use of a compound represented by formula (I) according to the above-described 1, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof for the manufacture of an agent for prevention and/or treatment of a CCRS-related disease; 34. a pharmaceutical composition according to the above-described 22, which is an inhibitor of cell migration; and 35. a process for preparation of the compound represented by formula (I) according to the above-described 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof.
The "hydrocarbon group” in the "hydrocarbon group which may have a substituent(s)" represented by R'* R'® R'® R'P RM Rf RC RM RV RX and RIL includes, for example, (a) CI1-15 alkyl such as methyl, ethyl, propyl, isopropyl, butyl,
® ® isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl etc ; (b) C3-8 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl efc.; (c) C2-10 alkenyl such as vinyl, allyl, 2-methylallyl, 2- butenyl, 3-butenyl, 3-octenyl etc; (d) C2-10 alkynyl such as ethynyl, 2-propynyl, 3- hexynyl etc; (e) C3-10 cycloalkenyl such as cyclopropenyl, cyclopentenyl, cyclohexenyl etc.; (f) C6-14 aryl such as phenyl, naphthyl ec. (g) C7-16 aralkyl such as benzyl, phenylethyl erc; (h) (C3-8 cycloalkyl)-(C1-4 alkyl) such as cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, 1-methyl-1-cyclohexylmethyl, cyclopropylethyl ec.
The "3- to 15-membered heterocycle" in the "3- to 15-membered heterocyclic group which may have a substituent(s)" represented by R!4 RIB , R'C R'P R'E RF RC,
RH RY R™ and R'" includes a "3- to 15-membered unsaturated heterocycle” or a "3- to 15-membered saturated heterocycle".
The "3- to 15-membered unsaturated heterocycle" includes, for example, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, thiophene, thiopyran, thiepine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, indolizine, benzofuran, 1sobenzofuran, benzothiophene, isobenzothiophene, dithianaphthalene, indazole, quinoline, isoquinoline, quinolizine, purine, phthalazine, pteridine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzimidazole, chromene, benzoxepine, benzoxazepine, benzoxadiazepine, benzothiepine, benzothiazepine, benzothiadiazepine, benzazepine, benzodiazepine, benzofurazan, benzothiadiazole, benzotriazole, carbazole, beta-carboline, acridine, phenazine, dibenzofuran, xanthene, dibenzothiophene, phenothiazine, phenoxazine, phenoxathiin, thianthrene, phenanthridine, phenanthroline, perimidine, pyrroline, imidazoline, triazoline, tetrazoline, pyrazoline, dihydropyridine, tetrahydropyridine, ~~ dihydropyrazine, tetrahydropyrazine, dihydropyrimidine, tetrahydropyrimidine, ~~ dihydropyridazine, tetrahydropyridazine, dihydroazepine, tetrahydroazepine, dihydrodiazepine, tetrahydrodiazepine, dihydrofuran, dihydropyran, dihydrooxepine, tetrahydrooxepine, dihydrothiophene, dihydrothiopyran, dihydrothiepine, tetrahydrothiepine, dihydrooxazole, dihydroisoxazole, dihydrothiazole, dihydroisothiazole, dihydrofurazan, dihydrooxadiazole, dihydrooxazine, dihydrooxadiazine, dihydrooxazepine, tetrahydrooxazepine, dihydrooxadiazepine, tetrahydrooxadiazepine, dihydrothiadiazole, dihydrothiazine, dihydrothiadiazine, dihydrothiazepine, tetrahydrothiazepine, dihydrothiadiazepine, tetrahydrothiadiazepine, indoline, isoindoline, dihydrobenzofuran, dihydroisobenzofuran, dihydrobenzothiophene, dihydroisobenzothiophene, dihydroindazole, dihydroquinoline, tetrahydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, dihydroquinoxaline,
® ® tetrahydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, benzoxathiane, dihydrobenzoxazine, dihydrobenzothiazine, pyrazinomorpholine, dihydrobenzoxazole, dihydrobenzothiazole, dihydrobenzimidazole, dihydrobenzazepine, tetrahydrobenzazepine, dihydrobenzodiazepine, 5S tetrahydrobenzodiazepine, benzodioxepane, dihydrobenzoxazepine, tetrahydrobenzoxazepine, ~~ dihydrocarbazole, tetrahydrocarbazole, dihydroacridine, tetrahydroacridine, dihydrodibenzofuran, dihydrodibenzothiophene, tetrahydrodibenzofuran, tetrahydrodibenzothiophene, dioxaindan, benzodioxane, chroman, benzodithiolane, benzodithiane etc.
The "3- to 15-membered saturated heterocycle" includes, for example, aziridine, azetidine, azocane, pyrrolidine, imidazolidine, triazolidine, tetrazolidine, pyrazolidine, piperidine, piperazine, perhydropyrimidine, perhydropyridazine, azepane (perhydroazepine), perhydrodiazepine, oxirane, oxetane, tetrahydrofuran, tetrahydropyran, perhydrooxepine, thiirane, thietane, tetrahydrothiophene, tetrahydrothiopyran, perhydrothiepine, tetrahydrooxazole (oxazolidine), tetrahydroisoxazole (isoxazolidine), tetrahydrothiazole (thiazolidine), tetrahydroisothiazole (isothiazolidine), tetrahydrofurazan, tetrahydrooxadiazole ~~ (oxadiazolidine), tetrahydrooxazine, tetrahydrooxadiazine, perhydrooxazepine, perhydrooxadiazepine, tetrahydrothiadiazole (thiadiazolidine), tetrahydrothiazine, tetrahydrothiadiazine, perhydrothiazepine, perhydrothiadiazepine, morpholine, thiomorpholine, oxathiane, perhydrobenzofuran, perhydroisobenzofuran, perhydrobenzothiophene, perhydroisobenzothiophene, perhydroindazole, perhydroquinoline, perhydroisoquinoline, perhydrophthalazine, perhydronaphthyridine, perhydroquinoxaline, perhydroquinazoline, perhydrocinnoline, perhydrobenzoxazole, perhydrobenzothiazole, perhydrobenzimidazole, perhydrocarbazole, perhydroacridine, perhydrodibenzofuran, perhydrodibenzothiophene, dioxolane, dioxane, dithiolane, dithiane, i) , a) , a () , w , or in | erc.
The "substituents" in the "hydrocarbon group which may have a substituent(s)" or 3- to 15-membered heterocyclic group represented by RM RB RC RP , R'E RF, RC
R'"™ RY R'™ and R include, for example, (1) nitro, (2) hydroxy group, (3) oxo, (4) thioxo, (5) cyano, (6) carbamoyl, (7) aminocarbonyl substituted by C1-8 hydrocarbon substituted by one or two substituent(s) selected from (a) hydroxyl, (b) amino, (c) C1-4 alkoxy, (d) mono- or disubstituted amino substituted by C1-8 hydrocarbon group, efc., (e) carboxyl, (f) Cl1-6 alkoxy-carbonyl etc. (e.g, N-methylaminocarbonyl, N- ethylaminocarbonyl, N-propylaminocarbonyl, N-butylaminocarbonyl, N- cyclohexylmethylaminocarbonyl, N,N-dimethylaminocarbonyl, N-butyl-N- cyclohexylmethylaminocarbonyl, N-cyclohexylaminocarbonyl, phenylaminocarbonyl, N- (2-methoxyethyl)aminocarbonyl, N-(2-hydroxyethyl)aminocarbonyl, N-(2-
@ ® aminoethyl)aminocarbonyl, N-[2-(N',N'-dimethylamino)ethylJaminocarbonyl, N-(2- carboxyethyl)aminocarbonyl, N-(2-methoxycarbonylethyl)aminocarbonyl, etc), (8) carboxy, (9) Cl1-6 alkoxy-carbonyl such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, zert- butoxycarbonyl, efc., (10)sulfo, (11) halogen such as fluorine, chlorine, bromine or iodine, (12) C1-6 alkoxy which may be substituted by halogen (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, difluoromethoxy or trifluoro, ethoxy), (13) phenoxy, (14) halogenophenoxy such as 0-, m- or p-chlorophenoxy, or o-, m- or p-bromophenoxy ezc., (15) C1-6 alkylthio such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, ferz-butylthio etc, (16) phenylthio, (17) C1-6 alkylsulfinyl such as methylsulfinyl ethylsulfinyl, propylsulfinyl, butylsulfinyl, etc., (18)
C1-6 alkylsulfonyl such as methylsulfony! or ethylsulfonyl, propylsulfonyl, butylsulfonyl, etc., (19) amino, (20) C1-6 lower acylamino such as acetylamino or propionylamino etc. (21) mono- or disubstituted amino substituted by hydrocarbon group (the "hydrocarbon group" has the same meanings as above "hydrocarbon group” and may be substituted by oxo, amino which may be substituted by optional substituents (e.g., hydrocarbon), carbamoyl, halogen or hydroxy group etc.) (e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamino, diethylamino, cyclohexylamino, 1- carbamoyl-2-cyclohexylethylamino, N-butyl-N-cyclohexylmethylamino or phenylamino etc), (22) C1-8 alkanoyl such as formyl or acetyl, propionyl, butyryl, isobutyryl, cyclohexylcarbonyl, efc., (23) C6-10 aryl-C1-4 lower acyl such as benzoyl, benzylcarbonyl, (24) 3- to 15-membered heterocyclic group, which includes 1 to 4 hetero atoms selected from oxygen, sulfur and nitrogen besides carbon atom, and optionally has 1 to 4 substituents selected from (a) halogen such as bromine, chlorine, or fluorine, (b) hydrocarbon optionally substituted by oxo or hydroxy group etc, (the "hydrocarbon group” has the same meanings as above "hydrocarbon group") such as methyl, ethyl, propyl, isopropyl, benzyl, cyclohexyl, cyclohexylmethyl or cyclohexylethyl etc, (c) halogenophenoxy such as o-, m- or p-chlorophenoxy, or o-, m- or p-bromophenoxy esc, and (d) oxo efc., such as thienyl, furyl, pyrazolyl, tetrahydopyranyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyromidinyl, pyridazinyl, quinolyl, isoquinolyl, indolyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, imidazolidinyl, piperidino, morpholino, dihydropyridyl, N-methylpiperazinyl, N- ethylpiperazinyl etc, (25) C1-10 haloalkyl such as difluoromethyl, trifluoromethyl, trifluoroethyl, chloromethyl, dichloromethyl, or trichloroethyl erc., (26) hydroxyimino, (27) akyloxyimino such as methyloxyimino or ethyloxyimino efc, (28) alkylsulfonylamino such as methylsulfonylamino, ethylsulfonylamino or benzylsulfonylamino efc., or (29) arylsulfonylamino such as phenylsulfonylamino or p- toluenesulfonylamino efc., (30) cyclic aminocarbonyl such as 1-aziridinylcarbonyl, 1-
® ® azetidinylcarbonyl, 1-pyrrolidinylcarbonyl, 1-piperidinylcarbonyl, N- methylpiperazinylcarbonyl, morpholinocarbonyl erc, (31) C1-8 hydrocarbon group substituted by 1 or 2 substituents selected from (a) hydroxy, (b) amino, (c) C1-4 alkoxy, (d) mono- or disubstituted amino substituted by C1-8 hydrocarbon group, efc., (e) aminocarbonyl substituted by CI1-8 hydrocarbon group, efc. which may have a substituent(s) (This substituents are selected from, for example, (a) hydroxy, (b) amino, (c)
C1-4 alkoxy, (d) mono- or disubstituted amino substituted by C1-8 hydrocarbon group, efc., (e) carboxy, (f) Cl1-6 alkoxy-carbonyl, and may have 1 or 2 group(s).), such as hydroxymethyl, hydroxyethyl, aminomethyl, methoxymethyl, N,N-dimethylaminomethyl, carbamoylmethyl, N-methylaminovarbonylmethyl, N,N-dimethylaminocarbonylmethyl, etc, (32) (C1-4 alkoxy)-(C1-4 alkyl) group such as methoxyethyl erc, (33) C1-8 alkanoyloxy group such as formyloxy, acetyloxy, propyonyloxy, butyryloxy, isobutyryloxy or cyclohexylcarbonyloxy etc., or benzoyloxy group, (34) amidino group, (35) imino group, (36) C1-8 alkanoylamide group such as formamide, acetamide, trifluoroacetamide, propionylamide, butyrylamide, isobutyrylamide, cyclohexylcarbonylamino erc., 37 benzamide group, (38) carbamoylamino group, (39) N-C1-4 alkylcarbamoylamino group such as N-methylcarbamoylamino, N-ethylcarbamoylamino, N-propylcarbamoylamino, N- 1sopropylcarbamoylamino, N-butylcarbamoylamino efc., (40) N,N-di-C1-4 alkylcarbamoylamino group such as N,N-dimethylcarbamoylamino, = N,N- diethylcarbamoylamino, N,N-dipropylcarbamoylamino, N,N-dibutylcarbamoylamino erc., (41) C1-3 alkylenedioxy group such as methylenedioxy or ethylenedioxy etc, (42) -
B(OH),, (43) epoxy group, (44) mercapto group, (45) sulfino group, (46) phosphono group, (47) sulfamoyl group, (48) C1-6 monoalkylsulfamoyl such as N-methylsulfamoyl, N- ~ ethylsulfamoyl, N-propylsulfamoyl, N-isopropyisulfamoyl or N-butylsulfamoyl efc., (49) di-C1-4 alkylsulfamoyl group such as N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, :
N,N-dipropylsulfamoyl or N,N-dibutylsulfamoyl etc., (50) phenylsulfinyl group, (51) phenylsulfonyl group, (52)azide group, or (53) hydrocarbon group (This "hydrocarbon group" have the same meanings as the above-described "hydrocarbon group", for example, methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, cyclohexenyl, phenyl, naphthyl, benzyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, efc.). The "hydrocarbon group which may have a substituent(s)" or "3- to 15-membered heterocyclic group which may have a substituent(s)" can have 1 to 10 of substituents selected from above (1) to (53). When the number of substituents is two or more, each substituent may be same or different.
The "nitrogen-containing heterocyclic group” in the "nitrogen-containing heterocyclic group which may have a substituent(s)" formed by R'€ and R'® or R!® and RY together with a nitrogen atom to which they bind include, for example, aziridine, azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, perhydropyrimidine,
® ® perhydropyridazine, tetrahydroazepine, azepane (perhydroazepine), tetrahydrodiazepine, perhydrodiazepine, tetrahydrooxazole (oxazolidine), tetrahydrothiazole (thiazolidine), tetrahydrooxazine, perhydrooxazepine, tetrahydrothiazine, perhydrothiazepine, morpholine, thiomorpholine ring, erc.
The "substituents" in the "nitrogen-containing heterocyclic group which may have a substituent(s)" formed by R'® and R'® or R" and RY together with a nitrogen atom to which they bind include have the same meanings as the "substituents" in the "hydrocarbon group which may have a substituent(s)" or "3- to 15-membered heterocyclic group which may have a substituent(s)" has the same meaning as the "hydrocarbon group which may have a substituent(s)" represented by R'* RIB R'¢ RP R'E RF RIC RM RY
R'¥, and R'".
The "spacer containing 1 to 3 atoms as a main chain" represented by X and Y means a space formed by 1 to 3 continued atoms of a main chain. In this case, the "number of atoms as a main chain" should be counted such that the number of atoms as a main chain becomes minimized. The "spacer having from 1 to 3 atoms as a main chain " include, for example, a bivalent group comprising 1 to 3 selected from -CR’R®-, -NR’-, -
CO-, -O-, -S-, -SO-, -SO,- and -C(=N-OR'"%)- (wherein R’ and R® are each independently hydrogen atom, C1-4 alkyl, -OR'" or phenyl, R® is hydrogen atom, C1-4 alkyl or phenyl,
R' and R'! are each independently hydrogen atom or C1-4 alkyl.). In the case, the "C1-4 alkyl" represented by R’ to R!® includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, fert-butyl etc. Concretely, the "spacer having from 1 to 3 atoms as a main chain" include, for example, -CR'R®-, -NR’-, -CO-, -O-, -S-, -C(=N-OR'%)-, -
NR’CO-, -CONR’-, -NR’COCR'R®- or -CONR’CR'R®- (wherein R’-R'® have the same meanings as described above). "C1-2 alkylene" represented by Y is methylene or ethylene.
The "3- to 15-membered carbocyclic group" in the "3- to 15-membered carbocyclic group or heterocyclic group which may have a substituent(s)" represented by ring A and ring B includes, for example, a "3- to 15-membered cyclic hydrocarbon" etc.
The "cyclic hydrocarbon" in the "3- to 15-membered cyclic hydrocarbon" includes, for example, an "unsaturated cyclic hydrocarbon" or a "saturated cyclic hydrocarbon". The "saturated cyclic hydrocarbon" includes, for example, cycloalkane such as cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cycloundecane, cyclododecane, cyclotridecane, cyclotetradecane or cyclopentadecane etc; perhydropentalene;, perhydroazulene; perhydroindene; perhydronaphthalene; perhydroheptalene; spiro[4.4]nonane; spiro[4.5]decane; spiro[5.5]undecane; bicyclo[2.2.1]heptane; bicyclo[3.1.1]heptane; bicyclo[2.2.2]octane; adamantane; noradamantane efc. The "unsaturated cyclic hydrocarbon" includes, for example, cycloalkene such as cyclopentene, cyclohexene, cycloheptene, cyclooctene, _ 18 -
® ® cyclopentadiene, cyclohexadiene, cycloheptadiene or cyclooctadiene efc; benzene; pentalene; azulene; indene; indan; naphthalene; dihydronaphthalene; tetrahydronaphthalene; heptalene; biphenylene; as-indacene: s-indacene; acenaphthene; acenaphthylene; fluorene; phenalene; phenanthrene; anthracene; bicyclo[2.2.1]hept-2-ene; bicyclo[3.1.1]hept-2-ene; bicyclo[2.2.2]oct-2-ene etc.
The "3- to 15-membered heterocyclic group" in "3- to 15-membered carbocyclic group or heterocyclic group which may have a substituent(s)" represented by ring A and ring B have the same meanings as the above-described "3- to 15-membered heterocyclic group" in "3- to 15-membered heterocyclic group which may have a substituent(s)" represented by RA R'E RC R'®, R'E RF RC RH RY R'¥ and R'"
The "substituents" in "3- to 15-membered carbocyclic group or heterocyclic group which may have a substituent(s)" represented by ring A and ring B have the same meanings as the "substituents" in the "hydrocarbon group which may have a substituent(s)" or "3- to 15-membered heterocyclic group which may have a substituent(s)" represented by
R%™ R'™® RC, R'® R'E RF, R'® R™ RY R™ and RY. The 1 to 10 substituents may exist wherever possible. When the number of substituents is two or more, each substituent may be same or different.
The "5- or 6-membered aromatic ring group" in the "S- or 6-membered aromatic ring group which may have a substituent(s)" represented by ring A and ring B, include, for example, benzene, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, triazine, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole or thiadiazole ring etc.
The "substituents" in the "S- or 6-membered aromatic ring group which may have a substituent(s)" represented by ring A and ring B have the same meanings as the "substituents" in the "hydrocarbon group which may have a substituent(s)" or "3- to 15- membered heterocyclic group which may have a substituent(s)" represented by R'4 R'E
RC R'P R'E R'F, RC RH RY RX and R'"™ The 1 to 10 substituents may exist wherever possible. When the number of substituents is two or more, each substituent may be same or different.
The "nitrogen-containing heterocyclic group" in the "3- to 15-membered nitrogen-containing heterocyclic group which may have a substituent(s)" represented by ring D refers to a heterocycle which may contain, in addition to at least one nitrogen atom besides carbon atom, 1 to 3 hetero atoms selected from nitrogen, oxygen and sulfur atoms.
The "3- to 15-membered nitrogen-containing heterocycle" includes a "3- to 15-membered nitrogen-containing unsaturated heterocycle" and "3- to 15-membered nitrogen-containing saturated heterocycle".
The "3- to 15-membered nitrogen-containing unsaturated heterocyclic group" includes, for example, pyrrole, imidazole, triazole, tetrazole, pyrazole, indole, isoindole,
\ _ ® indazole, purine, benzimidazole, benzoazepine, benzodiazepine, benzotriazole, carbazole,
B-carboline, phenothiazine, phenoxazine, perimidine, pyrroline, imidazoline, triazoline, tetrazoline, pyrazoline, dihydropyridine, tetrahydropyridine, dihydropyrazine, tetrahydropyrazine, ~~ dihydropyrimidine, tetrahydropyrimidine, dihydropyridazine, > tetrahydropyridazine, dihydroazepine, tetrahydroazepine, dihydrodiazepine, tetrahydrodiazepine, dihydrooxazole, dihydroisoxazole, dihydrothiazole, dihydroisothiazole, dihydrofurazan, dihydrooxadiazole, dihydrooxazine, dihydrooxadiazine, dihydrooxazepine, tetrahydrooxazepine, dihydrooxadiazepine, tetrahydrooxadiazepine, ~~ dihydrothiadiazole, dihydrothiazine, dihydrothiadiazine, dihydrothiazepine, dihydrothiadiazepine, tetrahydrothiadiazepine, indoline, isoindoline, dihydroindazole, dihydroquinoline, tetrahydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, dihydrobenzoxazine, dihydrobenzothiazine, pyrazinomorpholine, dihydrobenzoxazole, dihydrobenzothiazole, dihydrobenzimidazole, dihydrobenzoazepine, tetrahydrobenzoazepine, dihydrobenzodiazepine, tetrahydrobenzodiazepine, dihydrobenzooxazepine, tetrahydrobenzooxazepine, dihydrocarbazole, tetrahydrocarbazole, dihydroacridine, tetrahydroacridine; or 3- to 15-membered nitrogen-containing saturated heterocyclic group includes, for example, aziridine, azetidine, azocane, pyrrolidine, imidazolidine, triazolidine, tetrazolidine, pyrazolidine, piperidine, piperazine, perhydropyrimidine, perhydropyridazine, azepane (perhydroazepine), perhydrodiazepine, tetrahydrooxazole (oxazolidine), tetrahydroisoxazole (isoxazolidine), tetrahydrothiazole (thiazolidine), tetrahydroisothiazole (isothiazolidine), tetrahydrofurazan, tetrahydrooxadiazole (oxadiazolidine), tetrahydrooxazine, tetrahydrooxadiazine, perhydrooxazepine, perhydrooxadiazepine, tetrahydrothiadiazole ~~ (thiadiazolidine), tetrahydrothiazine, tetrahydrothiadiazine, tetrahydrothiazepine, perhydrothiazepine, perhydrothiadiazepine, morpholine, thiomorpholine, perhydroindazole, perhydroquinoline, perhydroisoquinoline, perhydrophthalazine, perhydronaphthyridine, perhydroquinoxaline, perhydroquinazoline, 30° perhydrocinnoline, perhydrobenzoxazole, perhydrobenzothiazole, perhydrobenzimidazole, perhydrocarbazole, perhydroacridine, i) ) , a) , ww () , ww [) , or rn \ elec.
The "substituents" in the "3- to 15-membered nitrogen-containing heterocyclic group which may have a substituent(s)" represented by ring D have the same meanings as the "substituents" in the "hydrocarbon group which may have a substituent(s)" or "3- to 15- membered heterocyclic group which may have a substituent(s)" represented by R'A R'E
R'“, R'®, R'E, RY R'S, R'™ RY R'X and R'™. The I to 10 substituents may exist
® ® wherever possible. When the number of substituents is two or more, each substituent may be same or different.
The "5- to 10-membered nitrogen-containing heterocyclic group” in the "5- to 10-membered nitrogen-containing heterocyclic group which may have a substituent(s)" represented by ring D refers to "S- to 10-membered nitrogen-containing heterocyclic group" of the above-described "3- to 15-membered nitrogen-containing heterocyclic group” represented by ring D. Examples of pyrrolidine, piperidine, piperazine, azepane, or tropane, efc. are included.
The "substituents" in the "5- to 10-membered nitrogen-containing heterocyclic group which may have a substituent(s)" represented by ring D have the same meanings as the "substituents" in the "hydrocarbon group which may have a substituent(s)" or "3- to 15- membered heterocyclic group which may have a substituent(s)" represented by R'*, R'E,
RC RP R'E RY RC, RM RY, RX and R'"". The 1 to 10 substituents may exist wherever possible. When the number of substituents is two or more, each substituent may be same or different.
The "hydroxy group which may be protected" represented by R? is the "hydroxy group” which may be protected by a "protecting group". The "protecting group" of hydroxy group includes, for example, (1) C1-6 alkyl group (e.g, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, etc.) which may have 1 to 4 of substituents selected from (a) halogen atom such as chlorine, bromine or fluorine etc.; (b) C6-10 aryl such as phenyl or naphthyl etc.; (c) C7-12 aralkyl group such as benzyl or phenylethyl ec ; and (d) nitro group etc, (2) C6-10 aryl (e.g., phenyl or naphthyl efc.) which may have 1 to 4 of substituents selected from (a) halogen atom such as chlorine, bromine or fluorine etc.; (b)
C1-6 alkyl group such as methyl, ethyl or propyl etc. (c) C6-10 aryl such as phenyl or naphthyl etc; (d) C7-12 aralkyl group such as benzyl or phenylethyl etc; and (e) nitro group etc., (3) C7-12 aralkyl group (e.g, benzyl, phenylethyl or naphthylmethyl esc.) which may have 1 to 4 of substituents selected from (a) halogen atom such as chlorine, bromine or fluorine efc.; (b) C1-6 alkyl group such as methyl, ethyl or propyl etc; (c) C6- 10 aryl such as phenyl or naphthyl etc; (d) C7-12 aralkyl group such as benzyl or phenylethyl efc ; and (e) nitro group efc., (4) formyl, (5) C1-6 alkyl-carbony! group (e.g, acetyl or propionyl etc.) which may have 1 to 4 of substituents selected from (a) halogen atom such as chlorine, bromine or fluorine etc ; (b) C1-6 alkyl group such as methyl, ethyl or propyl etc.; (c) C6-10 aryl such as phenyl or naphthyl efc.; (d) C7-12 aralkyl group such as benzyl or phenylethyl efc.; and (e) nitro group ezc., (6) C6-10 aryl-oxycarbonyl group (eg, phenyloxycarbonyl or naphthyloxycarbony! erc.) which may have 1 to 4 of substituents selected from (a) halogen atom such as chlorine, bromine or fluorine efc. ; (b)
C1-6 alkyl group such as methyl, ethyl or propyl etc.; (c) C6-10 aryl such as phenyl or naphthyl etc; (d) C7-12 aralkyl group such as benzyl or phenylethyl etc; and (e) nitro
® group efc., (7) C6-10 aryl-carbonyl group (e.g., benzoyl or naphthylcarbonyl etc.) which may have 1 to 4 of substituents selected from (a) halogen atom such as chlorine, bromine or fluorine etc; (b) C1-6 alkyl group such as methyl, ethyl or propyl etc; (c) C6-10 aryl such as phenyl or naphthyl ezc_; (d) C7-12 aralkyl group such as benzyl or phenylethyl etc. ; and (e) nitro group etc, (8) C7-12 aralkyl-carbonyl group (e.g, benzylcarbonyl or phenethylcarbonyl ezc.) which may have 1 to 4 of substituents selected from (a) halogen atom such as chlorine, bromine or fluorine etc.; (b) C1-6 alkyl group such as methyl, ethyl oo or propyl etc; (c) C6-10 aryl such as phenyl or naphthyl etc; (d) C7-12 aralkyl group such as benzyl or phenylethyl efc ; and (e) nitro group efc., (9) pyranyl or furanyl which may have 1 to 4 of substituents selected from (a) halogen atom such as chlorine, bromine or fluorine etc; (b) C1-6 alkyl group such as methyl, ethyl or n-propyl efc.; (c) C6-10 aryl such as phenyl or naphthyl efc.; (d) C7-12 aralkyl group such as benzyl or phenylethyl efc.; and (e) nitro group etc., or (10) tri-C1-4 alkylsilyl such as trimethylsilyl or triethylsilyl ezc.
The "substituents" in the "amino group which may have a substituent(s)" represented by R? includes hydrocarbon group which may have a substituent(s), -SO,R*" or =NR?*** (wherein R**! and R** is hydrocarbon group which may have a substituent(s)).
The "hydrocarbon group which may have a substituent(s)" has the same meaning as the "hydrocarbon group which may have a substituent(s)" represented by R'* R'E, R! R'P
R'E RF RIC R'"™ RY R™ and R™ The 1 or 2 substituents which amino group has may exist wherever possible. When the number of substituents is two or more, each substituent may be same or different. "Amino group which may have a substituent(s)" represented by R? is 0] 0
ENS or “gst
RST R%2 RS (wherein the arrow represents a binding position to ring D, and R’!, R*?, R™ and R** are each independently hydrogen atom, hydrocarbon group which may have a substituents), 3- to 15-membered heterocyclic group which may have a substituent(s), C1-4 alkoxy group which may have a substituent(s), phenoxy which may have a substituent(s) or benzyloxy which may have a substituent(s).). The "hydrocarbon group which may have a substituent(s)" and "3- to 15-membered heterocyclic group which may have a substituent(s)" have the same meanings as the "hydrocarbon group which may have a substituent(s)" and "3- to 15-membered heterocyclic group which may have a substituent(s)" represented by R'* R'® R! R!P R'E RY RC R'E RY R! K and R'E respectively. "Cl-4 alkoxy group" in the "C1-4 alkoxy group which may have a substituent(s)" includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy,
_ _ isobutoxy, sec-butoxy or tert-butoxy etc. The "substituents" of "Cl-4 alkoxy group which may have a substituent(s)", "phenoxy group which may have a substituent(s)" and "benzyloxy group which may have a substituent(s)" include, for example, the "substituents" in the "hydrocarbon group which may have a substituent(s)" represented by sR R'B RIC R'® RE RIF RIC RM RY RX and R'' ere,
The "hydrocarbon group which may have a substituent(s)" represented by R® have the same meanings as the "hydrocarbon group which may have a substituent(s)" represented by RA R'® RC, R'® R'E RY R'S R'E RY R'¥ and R'"". The 1 to 10 substituents which the hydrocarbon group has may exist wherever possible. When the number of substituents is two or more, each substituent may be same or different. The "hydrocarbon group which may have a substituent(s)" represented by R? is
N al
R52 (wherein the arrow represents a binding position to ring D, and R’* and R*® have the same meanings as described above.)
The "3- to 15-membered heterocyclic group which may have a substituent(s)" represented by R? has the same meanings as the "3- to 15-membered heterocyclic group which may have a substituent(s)" represented by R'* R'® RIC RIP R'E RF RIC R'® RY
RX and R'.
C1-4 alkyl represented by R® includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, etc.
The "hydrocarbon group which may have a substituent(s)" represented by R”! have the same meanings as the "hydrocarbon group which may have a substituent(s)" represented by RA R'E RC, R'P RE, RY R'C, R'™ RY R'¥ and R'".
The "C1-15 alkyl" represented by R’! have the same meanings as the "C1-15 alkyl" as the "hydrocarbon group" in the "hydrocarbon group which may have a substituent(s)" represented by RA R'E RC RP R'E R'E RIC RM RY R'® and R'".
The "aromatic ring group" in the "aromatic ring group which may have a substituent(s)" represented by R’! refers to the "mono-, bi- or tricyclic carbocyclic group or heterocyclic group which have aromaticity” of the "hydrocarbon group" in the "hydrocarbon group which may have a substituent(s)" and "3- to 15-membered heterocyclic group” in the "3- to 15-membered heterocyclic group which may have a substituent(s)" represented by R’*. The "mono-, bi- or tricyclic carbocyclic group which have aromaticity" include, for example, benzene, azulene, naphthalene, phenanthrene, anthracene ring, efc. The "mono-, bi- or tricyclic heterocyclic group which have
® ® aromaticity" include, for example, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, thiadiazole, indole, isoindole, benzofuran, 1sobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, purine, phthalazine, pteridine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzimidazole, benzofurazan, benzothiadiazole, benzotriazole, carbazole, beta-carboline, acridine, phenazine, dibenzofuran, dibenzothiophene, phenanthridine, phenanthroline, perimidine ring, etc.
The "substituents" in the “aromatic ring group which may have a substituent(s)" represented by R*' have the same meanings as the "substituents" in the "hydrocarbon group which may have a substituent(s)" or "3- to 15-membered heterocyclic group which may have a substituent(s)" represented by R'4 R'® R'® RIP RIE RIF , RIS,
R'™ RY R'™ and R'™". The I to 10 substituents may exist wherever possible. When the number of substituents is two or more, each substituent may be same or different.
The "mono- carbocyclic group or mono- heterocyclic group which have aromaticity" represented by R’' refers to monocyclic group of the above-described "aromatic ring group" represented by Rl. Examples of benzene, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole or thiadiazole ring etc. are included.
The "aromatic ring group which may have a substituent(s)" represented by R>® have the same meanings as the above-described "aromatic ring group which may have a substituent(s)" represented by R*!.
Unless otherwise specifically mentioned, all isomers are included in the present invention. For example, alkyl, alkenyl, Alkynyl, alkoxy, alkylthio, alkylene, alkenylene and alkynylene include straight chain and branched ones. Moreover, all of isomers due to double bond, ring and fused ring (E-, Z-, cis- and trans-forms), isomers due to presence of asymmetric carbon(s) efc. (R-, S-, o- and B-configuration, enantiomer and diastereomer), optically active substances having optical rotation (D-, L-, d- and l-forms), polar compound by chromatographic separation (more polar compound and less polar compound), equilibrium compounds, rotational isomers, a mixture thereof in any proportion and a racemic mixture are included in the present invention.
According to the present invention, symbol “Ny represents f-configuration and symbol “nw represents o-configuration, B-configuration or the mixture of them.
There is no particular limitation for the ratio of a-configuration and f3-configuration in the mixture.
® _
Salts: : The salt of the compound of formula (I) includes all of the salt which are non- toxic salts or pharmaceutically acceptable salts. With regard to the pharmaceutically acceptable salts, those which are low-toxic and soluble in water are preferred. Examples of appropriate salts of the compound of formula (I) are salt with alkaline metal (such as potassium, sodium and lithium), salt with alkaline earth metal (such as calcium and magnesium), ammonium salt (such as tetramethylammonium salt and tetrabutylammonium salt), salt with organic amine (such as triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl) methylamine, lysine, arginine and N-methyl-D- glucamine) and acid addition salt [such as inorganic acid salt (e.g., hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate and nitrate) and organic acid salt (e.g, acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, benzoate, citrate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, isothionate, glucuronate and gluconate), efc.]. The salt of the compound of the present invention also includes solvates and also solvates with the above-mentioned alkaline (earth) metal salt, ammonium salt, organic amine salt and acid addition salt. The solvate is preferably low- toxic and water-soluble. Examples of an appropriate solvate are solvates with water and with alcoholic solvent (such as ethanol). The compounds of the present invention are converted to low-toxic salts or pharmaceutically acceptable salts by known methods.
Moreover, the salt includes a quaternary ammonium salt. The quaternary ammonium salt of the compound represented by formula (I) is the compound where nitrogen of the compounds represented by formula (I) is quarternalized by R’ (R® is C1-8 alkyl or C1-8 alkyl substituted by phenyl.).
The salt also includes an N-oxide. The compound of the present invention can be converted into an N-oxide by known methods. The N-oxide is the compound where nitrogen of the compound represented by formula (I) is oxidized.
Prodrugs:
A prodrug of the compound of formula (I) means a compound which is converted to the compound of formula (I) by reaction with an enzyme, gastric acid or the like in the living body. For example, with regard to a prodrug of the compound of formula (I), when the compound of formula (I) has an amino group, compounds in which the amino group is, for example, acylated, alkylated or phosphorylated (e.g, compounds in which the amino group of the compound of formula (I) is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated, acetoxymethylated, tert-butylated, efc.); when the compound of formula (I) has a hydroxyl group, compounds
® where the hydroxyl group is, for example, acylated, alkylated, phosphorylated or borated (e.g, compounds in which the hydroxyl group of the compound of formula (I) is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated or dimethylaminomethylcarbonylated); and that the carboxyl group of the compound of formula (I) is, for example, esterified or amidated (e.g., compounds in which the carboxyl group of the compound of formula (I) is made into ethyl ester, phenyl ester, phenylethyl ester, carboxymethyl ester, dimethylaminomethyl ester, pivaloyloxymethyl ester, ethoxycarbonyloxyethyl ester, phthalidyl ester, (5-methyl-2-oxo0-1,3-dioxolen-4-yl)methyl ester, cyclohexyloxycarbonylethyl ester or methylamide). Those compounds may be produced by a known method per se. The prodrug of the compound of formula (I) may be either a hydrate or a non-hydrate. A prodrug of the compound of formula (I) may also be a compound which is converted to the compound of formula (I) under physiologic condition as described in "Iyakuhin no kaihatsu, Vol.7 (Bunshi-sekkei), pp.163-198 (Hirokawa-Shoten), 1990". And the compound of formula (I) may also be labeled by a radio isotope (such as °H, 4c, 3s 1251 erc)).
All definition represented by R', X,Y, ring A, ring B, ring D, and R? in the formula (I) in the present invention is preferred. All symbols in each preferred group listed below have the same meanings as described above.
Preferred as R' is, for example, -N(R'*)SO,-R'®, -SO,NR'R'?, -§(0),R!®, -
CONR'™RY NR COR", efc., and more preferred is, for example, -N(R'*)SO,-R'E, -
SONR'R'®, -8(0)nR'%, -CONR'RY, etc. Preferred as R'*, R'E, RIC, R'®, R'E, R'E,
RS RM RY” R'¥ and R'™ is, for example, hydrogen atom or hydrocarbon group which may have a substituent(s), efc. Most preferred as R' is, for example, -NHSO,CH;, -
NHSO,CH,CHs, -SO,NHCH;, -SO,CH3, -CONHCH,CH,OCHj, etc.
Preferred as X is, for example, a bond, -CR'R®-, -NR’-, -CO-, -O-, -S-, -SO-, -
SO;-, or -C(=N-OR!9)., efc. More preferably, X is bond, -O-, or -CH,-, etc.
Preferred as Y is, for example, methylene, ethylene or propylene etc. More preferably, Y is methylene, ethylene. Most preferably, Y is methylene.
Preferably, ring A or ring B is, for example, a "5- to10-membered carbocyclic group or heterocyclic group" (it refers to S- to 10-membered carbocyclic group or heterocyclic group of the above-described 3- to 15-membered carbocyclic or heterocyclic group) efc. More preferably is, for example, a "5- tolO-membered unsaturated carbocyclic group or heterocyclic group" (it refers to 5- to 10-membered unsaturated carbocyclic group or heterocyclic group of the above-described 3- to 15-membered carbocyclic or heterocyclic group) etc. More preferred is, for example, S- or 6-aromatic ring such as benzene, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, triazine, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole,
_ ® furazan, oxadiazole or thiadiazole ring etc. Most preferred is, for example, benzene or pyridine ring efc. Preferably, the substituent of ring A or ring B is, for example, hydrocarbon group, alkoxy, halogen atom, carboxy, alkanoylamide, etc, and more preferred 1s, for example, hydrocarbon group, alkoxy, halogen atom, efc., and most preferred is, for example, chloro atom, methyl, or methoxy, etc.
Preferably, ring D is, for example, a "5- to 10-membered nitrogen-containing heterocyclic group” (it refers to 5- to 10-membered nitrogen-containing heterocyclic group of the above-described 3- to 15-membered nitrogen-containing heterocyclic group) etc., and more preferred 1s, for example, tropane, pyrrolidine, piperidine, azepane, or piperazine ring, efc., and most preferred is, for example, piperidine ring. Preferably, ring D has no substituent or 1s substituted by hydrocarbon group, mono-C1-4 alkylamino group or di-C1- 4 alkylamino group efc. More preferably, ring D has no substituent.
Preferred as R® is, for example, hydrocarbon group which may have a substituent(s) or amino group which may have a substituent(s), efc. Preferred as the "substituents" is the "hydrocarbon group which may have a substituent(s)". Concretely, more preferred as R?, for example, 1 ae 0 i
A he
R51 R52 R52 R51 (wherein the arrow represents a binding position to ring D, each R*, R**>, R* and R* has the same meanings as described above.), efc., independently. Preferably, R*', R’*, R* or
R>* is, for example, hydrogen atom, hydrocarbon group which may have a substituent(s) or 3- to 15-membered heterocyclic group which may have a substituent(s) etc. Moreover, the compound wherein either among R** and R* is hydrogen atom is preferred. More preferred as R? is, for example, 0 Zn 0
J Ge or ALR gst H R56 R52 (R> has the same meaning as the "substituents" in the "hydrocarbon group which may have a substituent(s)" represented by R'* R'® R!® R'? R'F RY R'® R™ RY R' and
R'™: nis 0 to 5, and other symbols have the same meanings as described above), efc.
Preferred as R°! is, for example, hydrocarbon group which may have a substituent(s), etc, and more preferred is, for example, C1-15 alkyl which may have a substituent(s), C6-14 aryl which may have a substituent(s), or RR’ etc., and most preferred is, for example, butyl
® or phenyl which may have a substituent(s), etc. Preferred as the substituent is methyl, methoxy, trifluoromethyl, fluorine atom, etc., and more preferred is methyl or fluorine atom. Preferred as R* is, for example, halogen atom, carbamoyl, or aminocarbonyl substituted by C1-8 hydrocarbon group, etc., and more preferred is, for example, fluorine atom, chlorine atom, carbamoyl, N-methylaminocarbonyl, etc. Preferred as nis 1 to 3.
Preferred as R’® is mono- carbocyclic group or mono- heterocyclic group which have aromaticity which may have a substituent(s), and more preferred is benzene, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole or thiadiazole ring which may have a substituent(s), and most preferred is benzene ring which may have a substituent(s).
Preferred as the substituent is methyl, methoxy, trifluoromethyl, fluorine atom, efc., and more preferred is methyl or fluorine atom.
In the present invention, the compound represented by formula (I) including the combination of the above-described preferable group and ring is preferred.
For example, a compound wherein ring D is piperidine and Y is methylene group, ie., a compound represented by formula (la) 0),
X (FR (1a) (wherein all symbols have the same meanings as described above.); a compound wherein ring D is piperidine and Y is methylene group, R%is
Oo
REN RS
N
R51 R52 (wherein all symbols have the same meanings as described above.) , ie, a compound represented by formula (Ib)
SCYCASR x ENO)
RST RS? (wherein all symbols have the same meanings as described above); a compound wherein
X is -O-, Y is methylene group, ring A and ring B are each independently benzene which may have a substituent(s), ring D is piperidine , R%is
0]
JR
SW
(56 R52 (wherein all symbols have the same meanings as described above.) , i.e, a compound represented by formula (Ic) =, N 0)
NS PNR
RST R92 (wherein ring A'* and ring B'* are each independently benzene which may have a substituent(s) and other symbols have the same meanings as described above); a : compound wherein X is -O-, Y is methylene group, ring A and ring B are each independently benzene which may have a substituent(s), ring D is piperidine , R? is 0) ~ 1 Ge,
SNOW g51 H (wherein all symbols have the same meanings as described above.) , i.e., a compound represented by formula (Id) = =
Oo N N 51 H (wherein all symbols have the same meanings as described above.); a compound wherein ring D is tropane ring and Y is methylene group, R? is @)
JL R53
SNOW
56 52 (wherein all symbols have the same meanings as described above.) | ie, a compound represented by formula (Ie)
ROSCA LE hn. _R (le)
X ay
R® [52 (wherein all symbols have the same meanings as described above.); a compound wherein ring D is pyrrolidine ring and Y is methylene group, R? is
O
JIL RS3 ~~ N~
R56 R52 (wherein all symbols have the same meanings as described above.) , i.e, a compound represented by formula (If) 0,0, 5 _R>® (ID
X iy [R56 R52 (wherein all symbols have the same meanings as described above.); a compound wherein ring D is piperidine and Y is methylene group, R? is
O
Mr ha N” 56 R52 (wherein all symbols have the same meanings as described above) , i.e, a compound represented by formula (Ig)
CV OAS EH
53
X NNR (l9)
RSS R52 (wherein all symbols have the same meanings as described above.); a compound wherein ring D is azepane ring and Y is methylene group, R? is 0)
REN R53
N
56 h52
@ ® (wherein all symbols have the same meanings as described above) | ie. a compound represented by formula (Th)
X 53 Ih) vo
R3® R52 (wherein all symbols have the same meanings as described above.), salts thereof, N-oxides thereof, solvates thereof, and prodrugs thereof are preferred.
Preferred are compounds described in Examples, salts thereof, N-oxides thereof, solvates thereof, and prodrugs thereof More preferred are ¢8) 5-({[butyl(1-{4-[4-(methyisulfo nyl)phenoxy]benzyl}-4- piperidinyl)amino]carbonyl} amino)-2,4-difluorobenzamide, 2) 5-[({butyl[ 1-({6-[4-(methylsulfonyl)phenoxy]-3 -pyridinyl } methyl)-4- piperidinyl]amino} carbonyl)amino}-2,4-difluorobenzamide, (3) 5-({[butyl(1-{[6-(4-{ [(2-methoxyethyl)amino]carbonyl }phenoxy)-3- pyridinyljmethyl}-4-piperidinyl)amino]carbonyl} amino)-2,4-difluorobenzamide, 4) 5-{[(butyl{1-[(6-{ 4-[(ethylsulfonyl)amino]phenoxy}-3 -pyridinyl)methyl]-4- piperidinyl}amino)carbonyl]amino} -2,4-difluorobenzamide, 3) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyljoxy}-3 -methoxyphenyl)methanesulfonamide, ©) 5-{[(butyl{ 1-[(6-{2-methyl-4-[(methylsulfonyl)amino]phenoxy }-3- pyridinylymethyl]-4-piperidinyl}amino)carbonylJamino}-2-chloro-4-fluorobenzamide, ©) 2-(5-{[(butyl{ 1-[(6-{4-[(methylsulfonyl)amino] phenoxy}-3-pyridinyl)methyl]- 4-piperidinyl}amino)carbonyl}amino} -2,4-difluorophenyl)acetamide, (8) S-[({butyl[1-(4-{4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyl]amino} carbonyl)amino]-2,4-difluoro-N-methylbenzamide, (9) 5-{[(butyl{ 1-[(6- {4-[(methylsulfonyl)amino phenoxy} -3-pyridinyl)methyl]-4- piperidinyl} amino)carbonyl]amino}-2,4-difluorobenzamide, (10) N-(4-{[5-({4-{{[(4-fluorophenyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]oxy} phenyl)methanesulfonamide, (11) 5-[({butyl[1-(4-{ 4-[(methylamino)sulfonyl]phenoxy }benzyl)-4- piperidinyl]Jamino } carbonyl)amino]-2,4-difluorobenzamide, (12) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl}(3 -thienyl)amino]-1- piperidinyl } methyl)-2-pyridinyljoxy} phenyl)methanesulfonamide,
® ® (13) N-[4-({5-[(4-{3-thienyl[(3-thienylamino)carbonyl]amino}-1- piperidinyl)methyl]-2-pyridinyl} oxy)phenyl]methanesulfonamide, (14) 2-fluoro-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl}-4-piperidinyl}(phenyl)aminoJcarbonyl }amino)benzamide, (15) N-{4-[4-({4-[{[(4-fluorophenyl)amino]carbony! }(phenyl)amino]-1- piperidinyl} methyl)-3,5-dimethyl-1H-pyrazol-1-yl]phenyl} methanesulfonamide, (16) 4-[4-({4-[{[(4-fluorophenyl)amino]carbony! }(phenyl)amino]-1- piperidinyl} methyl)-3,5-dimethyl-1H-pyrazol-1-yl]-N-[2-(4- morpholinyl)ethyl]benzenesulfonamide, (17) N-(4-{[5-( {4-[{[(2,4-difluorophenyl)amino]carbonyl}(3-thieny!)amino]-1- piperidinyl} methyl)-2-pyridinyljoxy } phenyl)methanesulfonamide, (18) 2-chloro-N-methyl-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino] phenoxy}-3- pyridinyl)methyl]-4-piperidinyl}(phenyl)amino]carbonyl } amino)benzamide, (19) N-(4-{[5-({4-[({[4-chloro-3-(4- morpholinylcarbonyl)phenyl}amino} carbonyl)(phenyl)amino]-1 -piperidinyl}methyl)-2- pyridinyljoxy }phenyl)methanesulfonamide, (20) 2-fluoro-5- {[((3-fluorophenyl){ 1 -[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl}amino)carbonyl]amino} benzamide, 21) N-(3-fluorophenyl)-N'-(6-methyl-3-pyridinyl)-N-[ 1-({6-[4-
(methylsulfonyl)phenoxy]-3-pyridinyl} methyl)-4-piperidinyljurea,
(22) 2-[4-({4-[[({4-fluoro-3- [(methylsulfonyl)amino]phenyl}amino)carbonyl](phenyl)amino]-1- piperidinyl}methyl)phenoxy]-5-[(methylsulfonyl)amino]benzamide,
(23) 2-fluoro-N-methyl-5-({[{1-[(6- {4-[(methylsulfonyl)amino] phenoxy}-3-
pyridinyl)methyl]-4-piperidinyl}(phenyl)amino]carbonyl} amino)benzamide,
(24) 2-fluoro-N-methyl-5-({[[1-({6-[4-(methylsulfonyl)phenoxy]-3-
pyridinyl} methyl)-4-piperidinyl}(phenyl)amino]carbonyl }amino)benzamide,
(25) 2-[4-({4-[({[3-(acetylamino)-4-fluorophenyl]amino} carbonyl)(phenyl)amino]- 1-piperidinyl} methyl)phenoxy]-5-[ (methylsulfonyl)amino}benzamide,
(26) N'-(4-fluorophenyl)-N-[1-({ 6-[4-(methylsulfonyl)phenoxy]pyridin-3- yl}methyl)piperidin-4-yl]-N-phenylurea,
27 N-(4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl }methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide, (28) N-[2-fluoro-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy }-3-
pyridinyl)methyl]-4-piperidinyl }(phenyl)amino]carbonyl }amino)phenyl]acetamide, (29) N-{4-[(5-{[4-((3-fluorophenyl){[(6-methyl-3- pyridinyl)amino]carbonyl}amino)-1-piperidinylJmethyl }-2- pyridinyl)oxy]phenyl }methanesulfonamide,
® ® (30) 5-[({butyl[1-(4-{2-methyl-4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyl]Jamino }carbonyl)amino]-2,4-difluorobenzamide, (31) N-(4-{[5-({4-[{[(2,4-difluorophenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy }-3-methoxyphenyl)methanesulfonamide, (32) N-(4-{[5-({4-[{[(4-methylphenyl)amino]carbonyl} (phenyl)amino]-1- piperidinyl } methy!)-2-pyridinyljoxy } phenyl)methanesulfonamide, (33) N-(4-{[5-({4-[{[(4-chlorophenyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide, (34) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy } phenyl)acetamide, salts thereof, N-oxides thereof, solvates thereof, and prodrugs thereof, etc.
Most preferred are 2-fluoro-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy }-3- pyridinyl)methyl}-4-piperidinyl}(phenyl)amino]carbonyl }amino)benzamide,
N-(4-{[5-({4-[{[(6-methy!-3-pyridinyl)amino]carbony! }(phenyl)amino]-1- piperidinyl } methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide,
N-{[2-fluoro-5-({[{1-[(6- {4-[(methylsulfonyl)amino]phenoxy }-3- pyridinyl)methyl]-4-piperidinyl }(phenyl)amino]carbonyl }amino)phenyl]acetamide,
N-{4-[(5-{[4-((3-fluorophenyl){[(6-methyl-3- pyridinyl)amino]carbonyl }amino)-1-piperidinyl]methyl }-2- pyridinyl)oxy]phenyl} methanesulfonamide, 5-[({butyl[1-(4-{2-methyl-4-[(methylsulfonyl)amino]phenoxy} benzyl)-4- piperidinyl]amino} carbonyl)amino]-2,4-difluorobenzamide,
N-(4-{[5-({4-[{[(2,4-difluorophenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy}-3-methoxyphenyl)methanesulfonamide,
N-(4-{[5-({4-[{[(4-methylphenyl)amino]carbonyl}(phenyl)amino]-1- piperidinyl } methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide,
N-(4-{[5-({4-[{[(4-chlorophenyl)amino]carbonyl}(phenyl)amino]-1- piperidinyl }methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide,
N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl}(phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]Joxy }phenyl)acetamide, salts thereof, N-oxides thereof, solvates thereof, and prodrugs thereof, efc.
In the present invention, (1) N-{4-[(5-{[4-((3-methylpheny!){[(6-methy]-3- pyridinyl)amino]carbonyl }amino)-1-piperidinyl]methyl}-2- pyridinyl)oxy]phenyl} methanesulfonamide,
KX)
® 2) N-(2-fluoro-5-{[((3-methylpheny!){ 1-[(6- {4- [(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl}amino)carbonyl]amino} phenyl)acetamide, 3) N-(2-fluoro-5-{[((3-fluorophenyl){ 1-[(6-{4-
[(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino }phenyl)acetamide, 4) N-(2-fluoro-5-{[((3-fluorophenyl){ 1-[(6- {2-methyl-4- [(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino } phenylacetamide,
(5) N-[5-({[{1-{(6-{2-chloro-4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl} (3-fluorophenyl)amino]carbonyl} amino)-2- fluorophenyl]acetamide,
(6) N-{4-[(5-{[4-((3-fluorophenyl){[(6-methyl-3- pyridinyl)amino]carbonyl } amino)-1-piperidinylJmethyl }-2-pyridinyl)oxy]-3-
methylphenyl }methanesulfonamide,
(7 N-{3-chloro-4-[(5-{[4-((3-fluorophenyl){[(6-methy]-3- pyridinyl)amino]carbonyl } amino)-1-piperidinylJmethyl }-2-
pyridinyl)oxy]phenyl}methanesulfonamide,
(8) 2-[(5-{[4-((3-fluorophenyl) {[(6-methyl-3-pyridinyl)amino]carbonyl} amino)-1-
piperidinyl]methyl}-2-pyridinyl)oxy]-5-[(methylsulfonyl)amino]benzamide,
9) 2-[(5-{[4-((3-fluorophenyl){[(6-methyl-3-pyridinyl)amino]carbonyl }amino)-1- piperidinyl]methyl}-2-pyridinyl)oxy]-N-methyl-5-[(methylsulfonyl)amino]benzamide, (10) N-[4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy}-3 -(methylsulfonyl)phenyljmethanesulfonamide, (11) N-{2-[(5-{[4-((3-methylphenyl){[(6-methyl]-3- pyridinyl)amino]carbonyl }amino)-1 -piperidinyl]methyl }-2-pyridinyl)oxy]-5- [(methylsulfonyl)amino]phenyl } acetamide, (12) N-(4-{[5-({4-[[[(4-fluorophenyl)amino](imino)methyl](phenyl)amino]-1- piperidinyl}methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide, (13) N-(4-{[5-( 4-[{[(4-fluorophenyl)amino]carbonothioyl } (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide, (14) 2-fluoro-N-methyl-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-3-azetidinyl} (phenyl)amino]carbonyl}amino)benzamide, (15) N-(4-{[5-({ 3R)-3-[{[(4-fluorophenyl)amino]carbonyl } (phenyl)amino]-1- pyrrolidinyl}methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide, (16) N-[2-fluoro-5-({[{(35)-1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-3-pyrrolidinyl}(phenyl)amino]carbonyl }amino)phenyl acetamide,
& ® 17) N-(4-{[5-({(4R)-4-[{[(6-methyl-3-pyridinyl)amino]carbonyl } (phenyl)amino]- 1-azepanyl}methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide, (18) N-(4-{[5-({(4S)-4-[{[(4-chlorophenyl)amino]carbonyl }(phenyl)amino]-1- azepanyl } methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide, (19) 2-fluoro-5-({[(1-{[6-({4-[(methylsulfonyl)amino}pheny!}sulfonyl)-3-
pyridinyl]methyl}-4-piperidinyl)(phenyl)amino]carbonyl }amino)benzamide, (20) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl}(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJmethyl} phenyl)methanesulfonamide, (21) 2-{[5-({4-[{[(4-chlorophenyl)amino]carbonyl }(3-fluorophenyl)amino}-1-
piperidinyl}methyl)-2-pyridinyl]Joxy }-5-[(methylsulfonyl)amino]benzamide, (22) N-(3-methylphenyl)-N'-(6-methyl-3-pyridinyl)-N-[ 1-({6-[4- (methylsulfonyl)phenoxy]-3-pyridinyl}methyl)-4-piperidinyl urea, (23) N-[1-({6-[4-(ethylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4-piperidinyl]-N-(3- fluorophenyl)-N'-(6-methyl-3-pyridinyl)urea,
(24) N-(3-fluorophenyl)-N-[1-({6-[4-(isopropylsulfonyl)phenoxy]-3- pyridinyl} methyl)-4-piperidinyl]-N'-(6-methyl-3-pyridinyl)urea, (25) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJmethyl} phenyl)ethanesulfonamide, (26) 2-fluoro-5-{[((3-fluorophenyl) {1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-
pyridinyl)methyl]-3-azetidinyl }amino)carbonyl]amino }benzamide, (27) N-(4-{[5-({4-[{[(6-ethyl-3-pyridinyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl}methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide, (28) N-{4-[(5-{[4-((3-fluorophenyl){[(6-methy]-3- pyridinyl)amino]carbonyl} amino)- 1-piperidinyl]methyl }-6-methyl-2-
pyrndinyl)oxy]phenyl} methanesulfonamide, (29) N-[2-[(5-{[4-((3-fluorophenyl}{[(6-methyl-3- pyridinyl)amino]carbonyl } amino)- 1-piperidinyl]methyl }-2-pyridinyl)oxy]-5- (methylsulfonyl)phenyl]acetamide, (30) N-(4-{[5-({4-[{[(6-ethyl-3-pyridinyl)amino]carbonyl } (3-fluorophenyl)amino]-
1-piperidinyl}methyl)-2-pyridinyl]oxy }phenyl)methanesulfonamide, 3D N-{2-{[5-({4-[{[(4-chlorophenyl)amino]carbonyl} (3-flucropheny!)amino]-1- piperidinyl}methyl)-2-pyridinylJoxy}-5-[(methylsulfonyl)amino]phenyl } acetamide, (32) N-{2-[(5-{[4-((3-fluoropheny!){[(6-methyl-3- pyridinyl)amino]carbonyl}amino)- 1-piperidinyl]methyl}-2-pyridinyl)methyl]-5-
[(methylsulfonyl)amino]phenyl}acetamide, (33) N-[4-(5-{[4-((3-fluorophenyl){[(6-methyl-3- pyridinyl)amino]carbonyl } amino)-1-piperidinyl]methyl}-2- pyridinyl)phenyl]methanesulfonamide,
IN
® (34) 2-fluoro-5-({[{ 1-[(2-methyl-6- {4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl}-4-piperidinyl } (phenyl)amino]carbonyl }amino)benzamide, (395) N-{4-[(5-{[4-((3-fluorophenyl){[(6-methy]-3- pyridinyl)amino]carbonyl}amino)-1-piperidinyl]methyl }-2- pyndinyl)sulfonyl]phenyl} methanesulfonamide, (36) N-(4-{[5-({4-[{ [(4-chlorophenyl)amino]carbony!} (3-methylphenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide, 37) N-(4-{[5-({ 4-[{[(4-fluorophenyl)amino]carbonyl}(3-methylphenyl)amino]-1- piperidinyl } methyl)-2-pyridinyljoxy } phenyl)methanesulfonamide, (33) 2-fluoro-5-({[{ 1-[(2-methyl-6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinylymethy1]-4-piperidinyl } (3-methylphenyl)amino]carbonyl}amino)benzamide, 39) N-ethyl-2-fluoro-5-({[{ 1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl }(phenyl)amino]carbonyl }amino)benzamide, (40) 2-fluoro-N-methy!-5-({[{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl } (phenyl)amino]carbonothioyl }amino)benzamide, (4) 2-fluoro-5-{[((3-fluorophenyl){(3S)-1-[(6-{4- [(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-3- pyrrolidinyl }amino)carbonyl]amino } -N-methylbenzamide, (42) N-[5-({[{(45)-1-[(6-{4-[(ethylsulfonyl)amino]phenoxy}-3 -pyridinyl)methyl]- 4-azepanyl}(phenyl)amino]carbonyl}amino)-2-fluorophenyl]acetamide, (43) 2-{[5-({4-[({[3-(acetylamino)-4-fluorophenyl]amino } carbony!)(3- fluorophenyl)amino]-1-piperidinyl} methyl)-2-pyridinyl]oxy }-N-methyl-5- [(methylsulfonyl)amino)benzamide, (44) N-[5-({[{1-[(6-{2-chloro-4-[(ethylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl} (3-fluorophenyl)amino]carbonyl }amino)-2- fluorophenyl]acetamide, (45) 5-({[{(3R)-1-[(6-{4-[(ethylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-3- pyrrolidinyl}(phenyl)amino]carbonyl }amino)-2-fluorobenzamide, (46) N-(3-chloro-4-{[5-({4-[{[(4-chlorophenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide, 47) 5-({[{1-[(6-{2-(aminocarbonyl)-4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl } (3-fluorophenyl)amino}carbonyl }amino)-2-fluoro-N- methylbenzamide, (48) 2-fluoro-N-methy!-5-({{{ 1-[(6-{2-methyi-4- [(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl } (phenyl)amino]carbonyl}amino)benzamide, (49) N-(4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbony! }(phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]sulfonyl } phenyl)methanesulfonamide,
L
® (50) 2-fluoro-N-methyl-5-{[((3-methylphenyl){ 1-[(6-{4- [(methylsulfonyl)amino}phenoxy }-3-pyridinyl)methyl]-4- piperidinyl} amino)carbonyl]amino } benzamide, (51) 2-fluoro-5-{[((3-methylphenyl){ 1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl}amino)carbonyl]amino }benzamide, (52) 2-fluoro-5-{[((3-fluorophenyl){ 1-[(6-{4-[(methylsulfonyl)amino]}phenoxy}-3- pyridinyl)methyl]-4-piperidinyl }amino)carbonyl]amino}-N-methylbenzamide, (53) N-(3-methyl-4-{[5-({4-[ {[(6-methy]-3- pyridinyl)amino]carbonyl}(phenyl)amino]-1-piperidinyl }methyl)-2- pyridinyl]Joxy}phenyl)methanesulfonamide, (54) N-(3-chloro-4-{[5-({4-[ {[(6-methyl-3- pyridinyl)aminoJcarbonyl}(phenyl)amino]-1-piperidinyl methyl)-2- pyridinyl]oxy} phenyl)methanesulfonamide, (55) N-(4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbonyl }(pheny!)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy } phenyl)ethanesulfonamide, (56) N-(4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl } methyl)-2-pyrazinyi]oxy } phenyl)methanesulfonamide, (57) N-(4-{[5-({(3S)-3-[{[(6-methyl-3-pyridinyl)amino]carbonyl} (phenyl)amino]- 1-pyrrolidinyl } methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide, (58) N-(4-{[5-({(4S)-4-[{[(6-methy]-3-pyridinyl)amino]carbonyl } (phenyl)amino]- 1-azepanyl } methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide, (59) N-(4-{[5-({(3R)-3-[{[(6-methyl-3-pyridinyl)amino]carbonyl } (phenyl )amino]- 1-pyrrolidinyl} methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide, (60) 2-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy}-5-[(methylsulfonyl)amino]benzamide, (61) 2-{[5-({4-[({[3-(acetylamino)-4-fluorophenyl]amino } carbonyl)(3- fluorophenyl)amino]-1-piperidinyl} methyl)-2-pyridinyljoxy}-5- [(methylsulfonyl)amino]benzamide, (62) 2-{[5-({4-[{[(4-chlorophenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy}-5-[(methylsulfonyl)amino]benzamide, (63) N-[4-[(5-{[4-((3-fluorophenyl){[(6-methyl-3- pyridinyl)amino]carbonyl } amino)-1-piperidinylJmethyl}-2-pyridinyl)oxy]-3- (methylsulfonyl)phenyl}methanesulfonamide, (64) N-(4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]Jmethyl} phenyl)methanesulfonamide, (65) N-{4-[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]phenyl } methanesulfonamide,
® (66) N-{4-[(5-{[4-((3-methylphenyl){[(6-methyl-3- pyridinyl)amino]carbonyl }amino)-1-piperidinylJmethyl}-2- pyridinyl)oxy]phenyl} methanesulfonamide, 67) N-[5-({[{ 1-[(6-{4-[(ethylsulfonyl)amino]phenoxy } -3-pyridinyl)methyl]-4- piperidinyl }(3-fluorophenyl)amino]carbonyl }amino)-2-fluorophenyl]acetamide, (68) 2-fluoro-5-({[{1-[(6-{ 2-methyl-4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl}(phenyl)amino]carbonyl }amino)benzamide, (69) S-({[{1-[(6-¢ 4-[(ethylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl } (phenyl)amino]carbonyl }amino)-2-fluorobenzamide, and (70) N-{4-[(5-{[4-((3-fluorophenyl) {[(6-methy]-3- pyridinyl)amino]carbonyl } amino)-1-piperidinyl methyl }-2- pyridinyl)oxy]phenyl}ethanesulfonamide, salts thereof, N-oxides thereof, solvates thereof, and prodrugs thereof are also preferable.
Processes for the preparation of the compound of the present invention:
The compound of the present invention represented by formula (I) can be prepared by methods which properly improved and combined known methods, such as methods described below, methods described in Examples or methods described in
Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition (Richard C. Larock, John Wiley & Sons Inc, 1999). In each method described below, a starting material can be used as a salt thereof. An example of the salt includes a salt of compound of formula (I) described above.
Among the compounds represented by formula (I), a compound wherein a spacer which is adjacent with ring D is -CH,-, -CO- or -SO,- can be prepared by alkylation, amidation or sulfonamidation by a compound represented by formula (1)
Y'P—y2P__7P {a (1 xP (wherein Z is hydroxy group or a leaving group (e. g., halogen atom, p-toluenesulfonyloxy group, methanesulfonyloxy group, trifluoro methanesulfonyloxy group erc.), Y'F is a bond or a spacer containing 1 or 2 atoms as a main chain, Y*¥ is -CH,-, -CO- or -SO,-, and RF , x", ring A” and ring B® have the same meanings as R', X, ring A and ring B respectively.
With proviso that, carboxy group, hydroxy group, amino group or mercapto group in R'%,
Xk, YY! Y?* ring AF or ring BF may be protected, if necessary. Other symbols have the same meaning as described above.) and a compound represented by formula (2)
y ® on 0 — R® (2) (wherein R*® and ring D® have the same meanings as R* and D respectively. With proviso that, carboxy group, hydroxy group, amino group or mercapto group in R% or ring
D° may be protected, if necessary.), if necessary, followed by removal of the protecting group.
The alkylation 1s well known. For example, it may be carried out in an organic solvent (e.g., dimethylformamide, dimethylsulfoxide), in the presence of alkaline (e.g, potassium carbonate, sodium carbonate, triethylamine, ezc.), and in the presence or absence of sodium iodide or potassium iodide at about 0 to 150°C.
The amidation is known. For example, it includes the method : (1) via an acyl halide, (2) via a mixed acid anhydride, (3) using a condensing agent.
These methods are explained as follows. (1) The method via an acyl halide may be carried out, for example, by reacting carboxylic acid with an acyl halide (e.g, oxaly! chloride or thionyl chloride) in an organic solvent (e.g., chloroform, dichloromethane, diethyl ether or tetrahydrofuran) or without a solvent at about -20°C to reflux temperature. And then the obtained acyl halide derivative may be reacted with amine in an organic solvent (e.g, chloroform, dichloromethane, diethyl ether or tetrahydrofuran) in the presence of a base (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine or diisopropylethylamine etc.) at about 0 to 40°C. As an alternative, the obtained acyl halide derivative may be reacted with amine in an organic solvent (e.g, dioxane, tetrahydrofuran) using an alkaline aqueous solution (e.g, sodium hydrogen carbonate, sodium hydroxide) at about -78 to 40°C. (2) The method via a mixed acid anhydride may be carried out, for example, by reacting carboxylic acid with an acyl halide (e.g, pivaloyl chloride, p-toluenesulfonyl chloride or methanesulfonyl chloride) ‘or an acid derivative (e.g., ethyl chloroformate or isobutyl chloroformate) in an organic solvent (e.g., chloroform, dichloromethane, diethyl ether, tetrahydrofuran) or without a solvent, in the presence of a base (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine or diisopropylethylamine) at about 0 to 40°C. And then the obtained mixed acid anhydride derivative may be reacted with amine in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran), at about 0 to 40°C. (3) The method using a condensing agent may be carried out, for example, by reacting carboxylic acid with amine in an organic solvent (e.g, chloroform,
» ® dichloromethane, dimethylformamide, diethyl ether or tetrahydrofuran) or without a solvent, in the presence or absence of a base (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine), using a condensing agent (e.g., 1,3-dicyclohexyl carbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl] carbodiimide (EDC), 1,1'-carbodiimidazole (CDI), 2-chloro-1-methylpyridinium iodide, or 1-propanephosphonic acid cyclic anhydride (PPA)), in the presence or absence of 1-hydroxybenzotiazole (HOB), at about 0 to 40°C.
The reaction described in (1), (2) and (3) may be carried out under an inert gas (e.g, argon, nitrogen) to avoid water in order to obtain a preferable result.
The sulfoneamidation is well known. For example, it may be carried out by reacting sulfonic acid with acyl halide (e.g., oxaly! chloride or thionyl chloride, phosphorus pentachloride or phosphorus trichloride) in an organic solvent (e.g, chloroform, dichloromethane, dichloroethane, diethyl ether, tetrahydrofuran or tert-butyl methyl ether) or without a solvent at about -20°C to reflux temperature. And then the obtained sulfonyl halide derivative may be reacted with amine in an organic solvent (e.g., chloroform, dichloromethane, diethyl ether or tetrahydrofuran) in the presence of a base (e.g, diisopropylethylamine, pyridine, triethylamine, dimethylaniline or dimethylaminopyridine efc.) at about 0 to 40°C.
The removal of the protecting group is known and may be carried out by following method.
The carboxyl-protective group includes, for example, methyl, ethyl, allyl, rerz- butyl, trichloroethyl, benzyl (Bn) or phenacyl etc.
The protecting group of hydroxy includes, for example, methyl, trityl, methoxymethyl (MOM), 1-ethoxyethyl (EE), methoxyethoxymethyl (MEM), 2- tetrahydropyranyl (THP), trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldimethylsilyl (TBDMS), fert-butyldiphenylsilyl (TBDPS), acetyl (Ac), pivaloyl, benzoyl, benzyl (Bn), p-methoxybenzyl, allyloxycarbonyl (Alloc), and 2,2,2-trichloroethoxycarbonyl (Troc) etc.
The protecting group of amino includes such as benzyloxycarbonyl, fert- butoxycarbonyl, allyloxycarbonyl (Alloc), 1-methyl-1-(4-biphenyl)ethoxycarbonyl (Bpoc), trifluoroacetyl, 9-fluorenylmethoxycarbonyl (Fmoc), benzyl (Bn), p-methoxybenzyl, benzyloxymethyl (BOM) or 2-(trimethylsilyl)ethoxymethyl (SEM) ezc.
The protective group of mercapto includes, for example, benzyl, methoxybenzyl, methoxymethyl (MOM), 2-tetrahydropyranyl (THP), diphenylmethyl and acetyl (Ac) etc.
With regard to the protective group for carboxyl, hydroxyl, amino and mercapto, there is no particular limitation to the above ones so far as it is a group which is able to be easily and selectively detached. For example, a deprotection reaction may be carried out by a method mentioned in “T. W. Greene, Protective Groups in Organic
Synthesis, John Wiley & Sons Inc, 1999".
PY
®
The reaction for removing the protective group for carboxyl, hydroxyl, amino or mercapto is known and its examples are as follows. (1) a deprotection reaction by hydrolyzing reaction with an alkali: (2) a deprotection reaction under an acidic condition; (3) a deprotection reaction by hydrogenolysis; (4) a deprotection reaction of silyl; (5) a deprotection reaction using a metal; and (6) a deprotection reaction using metal complex.
Those methods will be specifically illustrated as follows. (1) A deprotection reaction using an alkali is carried out, for example, at about 0 to 40°C using a hydroxide of alkaline metal (such as sodium hydroxide, potassium hydroxide and lithium hydroxide), a hydroxide of alkaline earth metal (such as barium hydroxide and calcium hydroxide), a carbonate (such as sodium carbonate and potassium carbonate), an aqueous solution thereof or a mixture thereof in an organic solvent (such as methanol, tetrahydrofuran and dioxane efc.). 2) A deprotection reaction under an acidic condition is carried out, for example, at about 0 to 100°C in an organic acid (e.g., acetic acid, trifluoroacetic acid, methanesulfonic acid or p-toluenesulfonic acid), an inorganic acid (e.g, hydrochloric acid and sulfuric acid) or a mixture thereof (such as hydrogen bromide/acetic acid) in an organic solvent (such as dichloromethane, chloroform, dioxane, ethyl acetate and anisole etc.). 3) A deprotection reaction by hydrogenolysis is carried out, for example, at about 0 to 200°C in a hydrogen atmosphere of ordinary pressure or high pressure or in the presence of ammonium formate in the presence of a catalyst (such as palladium-carbon, palladium black, palladium hydroxide, platinum oxide and Raney nickel) in a solvent [such as an ether type (such as tetrahydrofuran, dioxane, dimethoxyethane and diethyl ether), an alcohol type (such as methanol and ethanol), a benzene type (such as benzene and toluene), a ketone type (such as acetone and methyl ethyl ketone), a nitrile type (such as acetonitrile), an amide type (such as dimethylformamide), water, ethyl acetate, acetic acid or a mixed solvent comprising two or more thereof]. 4) A deprotection reaction of silyl is carried out, for example, at about 0 to 40°C using tetrabutylammonium fluoride in an organic solvent miscible with water (such as tetrahydrofuran and acetonitrile eic.). ©) A deprotection reaction using metal is carried out, for example, at about 0 to 40°C with or without ultrasonic wave in the presence of powdery zinc in an acidic solvent (such as acetic acid, a buffer of pH 4.2 to 7.2 and a mixed solution of a solution thereof with an organic solvent such as tetrahydrofuran). (6) A deprotection reaction using a metal complex is carried out, for example, at about 0 to 40°C using a metal complex [such as tetrakistriphenylphosphine palladium (0), _4] -
® bis(triphenylphosphine) palladium (II) dichloride, palladium (II) acetate and tris(triphenylphosphine) rhodium (I) chloride] in the presence or absence of a phosphine agent (such as triphenyl phosphine) in the presence of a trap reagent (such as tributyltin hydride, triethylsilane, dimedone, morpholine, diethylamine and pyrrolidine), an organic acid (such as acetic acid, formic acid and 2-ethylhexanoic acid) and/or an organic acid salt (such as sodium 2-ethylhexanoate and potassium 2-ethylhexanoate) in an organic solvent (such as dichloromethane, dimethylformamide, tetrahydrofuran, ethyl acetate, acetonitrile, dioxane and ethanol), water or a mixed solvent thereof
Apart from the above, the deprotection may also be effected, for example, according to the methods described in T.W. Greene, Protective Groups in Organic
Synthesis, Wiley, New York, 1999.
As persons skilled in the art can easily understand that the aimed compound of the present invention is able to be easily produced by using appropriate ones among those deprotection reactions.
Among the compounds of the present invention represented by formula (I) , a compound wherein R? is amino group which may have a substituent(s), i.e., a compound represented by formula (I-a)
X
(wherein R*! is amino group which may have a substituent(s) and other symbols have the same meanings as described above) can be prepared by reductive amination of a compound represented by formula (3) p x" (wherein all symbols have the same meanings as described above) and a compound represented by formula (4)
Rn @ ~ R302 (wherein R*®' and R3% which are the same or different, are each a hydrogen atom or have the same meanings as the "substituents" of the above-described " amino group which may have a substituent(s)", and other symbols have the same meanings as described above.
With proviso that, carboxy group, hydroxy group, amino group or mercapto group in R**! -42 - . i
® ® or R3*? may be protected, if necessary.), if necessary, followed by removal of the protecting group.
The reductive amination is well known. For example, it may be carried out with reducing agent (e.g, sodium triacetoxyborohydride or sodium cyanoborohydride) at about 0 to 40°C in an organic solvent (e.g, dichloroethane, dichloromethane or dimethylformamide) in the presence or absence of tertiary amine (e.g, triethylamine or dusopropylethylamine), in the presence or absence of acetic acid.
The removal of the protecting group may be carried out by the above described method.
Among the compound of the present invention represented by formula (I), a compound wherein R? is 0
Sy
RS! R52 : (wherein all symbols have the same meanings as described above), i.e, a compound represented by formula (I-d)
Yo 0 0, DL,
X NH
R>1 R52 (wherein all symbols have the same meanings as described above.) can be prepared by a below reaction using a compound represented by formula (5) vZ xP H (wherein R*'F has the same meaning as R’! and other symbols have the same meanings as described above. With proviso that, carboxy group, hydroxy group, amino group or mercapto group in R’'¥ may be protected, if necessary.) and a compound represented by (©)
R*"—COOH (6) (wherein R>*" has the same meaning as RZ and other symbols have the same meanings as described above. With proviso that, carboxy group, hydroxy group, amino group or mercapto group in R’* may be protected, if necessary), if necessary, followed by removal of the protecting group.
® ®
The reaction is well known. For example, it may be carried out in an organic solvent (e.g., N,N-dimetylformamide, toluene or tetrahydrofuran) with base (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine or diisopropylethylamine) at about 20 to 120°C.
The removal of the protecting group may be carried out by the above described method.
Moreover, the compound represented by formula (I-d) can be prepared by a urea-forming reaction using the compound represented by formula (5) and a compound represented by formula (7)
R%—NH, (7) (wherein the symbol has the same meaning as described above.), if necessary, followed by removal of the protecting group.
The reaction is well known. For example, it may be carried out in an organic solvent (e.g., tetrahydrofuran or N,N-dimetylformamiden) in the presence of triphosgene with base (e.g., triethylamine) at about 0 to 40°C. Moreover, it may be carried out in an organic solvent (e.g., dichloromethane or N,N-dimetylformamiden) in the presence of 1,1'- carbonylbis-1H-imidazole (CDI) with base (e.g., triethylamine or N-methylmorpholine) or without base at about 0 to 80°C.
The removal of the protecting group may be carried out by the above described method.
Among a compound of the present invention represented by formula (I), a compound wherein Y is methylene, i.e., a compound represented by formula (I-€)
H, (a) © a (ie)
X
(wherein all symbols have the same meanings as described above) can be prepared by reductive amination of a compound represented by formula (8) w—{ a?) (&)oro (8)
XP
(wherein all symbols have the same meanings as described above.) and the compound represented by formula (2), if necessary, followed by removal of the protecting group.
The reductive amination and the removal of the protecting group may be carried out by the above described method.
® ®
Among the compounds represented by formula (I), a compound wherein at least one nitrogen atom is quaternary ammonium salt, i.e, a compounds of formula (1-2) 2
Xx? Q (wherein R'"2, R*%, X?, Y2, ring A%, ring B® and ring D* have the same meanings as R!, R?,
X,Y, ring A, ring B and ring D respectively, and N? is nitrogen atom. With the proviso that, at least one nitrogen atom is quaternary ammonium salt, and Q is a halogen ion.) can be prepared by reacting the compound of formula (I) with the compounds of formula (9)
R°—Q (9) (wherein R® is C1-8 alkyl or C1-8 alkyl substituted by phenyl, and Q is halogen.).
The reaction is well known, and it may be carried out, for example, in an organic solvent (acetone, dimethylformamide or methyl ethyl ketone etc.) at about 0 to 40°C.
Among the compounds of formula (I), a compound where at least one nitrogen is N-oxide, i.e, a compound of formula (I-3) 3 x3 (wherein R'>, R*?, X*, Y°, ring A?, ring B® and ring D® have the same meanings as R', R?,
X, Y, ring A, ring B and ring D respectively and N° is nitrogen atom. With the proviso that, at least one nitrogen atom represents N-oxide.) can be prepared by an oxidation of a compound of formula (I).
The oxidation is well known and it may be carried out, for example, in a suitable organic solvent (e.g., dichloromethane, chloroform, benzene, hexane or tert- butylalcohol) in the presence of an excessive oxidizing reagent (hydrogen peroxide, sodium periodate, acyl nitrite, sodium perborate, peroxidized acid (for example, 3- chloroperbenzoic acid or peracetic acid etc), OXONE (brand name, OXONE is an abbreviation for potassium peroxymonosulfate.), potassium permanganate or chromic acid efc.) at about 20 to 60°C.
The compound of the present invention can be prepared by these reactions or reactions modified a part of them.
Other starting compounds or compounds used as reagent are known compounds can be prepared easily by combination of known methods, for example the
® ® methods described in Comprehensive Organic Transformations: A Guide to Functional
Group Preparations, 2nd Edition (Richard C. Larock, John Willey & Sons Inc, 1999) or
Elmer J. Rauckman ef al., J. Org. Chem. vol 41, No.3, 1976, p564-565 etc.
In each reaction of the specification, the reactions with heating, as will be apparent to those skilled in the art, it may be carried with water bath, oil bath, sand bath and microwave.
In each reaction of the specification, it may be used a solid phase reagent which is supported by polymer (for example, polystyrene, polyacrylamide, polypropylene or polyethyleneglycol ezc.).
In each reaction of the specification, the obtained products may be purified by conventional techniques. For example, the purification may be carried out by distillation at atmospheric or reduced pressure, by high performance liquid chromatography with silica gel or magnesium silicate, by thin layer chromatography, by ion-exchange resin, by scavenger resin, by column chromatography, by washing or by recrystallization. The purification may be done each reaction or after several reactions.
In a reaction using polystyrene resin of the specification, the obtained products may be purified by conventional techniques. For example, the purification may be carried out by rinsing them with a solvent (dimethylformamide, dichloromethane, methanol, tetrahydrofuran, toluene, acetic acid/toluene, efc.) more than once.
Toxicity:
The toxicity of the compound represented by formula (I), the salt thereof, the
N-oxide thereof or the solvate thereof, or the prodrug thereof (hereinafter referred to as "the compound of the present invention") is very low and therefore it may be considered safe for pharmaceutical use.
Application to pharmaceuticals:
The compound of the present invention has good solubility and absorbability.
And the compound of the present invention has a week inhibitory activity against drug- metabolizing enzyme. These nature are the physical, chemical, and pharmaceutical property required to drugs, and the compound of the present invention have the proper conditions to an excellent drug [Ref. (The Merck Manual of Diagnosis and Therapy (17"
Ed), Merck & Co))].
It can be assessed that the compound of the present invention is useful as a drug by various experimental methods described below, methods described in Biological
Examples, and their methods which properly improved. It can be also easily assessed that the compound of the present invention has a good pharmacokinetic property such as a length of serum half-life, a stability in the gastrointestinal tract, an absorption of oral
® ® preparations, bioavailability, efc. by known methods, for example, a method described in "Yakubutsu bioavailability (Hyouka to kaizen no kagaku), July 6, 1998, Gendaiiryou-sha", efc. (I) Evaluation experiment of an inhibitory activity against drug-metabolizing enzymes of the compound of the present invention (1) Inhibitory activity against human CYP2C9
Inhibitory activity against human CYP2C9 of the compound of the present invention can be evaluated by a method of Sato ef al. (Yakubutsudotai (Xenobio. Metabol. and Dispos.), 16(2), 115-126 (2001)), which is improved in assaying accuracy and/or assaying sensitivity. (ii) Inhibitory activity against human CYP3A4
Inhibitory activity against human CYP3A4 of the compound of the present invention can be evaluated by an improved method described in Drug Metabolism and
Disposition, Vol.28(12), 1440-1448 (2000).
For example, a reaction solution consisted of potassium phosphate buffer (pH7.4) (final concentration: 200 mM), magnesium chloride hexahydrate (final concentration: 5 mM), substrate (7-benzyloxyquinoline (7-BQ), final concentration: 40 pM), and expression system microsome (Daiichikagakuyakuhin, final concentration: 0.25 mg/mL) is prepared. 100 pL of the reaction solution is dispensed in 96-well plate, and added by 50 pL of an aqueous solution containing test a compound and 0.8% acetonitrile, to carry out 10 minutes of preincubation at 37°C. 50 pL of a reduced nicotinamide adenine dinucleotide phospate (NADPH, 4 mM) is added to initiate a reaction. The fluorescence intensity of each well is measured at the time when NADPH is added and after incubated for 30 minutes. Excitation wavelength at 409 nm and emission wavelength at 530 nm of quinolinol, which is metabolite of substrate, is measured.
Inhibition ratio (%) of the test compound is calculated by the following calculation formula to obtain ICs, value.
Inhibition ratio (%) = [1-{(measured value when a test compound is added) -(blank value)/(control value-blank value)}]x100 (I) Evaluation experiment of a toxicity of the compound of the present invention (1) Single acute toxicity test in rat
The test compound is administered to six-week Crj:CD (SD) rat by single intravenous dose or single oral administration. Toxicity can be evaluated by contrast with
® ® value at no addition of the test compound. Basic evaluation of toxicity can be done by, for example, observation of performance status or locomotor activity, etc. (i1) Evaluation of the activity of the compound of the present invention against hERG I, current
According to the report by Zou et al. (Biophys. J, Vol.74, 230-241 (1998), using HEK293 cell overexpressed of human ether-a-go-go-related gene (hERG), max tale . current of hERG Ik, current induced by depolarization pulse followed by repolarization pulse is measured by patch-clamp recording. Rate of change (inhibition rate) is calculated by comparison max tale current between before addition of the test compound and 10 minutes after. The influence of the test compound against hERG I, current can be evaluated by the inhibition rate
The compounds of the present invention has the antagonistic activity against chemokine receptor, especially CCRS in animal included human, especially human, so they are useful in preventing and/or treating CCRS-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, ezc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection : of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes,
GVHD (graft-versus-host disease), efc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc ), allergic diseases (atopic dermatitis, urticaria, allergic bronchoplumonary aspergillosis, allergic eosinophilic gastroenteritis, etc), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, etc.), acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.
The compounds of the present invention has the inhibitory activity against cell migration in animal included human, especially human, so they are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, efc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, GVHD, efc.), immunosuppression, psoriasis, multiple sclerosis, etc), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc), allergic diseases (atopic dermatitis, urticaria, allergic bronchoplumonary aspergillosis, allergic eosinophilic gastroenteritis, efc.), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, efc.), acute
® ® respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.
For the purpose above described, the compounds of the present invention may be normally administered systemically or locally, usually by oral or parenteral administration.
The doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment. In the human adult, the doses per person are generally from 1 mg to 1000 mg, by oral administration, up to several times per day, and from 1 mg to 100 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration from 1 to 24 hours per day from vein.
As mentioned above, the doses to be used depend upon various conditions.
Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.
The compounds of the present invention may be administered for example, in the form of solid for oral administration, liquid forms for oral administration, injections, liniments or suppositories for parenteral administration.
Solid forms for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules. Capsules include hard capsules and soft capsules.
In such solid forms, one or more of the active compound(s) may be admixed with vehicles (such as lactose, mannitol, glucose, microcrystalline cellulose or starch), binders (such as hydroxypropyl cellulose, polyvinylpyrrolidone or magnesium metasilicate aluminate), disintegrants (such as cellulose calcium glycolate), lubricants (such as magnesium stearate), stabilizing agents, and solution adjuvants (such as glutamic acid or aspartic acid) and prepared according to methods well known in normal pharmaceutical practice. The solid forms may, if desired, be coated with coating agents (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate), or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin.
Liquid forms for oral administration include pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs. In such forms, one or more of the active compound(s) may be dissolved, suspended or emulsified into diluent(s) commonly used in the art (such as purified water, ethanol or a mixture thereof). Besides such liquid forms may also comprise some additives, such as wetting agents, suspending agents, emulsifying agents, sweetening agents, flavoring agents, aroma, preservative or buffering agent.
Injections for parenteral administration include sterile aqueous, suspensions, emulsions and solid forms which are dissolved or suspended into solvent(s) for injection
® ® immediately before use. In injections, one or more of the active compound(s) may be dissolved, suspended or emulsified into solvent(s). The solvents may include distilled water for injection, saline, vegetable oil, propylene glycol, polyethylene glycol, alcohol such as ethanol, or a mixture thereof. Injections may comprise some additives, such as stabilizing agents, solution adjuvants (such as glutamic acid, aspartic acid or
POLYSORBATESO (registered trade mark)), suspending agents, emulsifying agents, soothing agent, buffering agents, preservative. They may be sterilized at a final step, or may be prepared according to sterile methods. They may also be manufactured in the form of sterile solid forms such as freeze-dried products, which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before use.
Other forms for parenteral administration include liquids for external use, ointments and endermic liniments, inhalations, sprays, suppositories and vaginal suppositories which comprise one or more of the active compound(s) and may be prepared by methods known per se.
Sprays may comprise additional substances other than diluents, used ~~ commonly, stabilizers such as sodium hydrogensulfite and buffers capable of imparting isotonicity, for example, isotonic buffers such as sodium chloride, sodium citrate or citric acid.
The compounds of the present invention may be used together with other drugs, for example, preventive and/or treating agent(s) for HIV infection (particularly agents for : prevention and/or treatment for AIDS), or agent(s) for rejection in organ transplantation and/or autoimmune diseases. In that case, the drug as such may be mixed with pharmacologically acceptable excipient, binder, disintegrating agent, lubricant, stabilizer, solubilizer, diluent, efc. either separately or simultaneously to make into a pharmaceutical preparation and that can be administered either orally or parenterally as a pharmaceutical composition for prevention and/or treatment of HIV infection rejection in organ transplantation and/or autoimmune diseases.
The compounds of the present invention have an infection inhibiting activity to
HIV which acquired resistance to other agents for preventive and/or treating HIV infection (particularly agents for prevention and/or treatment for AIDS). Therefore, it is also able to be used for HIV-infected patients to whom other agents for preventive and/or treating
HIV infection are no longer effective. In that case, although the compound of the present invention may be used solely, it may be also used together with agents for preventive and/or treating HIV infection where infected HIV strain acquired resistance or with other drugs.
The present invention covers the combination of the compounds of the present invention with drugs which do not inhibit the HIV infection whereby preventive and/or treating effect for HIV infection is enhanced as compared with a single preparation.
® @
Examples of other agent for preventive and/or treating HIV infection used for a combination with the compounds of the present invention are reverse transcriptase inhibitor, protease inhibitor, chemokine antagonist (such as CCR2 antagonist, CCR3 antagonist, CCR4 antagonist, CCRS antagonist CXCR3 antagonist and CXCR4 antagonist), integrase inhibitor, fusion inhibitor, antibody to surface antigen of HIV and vaccine of HIV.
Reverse transcriptase inhibitors are concretely (1) nucleoside/nucleotide reverse transcriptase inhibitors: zidovudine (brand name: Retrovir), didanosine (brand name: Videx), zalcitabine (brand name: HIVID), stavudine (brand name: Zerit), lamivudine (brand name: Epivir), abacavir (brand name: Ziagen), adefovir, adefovir dipivoxil, emtricitabine (brand name: Coviracil) or PMPA (brand name: Tenofovir) etc. and (2) nonnucleoside reverse transcriptase inhibitors: nevirapine (brand name: Viramune), delavirdine (brand name: Rescriptor), efavirenz (brand name: Sustiva, Stocklin) or capravirine (AG1549) etc.
Protease inhibitors are concretely indinavir (brand name: Crixivan), ritonavir (brand name: Norvir), nelfinavir (brand name: Viracept), saquinavir (brand name: Invirase,
Fortovase), amprenavir (brand name: Agenerase), lopinavir (brand name: Kaletra) or tipranavir efc.
As chemokine antagonists, internal ligand of chemokine receptor, its derivatives, its non-peptide low molecular compound or antibody of chemokine receptor are included.
The examples of internal ligand of chemokine receptor are concretely, MIP-1a,
MIP-18, RANTES, SDF-1a, SDF-1§3, MCP-1, MCP-2, MCP-4, Eotaxin and MDC etc.
The derivatives of internal ligand are concretely, AOP-RANTES, Met-SDF-1a,
Met- SDF-1p3 etc.
Antibodies of chemokine receptor are concretely, Pro-140 etc.
CCR2 antagonists are concretely written in specification of W099/07351,
W099/40913, WO00/46195, WO00/46196, WO00/46197, WOO00/46198, WO00/46199,
WO00/69432 or WO00/69815 or in Bioorg. Med. Chem. Lett. 10, 1803 (2000) etc.
CCR3 antagonists are written in, for example, specification of DE19837386,
W099/55324, WO99/55330, WO00/04003, WO00/27800, WO00/27835, WO00/27843,
WQ000/29377, WOO00/31032, WO00/31033, W0O00/34278, WO00/35449, WO00/35451,
W000/35452, WO00/35453, WO00/35454, W0O00/35876, WO00/35877, WO00/41685,
WO00/51607, WOO00/51608, WO00/51609, W0O00/51610, WO00/53172, WO00/53600,
WO00/58305, WO00/59497, W0O00/59498, W000/59502, WO00/59503, W000/62814, WO00/73327 or WO01/09088 etc.
CCRS antagonists are, for example, TAK-779, SCH-351125 (SCH-C), SCH- 417690(SCH-D), UK-427857, GW873140 (ONO-4128), TAK-220 etc. Moreover, it includes compounds written in, for example, specification of W099/17773, W099/32100,
® ®
WO00/06085, WO00/06146, WO00/10965, WOO00/06153, WO00/21916, WO00/37455,
EP1013276, WO00/38680, WO000/39125, WO000/40239, WO00/42045, WQO00/53 175,
WQO00/42852, WOO00/66551, WO00/66558, WO00/66559, W0O00/66141, WO00/68203,
JP2000309598, WO00/51607, WO00/51608, W0O00/51609, WO00/51610, WO00/56729,
WO000/59497, WO00/59498, W000/59502, WO00/59503, W000/76933, W098/25605,
WO099/04794, WO99/38514, Bioorg. Med Chem. Lett. 11, 2663 (2003), Curr. Med. Chem.
Anti-Infective Agents, 4, 133 (2005), Current Opinion in Pharmacology, 4, 447 (2004), or
Current Opinion in Investigational Drugs, 5, 851 (2004), etc.
CXCR3 antagonists are written in, for example, specification of W0O01/16114,
WO02/083143, WO02/085862, US6469002, or WO03/101970, etc.
CXCR4 antagonists are, for example, AMD-3100, AMD-070, T-22, KRH- 1120, KRH-1636, KRH-2731 or the compounds written in specification of WO00/66112 elc.
Integrase inhibitors are Equisetin, Temacrazine, PL-2500, V-165, NSC-618929,
L-870810, L-708906 analog, S-1360, or 1838, etc.
Fusion inhibitors are concretely, T-20 (Pentafuside) and T-1249 etc.
The examples of combination agents written above are intended to illustrate the present invention, but do not limit them.
The typical examples of the usual the dosage level in clinical trials of reverse transcriptase inhibitors or protease inhibitors written below are intended to illustrate the present invention, but do not limit them.
Zidovudine: 100 mg capsule, 200 mg per dose, 3 times per day; 300 mg tablet, 300 mg per dose, twice per day, didanosine: 25-200 mg tablet, 125-200 mg per dose, twice per day; zalcitabine: 0.375-0.75 mg tablet, 0.75 mg per dose, 3 times per day; stavudine: 15-40 mg capsule, 30-40 mg per dose, twice per day; lamivudine: 150 mg tablet, 150 mg per dose, twice per day; abacavir: 300 mg tablet, 300 mg per dose, twice per day; nevirapine: 200 mg tablet, 200 mg per dose, once per day for 14 days and then twice per day; delavirdine; 100 mg tablet, 400 mg per dose, 3 times per day; efavirenz: 50-200 mg capsule, 600 mg per dose, once per day; indinavir: 200-400 mg capsule, 800 mg per dose, 3 times per day; ritonavir: 100 mg capsule, 600 mg per dose, twice per day; nelfinavir: 250 mg tablet, 750 mg per dose, 3 times per day, saquinavir: 200 mg capsule, 1,200 mg per dose, 3 times per day; amprenavir: 50-150 mg tablet, 1,200 mg per dose, twice per day. _52-
® ®
Examples of other agent for preventive and/or treating rejection in organ transplantation used for a combination with the compounds of the present invention are immunosuppressants.
Examples of the immunosuppressant include tacrolimus (FK506), cyclosporin, sirolimus (rapamycin), corticosteroids, azathioprine, mycophenolate mofetil, FTY-720, cyclophosphamide, or cell-surface ligand antibody, etc.
Examples of the cell-surface ligand antibody include Atgam, Thymoglobulin,
Simulect, Zanapax, or Orthoclone, etc.
Examples of other agent for preventive and/or treating autoimmune diseases used for a combination with the compounds of the present invention are nonsteroidal antiinflammatory drug, disease modifying anti-theumatic drug (DMARDs, slow-acting anti-rheumatic drug), steroids, immunosuppressant agent, antiinflammatory enzyme preparations, chondroprotective agents, T-cell inhibitors, TNFa inhibitor (include protein preparation such as anti-TNFa antibody), prostaglandin synthase inhibitor, IL-1 inhibitor,
IL-6 inhibitor (include protein preparation such as anti-IL-6 receptor antibody), interferon gamma agonists, prostaglandins, phosphodiesterase inhibitor, metalloproteinase inhibitor, etc.
Examples of the nonsteroidal antiinflammatory drug include sasapyrine, sodium salicylate, aspirin, aspirin dialuminate formulation, diflunisal, indomethacin, suprofen, ufenamate, dimethylisopropyl azulen, bufexamac, felbinac, diclofenac, tolmetin sodium, Clinoril, fenbufen, napmetone, proglumetacin, indomethacin farnesil, acemetacin, proglumetacin maleate, amfenac sodium, mofezolac, etodolac, ibuprofen, ibuprofen piconol, naproxen, flurbiprofen, flurbiprofen axethyl, ketoprofen, fenoprofen calcium, tiaprofenen, oxaprozin, pranoprofen, loxoprofen sodium, aluminoprofen, zaltoprofen, mefenamic acid, aluminum mefenamate, tolfenamic acid, floctafenine, ketophenylbutazone, oxyfenbutazone, piroxicam, tenoxicam, anpiroxicam, napageln cream, epirizole, tiaramide hydrochloride, tinoridine hydrochloride, emorfazone, sulpyrine, Migrenin, Saridon, Sedes
G, Amipylo N, Sorbon, pyrine system antipyretics, acetaminophen, phenacetin, dimethothiazine mesylate, simetride formulation, or antipyrine system antipyretics, ec.
Examples of the disease modifying anti-rheumatic drug (DMARDs, slow- acting anti-theumatic drug) include, for example, gold thioglucose, aurothiomalate sodium, auranofin, actarit, D-penicillamine preparations, lobenzarit disodium, bucillamine, hydroxychloroquine, salazosulfapyridine, methotrexate, or leflunomide, etc.
Examples of the steroids for external application include clobetasol propionate, 35s diflorasone acetate, fluocinonide, monometasone furancarboxylate, betamesone dipropionate, betamesone butyropropionate, betamesone valerate, difluprednate, budesonide, diflucortolone valerate, amcinonide, halcinonide, dexamethasone, dexamethasone propionate, dexamethasone valerate, dexamethasone acetate,
® hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone acetopropionate, deprodone propionate, prednisolone valeroacetate, fluocinolone acetonide, beclometasone dipropionate, triamcinonide acetonide, flumethasone pivalate, prednisolone, beclometasone propionate, and fludroxycortide, efc.
Examples of the steroids for internal use or injection include cortisone acetate, hydrocortisone, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, fludrocortisone acetate, prednisolone, prednisolone acetate, prednisolone sodium succinate, prednisolone butylacetate, prednisolone sodium phosphate, halopredon acetate, methyl prednisolone, methyl prednisolone acetate, methyl prednisolone sodium succinate, tnamicinolon, triamicinolon acetate, triamicinonolon acetonide, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, dexamethasone palmitate, paramethasone acetate, and betamethasone, etc.
Examples of the steroids as an inhalant include beclomethasonepropionate, fluticasone propionate, budesonide, flunisolide, triamicinolon, ST-126P, ciclesonide, dexamethasone palomitionate, monometasone furancarboxylate, prasterone sulfonate, deflazacort, methylprednisolone suleptanate, and methylprednisolone sodium succinate, etc.
Examples of the antiinflammatory enzyme preparations include, for example, lysozyme chloride, bromelain, pronase, serrapeptase, or streptokinase-streptodornase, efc.
Examples of the chondroprotective agents include, for example, hyaluronate sodium, glucosamine, chondroitin sulfate, and glucosaminoglycan polysulfate, etc.
Examples of TNFa inhibitor (include protein preparation such as anti-TNF antibody) include, for example, infliximab, adalimumab, or etanercept, etc.
Examples of the prostaglandin synthase inhibitor include, for example, salazosulfapyridine, mesalazine, olsalazine, 4-aminosalicylic acid, JTE-522, auranofin, carprofen, diphenpyramid, flunoxaprofen, flurbiprofen, indomethacin, ketoprofen, lornoxicam, loxoprofen, Meloxicam, oxaprozin, parsalmide, piproxen, piroxicam, piroxicam betadex, piroxicam cinnamate, tropine indomethacinate, zaltoprofen, and pranoprofen, etc.
Examples of IL-1 inhibitor (include protein preparation such as human IL-1 receptor antagonist) include, for example, anakinra, etc.
Examples of IL-6 inhibitor (include protein preparation such as anti-IL-6 receptor antibody) include, for example, MRA, etc.
Examples of the prostaglandins (hereinafter abbreviated as "PG") include PG receptor agonist, and PG receptor antagonist, efc. Examples of the PG receptor include
PGE receptor (EP1, EP2, EP3, and EP4), PGD receptor (DP, CRTH2), PGF receptor (FP),
PGI receptor (IP), or TX receptor (TP), etc.
Examples of the phosphodiesterase inhibitor include, for example, rolipram, cilomilast (trade name: Ariflo), Bay 19-8004, NIK-616, roflumilast (BY-217),
® ® cipamfylline (BGL-61063), atizolam (CP-80633), SCH-351591, YM-976, V-11294A, PD- 168787, D-4396, IC-485, or ONO-6126 as PDE-4 inhibitor, efc.
Examples of other agent for preventive and/or treating other allergic diseases, for example, asthma used for a combination with the compounds of the present invention are steroids, B, adrenoreceptor stimulant, leukotriene receptor antagonist, thromboxane synthetase inhibitor, thromboxane A, receptor antagonist, mediator releasing inhibitor, antihistamines, xanthine derivatives, anticholinergic agent, cytokine inhibitor, prostaglandins, forskolin, phosphodiesterase inhibitor, elastase inhibitor, metalloproteinase inhibitor, expectorant, and antibiotic.
Examples of the (3; adrenoreceptor stimulant include fenoterol hydrobromide, salbutamol sulfate, terbutaline sulfate, formoterol fumarate, salmeterol xinafoate, isoprotenol sulfate, orciprenalin sulfate, chloroprenalin sulfate, epinephrine, trimetoquinol hydrochloride, hexoprenalinmesy! sulfate, procaterol hydrochloride, tulobuterol hydrochloride, tulobuterol, pirbuterol hydrochloride, clenbuterol hydrochloride, mabuterol hydrochloride, ritodrine hydrochloride, bambuterol, dopexamine hydrochloride, meradrin tartrate, AR-C68397, levosalbutamol, R R-formoterol, KUR-1246, KUL-7211, AR- (89855, and S-1319, etc.
Examples of the leukotriene receptor antagonist include pranlukast hydrate, montelukast, zafirlukast, seratrodast, MCC-847, KCA-757, CS-615, YM-158, L-740515,
CP-195494, 1.M-1484, RS-635, A-93178, S-36496, BIIL-284, and ONO-4057, etc.
Examples of the thromboxane synthetase inhibitor include ozagrel hydrochloride, and imitrodast sodium, efc.
Examples of the thromboxane A, receptor antagonist include seratrodast, ramatroban, domitroban calcium dihydrate, and KT-2-962, etc.
Examples of the mediator releasing inhibitor include tranilast, sodium cromoglicate, anlexanox, repirinast, ibudilast, tazanolast, and pemilolast potassium, etc.
Examples of the antihistamines include ketotifen fumarate, mequitazine, azelastine hydrochloride, oxatomide, terfenadine, emedastine fumarate, epinastine hydrochloride, astemizole, ebastin, cetirizine hydrochloride, bepotastine, fexofenadine, lolatadine, deslolatadine, olopatadine hydrochloride, TAK-427, ZCR-2060, NIP-530, mometasone furoate, mizolastine, BP-294, andolast, auranofin, and acribastin, efc.
Examples of the xanthine derivatives include aminophylline, thoeophyline, doxophylline, cipamfylline, and diprophilline, efc. : Examples of the anticholinergic agent include ipratropium bromide, oxitroprum bromide, flutropium bromide, temiverine, tiotropium bromide, and revatropate (UK- 112166), etc.
Examples of the cytokine inhibitor include suplatast tosilate (trade name: IPD), etc.
® ®
Examples of the elastase inhibitors include ONO-5046, ONO-6818, MR-889,
PBI-1101, EPI-HNE-4, R-665, ZD-0892, ZD-8321, GW-311616, and AE-3763 etc.
Examples of the expectorant include foeniculated ammonia spirit, sodium hydrogencarbonate, bromhexine hydrochloride, carbocisteine, ambroxol hydrochloride, sustained release ambroxol hydrochloride, methylcysteine hydrochloride, acetyl cysteine,
L-ethylcysteine hydrochloride, and tyloxapol, etc.
Examples of antibiotics include cefuroxime sodium, meropenem trihydrate, : netilmicin sulfate, sisomicin sulfate, ceftibuten, PA-1806, IB-367, tobramycin, PA-1420, doxorubicin, astromicin sulfate, or cefetamet pivoxil hydrochloride etc.
Examples of antibiotics as an inhalant include PA-1806, IB-367, tobramycin,
PA-1420, doxorubicin, astromicin sulfate, or cefetamet pivoxil hydrochloride, etc.
The other pharmaceutical which supplement and/or enhance the prevention and/or treatment effect of the compound of the present invention is not limited to examples as described above. With regard to other pharmaceuticals which supplement and/or enhance the prevention and/or treatment effect of the compound of the present invention, not only that which has been found up to now but also that which will be found in future on the basis of the above-mentioned mechanism are included.
The nomenclature of compounds of the present invention is described below.
All the compounds described in the present specification were named using
ACD/Name (registered trademark, Advanced Chemistry Development Inc.) or ACD/Name
Batch (registered trademark, Advanced Chemistry Development Inc.), or named according to IUPAC nomenclature system. For example, a compound represented by
H
JL NS 00
N N 0 N
AN - HCI was named N-[6-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl} amino)-1- piperidinyl]methyl}phenoxy)-3-pyridinylJmethanesulfonamide hydrochloride.
In the present specification, "hydrochloride (or dihydrochloride)" means either hydrochloride or dihydrochloride, so it does not represent a mixture of hydrochloride and dihydrochloride. In the present specification, "dihydrochloride (or trihydrochloride)" means either dihydrochloride or trihydrochloride, so it does not represent a mixture of dihydrochloride and trihydrochloride. "-HCI or 2HCI" in the structure described in the present specification means either HCI or 2HCI, so it does not represent a mixture of HCI
® ® and 2HCL. "-2ZHCI or 3HCI" in the structure described in the present specification means either 2HCI or 3HCI, so it does not represent a mixture of 2HCI and 3HCI.
The compounds of the present invention represented by formula (I) has the antagonistic activity against chemokine receptor, especially CCRS, so they are useful in preventing and/or treating CCRS-related diseases.
The fact that the compound of the present invention has CCRS antagonism is demonstrated, for example, by the following experiment. The total operation is based on the basic genetic engineering to prepare gene highly expressing cells, and the ordinary methods are utilized. Also, in the assaying method of the present invention, in order to evaluate the compound of the present invention, accuracy of measurement and/or sensitivity of measurement is improved as described below. The detailed experimental methods are shown below. (I) Inhibition test on the binding of RANTES to CCRS5 (1) Isolation of human CCRS gene
Human placental cDNA is prepared using Marathon cDNA amplification kit (Clontech). PCR primers hCCR5Xbal-F1: 5-AGCTAGTCTAGATCCGTTCCCCTACAAGAAACTCTCC-3' (SEQ ID NO:1) and hCCRS5Xbal-R1: 5'-AGCTAGTCTAGAGTGCACAACTCTGACTGGGTCACCA-3' (SEQ ID NO:2) are designed based on the sequence of GenBank U54994.
Using the human placental cDNA as the template and using Ex Taq (Takara),
PCR reaction (2 minutes at 95°C > (30 seconds at 95°C, 45 seconds at 60°C, 1 minute at 72°C) x 35 times) is carried out. The thus amplified PCR product is subjected to a 1% agarose gel electrophoresis, purified using QIAquick Gel Extraction Kit (QUIAGEN) and then digests with a restriction enzyme Xbal. The digested fragments are ligated to an expression vector pEF-BOS-bsr using DNA Ligation Kit Ver. 2 (Takara) and transformed into Escherichia coli DHSa. By preparing the resulting plasmid pEF-BOS-bsr/hCCRS, its DNA sequence is verified. (2) Culturing of CHO cell
CHO-dhfr(-) 1s cultured using Ham's F-12 (containing fetal bovine serum (10%), penicillin (50 U/ml) and streptomycin (50 mg/ml)). Also, the transduced cell is cultured by adding blasticidin (5 mg/ml) to the above medium.
@ ® (3) Transduction into CHO cell
The plasmid pEF-BOS-bsr/hCCRS is transduced into the CHO-dhfr(-) cell using DMRIE-C reagent (Gibco BRL). After 48 hours, the medium is replaced with a medium containing 5 mg/ml of blasticidin to carry out the selection, thereby establishing a stably over-expressing cell. (4) Inhibition test on the binding of chemokine (RANTES, MIP-1a and MIP-1P) to CCRS (activity of chemokine to induce transient increase of Ca ion).
The thus established stable CHO cell overexpressing human CCRS5 (CCR5/CHO cell) is suspended in Ham's F-12 medium containing FBS (10%) and seeded at a density of 3.0x10° cells/well into a 96-well plate. One day after culturing at 37°C, the culture supernatant is discarded, and Ham's F-12 medium (containing Fura-2AM (5 uM),
Probenecid (2.5 mM) and HEPES (20 mM; pH 7.4)) is dispensed in 80 ul/well portions to carry out 1 hour of incubation at 37°C under shaded condition. After washing twice with 1x Hanks/HEPES (20 mM; pH 7.4) solution, the same solution is dispensed in 100 pl/well portions. Each of the test compounds is added to the thus Fura-2AM-incorporated
CCRS/CHO cell, and 3 minutes thereafter, a recombinant human CCRS ligand (RANTES,
MIP-1a or MIP-18) (PeproTach) diluted with 1x Hanks/HEPES (20 mM; pH 7.4) solution is added thereto to a final concentration (Rantes: 10 nM; MIP-1o.: 30 nM; MIP-1B: 30 nM).
Transient increase in the intracellular Ca®" concentration induced by the human CCRS5 ligand is measured using a Ca®" detector for 96 well use (Hamamatsu Photonics), and inhibition ratio (%) of the test compound is calculated by the following calculation formula.
Inhibition ratio = (Ec — Ea)/Ec x 100
Ec: measured value of Ca®” transient increase by CCRS ligand
Ea: measured value of Ca" transient increase by CCRS ligand when a test compound is added. (II) Migration test of human CCRS5 expressing cell (hCCR5-Ba/F3 cell): (1) Establishment of human CCRS5 expressing cell (1-A) Isolation of human CCRS5 gene
The isolation is carried out according to the method of the isolation of human
CCRS gene as described in the above method (I)-(1). (1-B) Culturing of Ba/F3 cell
Ba/F3 cells are statically cultured by using RMMI-1640 medium (Gibco BRL) containing antibiotics (Antibiotic-Antimycotic) (final concentration: penicillin G sodium (100 U/ml), streptomycin sulfate (100 pg/ml), amphotericin B (0.25 pg/ml) (Gibco BRL),
® _ fetal bovine serum (FBS) (10%), 2-mercaptoethanol (55 uM), mouse interlekin-3 (IL-3) (5 ng/ml) (Pepro Tech, Inc) in a carbon dioxide incubator (temperature: 37°C, CO, concentration: 5%, humidity: 95%). Exogenous gene stable hyperexpression cells are cultured in the above medium to which blasticidin (Kaken Pharmaceutical) is added to give a final concentration of 10 pg/ml. (1-C) Transformation to Ba/F3 cell
A plasmid for human CCRS5 expression (pEF-BOS-bsr/hCCRS5) is digested with Aafl for linearization. The linearized plasmid is purified by QIA quick PCR
Purification Kit (QIAGEN), and introduces into Ba/F3 cells by electroporation (Gene
Pulser (BIO RAD), 960 uF/250V). The cells are seeded into a 96-well culture plate at a density of 1,000, 100, 10 cells/100 ul/well, and cultured for 48 hours. Then, blasticidin is added thereto to give a final concentration of 10 pg/ml, followed by cloning of a blasticidin-resistant cell line to thereby establish a stable clone overexpressing the transfected exogenous gene (hCCR5-Ba/F3 cell). (1-D) Analysis of CCRS expression
The human CCRS5 expression level in the clone obtained by the method described in the above (1-C) is detected with FAC Sort (trade name, Becton, Dickinson) by detecting the cells with a fluorescence isothiocyanate (FITC)-labeled anti-human CCRS antibody (BD Pharmingen) and analyzed. In this connection, FITC-labeled mouse
IgG2ax (BD Pharmingen) is used as an isotype control antibody. (2) Cell migration test
Influence of a test compound on the migration ability of the human CCRS expressing Ba/F3 cell against RANTES, MIP-1a or MIP-1f is examined. First, 0.3 ml of 0 or 3 nM chemokine (RANTES, MIP-1a or MIP-1f)-containing medium is respectively added to the low room of Chemo T x 96 well plate (Neuro Probe). Next, a filter (pore size: S um) is set and a mixture solution (1x10° cells/well) of the test compound and the
CCR5-Ba/F3 cell prepared in advance is added at 65 ul. The test compound to be added is prepared by diluting it with 0.1% DMSO-containing medium to give a final concentration on the filter of 0, 0.01, 0.03, 0.1 or 0.3 uM. These cells are cultured in a
CO; incubator (37°C, 5% CO. relative humidity: 95%) for 3 hours, and then the medium and unmigrated cells on the filter are eliminated. Furthermore, the filter is removed, the microplate 1s centrifuged (1,500 rpm, 10 min, RT) and the supernatant is removed by decantation. The cells on the microplate are suspended in 100 ul of a phosphate buffer (PBS), and 1/10 portion thereof is further diluted with 90 pl of PBS, moves on a white
® plate for fluorescence assay, and uses as an assay sample for migrated cell numbers (final: 100 ul/well).
Next, Cell Titer-Glo Reagent (trade name, Promega) which is previously prepared at room temperature is added to the above assay sample for migrated cell numbers (100 upl/well), followed by gently mixing (300 rpm, 2 min with KA-
SCHUTTLER MTS4) for lysating the cells, the mixture is incubated at room temperature for 10 minutes, and the fluorescence is measured with wallac ARVO SX 1420
MULTILABEL COUNTER (trade name, Perkin Elmer) (detection by count/second).
The migrated cell numbers (naturally falling cell numbers) at a chemokine concentration of 0 nmol/l is used as the background, and the inhibition ratio of the test compound against the 0.1% DMSO control group is calculated.
The inhibition migration ratio (%) of the test compound is calculated by the following equation:
Inhibition ratio =—ESEa 10
Ec
Ec: (fluorescence measured value at the addition of 0.1% DMSO) - (fluorescence measured value of the naturally falling cells)
Ea: (fluorescence measured value at the addition of the test compound) - (fluorescence measured value of the naturally falling cells)
The following Preparation Examples, Biological Examples and Formulation
Examples are intended to illustrate the present invention, but do not limit them.
In chromatographic separations and TLC, the solvents in parenthesis show the eluting and developing solvents and the ratios of the solvents used are by volume.
NMR is a measured value of '"H NMR. The solvents in parenthesis in NMR show the solvents used for measurement.
Preparation Example
Example l
N-[6-(4-formylphenoxy)pyridin-3-yl]methanesulfonamide {4-[(5-nitropyridin-2-yl)oxy]phenyl}methanol was subjected to reduction of nitro group by using zinc and acetic acid, the obtained compound reacted with methanesulfonyl chloride in pyridine, and the obtained compound was subjected to oxidation by using manganese dioxide to give the title compound having the following physical data.
TLC: Rf 0.67 (dichloromethane : methanol =9 : 1);
Te
NMR (CDCl): 6 3.04, 6.56, 7.05, 7.29, 7.80, 7.94, 8.08, 9.99.
Example 2
N-butyl-N'-(2,4-difluorophenyl)-N-piperidin-4-ylurea hydrochloride
To a solution of tert-butyl 4-(butylamino)piperidin-1-carboxylate (1 g) in dimethylacetamide (13 ml) was added triethylamine (1.6 ml) and 2,4-difluorophenyl isocyanate (907 mg). The reaction mixture was stirred for 5 minutes at room temperature.
To reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and extracted with ethyl acetate. The extract was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. To the solution of the obtained compound (1.28 g) in ethyl acetate (2 ml) was added 4N hydrogen chloride in ethyl acetate solution (10 ml). The reaction mixture was stirred for 20 minutes at room temperature, and concentrated. The obtained residue was washed with tert-butyl methyl ether, dried to give the title compound having the following physical data.
TLC: Rf0.52 (dichloromethane : methanol : acetic acid =5: 1: 0.1);
NMR (CDsOD): 6 0.99, 1.34-1.47, 1.60-1.71, 1.95-2.01, 2.08-2.22, 3.03-3.13, 3.27-3.34, 3.44-3.50, 4.13, 7.00, 7.37, 8.01.
Example 3
N-[6-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl }amino)-1- piperidinyl]methyl} phenoxy)-3-pyridinylJmethanesulfonamide hydrochloride (or dihydrochloride)
H
BS NS 00
I N N Oo N oo - HCl or 2HCI
To a solution of the compound prepared in Example 1 (95 mg) and the compound prepared in Example 2 (80 mg) in dimethylformamide (1.5 ml) was added acetic acid (0.15 ml) and sodium triacetoxyborohydride (116 mg). The reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by column chromatography on silica gel (ethyl acetate : methanol = 10 : 1).
To a solution of the obtained compound was added 4N hydrogen chloride in ethyl acetate
_ solution. The reaction mixture was concentrated to give the title compound (115 mg) having the following physical data.
TLC: Rf 0.44 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): 4 0.98, 1.35-1.48, 1.58-1.70, 1.95-2.08, 2.18-2.34, 3.00, 3.08-3.20, 3.25- 3.34,3.57-3.65,4.19, 4.34, 6.89-7.03, 7.09, 7.25, 7.38, 7.60, 7.85, 8.06.
Examples 3(1)-3(107)
By the same procedure as described in Example 3 using the corresponding amine compounds and the corresponding aldehyde compounds, the following compounds of the present invention were obtained.
Example 3(1)
N-{4-[(6-{[4-(butyl {[(2,4-difluorophenyl)amino]carbonyl }amino)-1-piperidinyl methyl }- 3-pyridinyl)oxy]phenyl} methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.30 (chloroform : methanol = 10 : 1);
NMR (CD;OD): 6 0.99, 1.30-1.50, 1.60-1.80, 1.90-2.10, 2.20-2.40, 2.97, 3.20-3 40, 3.60- 3.70, 4.20, 4.47, 6.92-7.02, 7.09-7.12, 7.31-7.40, 7.47-7.58, 8.45.
Example 3(2)
N-{4-[4-({4-[{[(2-hydroxybutyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl} methyl)phenoxy]phenyl} methanesulfonamide hydrochloride
TLC: Rf 0.41 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 0.89, 1.20-1.42, 1.55-1.70, 2.05-2.17, 2.95, 3.08-3.28, 3.37-3.50, 4 21, 4.51,7.00,7.02,7.21-7.30, 7.41, 7.44-7.55.
Example 3(3)
N-{4-[4-({4-[butyl({[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]amino } carbonyl)amino]-1- piperidinyl} methyl)phenoxy]phenyl} methanesulfonamide dihydrochloride
TLC: Rf 0.40 (dichloromethane : methanol = 9 : 1);
NMR (CD;0OD): § 0.97, 1.31-1.42, 1.50-1.72, 1.91-2.01, 2.15-2.31, 2.95, 3.10-3.32,3.51- 3.60,3.87,4.23,4.30,4.35,7.03, 7.06, 7.29, 7.53, 7.98, 8.12.
Example 3(4) 5-[({butyl[1-(4-{4-[(methylsulfonyl)amino]phenoxy}benzyl)-4- piperidinyl]amino}carbonyl)amino]-2,4-difluoro-N-methylbenzamide hydrochloride
H
Oo N_
CH; H
F N_ _CH 0 N Bo \
A he
N N Oo
F H
EN + HCI
TLC: Rf 0.90 (chloroform : methanol = 4 : 1);
NMR (CD;OD): 6 0.97, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.10-2.30, 2.91, 2.95, 3.00-3.20, 3.20-3.40,3.50-3.60, 4.15, 4.29, 7.02-7.09, 7.12, 7.29, 7.50, 7.78.
Example 3(5)
N-{4-[4-({4-[{[(#rans-4-hydroxycyclohexyl)amino carbonyl } (phenyl)amino]-1- piperidinyl}methyl)phenoxy]phenyl } methanesulfonamide hydrochloride
TLC: Rf 0.46 (dichloromethane : methanol = 9 : 1);
NMR (CD;0D): 6 1.00-1.18, 1.21-1.37, 1.55-1.68, 1.71-1.89, 2.04-2.15, 2.95, 3.04-3.18, 3.38-3.54, 4.21, 4.60, 6.98-7.07, 7.18-7.23, 7.28, 7.41, 7.45-7.53.
Example 3(6)
N-[4-(4-{[4-(3-butenyl{[(2-hydroxybutyl)amino]carbonyl}amino)-1- piperidinyljmethyl} phenoxy)phenyl]methanesulfonamide hydrochloride
TLC: Rf 0.51 (dichloromethane : methanol = 9 : 1);
NMR (CD;0D): 8 0.95, 1.30-1.58, 1.90-2.00, 2.07-2.24, 2.28-2.38, 2.95, 3.02-3.35, 3.50- 3.60, 4.12, 4.28, 5.05, 5.11, 5.81, 7.03, 7.06, 7.29, 7.50.
Example 3(7)
N-butyl-N'-(2,4-difluorophenyl)-N-(1-{4-[4-(4-morpholinylsulfonyl)phenoxy]benzyl} -4- piperidinyl)urea hydrochloride
TLC: Rf 0.60 (dichloromethane : methanol = 20 : 1);
NMR (CDs0D): 6 0.99, 1.39-1.43, 1.60-1.70, 2.00-2 05, 2.16-2.30, 2.94-2.97, 3.06-3.28, 3.29-3.36, 3.52-3.61,3 69-3.72, 4.13, 4.23, 6.90-7.03, 7.20, 7.23, 7.37, 7.58. 7.78.
Example 3(8)
N-butyl-2-(2,4-difluorophenyl)-N-[1-(4-{4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyl]acetamide hydrochloride
TLC: Rf 0.41 (chloroform : methanol = 10 : 1);
®
NMR (ds-DMSO): & 0.92, 1.20-1.40, 1.40-1.60, 1.70-1.90, 2.20-2.40, 2.90-3.10, 2.97, 3.15-3.30, 3.30-3.50, 3.71, 4.05-4.30, 6.94-7.09, 7.12-7.25, 7.57, 9.34, 10.50.
Example 3(9)
N-{4-[(5-{[4-(butyl{[(1-methyl-1H-pyrazol-4-yl)amino]carbonyl}amino)-1- piperidinyl]methyl}-2-pyridinyl)oxy]phenyl } methanesulfonamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.16 (chloroform : methanol = 10 : 1);
NMR (CD;OD): 6 0.96, 1.30-1.45, 1.50-1.65, 1.90-2.05, 2.20-2.35, 2.98, 3.10-3.40, 3.50- 3.70, 4.00, 4.20, 4.36, 7.09-7.16, 7.32, 7.95, 8.06, 8.08, 8.31.
Example 3(10)
N-(4-{4-[(4-{{[(4-fluorophenyl)amino]carbonyl }[4-(methylsulfanyl)phenyl]amino}-1- piperidinyl)methyl]phenoxy } phenyl)methanesulfonamide hydrochloride
TLC: Rf 0.67 (dichloromethane : methanol =9 : 1);
NMR (CD;0D): 8 1.60-1.79, 2.10-2.20, 2.51, 2.95, 3.08-3.20, 3.42-3.55, 4.22, 4.64, 6.95, 7.02,7.03, 7.15-7.31, 7.39, 7.42.
Example 3(11)
N-(4-{4-[(4-{{[(4-fluorophenyl)amino]carbonyl }[3-(methylsulfanyl)phenyl]amino}-1- piperidinyl)methyl]phenoxy } phenyl)methanesulfonamide hydrochloride
TLC: Rf 0.67 (dichloromethane : methanol =9 : 1);
NMR (CD;O0D): & 1.62-1.80, 2.12-2.20, 2.51, 2.95, 3.04-3.22, 3.42-3.57, 4.22, 4.64, 6.89- 7.10, 7.17-7.32, 7.34-7.49.
Example 3(12)
N-butyl-2,4-difluoro-N-[1-(4-{4-[(methylsulfonyl)amino}phenoxy } benzyl)-4- piperidinyl]benzamide hydrochloride
TLC: Rf 0.41 (chloroform : methanol = 10 : 1);
NMR (dg-DMSO): § 0.70-0.90, 1.10-1.30, 1.40-1.60, 1.75-1.90, 2.30-2.55, 2.80-3.05, 2.96, 3.10-3.45, 4.00, 4.17, 7.00, 7.01-7.04, 7.12, 7.19-7.30, 7.42, 7.57, 9.35.
Example 3(13)
N-(4-{4-[(4-{{[(4-fluorophenyl)amino]carbonyl }[4-(methylsulfinyl)phenyl]amino}-1- piperidinyl)methyl}phenoxy } phenyl)methanesulfonamide hydrochloride
TLC: Rf 0.47 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): & 1.67-1.83, 2.14-2.23, 2.84, 2.95, 3.10-3.21, 3.46-3.55, 4.23, 4.67, 6.96, 7.00,7.02, 7.23, 7.28,7.43,7.54, 7.84.
_ ( }
Example 3(14)
N-(4-{4-[(4-{ {[(4-fluorophenyl)amino]carbonyl}[3-(methylsulfinyl)phenyl]amino}-1- piperidinyl)methyl]phenoxy } phenyl)methanesulfonamide hydrochloride
TLC: Rf 0.47 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 6 1.62-1.80, 2.14-2.25, 2.86, 2.95, 3.08-3.21, 3.47-3.55, 4.23, 4.66, 6.96, 7.01, 7.02, 7.20-7.30, 7.42, 7.51, 7.66, 7.70-7.80.
Example 3(15) N-(4-{4-[(4- {{[(4-flucrophenyl)amino}carbonyl}{4-(methylsulfonyl)phenyl}jamino}-1- piperidinyl)methyl]phenoxy } phenyl)methanesulfonamide hydrochloride
TLC: Rf 0.54 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): & 1.70-1.88, 2.14-2.23, 2.95, 3.10-3.20, 3.16, 3.46-3.55, 4.23, 4.64, 6.96, 7.01, 7.02, 7.24, 7.28, 7.43, 7.57, 8.08.
Example 3(16)
N-(4-{4-[(4-{{[(4-fluorophenyl)amino]carbonyl}[3-(methylsulfonyl)phenyl]amino }-1- piperidinyl)methyl]phenoxy } phenyl)methanesulfonamide hydrochloride
TLC: Rf 0.54 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): & 1.64-1.80, 2.17-2.28, 2.95, 3.10-3.21, 3.19, 3.45-3.55, 4.23, 4.67, 6.96, 7.01,7.02, 7.24, 7.28, 7.42, 7.66, 7.78, 7.89, 8.05.
Example 3(17)
N-[4-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl }amino)-1- piperidinyl]methyl}phenoxy)-3-methoxyphenyl]methanesulfonamide hydrochloride
TLC: Rf 0.50 (chloroform : methanol = 10 : 1);
NMR (CD;0D): § 0.97, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.15-2.30, 2.99, 3.05-3.20, 3.20- 3.40,3.50-3.60,3.74, 4.15, 4.25, 6.85-6.95, 6.99, 7.03, 7.38, 7.43.
Example 3(18) 5-{[(butyl{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl } amino)carbonyl]amino}-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
® ®
HoN 0
H
EOC TE" on “0 00
Fon "en, HCl or 2HCI
TLC: Rf 0.41 (chloroform : methanol = 10 : 1);
NMR (CD;0D): § 0.98, 1.30-1.45, 1.55-1.70, 1.95-2.10, 2.15-2.35, 2.98, 3.05-3.20, 3.25- 3.35,3.50-3.65, 4.15, 4.34, 7.09-7.18, 7.33, 7.86, 8.03, 8.28.
Example 3(19) 5-{[(butyl{ 1-[(5-{4-[(methylsulfonyl)amino]phenoxy}-2-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]Jamino}-2,4-difluorobenzamide dihydrochloride
TLC: Rf 0.36 (chloroform : methanol = 10 : 1);
NMR (CD30D): 6 0.99, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.20-2.40, 2.96, 3.20-3.40, 3.60- 3.70, 4.20, 4.45, 7.10, 7.15, 7.33, 7.44-7.50, 7.87, 8.44.
Example 3(20) 5-[({butyl[1-(4-{2-methoxy-4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinylJamino } carbonyl)amino]-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.34 (chloroform : methanol = 10 : 1);
NMR (CDs0D): 6 0.97, 1.30-1.50, 1.55-1.70, 1.90-2.10, 2.10-2.30, 2.99, 3.05-3.20, 3.20- 3.40, 3.50-3.60, 3.74, 4.15, 4.25, 6.87, 6.92, 7.03, 7.14, 7.42, 7.85.
Example 3(21) 5-[({butyl[1-(4-{2-chloro-4-[(methylsulfonyl)amino]phenoxy }benzy!)-4- piperidinylJamino } carbonyl)amino]-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.33 (chloroform : methanol = 10 : 1);
NMR (CD;OD): § 0.97, 1.30-1.50, 1.55-1.70, 1.90-2.10, 2.10-2.30, 3.01, 3.10-3 20, 3.25- 3.35,3.50-3.60, 4.15, 4.28, 6.99, 7.13, 7.14, 7.24, 7.43, 7.50, 7.85.
Example 3(22) 4-(4-{ [4-(buty] {[(2,4-difluorophenyl)amino]carbonyl}amino)-1- piperidinyl]methyl}phenoxy)-N-(2-hydroxyethyl)benzenesulfonamide hydrochloride
TLC: Rf 0.69 (dichloromethane : methanol = 10 : 1);
NMR (CD3;O0D): 6 0.98, 1.36-1.43, 1.59-1.70, 1.98-2.03, 2.18-2.30, 2.96, 3.09-3.30, 3.54, 3.54-3.61, 4.16, 4.33, 6.90-7.03, 7.16, 7.20, 7.37, 7.59, 7.86.
®
Example 3(23) 4-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl }amino)-1- piperidinyl]methyl } phenoxy)-N-[2-(dimethylamino)ethyl]benzenesulfonamide dihydrochloride
TLC: Rf 0.56 (dichloromethane : methanol = 2 : 1);
NMR (CD;0D): 6 0.98, 1.33-1.46, 1.59-1.70, 1.96-2.00, 2.20-2.35, 2.93, 3.05-3.12, 3.17- 3.30,3.52-3.56, 4.18, 4.30, 6.89-7.03, 7.19, 7.37, 7.61, 7.90.
Example 3(24)
N-{4-[4-({4-[{[(2,4-difluorophenyl)amino}carbonyl }(phenyl)amino]}-1- piperidinyl} methyl)phenoxy phenyl} methanesulfonamide hydrochloride
TLC: Rf 0.76 (ethyl acetate : methanol = 10 : 1),
NMR (CDsOD): d 1.60-1.80, 2.10-2.30, 2.95, 3.05-3.20, 3.40-3.55, 4.21, 4.65, 6.85-6.96, 6.99-7.04, 7.28, 7.35-7.40, 7.41, 7.51-7.58.
Example 3(25) 4-(4-{[4-(butyl{ [(2,4-difluorophenyl)amino]carbonyl }amino)-1- piperidinyl]methyl} phenoxy)-N-methylbenzenesulfonamide hydrochloride
TLC: Rf0.63 (ethyl acetate : methanol = 10 : 1);
NMR (CD;0D): 6 0.98, 1.36-1.46, 1.59-1.70, 1.99-2.04, 2.17-2.30, 2.53, 3.07-3.17, 3.24- 3.35,3.57-3.61, 4.15, 4.33, 6.89-7.03, 7.16, 7.20, 7.36, 7.57, 7.83.
Example 3(26) 4-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl }amino)-1- piperidinyl}methyl} phenoxy)-N,N-dimethylbenzenesulfonamide hydrochloride
TLC: Rf 0.67 (ethyl acetate : methanol = 10 : 1);
NMR (CD3;0D): 6 0.98, 1.34-1.46, 1.60-1.70, 1.99-2.03, 2.19-2.30, 2.68, 3.09-3.17, 3.25- 3.36,3.57-3.61,4.16,4.33,6.89-7.03, 7.18, 7.21, 7.36, 7.59, 7.78.
Example 3(27) 4-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl }amino)-1- piperidinyl]methyl} phenoxy)-N-(2-methoxyethyl)benzenesulfonamide hydrochloride
TLC: Rf 0.60 (ethyl acetate : methanol = 10 : 1);
NMR (CD3;OD): 6 0.98, 1.34-1.46, 1.60-1.70, 1.99-2 03, 2.19-2.30, 3.03, 3.09-3.17, 3.26, 3.26-3.30, 3.36, 3.56-3.61, 4.16, 4.33, 6.89-7.03, 7.14, 7.19, 7.37, 7.57, 7.85.
_ ®
Example 3(28) 4-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl }amino)-1- piperidinyl]methyl} phenoxy)-N-tetrahydro-2H-pyran-4-ylbenzenesulfonamide hydrochloride
TLC: Rf 0.57 (ethyl acetate : methanol = 10 : 1);
NMR (CD;0D): § 0.98, 1.36-1.53, 1.63-1.68, 2.01-2.04, 2.21-2.25, 3.07-3.37, 3.57361, 3.81-3.85,4.14, 4.33, 4.80, 6.89-7.03, 7.14, 7.19, 7.36, 7.57, 7.87.
Example 3(29)
N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }(phenyl)amino]-1-piperidinyl} methyl)- 2-pyridinyl]oxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
H
OL COR”
Non Zo ©
H
2) + HCl or 2HCI
TLC: Rf 0.53 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.60-1.80, 2.12-2.23, 2.97, 3.11-3.24, 3.48-3.58, 4.27, 4.67, 6.95, 7.06, 7.11, 7.21, 7.28-7.35, 7.48-7.60, 7.90, 8.18.
Example 3(30)
N-[5-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl }amino)-1- piperidinyl]methyl} phenoxy)-2-pyridinylJmethanesulfonamide hydrochloride
TLC: Rf 0.53 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): & 0.97, 1.34-1.44, 1.58-1.68, 1.96-2.05, 2.15-2,31, 3.03-3.18, 3.28, 3.25- 3.33,3.52-3.60, 4.17, 4.30, 6.88-7.04, 7.12, 7.14, 7.37, 7.51-7.60, 8.10.
Example 3(31) 5-({[butyl(1-{4-[4-(4-morpholinylsulfonyl)phenoxy]benzyi }-4- piperidinyl)amino]carbonyl}amino)-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.48 (chloroform : methanol = 10 : 1);
NMR (CD;OD): § 0.98, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.20-2.35, 2.96, 3.00-3.20, 3.20- 3.40,3.50-3.60,3.71, 4.10, 4.33, 7.11-7.24, 7.59, 7.78, 7.87.
®
Example 3(32) 5-[({butyl[ 1-(4-{4-[(tetrahydro-2H-pyran-4-ylamino)sulfonyl]phenoxy } benzy!)-4- piperidinyl]Jamino } carbonyl)amino]-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.40 (chloroform : methanol = 10 : 1);
NMR (CD;OD): 6 0.98, 1.30-1.50, 1.60-1.70, 1.90-2.10, 220-230, 3.10-3.20, 3.20-3.40, 3.50-3.70, 3.80-3.90, 4.15,4.33, 7.11-7.21, 7.60, 7.87, 7.88.
Example 3(33) 5-[({butyl[1-(4-{2,6-dimethyl-4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinylJamino }carbonyl)amino]-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.34 (chloroform : methanol = 10 : 1);
NMR (CD;OD): § 0.97, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.08, 2.20-2.30, 2.99, 3.00-3.20, 3.20-3.40, 3.50-3.60, 4.15, 4.26, 6.86, 7.04, 7.14, 7.45, 7.85.
Example 3(34) 5-[({butyl[1-(4-{4-[methyl(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyl]amino }carbonyl)amino]-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.40 (chloroform : methanol = 10 : 1);
NMR (CDsOD): & 0.98, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.15-2.30, 2.99, 3.00-3.20, 3.20- 3.40,3.30,3.50-3.60, 4.15, 4.30, 7.05-7.18, 7.45, 7.52, 7.86.
Example 3(35) 5-[({butyl[1-(4-{4-[(methylsulfonyl)amino]benzyl }benzyl)-4- piperidinyl]Jamino jcarbonyl)amino]-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.33 (chloroform : methanol = 10 : 1);
NMR (CDs0D): 4 0.97, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.15-2.30, 2.91, 3.00-3.20, 3.20- 3.40, 3.50-3.60, 3.98, 4.15, 4.27, 7.10-7.20, 7.34, 7.44, 7.85.
Example 3(36) 5-{[(butyl{1-[(3,5-dimethyl-1-{4-[(methylsulfonyl)amino]phenyl }-1H-pyrazol-4- yl)methyl]-4-piperidinyl } amino)carbonyl]amino}-2,4-difluorobenzamide dihydrochloride
TLC: Rf 0.20 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 0.98, 1.34-1.47, 1.60-1.72, 1.98-2.10, 2.27-2.50, 2.39, 2.43, 3.04, 3.12- 3.40,3.65-3.75, 4.24, 4.29, 7.15, 7.43, 7.49, 7.87.
Example 3(37) 5-({[(1-{4-[4-(aminosulfonyl)phenoxy]benzyl }-4- piperidinyl)(butyl)amino]carbonyl}amino)-2,4-difluorobenzamide hydrochloride
®
TLC: Rf 0.33 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): 6 0.98, 1.35-1.47, 1.58-1.70, 1.97-2.08, 2.18-2.32, 3.08-3.20, 3.23-3.35, 3.52-3.63, 4.16, 4.33, 7.10-7.24, 7.58, 7.64, 7.90.
Example 3(38) 5-[({butyl[1-(4- {4-[(methylamino)sulfonyl]phenoxy }benzyl)-4- ptperidinyl]amino }carbonyl)amino]-2,4-difluorobenzamide hydrochloride @) NH, 0 0
NZ
PIS H
N N 0 ne
H3C + HCI
TLC: Rf 0.47 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): 6 0.98, 1.32-1.47, 1.60-1.71, 1.98-2.10, 2.20-2.36, 2.53, 3.08-3.20, 3.26- 3.35,3.52-3.64, 4.18, 4.33, 7.14, 7.16, 7.19, 7.60, 7.83, 7.86.
Example 3(39) 5-[({butyl[1-(4-{4-[(dimethylamino)sulfonyl]phenoxy } benzyl)-4- piperidinyl]amino }carbonyl)amino]-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.55 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): 6 0.98, 1.32-1.49, 1.59-1.72, 1.97-2.09, 2.19-2.38, 2.68, 3.08-3.21, 3.23- 3.35,3.58-3.64,4.16,4.34,7.14,7.19,7.21, 7.60, 7.79, 7.86.
Example 3(40)
N-[4-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl }amino)-1- piperidinylJmethy!} phenoxy)-3-methylphenyl]methanesulfonamide hydrochloride
TLC: Rf0.39 (chloroform : methanol = 10 : 1);
NMR (CD;OD): § 0.97, 1.30-1.50, 1.55-1.70, 1.90-2.10, 2.10-2.30, 2.16, 2.96, 3.00-3.20, 3.20-3.40, 3.50-3.60, 4.15, 4.27, 6.91-6.99, 7.13, 7.20, 7.36, 7.46.
Example 3(41)
S-[({butyl[1-(4-{2-methyl-4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyljamino }carbonyl)amino]-2 4-difluorobenzamide hydrochloride
White amorphous powder,
TLC: Rf 0.28 (chloroform : methanol = 10 : 1);
® _
NMR (CD;0D): 4 0.98, 1.30-1.50, 1.55-1.70, 1.90-2.10, 2.10-2.30, 2.16, 2.96, 3.00-3.20, 3.20-3.40, 3.50-3.60, 4.10, 4.26, 6.91-6.97, 7.11-7.20, 7.46, 7.86.
Example 3(42) 4-[4-({4-[({[5-(aminocarbonyl)-2,4-difluorophenyl]amino }carbonyl)(butyl)amino]-1- piperidinyl } methyl)phenoxy]benzoic acid hydrochloride
TLC: Rf 0.49 (dichloromethane : methanol = 5 : 1);
NMR (CD;OD): & 0.98, 1.35-1.45, 1.60-1.70, 1.98-2.03, 2.20-2.30, 3.10-3.34, 3.56-3.60, 4.16, 4.33,7.07,7.14, 7.18, 7.57, 7.86, 8.04.
Example 3(43) 5-{[(butyl{ 1-[(6-{2-chloro-4-[(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]}-4- piperidinyl } amino)carbonyl]amino}-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.33 (chloroform : methanol = 10 : 1);
NMR (CDs;OD): & 0.97, 1.30-1.50, 1.55-1.70, 1.90-2.10, 2.20-2.40, 3.02, 3.10-3.25, 3.25- 3.40, 3.50-3.60, 4.20, 4.35, 7.10-7.26, 7.43, 7.86, 8.09, 8.26.
Example 3(44) 5-{[(butyl{1-[(6-{2-methoxy-4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl } amino)carbonyl}amino}-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.49 (dichloromethane : methanol = 9 : 1),
NMR (CDs;OD): 8 0.97, 1.33-1.47, 1.58-1.71, 1.97-2.08, 2.20-2.38, 3.01, 3.07-3.21, 3.25- 3.35,3.55-3.65,3.72, 4.18, 4.35, 6.90, 7.04-7.19, 7.86, 8.08, 8.29.
Example 3(45) 5-({[butyl(1-{4-[4-(methylsulfonyl)phenoxy]benzyl }-4- piperidinyl)amino]carbonyl }amino)-2 4-difluorobenzamide hydrochloride 0) NH, 0 0
E gq - N 0)
EN - HCI
TLC: Rf 0.50 (dichloromethane : methanol =9 : 1);
® ®
NMR (CD;OD): 6 0.98, 1.35-1.48, 1.59-1.70, 1.98-2.08, 2.19-2.34, 3.12, 3.08-3.21, 3.25- 3.35,3.55-3.64, 4.16, 4.34, 7.14, 7.21, 7.22, 7.61, 7.86, 7.95.
Example 3(46) 4-[4-({4-[{[(4-fluorophenyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl }methyl)phenoxy]benzoic acid hydrochloride
TLC: Rf 0.49 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 1.67-1.80, 2.12-2.22, 3.12-3 24, 3.48-3.55, 4.26, 4.68, 6.95, 7.05, 7.14, 7.22, 7.33, 7.47-7.60, 8.03.
Example 3(47) 4-[4-({4-[({[5-(aminocarbonyl)-2,4-difluorophenyl]amino }carbonyl)(butyl)amino]-1- piperidinyl } methyl)phenoxy]-3-methoxybenzoic acid hydrochloride
TLC: Rf 0.66 (chloroform : methanol =3 : 1);
NMR (CD;OD): 6 0.98, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.10-2.35, 3.05-3.20, 3.25-3.35, 3.50-3.60, 3.82,4.10, 4.28, 6.98, 7.09, 7.15, 7.47,7.77, 7.75, 7.86.
Example 3(48) 4-[4-({4-[({[S-(aminocarbonyl)-2,4-difluorophenyl]amino } carbonyl)(butyl)amino]-1- piperidinyl }Jmethyl)phenoxy]-3-chlorobenzoic acid hydrochloride
TLC: Rf 0.65 (chloroform : methanol =3 : 1);
NMR (CD;OD): § 0.98, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.20-2.35, 3.05-3.20, 3.25-3.35, 3.50-3.60, 4.10,4.33, 7.10-7.17,7.57, 7.86, 7.95, 8.14.
Example 3(49) 4-[4-({4-[({[5-(aminocarbonyl)-2 4-difluorophenyl]amino } carbonyl)(butyl)amino]-1- piperidinyl } methyl)phenoxy]-3-nitrobenzoic acid hydrochloride
TLC: Rf 0.51 (chloroform : methanol =3 : 1);
NMR (CD;0OD): 6 0.97, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.20-2.35, 3.00-3.15, 3.20-3.35, 3.50-3.60,4.15,4.29, 7.10-7.20, 7.58, 7.86, 8.20, 8.56.
Example 3(50) 5-[({butyl[1-(4-{3-methoxy-4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyl]amino }carbonyl)amino]-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.42 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 0.98, 1.32-1.47, 1.58-1.70, 1.97-2.08, 2.17-2.31, 2.91, 3.06-3 20, 3.24- 3.35, 3.51-3.63, 3.86, 4.13,4.29, 6.57. 6.81, 7.10, 7.14, 7.36, 7.51, 7.86.
® _
Example 3(51) 5-[({butyl[ 1-(4-{3-chloro-4-{(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyl]amino }carbonyl)amino]-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.44 (dichloromethane : methanol = 9 : 1),
NMR (CD;OD): § 0.98, 1.32-148, 1.60-1.72, 1.98-2.08, 2.12-231, 3.00, 3.08-3.20, 3.24- 3.35, 3.52-3.62, 4.15, 4.31, 7.00, 7.10-7.20, 7.51-7.59, 7.86.
Example 3(52) 5-({[butyl(1-{[6-(4-methoxyphenoxy)-3-pyridinylJmethyl }-4- piperidinyl)amino]carbonyl}amino)-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.39 (chloroform : methanol = 10 : 1);
NMR (CDs0D): § 0.97, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.20-2.35, 3.05-3.20, 3.20-3.35, 3.50-3.65, 3.81, 4.20, 4.34, 6.97-7.20, 7.86, 8.05, 8.31.
Example 3(53) 4-{[5-({4-[({[5-(aminocarbonyl)-2,4-difluorophenyl]amino} carbonyl)(butyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]Joxy } benzoic acid hydrochloride (or dihydrochloride)
TLC: Rf 0.63 (chloroform : methanol = 3 : 1);
NMR (CDsOD): 6 0.97, 1.30-1.45, 1.55-1.70, 1.85-2.00, 2.05-2.20, 2.65-2.85, 3.20-3.40, 4.05,4.10,7.09-7.21, 7.89, 7.97, 8.07, 8.23.
Example 3(54)
N-(4-{4-[(4-{phenyl[(tetrahydro-2H-pyran-4-ylamino)carbonyl]amino}-1- piperidinyl)methyl]phenoxy} phenyl)methanesulfonamide hydrochloride
TLC: Rf 0.46 (dichloromethane : methanol = 9 : 1),
NMR (CD;OD): § 1.24-1.40, 1.55-1.75, 2.05-2.15, 2.95, 3.04-3.18, 3.34-3.50, 3.68-3.84, 421, 4.60,698-7.04,7.22,728,7.41,7.45-7.56.
Example 3(55) 5-{[(butyl{ 1-[(5-{4-[(methylsulfonyl)amino]phenoxy}-2-pyrazinyl)methyl]-4- piperidinyl} amino)carbonyl]amino}-2,4-difluorobenzamide dihydrochloride
TLC: Rf 0.40 (dichloromethane : methanol = 9 : 1),
NMR (CD;OD): 8 0.99, 134-148, 1.59-1.72, 1.98-2.08, 2.21-2.38, 2.97, 3.17-3.38, 3.62- 3.71,4.18, 4.46,7.14, 7.18, 7.33, 7.67, 8.24, 8.54.
® _
Example 3(56) 5-[4-({4-[({[5-(aminocarbonyl)-2,4-difluorophenyl]amino }carbonyl)(butyl)amino]-1- piperidinyl} methyl)phenoxy]-2-[(methylsulfonyl)amino]benzoic acid hydrochloride
TLC: Rf 0.48 (dichloromethane : methanol = 5 : 1);
NMR (CD;OD): § 0.96, 1.28-1.47, 1.59-1.71, 1.95-2.06, 2.18-2.37, 3.02, 3.00-3.20, 3 24- 3.35,3.50-3.61, 4.15, 4.30, 7.08, 7.14, 7.25, 7.51, 7.67-7.72, 7.86.
Example 3(57) 2-[4-({4-[({[5-(aminocarbonyl)-2,4-difluorophenyl]amino } carbonyl)(butyl)amino]-1- piperidinyl} methyl)phenoxy]-5-[(methylsulfonyl)amino]benzoic acid hydrochloride
TLC: Rf 0.35 (dichloromethane : methanol = 5 : 1);
NMR (CDs;OD): 6 0.98, 1.31-1.48, 1.54-1.71, 1.94-2.04, 2.12-2.36, 3.00, 3.00-3.18, 3.20- 3.35,3.51-3.61,4.15,4.27, 6.98, 7.08, 7.14, 7.41-7.52, 7.82, 7.84.
Example 3(58)
N-[4-(4-{[4-(butyl{[(3,4-dicyanophenyl)amino]carbonyl } amino)-1- : piperidinyl]methyl} phenoxy)phenyl]methanesulfonamide hydrochloride
TLC: Rf 0.41 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 6 0.96, 1.31-1.42, 1.52-1.64, 1.98-2.07, 2.21-2.39, 2.95, 3.04-3.21, 3.28- 3.35,3.52-3.61, 4.19, 4.30, 7.03, 7.06, 7.29, 7.52, 7.79-7.89, 8.11.
Example 3(59)
N-[4-(4-{[4-(butyl {[(4-cyano-2,5-difluorophenyl)amino]carbonyl }amino)-1- piperidinyl]methyl} phenoxy)phenyl]methanesulfonamide hydrochloride
TLC: Rf 0.50 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 0.97, 1.35-1.46, 1.55-1.68, 1.95-2.06, 2.19-2.37, 2.95, 3.08-3.21, 3 24- 3.38,3.52-3.61, 4.18, 4.29, 7.03, 7.06, 7.29, 7.50, 7.60, 7.87.
Example 3(60)
S-({[butyl(1-{[6-(4-cyanophenoxy)-3-pyridinyl]methyl }-4- piperidinyl)amino}carbonyl}amino)-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.54 (dichloromethane : methanol = 10 : 1);
NMR (CD;0OD): § 0.98, 1.36-1.43, 1.59-1.67, 2.00-2.04, 2.21-2.32, 2.99-3.18, 3.26-3.30, 3.56-3.63,4.14, 4.36, 7.14, 7.21, 7.33, 7.80, 7.86, 8.06, 8.29.
® ®
Example 3(61) 3-({[[1-(4-{4-[(methylsulfonyl)amino]phenoxy}benzyl)-4- piperidinyl](phenyl)amino]carbonyl }amino)benzamide hydrochloride
TLC: Rf 0.33 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 1.63-1.80, 2.14-2.23, 2.95, 3.10-3.22, 3.47-3.55, 4.23, 4.69, 7.01, 7.03, 7.25-7.37, 7.40-7.60, 7.72.
Example 3(62) 4-[({butyl[ 1-(4-{4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyl]Jamino}carbonyl)amino]benzamide hydrochloride
TLC: Rf 0.33 (chloroform : methanol =7 : 1);
NMR (CD;0OD): 6 0.97, 1.30-1.50, 1.50-1.70, 1.95-2.10, 2.10-2.30, 2.95, 3.00-3.20, 3.20- 3.40, 3.50-3.60, 4.20, 4.30, 7.02-7.08, 7.29, 7.47-7.52, 7.80.
Example 3(63)
N-{4-[4-({4-[butyl({[2,4-difluoro-5-(4- morpholinylcarbonyl)phenyl]amino } carbonyl)amino]-1- piperidinyl }methyl)phenoxy]phenyl} methanesulfonamide hydrochloride
TLC: Rf 0.38 (chloroform : methanol = 10 : 1);
NMR (CD;OD): § 0.98, 1.30-1.50, 1.60-1.70, 1.95-2.05, 2.10-2.30, 2.95, 3.00-3.20, 3.20- 3.50, 3.50-3.70, 3.70-3.80, 4.10, 4.29, 7.02-7.08, 7.15, 7.29, 7.46, 7.49.
Example 3(64) 5-[({butyl[ 1-(4-{4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinylJamino }carbonyl)amino]-2,4-difluoro-N-(2-methoxyethyl)benzamide hydrochloride
TLC: Rf 0.44 (chloroform : methanol = 10 : 1);
NMR (CD;0OD): 5 0.98, 1.30-1.50, 1.60-1.75, 1.90-2.10, 2.15-2.35, 2.95, 3.00-3.20, 3.20- 3.40, 3.50-3.60, 3.55, 4.13,4.28, 7.02-7.08, 7.13, 7.29, 7.49, 7.78.
Example 3(65) 5-[({butyl[ 1-(4-{4-[(methylsulfonyl)amino]phenoxy } benzy!)-4- piperidinyl]amino}carbonyl)amino}-2,4-difluoro-N,N-dimethylbenzamide hydrochloride
TLC: Rf 0.46 (chloroform : methanol = 10: 1);
NMR (CD;OD): 6 0.98 1.30-1.50, 1.60-1.80, 1.90-2.10, 2.20-2.30, 2.95, 2.97, 3.05-3.20, 3.10, 3.25-3.35, 3.50-3.60, 4.15, 4.29, 7.02-7.08, 7.14, 7.29, 7.43, 7.50.
_ ®
Example 3(66)
S-[({butyl[1-(4-{4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinylJamino }carbonyl)amino]-2,4-difluoro-N-(2-hydroxyethyl)benzamide hydrochloride
TLC: Rf 0.38 (chloroform : methanol = 10 : 1);
NMR (CDs;0D): 6 0.98, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.10-2.30, 2.95, 3.05-3.20, 3.20- 3.40, 3.50, 3.50-3.60, 3.67, 4.15, 4.27, 7.02-7.07, 7.13, 7.29, 7.50, 7.81.
Example 3(67)
N-{4-[(5-{[4-(butyl{[(1-methyl-1H-pyrazol-4-yl)amino]carbonyl }amino)-1- piperidinyl]methyl}-2-pyridinyl)oxy]-3-chlorophenyl } methanesulfonamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.57 (chloroform : methanol =7 : 1);
NMR (CD;OD): § 0.96, 1.30-1.45, 1.50-1.65, 1.90-2.10, 2.20-2.40, 3.02, 3.10-3.50, 3.50- 3.65,4.08 425 437, 7.16, 7.24-7.26, 7.43, 8.12, 8.16, 8.23, 8.28.
Example 3(68)
N-{4-[(5-{[4-(butyl{[(1-methyl-1H-pyrazol-4-yl)amino]carbonyl }amino)-1- piperidinyljmethyl}-2-pyridinyl)oxy]-3,5-dimethylphenyl } methanesulfonamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.56 (chloroform : methanol =7 : 1);
NMR (CD;0D): 8 0.96, 1.30-1.50, 1.50-1.65, 1.90-2.05, 2.08, 2.20-2.40, 2.98, 3.10-3.40, 3.55-3.65, 4.06, 4.25, 4.37, 7.05, 7.08, 8.13, 8.16, 8.20, 8.33.
Example 3(69) 5-{[(butyl{1-[(6-{2-methyl-4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino }-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.43 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 0.97, 1.32-1.45, 1.58-1.70, 1.95-2.07, 2.14, 2.20-2.40, 2.98, 3 08-321, 3.24-3.37,3.55-3.64, 4.20, 4.36, 7.02-7.25, 7.86, 8.14, 8.34.
Example 3(70) 5-{[(butyl{1-[(6-{2,6-dimethyl-4-[(methylsulfonyl)Jamino}phenoxy }-3-pyridinyl)methyl]- 4-piperidinyl jamino)carbonyl]amino }-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.44 (dichloromethane : methanol =9 : 1);
®
NMR (CD;0D): & 0.97, 1.32-1.45, 1.58-1.70, 1.95-2.08, 2.08, 2.21-2.39, 2.98, 3.08-3.21, 3.24-3.35, 3.55-3.65, 4.20, 4.36, 7.05, 7.08, 7.14, 7.86, 8.14, 8.33.
Example 3(71) 5-[({2-butynyl[1-(4-{4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyl]amino }carbonyl)amino]-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.52 (dichloromethane : methanol =9 : 1);
NMR (CD;0OD): & 1.82, 2.01-2.12, 2.12-2.31, 2.95, 3.08-3.19, 3.52-3.61, 4.10, 4.29, 4.32, 7.03, 7.06, 7.15, 7.29, 7.51, 7.96.
Example 3(72) 2,4-difluoro-5-({[[ 1-(4-{4-[(methylsulfonyl)amino phenoxy } benzyl)-4- piperidinyl](propyl)amino]carbonyl} amino)benzamide hydrochloride
TLC: Rf 0.51 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 0.97, 1.62-1.75, 1.98-2.08, 2.18-2.30, 2.95, 3.02-3.18, 3.21-3.33, 3.52- 3.60,4.14, 428, 7.03, 7.06, 7.14, 7.29, 7.50, 7.85.
Example 3(73)
N-{4-[4-({4-[butyl({[2,4-difluoro-5-(hydroxymethyl)phenyl]amino } carbonyl)amino]-1- piperidinyl }methyl)phenoxy]phenyl} methanesulfonamide hydrochloride
TLC: Rf 0.80 (chloroform : methanol = 7 : 1);
NMR (CDsOD): § 0.98, 1.30-1.50, 1.60-1.75, 1.90-2.10, 2.20-2.35, 2.96, 3.05-3.20, 3.20- 3.40, 3.50-3.65, 4.20, 4.29, 4.60, 6.97, 7.03, 7.06, 7.29, 7.46, 7.52.
Example 3(74) : 2,4-difluoro-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl }(pentyl)amino]carbonyl }amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.52 (dichloromethane : methanol = 9 : 1);
NMR (CD;0OD): 6 0.93, 1.28-1.45, 1.60-1.71, 1.97-2.08, 2.20-2.38, 2.98, 3.08-3.22, 3.25- 3.35,355-3.64, 4.18, 4.35, 7.09-7.20, 7.33, 7.86, 8.08, 8.31.
Example 3(75) 5-{[(butyl{1-[(6-{4-[(ethylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl}-4- piperidinyl }amino)carbonyl}amino}-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
0 NH,
F N
ISSR SSN A pp 00
N N 0) £ H + HCl or 2HCI
HsC
TLC: Rf 0.48 (dichloromethane : methanol = 9 : 1),
NMR (CD;OD): & 0.97, 1.32, 1.28-1.45, 157-170, 1.95-2.08, 2.21-2.38, 3.11, 3.08-3 21, 3.25-3.35,3.52-3.64, 4.18, 4.35, 7.07-7.17, 7.33, 7.86, 8.08, 8.31.
Example 3(76)
N-(4-{[5-({4-[{[(1-methyl-1H-pyrazol-4-yl)amino]carbonyl} (pentyl)amino]-1- piperidinyl} methyl)-2-pyridinyljoxy }phenyl)methanesulfonamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.50 (dichloromethane : methanol = 9 : 1),
NMR (CD;0D): 8 0.92, 1.28-1.42, 1.52-1.64, 1.92-2.04, 2.20-2.38, 2.98, 3.10-3.29, 3.52- 3.64, 4.04, 424,437,7.11,7.16, 7.34, 8.05, 8.12, 8.14, 8 34.
Example 3(77)
N-{4-[(5-{[4-(butyl {[(1-ethyl-1H-pyrazol-4-yl)amino]carbonyl } amino)-1- piperidinylJmethyl}-2-pyridinyl)oxy ]phenyl} methanesulfonamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.50 (dichloromethane : methanol = 9 : 1),
NMR (CD;OD): 6 0.97, 1.28-1.42, 1.52, 1.50-1.64, 1.90-2.02, 2.20-2.38, 2.98, 3.04-3.29, 3.51-3.64, 4.24, 430-4.44, 7.13, 7.16, 7.34, 8.05-8.16, 8.21, 8.34.
Example 3(78) 5-[({butyl[1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- : piperidinyl]amino }carbonyl)amino]-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
® _
HoN 0 0, 0 oy Be
F en, + HC! or 2HCI
TLC: Rf 0.48 (chloroform : methanol =7 : 1);
NMR (CDs;OD): 6 0.98, 1.30-1.50, 1.55-1.70, 2.00-2.10, 2.20-2.40, 3.05-3.20, 3.15, 3.25- 3.40, 3.50-3.70, 4.20, 4.36, 7.14, 7.22, 7.40, 7.86, 8 01, 8.07, 8.29.
Example 3(79) 2,4-difluoro-5-({[[1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl} methyl)-4- piperidinyl](pentyl)amino]carbonyl }amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.44 (chloroform : methanol =7 : 1),
NMR (CD;OD): 6 0.94, 1.30-1.45, 1.60-1.75, 2.00-2.10, 2.15-2.40, 3.00-3.20, 3.15, 3.20- 3.40, 3.50-3.70, 4.15, 4.35, 7.14, 7.22, 7.39, 7.86, 8.01, 8.05, 8.29.
Example 3(80) 2,4-difluoro-5-({[{1-[(6-{2-methyl-4-[(methylsulfonyl)amino]}phenoxy}-3- pyridinyl)methyl]-4-piperidinyl }(pentyl)amino]carbonyl }amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.46 (chloroform : methanol =7 : 1);
NMR (CD;OD): § 0.93, 1.30-1.45, 1.60-1.75, 1.95-2.10, 2.13, 2.15-2.30, 2.98, 3.10-3 40, 3.55-3.65,4.15,4.34,7.01-7.21, 7.86, 8.04, 8.26.
Example 3(81) 5-({[{ 1-[(6-{2,6-dimethyl-4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyi)methyl}-4- piperidinyl } (pentyl)amino]jcarbonyl }amino)-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.50 (chloroform : methanol =7 : 1);
NMR (CD;0D): § 0.93, 1.30-1.45, 1.60-1.70, 2.00-2.10, 2.06, 2.15-2.30, 2.99, 3.00-3 40, 3.50-3.70, 4.10, 4.32, 7.03, 7.08, 7.14, 7.86, 7.98, 8.20.
Example 3(82) 5-({[{1-[(6-{4-[(ethylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl } (pentyl)amino]carbonyl }amino)-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
® _
TLC: Rf 0.46 (chloroform : methanol = 7: 1),
NMR (CD;OD): & 0.93, 1.30-1.45, 1.33, 1.60-1.70, 2.00-2.10, 2.20-2.40, 3.00-3.40, 3.11, 3.50-3.70, 4.15, 4.34, 7.08-7.17, 7.32, 7.86, 8.03, 8.28.
Example 3(83) 5-({[{1-[(6-{2-chloro-4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl}(pentyl)amino]carbonyl}amino)-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.45 (chloroform : methanol = 7: 1);
NMR (CD;OD): § 0.93, 1.30-1.50, 1.60-1.75, 2.00-2.10, 2.15-2.25, 3.02, 3.05-3.35, 3.50- 3.70, 4.10, 4.33, 7.14-7.28, 7.42, 7.86, 8.00, 8.20.
Example 3(84)
N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl}(phenyl)amino]-1-piperidinyl } methyl)- 2-pyridinyl]oxy}-3-methoxyphenyl)methanesulfonamide hydrochloride (or dihydrochloride)
H
ONS As Ser
N N = 0 00
H OMe - HCI or 2HCI
TLC: Rf 0.45 (dichloromethane : methanol =9 : 1),
NMR (CD;0D): § 1.64-1.82, 2.11-2.21, 3.00, 3.10-3.24, 3.48-3.57, 3.71, 431, 4.67, 6 87- 7.00, 7.02-7.09, 7.12, 7.20, 7.32, 7.45-7.59, 8.03, 8.26.
Example 3(85) N-(4-{[5-({4-[{[(2,4-difluorophenyl)amino]carbonyl } (phenyl)amino}-1- piperidinyl } methyl)-2-pyridinyt]oxy }-3-methoxyphenyl)methanesulfonamide hydrochloride (or dihydrochloride)
Amorphous powder,
TLC: Rf 0.45 (dichloromethane : methanol =9 : 1),
NMR (CD;0OD): § 1.67-1.82, 2.11-2.24, 3.00, 3.12-3.24, 3.50-3.57, 3.71, 4.30, 4.67, 6.84- 6.97,7.01-7.08, 7.11, 7.35, 7.48-7.61, 8.02, 8.24.
] _
Example 3(86) 5-{[(butyl{1-[(6-{2-methyl-4-[(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonylJamino}-2-chloro-4-fluorobenzamide hydrochloride (or dihydrochloride)
HoN 0)
H
Cl 1 ISR! Nog Cs
N" ON Zo 00
F H LL ~ CH;
CH; + HCl or 2HCI
TLC: Rf 0.40 (chloroform : methanol = 10 : 1);
NMR (CD30D): 6 0.97, 1.30-1.50, 1.55-1.70, 1.90-2.10, 2.12, 2.20-2.40, 2.97, 3.00-3.20, 3.25-3.35,3.50-3.70, 4.20, 4.33, 7.00-7.21, 7.32, 7.66, 8.01, 8.24.
Example 3(87) 5-{[(butyl{1-[(6-{4-[(ethylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino }-2-chloro-4-fluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.40 (chloroform : methanol = 10 : 1);
NMR (CD;0D): § 0.98, 1.33, 1.35-1.50, 1.60-1.70, 1.95-2.10, 2.20-2.40, 3.10, 3.10-3.20, 3.20-3.40, 3.50-3.65, 4.15, 4.33, 7.08-7.12, 7.30-7.34, 7.65, 7.99. 8 24.
Example 3(88) 5-{[(butyl{ 1-[(6-{4-[(ethylsulfonyl)amino]-2-methylphenoxy } -3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino}-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.62 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): & 0.98, 1.33, 1.28-1.45, 1.59-1.70, 1.97-2.08, 2.12, 2.18-2.34, 3.11, 3.06- 3.20, 3.25-3.35, 3.52-3.63, 4.12, 4.33, 7.00, 7.07, 7.13, 7.15, 7.20, 7.86, 8.01, 8.24.
Example 3(89) 5-{[(butyl{ 1-[(6-{2-methyl-4-[(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino }-2,4-difluoro-N-methylbenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.53 (dichloromethane : methanol =9 : 1);
_
NMR (CD;0D): 6 0.97, 1.30-1.47, 1.58-1.70, 1.95-2.07, 2.13, 2.20-2.37, 2.91, 2.98, 3.04- 3.21,3.22-3.35,3.52-3.64, 4.18, 4.34, 7.01-7.24,7.79, 8.06, 8 27.
Example 3(90) 5-{[(butyl{1-[(6-{4-[(ethylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino }-2, 4-difluoro-N-methylbenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.53 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): 8 0.98, 1.33, 1.30-1.47, 1.59-1.70, 1.98-2.05, 2.20-2.38, 2.91, 3.11, 3.07- 3.21,3.22-3.35,3.52-3.64, 4.18, 4.35, 7.08-7.16, 7.32, 7.79, 8.06, 8.29.
Example 3(91) 5-{[(butyl{1-[(6-{2-chloro-4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino}-2,4-difluoro-N-methylbenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.53 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 0.97, 1.32-1.45, 1.58-1.70, 1.97-2.05, 2.20-2.37, 2.91, 3.02, 3.04-3.21, 3.22-3.35,3.51-3.62,4.18, 4.34, 7.06-7.29, 7.42,7.79, 8.06, 8.23.
Example 3(92) 5-{[(butyl{1-[(6-{2-methoxy-4-[(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl}-4- piperidinyl }amino)carbonyl]amino}-2,4-difluoro-N-methylbenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.52 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 0.97, 1.32-1.45, 1.58-1.70, 1.95-2.05, 2.19-2.37, 2.91, 3.00, 3.04-3.21, 3.22-3.35,3.54-3.62, 3.72, 4.18, 4.34, 6.90, 7.04-7.17, 7.79, 8.06, 8.27.
Example 3(93) 2-(5-{[(butyl{ 1-[(6- {4-[(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl}-4- piperidinyl }amino)carbonyl]amino}-2,4-difluorophenyl)acetamide hydrochloride (or dihydrochloride)
NH»
O H
F N_. CH
LOC, rR 00
N7 ON Zo
FoR Ll
CH; + HCI or 2HCI
TLC: Rf 0.42 (chloroform : methanol = 7 : 1),
NMR (CD;OD): § 0.97, 1.30-1.50, 1.50-1.70, 1.95-2.10, 2.15-2 30, 2.97, 3.05-3 20, 3 20- 3.40,3.50-3.60, 3.53,4.10, 4.33, 7.00, 7.08-7.14, 7.30-7.34, 7.97, 8.24.
Example 3(94) 2-[2,4-difluoro-5-({[{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl }(pentyl)amino}carbonyl }amino)phenyl]acetamide hydrochloride (or dihydrochloride) :
TLC: Rf 0.43 (chloroform : methanol =7 : 1);
NMR (CD;0D): 6 0.93, 1.30-1.50, 1.55-1.75, 1.90-2.10, 2.15-2.35, 2.97, 3.10-3.20, 3.20- 3.40, 3.50-3.60, 3.53, 4.15, 4.33, 7.00, 7.08-7.14, 7.30-7.34, 7.99, 8.25.
Example 3(95) 5-{[(butyl{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino }-2,4-difluoro-N-methylbenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.41 (chloroform : methanol = 7 : 1);
NMR (CD;OD): 8 0.98, 1.35-1.50, 1.65-1.80, 1.95-2.10, 2.20-2.35, 2.91, 2.97, 3.05-3.20, 3.20-3.40, 3.55-3.70, 4.10, 4.34, 7.08-7.16, 7.32, 7.80, 8.00, 8.24.
Example 3(96) 2,4-difluoro-N-methyl-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy }-3- pyridinyl)methyl]-4-piperidinyl }(pentyl)amino]carbonyl }amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.43 (chloroform : methanol = 7 : 1),
NMR (CD;0D): § 0.93, 1.30-1.50, 1.60-1.75, 1.95-2.10, 2.20-2.40, 2.91, 2.97, 3.05-3.20, 3.20-3 40, 3.50-3.70, 4.15, 4.34, 7.08-7.16, 7.32, 7.79, 8.00, 8.24.
® ®
Example 3(97) 5-({[{1-[(6-{4-[(ethylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl}-4- piperidinyl}(pentyl)amino]carbonyl}amino)-2,4-difluoro-N-methylbenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.45 (chloroform : methanol = 7 : 1);
NMR (CD;0D): 6 0.93, 1.33, 1.30-1.45, 1.60-1.70, 1.90-2.10, 2.15-2.30, 2.91, 3.05-3.20, 3.10, 3.20-3.40, 3.50-3.60, 4.10, 4.33, 7.07-7.16, 7.32, 7.79, 7.97, 8.24.
Example 3(98) 2,4-difluoro-N-methyl-5-({[{1-[(6-{2-methyl-4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl } (pentyl)amino]carbonyl }amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.45 (chloroform : methanol = 7 : 1);
NMR (CD;0D): § 0.93, 1.30-1.40, 1.60-1.70, 1.95-2.05, 2.13, 2.20-2.40, 2.91, 2.98, 3.05- 3.20, 3.20-3.40,3.55-3.65,4.15, 4.34, 7.11-7.21, 7.79, 8.04, 8.26.
Example 3(99)
N-[4-(4-{[4-(butyl{[(1,5-dimethyl-1H-pyrazol-4-yl)amino]carbonyl }amino)-1- piperidinyl]methyl} phenoxy)phenyljmethanesulfonamide dihydrochloride
TLC: Rf 0.84 (chloroform : methanol = 4 : 1);
NMR (CD;0D): 6 0.97, 1.30-1.50, 1.60-1.80, 1.90-2.10, 2.10-2.30, 2.27, 2.95, 3.00-3.20, 3.20-3.40, 3.50-3.60, 3.92, 4.20, 4.29, 7.02-7.08, 7.31, 7.51, 7.84.
Example 3(100) 4-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl }amino)-1- piperidinylJmethyl} phenoxy)-N-[2-(dimethylamino)ethyl]benzenesulfonamide dihydrochloride
TLC: Rf 0.40 (dichloromethane : methanol = 5 : 1);
NMR (CD;OD): & 0.98, 1.36-1.43, 1.60-1.70, 1.98-2.02, 2.20-2.35, 2.94, 3.10-3.34, 3.56- 3.60,4.21,4.34,6.90-7.01,7.18-7.21, 7.36, 7.62, 7.89.
Example 3(101) 5-{[(butyl{1-[(6-{4-[(methylsulfonyl)amino}phenoxy}-1-oxide-3-pyridinyl)methyl}-4- piperidinyl }amino)carbonyl]amino }-2,4-difluorobenzamide hydrochloride
TLC: Rf0.54 (chloroform : methanol =4 : 1);
NMR (CD;0D): 6 0.99, 1.30-1.50, 1.55-1.70, 1.95-2.15, 2.20-2.40, 3.01, 3.10-3.40, 3.55- 3.70, 4.15, 4.39, 7.12-7.21, 7.25, 7.40, 7.81, 7.87, 8.70.
® @
Example 3(102) 5-[({butyl[1-(4-{4-[(methylsulfonyl)amino]phenoxy }benzyl)-4- piperidinyl]amino }carbonyl)amino]-N-[2-(dimethylamino)ethyl]-2 4-difluorobenzamide dihydrochloride
TLC: Rf0.17 (chloroform : methanol = 10 : 1);
NMR (CD;0D): 6 0.98, 1.30-1.50, 1.60-1.80, 1.90-2.10, 2.20-2.40, 2.95, 2.98, 3.00-3.20, 3.20-3.40, 3.50-3.80, 4.20, 4.29, 7.02-7.08, 7.17, 7.29, 7.52, 7.91.
Example 3(103)
S5-{[(benzyl{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl}amino }-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.51 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 1.97-2.06, 2.07-2.22, 2.97, 3.04-3.18, 3.47-3.58, 4.30, 4.37, 4.66, 7.04- 7.17,7.21-7.45, 7.89, 8.00, 8.24.
Example 3(104) methyl 4-[4-({4-[({[5-(aminocarbonyl)-2,4-difluorophenyl}amino }carbonyl)(butyl)amino]- 1-piperidinyl } methyl)phenoxy]-3-methoxybenzoate hydrochloride
TLC: Rf 0.58 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): & 0.98, 1.32-1.44, 1.58-1.70, 1.95-2.04, 2.12-2.30, 3.08-3.18, 3.22-3.35, 3.51-3.61, 3.82, 3.91,4.14, 4.28, 6.99, 7.09, 7.14, 7.47, 7.67, 7.73, 7.85.
Example 3(105) 2,4-difluoro-5-{[(hexyl{1-[(6-{4-[(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]- 4-piperidinyl jamino)carbonyl]amino }benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.47 (chloroform : methanol =7 : 1);
NMR (CDsOD): 6 0.91, 1.30-1.50, 1.60-1.70, 2.00-2.10, 2.20-2.35, 2.97, 3.00-3.20, 3.20- 3.40, 3.50-3.70, 4.10, 4.33, 7.08-7.18, 7.32, 7.86, 7.98, 8.24.
Example 3(106) methyl N-[4-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl }amino)piperidin-1- yl]methyl } phenoxy)phenyl]-N-(methylsulfonyl)glycinate hydrochloride
TLC: Rf 0.46 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 0.96, 1.27-1.44, 1.55-1.90, 2.10-2.20, 2.95-3.07, 3.08, 3.21-3.34, 3.53, 3.74, 4.05, 4.46, 6.85-7.04,7.03-7.45, 7.47.
_ ®
Example 3(107) methyl N-{4-[4-({4-[({[5-(aminocarbonyl)-2 4- difluorophenyl]amino} carbony!)(butyl)amino]piperidin-1-yl } methyl)phenoxy]phenyl }-N- (methylsulfonyl)glycinate hydrochloride
TLC: Rf 0.52 (dichloromethane : methanol =9 : 1);
NMR (CDsOD): 4 0.97, 1.32-1.42, 1.58-1.68, 1.70-1.97, 2.12-2.28, 2.99-3.12, 3.08, 3.20- 3.35,3.57,3.74, 4.02, 4.46, 6.92-7.04, 7.16, 7.36, 7.47, 8.54.
Example 4 5-{[(butyl{1-[(6-{4-[(methylamino)carbonyl]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl } amino)carbonyl]amino}-2,4-difluorobenzamide hydrochloride (or dihydrochloride) 0 NH, 0 "GQ 0 N SN NCH
TT
N N 0)
Fon Is + HCl or 2HCI
H;C
To a solution of the compound prepared in Example 3(53) (132 mg) in dimethylformamide (1 ml) was added 1-hydroxybenzotriazole (46 mg), 1-ethyl-3-[3- (dimethylamino)propyl]carbodiimide hydrochloride (65 mg) and a solution of 33% methylamine in methanol (32 pl). The reaction mixture was stirred for 2.5 hours at room temperature. To the mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and extract with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by column chromatography on silica gel (ethyl acetate : methanol = 5: 1). To a solution of the obtained compound in ethyl acetate was added 4N hydrogen chloride in ethyl acetate solution. The reaction mixture was concentrated to give the title compound (73 mg) having the following physical data.
TLC: Rf 0.48 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 0.97, 1.32-1.45, 1.58-1.70, 1.95-2.08, 2.25-2.40, 2.92, 3.10-3.22, 3.27- 3.38,3.58-3.64, 4 24, 4.37, 7.13, 7.15, 7.24, 7.86, 7.90, 8.12, 8.33.
®
Qe
Examples 4(1) - 4(9)
By the same procedure as described in Example 4 using the corresponding amine compounds instead of methylamine and the compound prepared in Example 3(53) or the compound prepared in Example 3(47), the following compounds of the present invention were obtained.
Example 4(1) 5-({[[1-({6-[4-(aminocarbonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl](butyl)amino]carbonyl }amino)-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.47 (dichloromethane : methanol =9 : 1),
NMR (CD;OD): § 0.98, 1.35-1.48, 1.59-1.70, 1.95-2.08, 2.19-2.38, 3.06-3.22, 3.24-3.35, 3.55-3.65,4.18,4.36,7.14,7.16, 7.23, 7.86, 7.96, 8.05, 8.30.
Example 4(2) 5-{[(butyl{ 1-[(6-{4-[(dimethylamino)carbonyl]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl } amino)carbonyl]amino}-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.50 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 0.97, 1.34-1.45, 1.58-1.70, 1.95-2.08, 2.20-2.40, 3.02-3.22, 3.24-3.35, 3.52-3.65, 4.19, 4.36, 7.14, 7.16, 7.25, 7.52, 7.86, 8.09, 8.30.
Example 4(3) 5-[({butyl[1-({6-[4-(4-morpholinylcarbonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl]amino }carbonyl)amino]-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.50 (dichloromethane : methanol =9 : 1);
NMR (CD;0D): & 0.98, 1.32-1.47, 1.59-1.70, 1.95-2.08, 2.20-2.39, 3.10-3.20, 3.25-3.35, 3.45-3.82 4.18, 436,7.14,7.16,7.25,7.52, 7.86, 8.08, 8.30.
Example 4(4) 5-({[butyl(1-{[6-(4-{[(2-methoxyethyl)amino]carbony!}phenoxy)-3-pyridinylJmethyl }-4- piperidinyl)amino]carbonyl}amino)-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
»
Oo NH 2 9)
F O. 2 OC OH =
N N 0)
E H
- HCl or 2HCI
H,C
TLC: Rf 0.50 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 6 0.98, 1.35-1.47, 1.60-1.70, 1.95-2.08, 2.20-2.38, 3.08-3.21, 3.25-3.40,
S 3.57,3.51-3.64,4.16,436,7.14,7.16, 7.23, 7.86, 7.90, 8.05, 8.30.
Example 4(5) 5-[({butyl[1-({6-[4-({[2-(dimethylamino)ethyl]amino } carbonyl)phenoxy]-3- pyridinyl } methyl)-4-piperidinylJamino } carbonyl)amino]-2,4-difluorobenzamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.35 (dichloromethane : methanol = 5 : 1),
NMR (CD;0D): § 0.97, 1.35-1.45, 1.59-1.70, 1.94-2.05, 2.23-2.40, 2.99, 3.10-3.22, 3.22- 3.35, 3.40, 3.55-3.65, 3.78, 4.22, 4.37, 7.14, 7.17, 7.27, 7.86, 7.99, 8.13, 8.34.
Example 4(6) 5-({[butyl(1-{[6-(4-{[(2-methoxyethyl)amino]carbonyl}-2,6-dimethylphenoxy)-3- pyridinylJmethyl } -4-piperidinyl)amino]carbonyl }amino)-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.51 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 0.97, 1.34-1.46, 1.57-1.68, 1.98-2.08, 2.13, 2.18-2.35, 3.08-3.21, 3.22- 3.40, 3.56, 3.51-3.64,4.17,4.33,7.11, 7.14, 7.62, 7.86, 8.06, 8.22.
Example 4(7) 5-({{(1-{4-[4-(aminocarbonyl)-2-methoxyphenoxy]benzyl } -4- piperidinyl)(butyl)amino]carbonyl}amino)-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.41 (dichloromethane : methanol =9 : 1);
NMR (CD;0D): 6 0.98, 1.32-1.47, 1.58-1.70, 1.97-2.05, 2.12-2.31, 3.04-3.18, 3.22-3.35, 3.51-3.60, 3.82,4.15,4.27,6.97,7.09, 7.14, 7.47,7.53, 7.65, 7.85.
MN
®
Example 4(8) 5-{[(butyl{1-[4-(2-methoxy-4-{[(2-methoxyethyl)amino]carbonyl}phenoxy)benzyl]-4- piperidinyl }amino)carbonyl]amino }-2 4-difluorobenzamide hydrochloride
TLC: Rf 0.53 (dichloromethane : methanol = 9 : 1),
NMR (CD;OD): 6 0.98, 1.32-1.47, 1.58-1.70, 1.95-2.04, 2.12-2.30, 3.04-3.18, 3.22-3.35, 3.50-3.61,3.57,3.82,4.14,427,697,7.09, 7.14, 7.45, 7.47, 7.61, 7.85.
Example 4(9) 5-({[butyl(1-{4-[2-methoxy-4-(4-morpholinylcarbonyl)phenoxy]benzyl }-4- piperidinyl)amino]carbonyl }amino)-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.52 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): & 0.98, 1.32-1.44, 1.58-1.70, 1.95-2.04, 2.12-2.30, 3.04-3.17, 3.22-3.35, 3.47-3.81,3.79,4.14,4.27,6.97,7.05, 7.12, 7.14, 7.20, 7.45, 7.85.
Example 5 [[4-(4-{[4-(butyl{[(2,4-difluorophenyl)amino]carbonyl }amino)-1- piperidinyljmethyl} phenoxy)phenyl](methylsulfonyl)amino]acetic acid hydrochloride 0
Lo gel ScasPers
J eke
N N 0
FA + HCI
H1C
To a solution of the compound prepared in Example 3(106) (80 mg) in methanol (1 ml) was added 2N aqueous solution of sodium hydroxide (0.5 ml). The reaction mixture was stirred for 2.5 hours at room temperature. To the reaction mixture on ice bath was added IN hydrochloric acid until the pH of the solution was below 5, then it was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, concentrated. The obtained residue was purified by column chromatography on silica gel (dichloromethane : methanol = 9 : 1). To a solution of the obtained compound in ethyl acetate was added 4N hydrogen chloride in ethyl! acetate solution. The reaction mixture was concentrated to give the title compound (64 mg) having the following physical data.
TLC: Rf 0.45 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 0.98, 1.32-1.45, 1.57-1.70, 1.92-2.05, 2.12-2.31, 3.09, 3.06-3.20, 3.22- 3.35,351-361,417,430,4.43, 6.88-7.05,7.06,7.12,736,751-7.58.
Ye
Example 5(1) [{4-[4-({4-[({[5-(aminocarbonyl)-2,4-difluorophenyl amino } carbonyl )(butyl)amino]-1- piperidinyl } methyl)phenoxy]phenyl}(methylsulfonyl)amino]acetic acid hydrochloride
By the same procedure as described in Example 5 using the compound prepared in Example 3(107), the following the title compound was obtained.
TLC: Rf 0.17 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): 6 0.97, 1.30-1.42, 1.57-1.70, 1.90-2.02, 2.11-2.30, 2.95-3.10, 3.10, 3.23- 3.40,3.41-3.52, 4.16, 421, 4.30, 7.01, 7.06, 7.13, 7.48, 7.57, 7.86.
Example 6(1) - 6(20)
By the same procedure as described in Example 3 using the corresponding aldehyde compound instead of the compound prepared in Example 1 and the corresponding amine compound instead of the compound prepared in Example 2, the following compounds of the present invention were obtained.
Example 6(1) 2-(5-{[(butyl{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl}-4- piperidinyl }amino)carbonyl]amino }-2,4-difluorophenyl)acetamide hydrochloride (or dihydrochloride)
NH, 0 H
OSS ANSL
No Zo °0
Fon Lo
CH, + HCl or 2HCI
TLC: Rf 0.42 (chloroform : methanol =7 : 1);
NMR (CD;OD): 5 0.97, 1.30-1.50, 1.50-1.70, 1.95-2.10, 2.15-2.30, 2.97, 3.05-3.20, 3.20- 3.40, 3.50-3.60, 3.53, 4.10, 4.33, 7.00, 7.08-7.14, 7.30-7.34, 7.97, 8.24.
Example 6(2) 2-[2,4-difluoro-5-({[{1-[(6-{4-[(methylsulfonyl)amino phenoxy }-3-pyridinyl)methyl]-4- piperidinyl }(pentyl)aminojcarbonyl}amino)phenyl]acetamide hydrochloride (or : dihydrochloride)
w
TLC: Rf 0.43 (chloroform : methanol = 7 : 1);
NMR (CD;0D): 4 0.93, 1.30-1.50, 1.55-1.75, 1.90-2.10, 2.15-2.35, 2.97, 3.10-3.20, 3.20- 3.40, 3.50-3.60, 3.53, 4.15, 4.33, 7.00, 7.08-7.14, 7.30-7.34, 7.99, 8.25.
Example 6(3) 5-{[(butyl{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl}-4- piperidinyl}amino)carbonyl]amino}-2,4-difluoro-N-methylbenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.41 (chloroform : methanol = 7 : 1);
NMR (CDs;OD): § 0.98, 1.35-1.50, 1.65-1.80, 1.95-2.10, 2.20-2.35, 2.91, 2.97, 3.05-3.20, 3.20-3.40, 3.55-3.70, 4.10, 4.34, 7.08-7.16, 7.32, 7.80, 8.00, 8.24.
Example 6(4) 2,4-difluoro-N-methyl-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyrndinyl)methyl]-4-piperidinyl }(pentyl)amino]carbonyl }amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.43 (chloroform : methanol = 7 : 1);
NMR (CD;OD): § 0.93, 1.30-1.50, 1.60-1.75, 1.95-2.10, 2.20-2.40, 2.91, 2.97, 3.05-3 20, 3.20-3.40, 3.50-3.70, 4.15, 4.34, 7.08-7.16, 7.32, 7.79, 8.00, 8.24.
Example 6(5) 5-({[{1-[(6-{4-[(ethylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl}(pentyl)amino]carbonyl }amino)-2,4-difluoro-N-methylbenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.45 (chloroform : methanol =7 : 1);
NMR (CD;0D): 6 0.93, 1.33, 1.30-1.45, 1.60-1.70, 1.90-2.10, 2.15-2.30, 2.91, 3.05-3.20, 3.10, 3.20-3.40, 3.50-3.60, 4.10, 4.33, 7.07-7.16, 7.32, 7.79, 7.97, 8.24.
Example 6(6) 2,4-difluoro-N-methyl-5-({[{ 1-[(6-{2-methyl-4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl}-4-piperidinyl }(pentyl)amino]carbonyl }amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.45 (chloroform : methanol = 7 : 1);
NMR (CD;OD): § 0.93, 1.30-1.40, 1.60-1.70, 1.95-2.05, 2.13, 2.20-2.40, 2.91, 2.98, 3.05- 3.20, 3.20-3.40, 3.55-3.65, 4.15, 4.34, 7.11-7.21, 7.79, 8.04, 8.26.
®
Example 6(7) 5-{[(butyl{ 1-[(6-{2-chloro-4-[(ethylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino }-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.46 (dichloromethane : methanol =9 : 1),
NMR (CD;OD): 6 0.97, 1.33, 1.30-1.47, 1.59-1.70, 1.95-2.08, 2.20-2.37, 3.15, 3.05-3.20, 3.22-3.35, 3.52-3.62, 4.18, 4.34, 7.10-7.28, 7.41, 7.86, 8.05, 8.24.
Example 6(8) 5-({[(1-{4-[4-(aminocarbonyl)phenoxy]benzyl }-4- piperidinyl)(butyl)amino]carbonyl}amino)-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.40 (dichloromethane : methanol = 9 : 1);
NMR (CDs;OD): & 0.98, 1.32-1.49, 1.59-1.70, 1.95-2.09, 2.19-2.38, 3.08-3.20, 3.27-3.35, 3.51-3.65, 4.18, 4.32, 7.07, 7.08, 7.16, 7.57, 7.86, 7.91.
Example 6(9) 5-({[butyl(1-{4-[4-(4-morpholinylcarbonyl)phenoxy]benzyl}-4- piperidinyl)amino]carbonyl }amino)-2,4-difluorobenzamide hydrochloride
TLC: Rf 0.45 (dichloromethane : methanol =9 : 1);
NMR (CDsOD): 8 0.98, 1.31-1.47, 1.60-1.70, 1.98-2.07, 2.15-2.30, 3.04-3.20, 3.25-3.35, 3.50-3.80, 4.13, 4.31, 7.08-7.18, 7.48, 7.54, 7.86.
Example 6(10) 2-{5-[({butyl[1-(4-{4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyl]amino } carbonyl)amino]-2,4-difluorophenyl}acetamide hydrochloride
TLC: Rf 0.42 (chloroform : methanol = 7: 1),
NMR (CD;OD): 8 0.98, 1.30-1.50, 1.60-1.75, 1.95-2.10, 2.10-2.30, 2.95, 3.05-3.40, 3.53, 3.55-3.65, 4.15,4.28, 7.00-7.08, 7.28, 7.29, 7.49.
Example 6(11) 2-{5-[({butyl[ 1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl} methyl)-4- piperidinylJamino }carbonyl)amino}-2,4-difluorophenyl}acetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.44 (chloroform : methanol =7: 1);
NMR (CD;0D): & 0.98, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.15-2.30, 3.05-3.40, 3.15, 3.53, 3.55-3.65, 4.15, 4.36, 7.00, 7.23, 7.33, 7.40, 8.01, 8.04, 8.29.
L
Example 6(12) 2-{5-[({butyl[1-({6-[2-chloro-4-(methylsulfonyl)phenoxy]-3 -pyridinyl } methyl)-4- piperidinyl]Jamino } carbonyl)amino]-2,4-difluorophenyl}acetamide hydrochloride (or oT dihydrochloride)
TLC: Rf 0.42 (chloroform : methanol = 7 : 1);
NMR (CD;OD): § 0.98, 1.30-1.50, 1.60-1.70, 1.95-2.10, 2.15-2.35, 3.00-3.40, 3.30, 3.53, 3.55-3.65,4.15,4.37,7.00, 7.25, 7.33, 7.35, 7.53, 8.06, 8.16, 8.31.
Example 6(13) 2-[5-({[{1-[(6-{4-[(ethylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl}(pentyl)amino]carbonyl }amino)-2,4-difluorophenyl)acetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.33 (chloroform : methanol = 7 : 1);
NMR (CD;0D): 5 0.93, 1.30-1.50, 1.33, 1.60-1.70, 1.90-2.10, 2.15-2.35, 3.00-3 40, 3.10, 3.53,3.55-3.65,4.10,4.33, 7.00, 7.07-7.13, 7.32, 7.33, 7.97, 8.24.
Example 6(14) 2-[2,4-difluoro-5-({[{ 1-[(6-{2-methyl-4-[(methylsulfonyl)amino]phenoxy }-3- pyridinyl)methyl]-4-piperidinyl}(pentyl)amino]carbonyl }amino)phenyl]acetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.45 (chloroform : methanol = 7 : 1);
NMR (CD;0D): § 0.93, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.12, 2.20-2.40, 2.97, 3.00-3 40, 3.53,3.55-3.65, 4.15, 4.33, 6.96-7.21, 7.33, 8.01, 8.24.
Example 6(15) 2-[2,4-difluoro-5-({[[1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl](pentyl)amino]carbonyl}amino)phenylJacetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.39 (chloroform : methanol = 7 : 1);
NMR (CD;OD): § 0.93, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.10-2.30, 3.00-3.40, 3.15, 3.53, 3.55-3.65, 4.15, 4.36, 7.00, 7.22, 7.33, 7.40, 8.01, 8.04, 8.29.
Example 6(16) 2-[5-({[[1-({6-[2-chloro-4-(methylsulfonyl)phenoxy]-3-pyridinyl } methy1)-4- piperidinyl](pentyl)amino]carbonyl }amino)-2,4-difluorophenyl]acetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.44 (chloroform : methanol = 7 : 1);
_ ®
NMR (CDsOD): & 0.94, 1.30-1.50, 1.60-1.70, 1.90-2.10, 2.10-2 30, 3.00-3.40, 3.30, 3.53, 3.55-3.65,4.10, 4.35, 7.00, 7.25, 7.33, 7.37, 7.52, 8.05, 8.16, 8.31.
Example 6(17) N'-(4-fluorophenyl)-N-[1-({6-[4-(methylsulfony!)phenoxy]pyridin-3-yl }methyl)piperidin- 4-yl]-N-phenylurea hydrochloride (or dihydrochloride) 0, 0 peEVe as Na
NON “0
H
) + HCl or 2HCI
TLC: Rt 0.54 (dichloromethane : methanol =9 : 1);
NMR (CDs0D): & 1.62-1.80, 2.14-2.03, 3.14, 3.12-3.25, 3.48-3.58, 4.30, 4.67, 6.95, 7.16- 7.25, 7.30-7.40, 7.46-7.58, 7.96, 8.00, 8.22.
Example 6(18)
N-[1-({6-[2-chloro-4-(methylsulfonyl)phenoxy]pyridin-3-yl} methyl)piperidin-4-y1]-N'-(4- fluorophenyl)-N-phenylurea hydrochloride (or dihydrochloride)
TLC: Rf 0.54 (dichloromethane : methanol =9 : 1);
NMR (CDsOD): & 1.62-1.80, 2.15-2.23, 3.12-3.28, 3.31, 3.49-3.59, 4.30, 4.68, 6.95, 7.10, 7.18-7.25, 7.30-7.40, 7.49-7.58, 7.98, 8.15, 8.24.
Example 6(19)
N-[1-({6-[2-chloro-4-(methylsulfonyl)phenoxy]pyridin-3-yl} methyl)piperidin-4-y1]-N'- (2,4-difluorophenyl)-N-phenylurea hydrochloride (or dihydrochloride)
TLC: Rf 0.54 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.62-1.80, 2.15-2.25, 3.10-3.30, 3.31, 3.50-3.60, 4.31, 4.68, 6.84-6.96, 7.21, 7.30-7.39, 7.48-7.60, 7.98, 8.15, 8.24.
Example 6(20) 5-({[butyl(1-{[6-(4-{[(2-methoxyethyl)amino]carbonyl }-2-methylphenoxy)pyridin-3- yl]methyl}piperidin-4-yl)amino]carbonyl }amino)-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.52 (dichloromethane : methanol =9 : 1);
® ®
NMR (CDs;OD): 6 0.97, 1.32-1.47, 1.60-1.70, 1.97-2.04, 2.21, 2.20-2.37, 3.10-3.20, 3.21- 3.40, 3.57, 3.50-3.62, 4.18, 4.34, 7.10-7.20, 7.72, 7.80, 7.86, 8.06, 8.26.
Example 7(1) - 7(121)
By the same procedure as described in Example 3 using the corresponding aldehyde compound instead of the compound prepared in Example 1 and the corresponding amine compound instead of the compound prepared in Example 2, and it was converted into free form, if necessary, the following compounds of the present invention were obtained.
Example 7(1) 5-({{[1-({6-[2,6-dimethyl-4-(methylsulfonyl)phenoxy]-3 -pyridinyl }methyl)-4- piperidinyl](pentyl)amino]carbonyl}amino)-2, 4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.42 (chloroform : methanol =7 : 1);
NMR (CDsOD): § 0.93, 1.30-1.50, 1.60-1.80, 1.95-2.10, 2.17, 2.20-2.35, 3.00-3.40, 3.14, 3.50-3.70, 4.15, 4.33, 7.14, 7.21, 7.74, 7.86, 8.07, 8.18.
Example 7(2) 5-({[[1-({6-[2-chloro-4-(methylsulfony!)phenoxy]-3-pyridinyl} methyl)-4- piperidinyl](pentyl)amino]carbonyl }Jamino)-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.48 (chloroform : methanol = 7 : 1);
NMR (CD;O0D): § 0.93, 1.30-1.50, 1.60-1.80, 1.95-2.10, 2.20-2.40, 3.10-3.40, 3.30, 3.50- 3.70,4.15,4.37, 7.14, 7.25, 7.35, 7.53, 7.86, 8.10, 8.16, 8.32.
Example 7(3)
S-[({butyl[1-({6-[2-chloro-4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinylJamino }carbonyl)amino]-2-fluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf0.35 (chloroform : methanol = 7 : 1);
NMR (CD;0D): § 0.97, 1.30-1.50, 1.60-1.80, 1.95-2.10, 2.20-2.40, 3.10-3.40, 3 30, 3.50- 3.70, 4.15, 4.36, 7.14, 7.25, 7.35, 7.50, 7.53, 7.78, 8.07, 8.16, 8.32.
Example 7(4)
S-[({butyl[1-({6-[2-methyl-4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinylJamino } carbonyl)amino]-2-fluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.36 (chloroform : methanol = 7 : 1);
_ ®
NMR (CD;0D): § 0.97, 1.30-1.50, 1.55-1.70, 1.90-2.10, 2.20-2.40, 2.26, 3.00-3.40, 3.14, 3.50-3.70, 4.20, 4.35, 7.11-7.30, 7.53, 7.76-7.85, 7.92, 8.07, 8.24.
Example 7(5) 2,4-difluoro-5-{[(hexyl{1 -[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]- 4-piperidinyl }amino)carbonyl}amino }benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.37 (chloroform : methanol =7 : 1);
NMR (CD;OD): 8 0.98, 1.30-1.50, 1.60-1.70, 1.90-2.05, 2.20-2.35, 2.97, 3.00-3.35, 3.50- 3.70, 4.20, 4.34, 7.08-7.17, 7.32, 7.86, 8.02, 8.24.
Example 7(6) 2,4-difluoro-5-{[((2-methylbenzyl){1-[(6-{ 4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl }amino)carbonyl)amino } benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.53 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.98-2.20, 2.36, 2.97, 3.04-3.18, 3.48-3.57, 4.30, 4.43, 4.57, 7.04-7.33, 7.85, 7.98. 8.23.
Example 7(7) 2,4-difluoro-5-({[[ 1-({6-[2-methyl-4-(methylsulfonyl)phenoxy]-3 -pyridinyl } methyl)-4- piperidinyl](pentyl)amino]carbonyl }Jamino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.38 (chloroform : methanol = 7 : 1);
NMR (CD;OD): § 0.94, 1.30-1.50, 1.60-1.80, 1.90-2.10, 2.26, 2.20-2.40, 3.05-3 40, 3.14, 3.50-3.70, 4.15, 4.33, 7.11-7.29, 7.81-7.89, 7.92, 8.03, 8.23.
Example 7(8) 2,4-difluoro-5-{[({ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl}amino)carbonyl]Jamino }benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.37 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.65-1.80, 2.20-2.30, 2.98, 3.08-3.21, 3.50-3.60, 3.83, 4.34, 7.07-7.19, 733,802,827, 838.
Example 7(9)
N'-(4-fluorophenyl)-N-[1 -({6-[2-methoxy-4-(methylsulfonyl)phenoxy]-3- pyridinyl}methyl)-4-piperidinyl]-N-phenylurea hydrochloride (or dihydrochloride)
TLC: Rf 0.55 (dichloromethane : methanol = 9 : 1);
NMR (CD;0D): § 1.64-1.80, 2.12-2.22, 3.17, 3.10-3.25, 3.48-3.58, 3.79, 4.27, 4.67, 6.95, 7.12,7.22,7.30-7.38, 7.45-7.64, 7.93, 8.12.
_ ®
Example 7(10)
N'-(2,4-difluorophenyl)-N-[1-({6-[2-methyl-4-(methylsulfonyl)phenoxy]-3- pyridinyl} methyl)-4-piperidinyl]-N-phenylurea hydrochloride (or dihydrochloride)
TLC: Rf 0.56 (dichloromethane : methanol = 9 : 1);
NMR (CD3;OD): 6 1.65-1.80, 2.15-2.28, 2.24, 3.13, 3.12-3.24, 3.50-3.58, 4.29, 4.68, 6.85- 6.98, 7.17, 7.26, 7.34-7.38, 7.48-7.60, 7.81, 7.91, 7.98, 8.17.
Example 7(11) N'-(2,4-difluoropheny!l)-N-[1-({6-[2,6-dimethyl-4-(methylsulfonyl)phenoxy]-3- pyridinyl}methyl)-4-piperidinyl]-N-phenylurea hydrochloride (or dihydrochloride)
TLC: Rf 0.56 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): 6 1.62-1.80, 2.15, 2.12-2.23, 3.13, 3.10-3.24, 3.50-3.58, 4.27, 4.68, 6.85- 6.98, 7.18, 7.33-7.37, 7.50-7.60, 7.73, 7.96, 8.11.
Example 7(12)
N'-(2,4-difluorophenyl)-N-{1-({6-[2-methoxy-4-(methylsulfonyl)phenoxy]-3- pyridinyl} methyl)-4-piperidinyl]-N-phenylurea hydrochloride (or dihydrochloride)
TLC: Rf 0.55 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): 6 1.64-1.80, 2.15-2.24, 3.17, 3.12-3.25, 3.48-3.58, 3.79, 4.28, 4.68, 6.85- 6.98,7.12, 7.33-7.37, 7.50-7.60, 7.95, 8.13.
Example 7(13) 2,4-difluoro-5-[({ hexyl 1-({6-[2-methoxy-4-(methylsulfonyl)phenoxy]-3- pyridinyl}methyl)-4-piperidinylJamino}carbonyl)amino]benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.35 (chloroform : methanol =7 : 1);
NMR (CDs;OD): § 0.91, 1.25-1.45, 1.60-1.75, 1.90-2.10, 2.20-2.40, 3.05-3.40, 3.14, 3.50- 3.70,3.81, 4.15, 4.35, 7.14, 7.15, 7.38, 7.60-7.65, 7.86, 8.09, 8.24.
Example 7(14)
N'-(4-fluorophenyl)-N-[1-({6-[2-methyl-4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)- 4-piperidinyl]-N-phenylurea hydrochloride (or dihydrochloride)
TLC: Rf 0.75 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): & 1.63-1.80, 2.12-2.23, 2.24, 3.13, 3.10-3.25, 3.48-3.57, 4.29, 4.67, 6.95, 7.15-7.35,7.47-7.60, 7.81, 7.91, 7.97, 8.17.
® _
Example 7(15)
N-[1-({6-[2,6-dimethyl-4-(methylsulfonyl)phenoxy]-3-pyridinyl} methyl)-4-piperidinyl]-
N'-(4-fluorophenyl)-N-phenylurea hydrochloride (or dihydrochloride)
TLC: Rf 0.75 (dichloromethane : methanol = 9 : 1);
NMR (CDs;OD): & 1.64-1.80, 2.15, 2.10-2.23, 3.13, 3.10-3.25, 3.48-3.58, 4.27, 4.67, 6.95, 7.15-7.25,7.30-7.35, 7.48-7.60, 7.73, 7.97, 8.11.
Example 7(16) 5-{[(butyl{1-[(2-methyl-6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino}-2,4-difluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.56 (dichloromethane : methanol =9 : 1),
NMR (CD;0D): 6 0.98, 1.32-1.45, 1.58-1.70, 1.95-2.05, 2.24-2.40, 2.67, 2.99, 3.20-3.35, 3.60-3.69, 4.28, 4.43, 6.95, 7.14, 7.22, 7.37, 7.87, 8.20.
Example 7(17) 4-chloro-2-fluoro-5-({[[ 1-({6-[2-methyl-4-(methylsulfonyl)phenoxy]-3-pyridinyl } methy!)- 4-piperidinyl](pentyl)amino]carbonyl} amino)benzamide hydrochloride (or : dihydrochloride)
TLC: Rf 0.55 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 0.94, 1.30-1.50, 1.67-1.80, 1.98-2.06, 2.26, 2.19-2.38, 3.10-3.20, 3.14, 3.25-3.35,3.55-3.65, 4.20, 4.34, 7.21, 7.28, 7.41, 7.83, 7.90-7.99. 8.06, 8.24.
Example 7(18) 4-chloro-5-({[[1-({6-[2,6-dimethyl-4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl](pentyl)amino]carbonyl}amino)-2-fluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.55 (dichloromethane : methanol =9 : 1);
NMR (CD;0D): 6 0.94, 1.30-1.47, 1.65-1.80, 1.98-2.08, 2.17, 2.15-2.35, 3.08-3.20, 3.13, 3.25-3.35,3.55-3.65, 4.19, 4.33, 7.21, 7.41, 7.74, 7.97, 8.06, 8.18.
Example 7(19) 5-{[(butyl{1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyi]amino }-4-chloro-2-fluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.54 (dichloromethane : methanol =9 : 1);
NMR (CD3;0D): & 0.98, 1.35-1.48, 1.62-1.75, 1.98-2.08, 2.19-2.38, 2.97, 3.08-3.20, 3.25- 3.35,3.55-3.63,4.17, 4.34, 7.09, 7.13, 7.32, 7.42, 7.94, 8.02, 8.27.
® ®
Example 7(20)
S-[({butyl[1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinylJamino} carbonyl)amino}-4-chloro-2-fluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.54 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 0.99, 138-150, 1.64-1.75, 1.98-2.07, 2.20-2.38, 3.15, 3.08-3.20, 3.25- 335,3.58-3.65, 4.18, 4.36, 7.22, 7.40, 7.41, 7.94, 8.02, 8.07, 8.30.
Example 7(21) 5-[({butyl[1-({6-[2-chloro-4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl]amino } carbonyl)amino]-4-chloro-2-fluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.55 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): 4 0.99, 1.38-1.45, 1.64-1.75, 1.98-2.07, 2.20-2.38, 3.08-3.22, 3.25-3.35, 3.31,3.58-3.65, 4.18, 4.37,7.25, 7.36, 7.41, 7.53, 7.94, 8.09, 8.16, 8.32.
Example 7(22) 5-[({butyl[1-({6-[2,6-dimethyl-4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl]amino}carbonyl)amino]-4-chloro-2-fluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.56 (dichloromethane : methanol = 9 : 1),
NMR (CD;OD): § 0.98, 1.35-1.48, 1.62-1.75, 1.97-2.08, 2.17, 2.19-2.38, 3.08-3.21, 3.14, 3.25-3.35,3.52-3.65, 4.19, 4.33, 7.21, 7.41, 7.73, 7.94, 8.07, 8.18,
Example 7(23)
N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }(phenyl)amino]-1-piperidinyl } methyl)- 2-pyrazinyl]oxy }phenyl)methanesulfonamide dihydrochloride
TLC: Rf 0.50 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): & 1.70-1.84, 2.14-2.23, 2.97, 3.20-3.35, 3.55-3.65, 4.40, 4.68, 6.95, 7.17, 7.22,7.29-7.38, 7.48-7.60, 8.19, 8.48.
Example 7(24)
N-(4-{[5-({4-[[(cyclohexylamino)carbonyl](phenyl)amino}-1-piperidinyl } methy!)-2- pyridinylJoxy}phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.51 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): & 0.93-1.15, 1.20-1.38, 1.49-1.80, 2.08-2.18, 2.97, 3.10-3.21, 3.47-3.58, 4.28,4.62,707,7.12,7.18-7.25, 733, 7.42-7.55, 7.98, 8.23.
® ®
Example 7(25)
N-[4-({5-[(4-{phenyl[(3-thienylamino)carbonyl]amino }-1-piperidinyl)methyl]-2- pyridinyl}oxy)phenyl]methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.50 (dichloromethane : methanol =9 : 1);
NMR (CD;0D): 6 1.64-1.80, 2.12-2.20, 2.98, 3.12-3.26, 3.50-3.59, 4.32, 4.68, 6.91, 7.10, 7.04-7.20, 7.27-7.37,7.48-7.60, 8.07, 8.31.
Example 7(26)
N-(4-{[5-({4-[(anilinocarbonyl)(phenyl)amino]-1-piperidinyl jmethyl)-2- pyridinylJoxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.56 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 6 1.62-1.80, 2.15-2.24, 2.97, 3.12-3.23, 3.49-3.57, 4.27, 4.68, 6.97-7.14, 7.18-7.22, 7.28-7.38, 7.48-7.60, 7.89, 8.17.
Example 7(27)
N-(4-{[5-({4-[[(benzylamino)carbonyl](phenyl)amino]-1-piperidinyl } methyl)-2- pyridinylJoxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.55 (dichloromethane : methanol =9 : 1);
NMR (CD;0D): § 1.60-1.78, 2.08-2.18, 2.97, 3.08-3.21, 3.48-3.55, 4.25, 4.29, 4.64, 7.08, 7.10-7.27, 7.32, 7.40-7.58, 8.01, 8.27.
Example 7(28)
N-{4-[(5-{[4-(phenyl{[(2-phenylethyl)amino]carbonyl }amino)- 1-piperidinylJmethyl}-2- pyridinyl)oxy]phenyl}methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.55 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.57-1.73, 2.04-2.13, 2.67, 2.98, 3.10-3.22, 3.27-3.35, 3.48-3.55, 431, 4.60, 7.04-725, 7.34, 7.40-7.47, 8.06, 8.31.
Example 7(29)
N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }(3-thieny})amino]-1- piperidinyl } methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
H
F N._. CH 0 N SN Su
A ge
N N 0
H
QO
\ S + HCl or 2HCI
TLC: Rf 0.30 (chloroform : methanol = 10 : 1);
NMR (CD;OD): § 1.60-1.80, 2.10-2.20, 2.97, 3.10-3.25, 3.50-3.60, 4.29, 4.65, 6.93-7.13, 7.22-7.33,7.53,7.61,794, 8.21.
Example 7(30)
N-[4-({5-[(4-{3-thienyl[(3-thienylamino)carbonyl]amino}-1 -piperidinyl)methyl]-2- pyridinyl}oxy)phenyl]methanesulfonamide hydrochloride (or dihydrochloride)
N..CH
SHNeasNey 4
NN = 00
N N 0)
H
QO
\ S + HCl or 2HCI
TLC: Rf 0.55 (dichloromethane : methanol =9 : 1);
NMR (CDsOD): 5 1.62-1.78, 2.11-2.20, 2.97, 3.12-3.25, 3.48-3.58, 4.28, 4.67, 6.95, 7.00, 7.06,7.11,7.17-7.23,7.31, 7.49, 7.60, 7.90, 8.18.
Example 7(31)
N-(4-{[5-({4-[{[(3-fluorophenyl)amino]carbonyl}(phenyl)amino]-1 -piperidinyl} methyl)- 2-pyridinyl]oxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.56 (dichloromethane : methanol = 9 : 1);
NMR (CDsOD): & 1.62-1.80, 2.12-2.24, 2.97, 3.12-3.25, 3 48-3.58, 4.27, 4.68, 6.72, 6.93, 7.03-7.35, 7.48-7.60, 7.89, 8.17.
Example 7(32)
N-(4-{[5-({4-[{[(2-fluorophenyl)amino]carbonyl } (phenyl)amino]- 1-piperidinyl } methyl)- 2-pyridinylJoxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.56 (dichloromethane : methanol =9 : 1);
® [
NMR (CD;OD): 5 1.63-1.80, 2.18-2.25, 2.97, 3.12-3.25, 3.48-3.58, 4.28, 4.69, 6.98-7.15, 7.31, 7.35-7.40, 7.50-7.62, 7.73, 7.90, 8.17.
Example 7(33)
N-(4-{[5-({4-[{[(4-methoxyphenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl}methyl)-2-pyridinylJoxy }phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.48 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): 5 1.62-1.80, 2.13-2.21, 2.97, 3.12-3.25, 3.48-3.57, 3.73, 4.27, 4.67, 6.79, 7.05,7.09, 7.10, 7.28-7.35, 7.47-7.58, 7.90, 8.17.
Example 7(34)
N-(4-{[5-({4-[{[(3-methoxyphenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl}methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.48 (dichloromethane : methanol =9 : 1);
NMR (CDs;0D): 8 1.62-1.80, 2.13-2.25, 2.97, 3.12-3.25, 3.48-3.57, 3.72, 4.28, 4.67, 6.58, 6.73, 6.94, 7.04-7.15, 7.29-7.35, 7.49-7.60, 7.90, 8.18.
Example 7(35)
N-(4-{[5-({4-[{[(2-methoxyphenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.48 (dichloromethane : methanol =9 : 1),
NMR (CD;0D): § 1.62-1.80, 2.15-2.27, 2.97, 3.12-3.25, 3.50-3.60, 3.55, 4.29, 4.71, 6.80- 6.97,7.05, 7.11, 7.31, 7.37, 7.51-7.64, 7.91, 7.95, 8.18.
Example 7(36)
N-(4-{[5-({4-[{[(4-methylphenyl)amino]carbony! }(phenyl)amino]-1-piperidinyl } methyl)- 2-pyridinyl]oxy}phenyl)methanesulfonamide
Amorphous powder;
TLC: Rf 0.48 (dichloromethane : methanol =9 : 1),
NMR (CD;OD): & 1.34-1.50, 1.80-1.91, 2.10-2.20, 2.23, 2.83-2.98, 2.95, 3.44, 4.43, 6.88, 6.98-7.10, 7.28, 7.45-7.57, 7.73, 7.98.
Example 7(37)
N-(4-{[5-({4-[{[(3-methylphenyl)amino]carbony!}(phenyl)amino]-1-piperidinyl } methyl)- 2-pyridinyl]oxy } phenyl)methanesulfonamide
® [
TLC: Rf 0.48 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): & 1.35-1.50, 1.80-1.91, 2.08-2.20, 2.24, 2.84-2.98 2.94, 3.44, 4.43, 6.80, 6.87, 6.97-7.12, 7.26-7.34, 7.44-7.58, 7.73, 7.98.
Example 7(38)
N-(4-{[5-({4-{{[(2-methylphenyl)amino]carbonyl} (phenyl)amino]}- 1-piperidinyl } methy!)- 2-pyridinyl]oxy } phenyl)methanesulfonamide
TLC: Rf 0.48 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 6 1.38-1.54, 1.84-1.96, 1.91, 2.10-2.20, 2.85-2.98, 2.95 3.44, 4.43, 6.88, 6.97,7.02-7.14,7.28, 7.35, 7.42-7.60, 7.73, 7.98.
Example 7(39)
N-(4-{[5-({4-[{[(4-chlorophenyl)amino]carbonyl} (phenyl)amino]- I-piperidinyl } methy})- 2-pyridinyljoxy }phenyl)methanesulfonamide
White amorphous powder;
TLC: Rf 0.52 (dichloromethane : methanol =9 : 1);
NMR (CDCh) : 6 1.32-1.48, 1.80-1.89, 2.08-2.20, 2.82-2.90, 3.01, 3.40, 4.53, 5.83, 6.43, 6.85, 7.08-7.28, 7.44-7.55, 7.61, 8.00.
Example 7(40)
N-(4-{[5-({4-[{[(3-chlorophenyl)amino]carbonyl}(phenyl)amino]-1-piperidinyl } methyl)- 2-pyridinyl]oxy } phenyl)methanesulfonamide
TLC: Rf 0.52 (dichloromethane : methanol = 9 : 1),
NMR (CDCl) : & 1.32-1.50, 1.80-1.90, 2.08-2.20, 2.82-2.90, 3.01, 3.41, 4.53, 5.85, 6.52, 6.85,6.94,7.02-7.15, 7.19-7.28, 7.35, 7.44-7.55, 7.61, 8 Ol.
Example 7(41)
N-(4-{[5-({4-[{[(2-chlorophenyl)amino]carbonyl}(phenyl)amino]-1-piperidinyl} methyl)- 2-pyridinyl]oxy } phenyl)methanesulfonamide
TLC: Rf0.52 (dichloromethane : methanol = 9 : 1);
NMR (CDCl) : 8 1.38-1.53, 1.82-1.90, 2.08-2.20, 2.83-2.92, 3.01, 3.41, 453, 6.47, 6.59, . 6.85,687,7.12,7.18,7.22-7.28, 7.42-7.55, 7.61, 8.01, 8.27.
Example 7(42)
N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }( 1-methyl-1H-pyrazol-4-yl)amino]-1- piperidinyl } methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide
TLC: Rf 0.40 (dichloromethane : methanol = 9 : 1);
® [
NMR (CDCl) : 3 1.30-1.48, 1.70-1.80, 2.08-2.19, 2.81-2.90, 3.01, 3.41, 3.96, 4.46, 6.26, 6.35,6.85,692,7.11, 7.18-7.28, 7.37, 7.61, 8.01.
Example 7(43) 2-fluoro-5-({[{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl }(phenyl)amino]carbonyl }amino)benzamide
HoN 0
H
ACN SSRs Te rr.
NON “0 0 fe
Free form;
White amorphous powder; :
TLC: Rf 0.45 (dichloromethane : methanol =9 : 1);
NMR (CDCls) : § 1.32-1.48, 1.80-1.90, 2.08-2.20, 2.81-2.92, 3.00, 3.40, 4.55, 5.86, 5.97, 6.62-6.77, 6.85, 7.06, 7.11, 7.18-7.30, 7.34, 7.45-7.55, 7.61, 8.00, 8.04.
Hydrochloride (or dihydrochloride);
White amorphous powder;
TLC: Rf 0.45 (dichloromethane : methanol = 9 : 1);
NMR (CDs;OD): 6 1.62-1.81, 2.12-2.23, 2.97, 3.12-3.35, 3.47-3.58, 4.29, 4.67, 7.07-7.16, 7.29-7.36, 7.43, 7.48-7.58, 7.68, 7.95, 8.22.
Example 7(44) 4-fluoro-N-{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl }-N-phenylbenzamide
TLC: Rf 0.58 (chloroform : methanol = 7 : 1);
NMR (CDCl) : 6 1.50-1.70, 1.85-1.95, 2.10-2.30, 2.85-2.95, 2.98, 3.41, 4.72, 6.75-6.84, 6.95-6.98, 7.07, 7.19-7.25, 7.59, 7.99.
Example 7(45)
N-[4-({5-[(4-{phenyl[(3-pyridinylamino)carbonyl]amino}-1-piperidinyl)methyl]-2- pyrdinyl}oxy)phenyl]methanesulfonamide
TLC: Rf 0.40 (dichloromethane : methanol = 9 : 1);
® [J
NMR (CDCl) : 5 1.34-1.50, 1.80-1.90, 2.10-2.20, 2.80-2.90, 3.00, 3.40, 4.54, 5.87, 6.83, 7.09, 7.18, 7.20-7.28, 7.45-7.55, 7.59, 7.91, 7.99, 8.16, 8.20.
Example 7(46)
N-(4-{[5-({4-[(aminocarbonyl)(phenyl)amino]-1-piperidinyl } methyl)-2- pyridinyl]oxy } phenyl)methanesulfonamide
TLC: Rf 0.38 (dichloromethane : methanol =9 : 1);
NMR (CDCl) : 8 1.30-1.44, 1.76-1.85, 2.08-2.18, 2.80-2.88, 3.01, 3.39, 4.20, 4.48, 6.83, 6.90, 7.11, 7.13-7.18, 7.22-7.28, 7.35-7.45, 7.59, 7.98.
Example 7(47)
N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }(4-methoxyphenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide
TLC: Rf 0.43 (dichloromethane : methanol =9 : 1);
NMR (CDCl) : 6 1.31-1.49, 1.77-1.86, 2.09-2.18, 2.81-2.90, 3.01, 3.40, 3.86, 4.50, 5.85, 6.38, 6.84, 6.89, 6.96, 7.08-7.25, 7.60, 7.99.
Example 7(48)
N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }(3-methoxyphenyl)amino]-1- piperidinyl}methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide
TLC: Rf 0.43 (dichloromethane : methanol = 9 : 1);
NMR (CDCl) : 8 1.37-1.51, 1.80-1.89, 2.08-2.18, 2.81-2.90, 3.01, 3.40, 3.83, 4.51, 5.87, 6.38, 6.73, 6.80, 6.84, 6.90, 6.98, 7.08-7.26, 7.37, 7.60, 8.00.
Example 7(49)
N-(4-{[5-({3-[{[(4-fluorophenyl)amino]carbonyl }(phenyl)amino]-8-azabicyclo[3.2.1]oct- 8-yl} methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.29 (chloroform : methanol = 10: 1);
NMR (CD;OD): § 1.90-2.05, 2.20-2.30, 2.35-2.50, 2.60-2.75, 2.97, 3.85-3.95, 4.16, 4.55, 6.92-6.98,7.06-7.14, 7.19-7.24, 7.29-7.33, 7.36-7.40, 7.48-7.58, 8.01, 8.25.
Example 7(50) 4-{[5-({4-[{[(4-fluorophenyl)amino]carbony!} (phenyl)amino]-1-piperidinyl} methy1)-2- pyridinylJoxy} benzoic acid hydrochloride (or dihydrochloride)
TLC: Rf 0.39 (chloroform : methanol = 10 : 1);
NMR (CD;0D): & 1.65-1.80, 2.10-2.25, 3.10-3.30, 3.50-3.60, 4.30, 4.65, 6.92-6.98, 7.13, 7.19-7.24,7.31-7.34,7.49-7.55, 7.96, 8.08, 8.25.
® ®
Example 7(51)
N-(4-{[5-({4-[{[(2,4-difluorophenyl)amino]carbonyl} (phenyl)amino]-1- piperidinyl}methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.63 (chloroform : methanol = 10 : 1);
NMR (CD;OD): 4 1.65-1.80, 2.10-2.30, 2.98, 3.10-3.30, 3.50-3.60, 4.31, 4.70, 6.88-6.92, 7.09, 7.15, 7.32-7.34, 7.33, 7.51-7.58, 8.04, 8.29.
Example 7(52)
N-(4-{[5-({4-[{[(3-fluoro-4-methoxyphenyl)amino]carbony!} (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.50 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.65-1.82, 2.12-2.22, 2.98, 3.12-3.28, 3.48-3.58, 3.79, 4.32, 4.67, 6.84- 6.96, 7.09, 7.13-7.22, 7.28-7.38, 7.45-7.58, 8.05, 8.30.
Example 7(53)
N-(4-{[5-({4-[{ [(3-chloro-4-methoxyphenyl)amino]carbonyl} (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyljoxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.50 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.68-1.82, 2.12-2.22, 2.98, 3.12-3 28, 3.48-3.58, 3.81, 4.32, 4.68, 6.92, 7.06,7.09, 7.16, 7.30-7.38, 7.45-7.58, 8.05, 8.30.
Example 7(54)
N-(4-{[5-({4-[ {[(6-methyl-3 -pyridinyl)amino]carbonyl}(phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]Joxy} phenyl)methanesulfonamide dihydrochloride (or trihydrochloride)
H
Soy “0 0
H
9 + 2HC! or 3HCI
Amorphous powder;
TLC: Rf 0.48 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): & 1.68-1.85, 2.12-2.25, 2.68, 2.97, 3.15-3.28, 3.50-3.60, 4.31, 4.71, 7.07, 7.13,7.29-7.38,7.50-7.62, 7.73, 8.01, 8.25, 8.31, 8.97.
Example 7(55)
N-(4-{[5-({4-[ {[(4-fluorophenyl)amino]carbony!}(phenyl)amino]-1-piperidinyl }methyl)- 2-pyridinyl]oxy} phenyl)acetamide hydrochloride (or ihydrochloride)
Amorphous powder;
TLC: Rf 0.23 (chloroform : methanol = 10 : 1);
NMR (CD;OD): & 1.60-1.80, 2.10-2.25, 3.10-3.25, 3.50-3.60, 3.55, 4.28, 4.70, 6.95, 7.04- 7.10, 7.19-7.24,7.31-7.38, 7.49-7.55, 7.93, 8.21.
Example 7(56)
N-{4-[4-({4-[{[(4-fluorophenyl)amino]carbony! }(phenyl)amino]-1-piperidinyl } methyl)- 3,5-dimethyl-1H-pyrazol-1-yl]phenyl} methanesulfonamide dihydrochloride
CH
E 3 0) N —
J AN NH
N N N EAC I
H H3C 075 CH; 0 + 2HCI
TLC: Rf 0.21 (chloroform : methanol = 10 : 1);
NMR (CD;OD): & 1.70-1.85, 2.10-2.25, 2.31, 2.33, 3.03, 3.20-3.35, 3.55-3.65, 4.20, 4.70, 6.96, 7.21-7.25, 7.33-7.41, 7.50-7.56.
Example 7(57) 4-[4-({4-[{[(4-fluorophenyl)amino]carbonyl } (phenyl)amino]-1-piperidinyl} methyl)-3,5- dimethyl-1H-pyrazol-1-yl]-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide trihydrochloride
_ ®
F CH;
TLE OT E-Lo A
NTN Heo oN in— 0) + 3HCI
TLC: Rf 0.20 (chloroform : methanol = 10 : 1);
NMR (CD;0D): 6 1.70-1.85, 2.10-2.25, 2.34, 2.41, 3.20-3.40, 3.50-3.65, 3.80-3.95, 4.00- 4.15,4.21,4.70, 6.96, 7.20-7.25, 7.35, 7.45-7.56, 7.75, 8.05.
Example 7(58)
N-{4-[(5-{[4-((3,5-dimethyl-4-isoxazolyl){[(4-fluorophenyl)amino]carbonyl }amino)-1- piperidinyl]methyl}-2-pyridinyl)oxy]phenyl} methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.53 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.68-1.88, 2.09-2 23, 2.20, 2.40, 2.97, 3.12-3.25, 3.50-3.60, 4.32, 4.60, 6.99, 7.09, 7.13, 7.25-7.35, 8.01, 8.25.
Example 7(59)
N-{4-[(5-{[4-(1,3-benzothiazol-6-yI{[(4-fluorophenyl)amino]carbonyl }amino)-1- piperidinyl]methyl}-2-pyridinyl)oxy]phenyl} methanesulfonamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.49 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.68-1.85, 2.19-2.28, 2.97, 3.12-3.25, 3.50-3.60, 4.30, 4.71, 6.94, 7.07, 7.13,7.23, 7.32, 7.51, 8.00, 8.15, 8.20, 8.25, 9.46.
Example 7(60)
N-(4-{[5-({4-[{[(3,4-difluoropheny!)amino]carbony! } (phenyl)amino]-1- piperidinyl}methyl)-2-pyridinyljoxy} phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.51 (dichloromethane : methanol = 9 : 1);
NMR (CD;0D): 5 1.64-1.81, 2.12-2.22, 2.97, 3.12-3.25, 3.48-3.58, 4.29, 4.68, 6.93, 7.02- 7.15,7.28-7.35, 7.38, 7.45-7.58, 7.95, 8 21.
@
Example 7(61)
N-(4-{ [5-({4-[[(2,3-dihydro-1,4-benzodioxin-6-ylamino)carbonyl)(phenyl)amino}-1- piperidinyl } methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf0.51 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 4 1.63-1.80, 2.12-2.22, 2.97, 3.11-3.25, 3.48-3.55,4.17, 4.29, 4 68, 6.56, 6.66, 6.81, 7.07, 7.12, 7.27-7.35, 7.45-7.58, 7.96, 8.22.
Example 7(62)
N-(4-{[5-({4-[{[(2,4-difluorophenyl)amino]carbonyl} (3-thienyl)amino]-1- piperidinyl} methyl)-2-pyridinyl|oxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
H poSNsasNer:Y
N" ON “No °°
H
AN
>
S + HCI or 2HCI
TLC: Rf 0.52 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 6 1.63-1.80, 2.12-2.22, 2.97, 3.12-3.25, 3.48-3.58, 4.28, 4.68 6.85-6.98, 7.03-7.08,7.11, 7.31, 7.53-7.60, 7.64, 7.89, 8.18,
Example 7(63)
N-(4-{[5-({4-[{[(3,4-difluorophenyl)amino]carbony!} (3-thienyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy} phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.52 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 1.62-1.80, 2.10-2.20, 2.97, 3.12-3.25, 3.48-3.58, 4.28, 4.68, 6.94-7.16, 7.31, 7.40, 7.51, 7.61, 7.90, 8.18.
Example 7(64)
N-(4-{ [5-({4-[{[(4-fluorophenyl)amino]carbonyl } (2-methoxyphenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy} phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.52 (dichloromethane : methanol = 9 : 1);
® [ _
NMR (CD;OD): 6 1.61-1.83, 2.15-2.25, 2.97, 3.10-3.22, 3.48-3.56, 3 84, 4.28, 4.58, 6.95, 7.05-7.29, 7.32, 7.46, 7.97, 8.23.
Example 7(65)
N-{4-[(5-{[4-((4-fluoropheny]){ [(4-fluorophenyl)amino]carbonyl }amino)-1- piperidinylJmethyl}-2-pyridinyl)oxy]phenyl}methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.52 (dichloromethane : methanol =9 : 1);
NMR (CDsOD): 6 1.60-1.78, 2.12-2.21, 2.97, 3.10-3.25, 3.48-3.58, 4.28, 4.65, 6.95, 7.05, 7.09,7.19-737,7.90, 8.17.
Example 7(66)
N-{4-[(5-{[4-((3-fluorophenyl){ [(4-fluorophenyl)amino]carbonyl }amino)-1- piperidinyl]methyl}-2-pyridinyl)oxy]phenyl} methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.52 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 8 1.65-1.85, 2.12-2.25, 2.97, 3.12-3.25, 3.48-3.58, 4.28, 4.65, 6.95, 7.04- 7.20, 7.22-7.33, 7.30, 7.53, 7.90, 8.17.
Example 7(67)
N'-(4-chlorophenyl)-N-[1 -({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl} methyl)-4- piperidinyl]-N-phenylurea hydrochloride (or dihydrochloride)
TLC: Rf 0.26 (ethyl acetate),
NMR (CDsOD): § 1.60-1.80, 2.10-2.30, 3.10-3.30, 3.14, 3.50-3.60, 4.30, 4.65, 7.17-7.23, 7.31-7.39,7.52-7.55,7.90-8.02, 8.21.
Example 7(68)
N'-(4-fluorophenyl)-N-[1-({ 6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl]-N-(3-thienyl)urea hydrochloride (or dihydrochloride)
TLC: Rf 0.29 (chloroform : methanol = 10 : 1);
NMR (CD;OD): 6 1.60-1.80, 2.05-2.20, 3.14, 3.15-3.25, 3.50-3.60, 4.29, 4.65, 6.97, 7.04, 7.18-7.27,7.38,7.52, 7.61, 7.96-8.02, 8.23.
Example 7(69) 2-chloro-N-methyl-5-({[{ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy} -3-pyridinyl)methyl]- 4-piperidinyl }(phenyl)amino]carbonyl}amino)benzamide hydrochloride (or dihydrochloride)
N._0
H;C~ i N CH 2,070 re (ONO)
N N 0
H
- HCl or 2HCI
TLC: Rf 0.50 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.65-1.81, 2.12-2.22, 2.86, 2.97, 3.12-3.25, 3.49-3.58, 4.29, 4.67, 7.07, 7.13,7.25-7.35,7.43,7.46-7.60, 7.96, 8.22.
Example 7(70) 2-chloro-N,N-dimethyl-5-({[{ 1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl}-4-piperidinyl}(phenyl)amino}carbonyl }amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.50 (dichloromethane : methanol = 9 : 1);
NMR (CD3;OD): 8 1.65-1.81, 2.12-2.22, 2.86, 2.97, 3.08, 3.12-3.25, 3.49-3.58, 4.30, 4.67, 7.08, 7.14, 7.27-7.36, 7.48-7.60, 7.99, 8.25.
Example 7(71)
N-(4-{[5-({4-[{ [(4-chloro-3-nitrophenyl)amino]carbony!} (phenyl)amino]-1- piperidinyl } methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide
TLC: Rf 0.39 (chloroform : methanol = 7 : 1);
NMR (CDCl) : & 1.40-1.60, 1.80-1.90, 2.10-2.20, 2.80-2.90, 2.99, 3.46, 4.51, 4.64, 6.08, 6.84,7.09,721-727,731-7.41,7.51-7.54, 7.61, 7.89, 8.01.
Example 7(72)
N-(4-{[5-({4-[({[4-(methylsulfony!)phenyl]amino} carbonyl)(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.52 (chloroform : methanol = 10 : 1);
NMR (CDsOD): § 1.65-1.85, 2.10-2.30, 2.97, 3.05, 3.10-3.30, 3.50-3.60, 4.29, 4.70, 7.06, 7.11, 7.30-7.35, 7.32, 7.51-7.58, 7.77, 7.94. 8.20.
® ®
Example 7(73)
N-(4-{[5-({4-[({[3-(methylsulfonyl)p henyl]amino }carbonyl)(phenyl)amino]-1- piperidinyl }methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.49 (chloroform : methanol = 10 : 1);
NMR (CD3;0D): 6 1.65-1.85, 2.10-2.25, 2.98, 3.07, 3.10-3.30, 3.50-3.60, 4.31, 4.70, 7.08, 7.15,7.31-7.36, 7.44-7.59, 8.02, 8.02, 8.26.
Example 7(74) 2-chloro-5-({[[1-(4-{4-[(methylsulfonyl)amino]phenoxy }benzyl)-4- piperidinyl](phenyl)amino]carbonyl}amino)benzamide hydrochloride
TLC: Rf 0.43 (dichloromethane : methanol = 9 : 1);
NMR (CDsOD): 8 1.62-1.79, 2.12-2.22, 2.95, 3.10-3.22, 3.45-3.55, 4.22, 4.67, 7.01, 7.02, 7.25-7.34, 7.41, 7.46-7.58.
Example 7(75)
N-(4-{[5-({4-[({[4-chloro-3-(4- morpholinylcarbonyl)phenyl]amino} carbony!)(phenyl)amino]-1-piperidinyl} methyl)-2- pyridinylJoxy } phenyl)methanesulfonamide hydrochloride (or dihydrochloride) 07 lo
N CH
ROSSA er:
N" ON “0 © 0
H
9 * HCI or 2HCI
TLC: Rf 0.43 (dichloromethane : methanol = 9 : 1);
NMR (CDsOD): 1.65-1.82, 2.12-2.22, 2.98, 3.14-3.35, 3.49-3.80, 4.31, 4.67, 7.08, 7.14, 7.28-7.37,7.45-7.59, 8.02, 8.27.
Example 7(76) 2-chloro-5-({[{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl} (phenyl)amino]carbonyl}amino)benzoic acid hydrochloride (or dihydrochloride)
®
TLC: Rf 0.48 (dichloromethane : methanol = 5 : 1);
NMR (CD;OD): 6 1.64-1.82, 2.12-2.25, 2.97, 3.12-3.24, 3.47-3.60, 4.29, 4.67, 7.06, 7.11, 7.28-7.36, 7.41, 7.45-7.60, 7.82, 7.94, 8.20.
Example 7(77)
N'-(4-chloro-3-nitrophenyl)-N-{1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl]-N-phenylurea
TLC: Rf 0.50 (ethyl acetate),
NMR (CDCl3) : 6 1.35-1.55, 1.80-1.90, 2.10-2.25, 2.90-3.00, 3.06, 3.44, 4.50, 6.04, 6.93, 7.20-7.39, 7.31-7.41, 7.50-7.53, 7.67, 7.92-8.05.
Example 7(78) 2-[4-({4-[{[(4-fluorophenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl} methyl)phenoxy]-5-[(methylsulfonyl)amino]benzamide hydrochloride
TLC: Rf0.53 (dichloromethane : methanol =9 : 1),
NMR (CD;OD): § 1.62-1.79, 2.12-2.21, 2.99, 3.08-3.22, 3.43-3.57, 4.23, 4.67, 6.95, 7.01, 7.06, 7.22, 7.29-7.35, 7.32-7.59, 7.70.
Example 7(79) 2-fluoro-5-({[[1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl](phenyl)amino]carbonyl}amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.45 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 1.64-1.81, 2.13-2.25, 3.14, 3.10-3.25, 3.50-3.58, 4.31, 4.67, 7.08, 7.19, 7.30-7.58, 7.69, 7.95-8.04, 8.23.
Example 7(80) 2-fluoro-5-{[((3-fluorophenyl) { 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl}-4-piperidinyl }amino)carbonyl]amino}benzamide hydrochloride (or dihydrochloride)
HoN Oo
N CH gore ore
N" ON Zo °°
H
F + HCl or 2HCI
® ®
TLC: Rf 0.49 (dichloromethane : methanol =9 : 1);
NMR (CD;0D): & 1.68-1.85, 2.14-2.23, 2.97, 3.12-3.25, 3.50-3.58, 4.30, 4.65, 7.04-7.19, 7.25,7.31, 7.46, 7.51, 7.70, 7.92, 8.23.
Example 7(81) 2-fluoro-5-[({(3-fluoropheny!)[ 1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl}amino }carbonyl)amino}benzamide hydrochloride (or dihydrochloride)
TLC: Rf0.52 (dichloromethane : methanol =9 : 1);
NMR (CD3;OD): 6 1.68-1.87, 2.15-2.25, 3.14, 3.12-3.25, 3.50-3.58, 4.31, 4.67, 7.09, 7.12- 7.20, 7.25, 7.37, 7.46, 7.54, 7.71, 7.90-8.04, 8.23.
Example 7(82) 2-fluoro-5-[({(3-fluorophenyl)[ 1-({6-[2-methoxy-4-(methylsulfonyl)phenoxy]-3- pyridinyl} methyl)-4-piperidinyl]Jamino}carbonyl)amino]benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.52 (dichloromethane : methanol = 9 : 1);
NMR (CD3OD): 8 1.67-1.85, 2.15-2.25, 3.17, 3.12-3.25, 3.48-3.58, 3.80, 4.28, 4.65, 7.04- 7.19, 7.25, 7.35, 7.46, 7.50-7.65, 7.71, 7.95, 8.13.
Example 7(83)
N-[2-fluoro-5-({[{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl}-4- piperidinyl }(phenyl)amino]carbonyl}amino)phenyl]acetamide hydrochloride (or dihydrochloride)
CH;
So
F N CH su Vsas Nery
PS > OO
N N 0
H
) + HCI or 2HCI
White amorphous powder;
TLC: Rf 0.36 (chloroform : methanol = 10 : 1);
NMR (CDs;OD): 8 1.60-1.80, 2.10-2.30, 2.12, 2.97, 3.10-3.25, 3.45-3.55, 4.27, 4.65, 7.00- 7.12,7.30-7.33, 7.49-7.55, 7.78, 7.90, 8.18.
®
Example 7(84)
N-[2-fluoro-5-({[{ 1-[(6-{2-methoxy-4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl}(phenyl)amino]carbonyl }amino)phenyl]acetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.31 (chloroform : methanol = 10 : 1);
NMR (CD;OD): § 1.60-1.80, 2.10-2.30, 2.12, 2.99, 3.10-3.25, 3.45-3.55, 3.69, 4.26, 4.65, 6.87, 6.98-7.08, 7.06, 7.31-7.34, 7.49-7.55, 7.78, 7.86. 8.11.
Example 7(85)
N-[2-fluoro-5-({[[1 -({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl} methyl)-4- piperidinyl](phenyl)amino]carbonyl }amino)phenyl]acetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.53 (chloroform : methanol = 10 : 1);
NMR (CD;OD): § 1.60-1.80, 2.10-2.30, 2.12, 3.10-3.25, 3.14, 3.45-3.55, 4.30, 4.65, 7.00- 7.05, 7.19, 7.31-7.39, 7.50-7.55, 7.90, 7.94-8.02, 8.11.
Example 7(86)
N-[2-fluoro-5-({[[1-({6-[2-methoxy-4-(methylsulfonyl)phenoxy]-3 -pyridinyl} methyl)-4- piperidinyl](phenyl)amino]carbonyl}amino)phenyljacetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.52 (chloroform : methanol = 10 : 1);
NMR (CD;0D): 5 1.60-1.80, 2.10-2.30, 2.12, 3.10-3.25, 3.17, 3.45-3.55, 3.79, 4.26, 4.66, 7.00-7.11, 7.19, 7.31-7.36, 7.49-7.63, 7.78, 7.78, 8.11.
Example 7(87) 2-fluoro-5-{[((3-fluorophenyl){1-[(6-{ 2-methoxy-4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl}-4-piperidinyl }amino)carbonyl]Jamino } benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.44 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.69-1.85, 2.12-2.25, 3.00, 3.12-3.25, 3.48-3.58, 3.70, 4.28, 4.65, 6.87, 6.99-7.19, 7.25, 7.46, 7.54, 7.71, 7.93, 8.17.
Example 7(88) 2-fluoro-5-({[{1-[(6-{ 2-methoxy-4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl}(phenyl)amino]carbonyl }amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.44 (dichloromethane : methanol = 9 : 1);
® ®
NMR (CD;OD): 5 1.64-1.81, 2.12-2.24, 3.00, 3.12-3.25, 3.48-3.58, 3.70, 4.28, 4.67, 6.87, 7.00-7.12, 7.29-7.35, 7.42, 7.47-7.58, 7.68, 7.94, 8.18.
Example 7(89) 2-fluoro-5-({[[1-( {6-[2-methoxy-4-(methylsulfonyl)phenoxy]-3-pyridinyl} methyl)-4- piperidinyl](phenyl)amino]carbonyl }amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.44 (dichloromethane : methanol = 9 : 1);
NMR (CDs;OD): & 1.64-1.80, 2.12-2.22, 3.17, 3.12-3.25, 3.48-3.58, 3.79, 4.28, 4.67, 7.04- 7.14,7.29-7.38, 7.43, 7.48-7.64, 7.68, 7.94 8 13.
Example 7(90)
N-{4-[(5-{[4-((3-fluorophenyl){[(6-methy]-3 -pyridinyl)amino]carbonyl }amino)-1- piperidinyl]methyl}-2-pyridinyl)oxy]phenyl } methanesulfonamide dihydrochloride (or trthydrochloride)
H
H3C _N o N NN Nog CH
CLE Cr OK
NNT “No
H
9! + 2HCl or 3HCI
F
White amorphous powder;
TLC: Rf 0.49 (dichloromethane : methanol = 9 : 1);
NMR (CDs;OD): § 1.70-1.90, 2.12-2.25, 2.68, 2.97, 3.12-3.35, 3.48-3.60, 4.33, 4.70, 7.08, 7.12-7.23, 7.25-7.35, 7.55, 7.73, 8.05, 8.23-8 34. 8.96.
Example 7(91)
N-(3-fluorophenyl)-N'-(6-methyl-3-pyridinyl)-N-[ 1-({6-[4-(methylsulfonyl)phenoxy]-3- pyridinyl}methyl)-4-piperidinyl]urea dihydrochloride (or trihydrochloride)
Q.0 x NN = 0
H
“1 + 2HCl or 3HCI
F
® ®
TLC: Rf 0.50 (dichloromethane : methanol = 9 : 1),
NMR (CD;0D): § 1.70-1.90, 2.12-2.25, 2.68, 3.14, 3.12-3.35, 3.48-3.60, 4.33, 4.70, 7.12- 721,7.29, 7.38, 7.56, 7.73, 8.00, 8.03, 8.22-8.36, 8.96.
Example 7(92)
N-(3-fluorophenyl)-N-[1-({6-[2-methoxy-4-(methylsulfonyl)phenoxy]-3- pyridinyl } methyl)-4-piperidinyl]-N'-(6-methyl-3-pyridinyl)urea dihydrochloride (or trihydrochloride)
TLC: Rf 0.50 (dichloromethane : methanol =9 : 1);
NMR (CD3;0OD): 6 1.70-1.90, 2.12-2.25, 2.68, 3.17, 3.12-3.35, 3.48-3.60, 3.80, 4.30, 4.70, 7.12, 7.15-7.23, 7.29, 7.35, 7.51-7.64, 7.73, 7.99, 8.15, 8.31, 8.96.
Example 7(93)
N-[2-fluoro-5-({[{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl}(phenyl)amino]carbonyl}amino)phenyl]methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.33 (ethyl acetate : methanol = 10 : 1);
NMR (CD3;0D): 8 1.60-1.80, 2.10-2.30, 2.97, 2.97, 3.10-3.25, 3.40-3.60, 4.27, 4.65, 7.03- 7.11,7.29-7.33,7.44-7.54, 787, 8.16.
Example 7(94)
N-[2-fluoro-5-({{[1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl }methyl)-4- piperidinyl](phenyl)amino]carbony! }amino)phenyl]methanesul fonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.41 (ethyl acetate : methanol = 10 : 1);
NMR (CD;OD): 6 1.60-1.80, 2.10-2.30, 2.97, 3.14, 3.15-3.25, 3.45-3.55, 4.30, 4.62, 7.03- 7.06, 7.18, 7.31-7.39, 7.44-7.54, 7.95-8.02, 8.22.
Example 7(95)
N-[2-fluoro-5-({[[1-({6-[2-methoxy-4-(methylsulfonyl)phenoxy]-3-pyridinyl }methyl)-4- piperidinyl](phenyl)amino]carbonyl }amino)phenyl]methanesulfonamide hydrochloride (or dihydrochloride)
TLC: Rf 0.39 (ethyl acetate : methanol = 10 : 1);
NMR (CD;0OD): & 1.60-1.80, 2.10-2.25, 2.97, 3.10-3.25, 3.17, 3.45-3.55, 3.79, 4.26, 4.65, 7.03-7.06, 7.12, 7.31-7.36, 7.45-7.63, 7.91, 8.10.
Example 7(96) 2-[4-({4-[[({4-fluoro-3-[(methylsulfonyl)amino]phenyl }amino)carbonyl](phenyl)amino]- 1-piperidinyl} methyl)phenoxy]-5-[(methylsulfonyl)amino]benzamide hydrochloride
H3G -S=0
HN 5 H
E
0 N N.g-CHa //\\
A do
N N 0
H
4 hu * HCI
TLC: Rf 0.20 (ethyl acetate : methanol = 10 : 1);
NMR (CD;0D): 6 1.60-1.80, 2.10-2.30, 2.97, 2.99, 3.10-3.20, 3.45-3.55, 4.23, 4.65, 6.99- 7.04,7.31-7.55, 7.69.
Example 7(97) 2-fluoro-N-methyl-5-({[{ 1-[(6- {4-[(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]- 4-piperidinyl } (phenyl)amino]carbonyl }amino)benzamide hydrochloride (or dihydrochloride)
N._0 o N SN SCT
Pg o be =
N N Oo
H
- HCl or 2HCI
TLC: Rf 0.50 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 1.65-1.81, 2.12-2.23, 2.89, 2.97, 3.12-3.25, 3.48-3.58, 4.29, 4.67, 7.01- 7.15,7.27-735,7.40,747-757,7.61, 7.95, 8.21.
Example 7(98) 2-fluoro-N-methyl-5-({[[ 1-({ 6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl](phenyl)amino]carbonyl}amino)benzamide hydrochloride (or dihydrochloride)
N._O
F S. 8 ONC =
N N 0)
H
) - HCl or 2HCI
TLC: Rf 0.50 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 5 1.65-1.81, 2.12-2.23, 2.89, 3.14, 3.12-3.25, 3.48-3.59, 4.30, 4.67, 7.06, 7.18,7.30-7.43, 7.47-1.57, 7.61, 7.94-8.05, 8.22.
Example 7(99)
N'-(6-methyl-3-pyridinyl)-N-[1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl} methyl)-4- piperidinyl]-N-phenylurea dihydrochloride (or trihydrochloride)
TLC: Rf 0.49 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): & 1.70-1.87, 2.12-2.24, 2.68, 3.14, 3.17-3.35, 3.50-3.60, 4.33, 4.71, 7.18, 7.32-7.36, 7.38, 7.42-7.59, 7.72, 8.00, 8.05, 8.27, 8.30, 8.96.
Example 7(100) 2-[4-({4-[({[3-(acetylamino)-4-fluorophenyl]amino } carbonyl)(phenyl)amino]-1- piperidinyl} methyl)phenoxy]-5-[(methylsulfonyl)amino]benzamide hydrochloride bis
HN CH; H
F N._.. CH 0 N S0 ’
Bis &o
N N 0)
H
0) NH, + HCI
TLC: Rf 0.43 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 6 1.61-1.80, 2.12, 2.05-2.22, 2.99, 3.05-3.21, 3.45-3.55, 4.23, 4.67, 6.97- 7.08, 7.28-7.35, 7.35-7.58, 7.69, 7.77.
® o
Example 7(101)
N-(3-methyl-4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl}methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.48 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): & 1.68-1.85, 2.11, 2.12-2.23, 2.67, 2.97, 3.12-3.28, 3.50-3.60, 4.30, 4.71, 7.02,7.04,7.15,7.20,7.31-7.38, 7.49-7.60, 7.73, 8.00, 8.17, 8.22, 8.31, 8.96.
Example 7(102)
N-(3-chloro-4-{[5-({4-[{[(6-methyl-3-pyridiny])amino]carbony! }(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide dihydrochloride (or trthydrochloride)
TLC: Rf 0.48 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 8 1.65-1.85, 2.12-2.25, 2.67, 3.01, 3.15-3.28, 3.48-3.58, 4.30, 4.72, 7.12, 7.19-7.28, 7.31-7.37, 7.41, 7.48-7.60, 7.74, 7.98, 8.17, 8.30, 8.97.
Example 7(103)
N-(4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbonyl }(phenyl)amino]-1- : piperidinyl } methyl)-2-pyridinylJoxy} phenyl)ethanesulfonamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.48 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 4 1.32, 1.70-1.85, 2.15-2.25, 2.68, 3.11, 3.15-3.28, 3.50-3.60, 4.33, 4.71, 7.08, 7.14, 7.30-7.38, 7.50-7.60, 7.73, 8.07, 8.28-8.35, 8.96.
Example 7(104)
N-{4-[(5-{[4-((3-methylphenyl){[(6-methyl-3-pyridinyl)amino]carbony! }amino)-1- piperidinylJmethyl}-2-pyridinyl)oxy]phenyl} methanesulfonamide dihydrochloride (or trthydrochloride)
TLC: Rf 0.48 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.68-1.87, 2.12-2.23, 2.41, 2.68, 2.97, 3.13-3.28, 3.50-3.60, 4.31 4.71, 7.05-7.18,7.29-7.37,7.43, 7.73, 8.01, 8.13, 8.26, 8.31, 8.96.
Example 7(105) 2-fluoro-5-{[((3-methylphenyl){1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl }amino)carbonylJamino }benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.46 (dichloromethane : methanol = 9 : 1);
® ®
NMR (CD;0D): 6 1.65-1.81, 2.12-2.24, 2.40, 2.97, 3.13-3.28, 3.48-3.58, 4.29, 4.67, 7.04- 7.17, 7.28-7.35, 737-747, 7.68, 7.95, 8.21.
Example 7(106) 2-fluoro-N-methyl-5-{[((3-methylphenyl){ 1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl}amino)carbonyl]Jamino } benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.49 (dichloromethane : methanol =9 : 1);
NMR (CD;O0D): § 1.65-1.81, 2.12-2.22, 2.40, 2.89, 2.97, 3.12-3.26, 3.48-3.58, 4.30, 4.67, 7.02-7.18,7.28-7.35, 7.36-7.44, 7.61, 7.99, 8 25.
Example 7(107)
N-(2-fluoro-5-{[((3-methylphenyl){ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl}-4-piperidinyl }amino)carbonyl]Jamino } phenyl)acetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.45 (ethyl acetate : methanol = 10 : 1);
NMR (CDsOD): § 1.60-1.80, 2.10-2.25, 2.12, 2.40, 2.97, 3.10-3.30, 3.50-3.60, 4.27, 4.65, 7.00-7.15, 7.30, 7.31, 7.42, 7.78, 7.90, 8.17.
Example 7(108)
N-(2-fluoro-5-{[((3-fluorophenyl){ 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl }amino)carbonyl]amino } phenyl)acetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.46 (ethyl acetate : methanol = 10 : 1);
NMR (CD;OD): § 1.60-1.80, 2.10-2.25, 2.13, 2.97, 3.10-3.30, 3.50-3.60, 4.28, 4.65, 6.98- 7.17,7.29, 7.31, 7.54, 7.82, 7.94, 8.20.
Example 7(109)
N-(4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbony! } (phenyl)amino]-1- piperidinyl ymethyl)-2-pyrazinyl]oxy} phenyl)methanesulfonamide trihydrochloride
TLC: Rf 0.49 (dichloromethane : methanol = 9 : 1);
NMR (CDsOD): 6 1.71-1.88, 2.15-2.26, 2.68, 2.97, 3.22-3.35, 3.58-3.68, 4.42, 4.75, 7.17, 7.29-7.38,7.52-7.62, 7.73, 8.17, 8.20, 8.31, 8.48, 8.97.
Example 7(110) 2-fluoro-5-{{((3-fluorophenyl) { 1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl }amino)carbonyl}amino }-N-methylbenzamide hydrochloride (or dihydrochloride)
_ ®
TLC: Rf 0.45 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): 6 1.70-1.85, 2.15-2.23, 2.89, 2.97, 3.12-3.25, 3.50-3.58, 4.30, 4.65, 7.03- 7.19, 7.25, 7.32, 7.42, 7.54, 7.65, 7.99. 8.25.
Example 7(111)
N-(4-{[5-({4-[ {[(6-methyl-3-pyridinyl)amino]carbonyl } (phenyl)amino]-1- azepanyl}methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.42 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): 6 1.70-2.50, 2.67, 2.98, 3.18-3.35, 3.40-3.62, 4.37, 4.50, 7.10, 7.16, 7.30- 7.40, 7.48-7.60, 7.72, 8.12, 8.29, 8.33, 8.96.
Example 7(112)
N-(4-{[5-({ BR)-3-[{[(6-methyl-3-pyridinyl)amino]carbonyl } (phenyl )amino]-1- pyrrolidinyl}methyl)-2-pyridinyljoxy } phenyl)methanesulfonamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.48 (dichloromethane : methanol = 9 : 1);
NMR (CDsOD): & 2.40, 2.65, 2.69, 2.98, 3.41-3.65, 3.80-3.98, 4.30-4.72, 7.08-7.20, 7.28- 7.62,7.74, 8.14, 8.32, 8.39, 8.51, 8.97.
Example 7(113)
N-(4-{[5-({(3S)-3-[{ [(6-methyl-3-pyridiny]l)amino]carbonyl} (phenyl)amino]-1- pyrrolidinyl} methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide dihydrochloride (or trthydrochloride)
TLC: Rf 0.48 (dichloromethane : methanol =9 : 1);
NMR (CD;0D): § 2.40, 2.65, 2.69, 2.98, 3.41-3.65, 3.80-3.98, 4.30-4.72, 7.08-7.20, 7.28- 7.62,7.74, 8.14, 8.32, 8.39, 8.51, 8.97.
Example 7(114)
N-(2-fluoro-5-{[((3-fluorophenyl) {1-[{(6-{2-methyl-4-[(methylsulfonyl)amino]phenoxy}- 3-pyridinyl)methyl]-4-piperidinyl }amino)carbonylJamino } phenyl)acetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.29 (ethyl acetate : methanol = 10 : 1);
NMR (CD;OD): 8 1.65-1.90, 2.00-2.20, 2.11, 2.12, 2.97, 3.10-3.30, 3.50-3.60, 4.27, 4.63, 6.98-7.06, 7.13-7.27,7.53,7.81,7.94, 8.17.
®
Example 7(115)
N-{5-({[{1-[(6-{4-[(ethylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4-piperidinyl }(3- fluorophenyl)amino]carbonyl } amino)-2-fluorophenyljacetamide hydrochloride (or dihydrochloride)
TLC: Rf 0.24 (ethyl acetate : methanol = 10 : 1),
NMR (CD;OD): 6 1.32, 1.60-1.80, 2.10-2.30, 2.12, 3.08, 3.10-3.25, 3.50-3.60, 4.29, 4.70, 7.00-7.16, 7.25,7.31, 7.54, 7.81, 7.95, 8.22.
Example 7(116) 2-fluoro-5-({[{1-[(6-{2-methyl-4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]- 4-piperidinyl }(phenyl)amino]carbony! }amino)benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.48 (dichloromethane : methanol = 9 : 1);
NMR (CD;OD): § 1.68-1.82, 2.12, 2.09-2.22, 2.98, 3.12-3.25, 3.48-3.59, 431, 4.68, 7.01- 7.23,7.30-7.37,7.43, 7.47-7.58, 7.68, 8.03, 8.27.
Example 7(117)
S-({[{1-[(6-{4-[(ethylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl } (phenyl)amino]carbonyl}amino)-2-fluorobenzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.48 (dichloromethane : methanol =9 : 1);
NMR (CD;OD): § 1.32, 1.65-1.82, 2.12-2.22, 3.10, 3.10-3.25, 3.49-3.58 431, 4.68, 7.05- 7.10, 7.13, 7.29-7.36, 7.43, 7.47-7.58, 7.68, 8.02, 8.28.
Example 7(118)
N-{4-[(5-{[4-((3-fluorophenyl){[(6-methy!-3-pyridinyl)amino]carbonyl }amino)-1- piperidinylJmethyl}-2-pyridinyl)oxy]pheny! }ethanesulfonamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.46 (dichloromethane : methanol =9 : 1),
NMR (CD;OD): 6 1.32, 1.72-1.90, 2.12-2.25, 2.68, 3.11, 3.18-3.30, 3.50-3.60, 4.34, 4.70, 7.07-7.23, 7.29, 7.33, 7.56, 7.74, 8.10, 8.29-8.38, 8.97.
Example 7(119) 2-{[5-({4-[{ [(6-methyl-3-pyridiny])amino]carbonyl } (phenyl)amino]-1- piperidinyl}methyl)-2-pyridinyl]oxy}-5-[(methylsulfonyl)amino]benzamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.69 (chloroform : methanol = 5: 1);
NMR (CDs;OD): § 1.70-1.90, 2.10-2.30, 2.68, 2.93, 3.20-3.40, 3.50-3.60, 4.41, 4.70, 7.04, 7.33-7.43, 7.50-7.60, 7.73, 7.96, 8.17, 8.27, 8.30, 8.54, 8.96.
Example 7(120) 2-[(5-{[4-((3-fluorophenyl){[(6-methyl-3-pyridinyl)amino]carbonyl }amino)-1- piperidinyl]methyl}-2-pyridinyl)oxy]-5-{(methylsulfonyl)amino]benzamide dihydrochloride (or trihydrochloride)
TLC: Rf 0.59 (chloroform : methanol = 5 : 1);
NMR (CD;0D): § 1.70-1.90, 2.10-2.30, 2.68, 2.93, 3.20-3.40, 3.50-3.70, 4.41, 4.70, 7.03, 7.15-7.20, 7.30, 7.41, 7.56, 7.74, 7.96, 8.25-8.35, 8.39, 8.54, 8.97.
Example 7(121) 2-{[5-({4-[({[3-(acetylamino)-4-fluorophenyl]amino } carbonyl)(3-fluorophenyl)amino]-1- piperidinyl} methyl)-2-pyridinyljoxy }-5-[(methylsulfonyl)amino]benzamide hydrochloride (or dihydrochloride)
TLC: Rf 0.56 (chloroform : methanol = 5 : 1),
NMR (CDs;0OD): 6 1.70-1.90, 2.10-2.30, 2.12, 2.93, 3.20-3.40, 3.50-3.70, 4.37, 4.65, 6.99- 7.10,7.03, 7.15-7.20, 7.25, 7.40, 7.54, 7.82, 7.96, 8.15, 8.28, 8 49.
Example 8 4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }(phenyl)amino]-1-piperidinyl } methyl)-2- pyridinylJoxy }-N-(2-methoxyethyl)benzamide hydrochloride (or dihydrochloride) 0]
F o N SN NT
A Ho
N° 'N 0 HC”
H
A) + HCl or 2HCI
To a solution of the compound prepared in Example 7(50) (80 mg) in N,N- dimethylformamide (3 ml) was added O-(7-azabenzotriazol-1-yl)-N,N,N'N'- tetramethyluronium hexafluorophosphate (84 mg), diisopropylethylamine (38 ul) and 1- methoxyethylamine (19 pl), and stirred overnight. To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, extracted with ethyl acetate.
The organic layer was dried over anhydrous sodium sulfate, concentrated. The obtained
_ residue was treated with 4N hydrogen chloride in ethyl acetate solution to give the title compound (65 mg) having the following physical data.
TLC: Rf 0.49 (chloroform : methanol = 10 : 1);
NMR (CD;OD): § 1.65-1.80, 2.10-2.25, 3.10-3.30, 3.30-3.40, 3.50-3.60, 3.56, 4.29, 4.70, 692-698 7.11,7.19-7.24, 731-7.34, 7.52-7.55, 7.89, 7.90, 8.20.
Example 8(1)
N'-(4-fluorophenyl)-N-[1-({6-[4-(4-morpholinylcarbonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl]-N-phenylurea hydrochloride (or dihydrochloride)
By the same procedure as described in Example 8 using morpholine instead of 1-methoxyethylamine the following the title compound having the following physical data was obtained.
TLC: Rf 0.51 (chloroform : methanol = 10 : 1);
NMR (CD;0D): § 1.65-1.80, 2.10-2.25, 3.10-3.25, 3.40-3.55, 3.55-3.80, 4.26, 4.65, 6.92- 6.95,7.11, 7.19-7.23, 7.32-7.34, 7.49-7.55, 7.94, 8.18.
Example 9
N-(4-{[5-({4-[{[(3-amino-4-chlorophenyl)amino}carbonyl } (phenyl )amino]-1- piperidinyl} methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide dihydrochloride (or trihydrochloride)
NH
Cl N CH,
CLEC CT
NON Zo © 0
H
0) - 2HCl or 3HCI
To a solution of the compound prepared in Example 7(71) (720 mg) in acetic acid (10 ml) and water (10 ml) was added iron powder (244 mg), and the mixture was stirred for 2 hours at 40 °C. The reaction mixture was filtrated through Celite (registered trademark). After the filtrate was neutralized with IN aqueous solution of sodium hydroxide, it was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by column chromatography on silica gel (dichloromethane : methanol = 20 : 1). To this free form treated with 4N hydrogen chloride in ethyl acetate solution to give the title compound (420 mg) having the following physical data.
@ ®
TLC: Rf 0.48 (chloroform : methanol = 10 : 1);
NMR (CD;0D): 5 1.65-1.80, 2.10-2.30, 2.97, 3.10-3.25, 3.50-3.60, 4.28, 4.70, 7.05, 7.10, 7.15,7.29-7.32, 7.30, 7.37, 7.50-7.55, 7.72, 7.90, 8.17.
Example 10
N-[2-chloro-5-({[{1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methy!]-4- piperidinyl}(phenyl)amino]carbonyl }amino)phenylJmethanesulfonamide hydrochloride (or dihydrochloride)
Hs °F “NH ’
LE OO Or =
N N 0) 9 - HCl or 2HCI
To mixture of the free form compound prepared in Example 9 (160 mg) and triethylamine (36 pl) in tetrahydrofuran (5 ml) was added methanesulfonyl chloride (20 wl), and the mixture was stirred overnight at room temperature. The reaction mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was dissolved in tetrahydrofuran (10 ml), and to this solution was added tetrabutylammonium fluoride (146 pl). The mixture was stirred for 3 hours at 60 °C. To the mixture was added water, extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by column chromatography on silica gel (dichloromethane methanol = 20 : 1). The obtained compound was treated with 4N hydrogen chloride in ethyl acetate solution to give the title compound (35 mg) having the following physical data.
TLC: Rf 0.48 (chloroform : methanol = 10 : 1);
NMR (CD;OD): § 1.65-1.80, 2.10-2.25, 2.97, 2.97, 3.10-3.25, 3.50-3.60, 4.29, 4.70, 7.06, 7.10-7.15, 7.28-7.34,7.52-7.58, 7.94, 8.21.
Example 11
N-[2-chloro-5-({[{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl}(phenyl)amino]carbonyl }amino)phenyl]acetamide hydrochloride (or dihydrochloride)
x
H,C NH ci N.__ CH
PR | oie =
N N 0
H
+ HCl or 2HCI
To a solution of the free form compound prepared in Example 9 (160 mg) in pyridine (4 ml) was added acetic acid anhydride (72.4 pl), and the mixture was stirred overnight at room temperature. The reaction mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated. To a solution of the obtained residue in methanol (4 ml) was added 28% sodium methoxde in methanol solution (506 pl), stirred for 30 minutes at room temperature. The reaction mixture was concentrated, added water, and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was treated with 4N hydrogen chloride in ethyl acetate solution to give the title compound (64 mg) having the following physical data.
TLC: Rf 0.40 (chloroform : methanol = 10 : 1);
NMR (CD;0D): 8 1.65-1.80, 2.13, 2.15-2.25, 2.97, 3.10-3.35, 3.50-3.60, 4.30, 4.65, 7.07, 7.12-7.16, 7.25-7.34, 7.49-7.51, 7.68, 7.99, 8 25.
Example 12
N-[2-chloro-5-({[[1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinyl](phenyl)amino]carbonyl}amino)phenyl]acetamide hydrochloride (or dihydrochloride)
HN 0) 0 0 \\ //
Cl AN S<
RTC Ce =
N N 0
H
) + HCI or 2HC!
J
®
To a solution of amine compound prepared by the reduction which procedure was described in Example 9 using the compound prepared in Example 7(77) (160 mg) and 1,8-diazabicyclo[5 4 .OJlundec-7-ene (34 ul) in tetrahydrofuran (5 ml) was added acetic acid anhydride (63 ul), and the mixture was refluxed for 4 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. To a solution of the obtained residue in methanol (4 ml) was added 28% sodium methoxde in methanol solution (447 pl), stirred for 30 minutes at room temperature. The reaction mixture was concentrated, added water, and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated.
The obtained residue was purified by column chromatography on silica gel (ethyl acetate methanol = 20 : 1). The obtained compound was treated with 4N hydrogen chloride in ethyl acetate solution to give the title compound (89 mg) having the following physical data.
TLC: Rf 0.56 (ethyl acetate : methanol = 10: 1);
NMR (CD;0D): 6 1.60-1.80, 2.10-2.25, 2.14, 3.14, 3.15-3.30, 3.50-3.60, 4.30, 4.70, 7.15- 7.39,7.51-7.55, 7.68, 7.96, 8.00, 8.22.
Biological Examples
It is proved by the following experiment that the compound of the present invention represented by formula (I) has the antagonistic activity against chemokine receptor, especially CCRS, and the inhibitory activity against cell migration, and also has the proper condition to be a very useful medicament.
Biological Example 1
Antagonistic activity test against CCR5
It can be proved by, for example, the procedure described in JP-A-2004- 256531 that the compound of the present invention has the antagonistic activity against
CCRS.
Biological Example 2
Cell migration test
It was proved by, for example, the following experiment that the compound of the present invention has the inhibitory activity against cell migration.
Preparation of PBMC (peripheral blood mononuclear cell)
Human venous blood (50 mL) collected by using syringe with heparin sodium (final concentration: 10 U/mL, heparin sodium injection 1000 U/mL, Shimizu
J
Pharmaceutical Co., Ltd.) was stored into 50 mL of conical tube made by polypropylene.
To a Lymphoprep tube (HY COMED PHARMA, Cat.No 1019818), 16.5 mL of DPBS ) (GIBCO, CatNo. 14190-136) and a blood sample were added, jiggled several times, then centrifuged at 3000 rpm for 10 minutes at room temperature. About 7 mL of PBMC pahse (center phase) was collected into 50 mL of conical tube made by polypropylene using a Pasteur pipette, and DPBS (-) was added to a final concentration (50 mL), than centrifuged at 1200 rpm for 10 minutes at room temperature. After removing a supernatant, residue was redissolved with 50 mL of DPBS (-). The suspension of the cell was centrifuged at 1500 rpm for 3 minutes at room temperature. The supernatant was removed, then 3 mL of hemolysis buffer (0.8% NH,CI, 0.1% KHCO;, 1 mmol/L EDTA) was added thereto to suspend enough, and then left 2 minutes at room temperature. The suspension was added by 30 mL of DPBS (-), centrifuged at 1500 rpm for 3 minutes at room temperature. The supernatant was removed to give PBMC.
Culture of human PBMC
After anti human CD3 antibody OKT3 (Janssen Pharmaceutical K.K., 1 ng/mL) coated 24 well plate overnight at 4°C, it was blocked by culture medium (RPMI 1640 (GIBCO, Cat.No. 11875-085), 10% FBS (GIBCO, Cat No. 112318-028), 1% PSF (GIBCO, Cat.No. 15240-096)) in 30 minutes at 37°C. Prepared human PBMC was seeded into the plate coated by OKT3 (2 x 10° cells / well), cultured in a few days at 37°C.
PBMC was collected, and seeded into the plate uncoated by OKT3 (2 x 10° cells/well) in the presence of human IL2 (5 ng/mL), then cultured. PBMC was subculture every two or three days.
Analysis of human CCRS expression using FACS
After 10 uL of FITC labeled anti human CCRS antibody (2D7) (BD
Pharmingen, Cat.No. 555992) and PE labeled anti human CD45RO antibody (BD
Pharmingen, Cat.No. 347967) was added to the human PBMC cultured in 1 x 10° cells, the mixture was shaded 15 minutes or left 30 minutes on the ice, then DPBS (GIBCO) was added thereto and washed. The cell was suspended with 500 pL of DPBS, and then fluorescence intensity was measured by using FACS.
In vitro experiment of cell migration 50 uL of 5 x 10° cells of the human PBMC suspension (culture medium) and 50 pL of the solution of the test compound (0-2 umol/L: double concentration of a final concentration) were added to an upper well of transwell (coster), and 300 pL of 60 nmol/L of the human MIP-18 (Pepro tech, Cat. No. 300-09) and 300 pL of a double concentration of the solution of the test compound were added to a lower well. It was prepared that a
[ ® concentration of DMSO in upper well was 0.01%. The solution was incubated 1.5 hours in the atmosphere of carbon dioxide gas (37°C, 5% CO,, degree of humidity: 95%).
After the solvent of upper well was aspirated, 100 pL of 20 umol/L of EDTA /DPBS -) was added thereto, and incubated 30 minutes at 4°C, then centrifuged at 1500 rpm for 5 minutes. 100 pL of the solution was transferred to white 96 well plate for fluorescence from lower well by pipetting, an amount of cells was measured by using Celltiter Glo (Promega) (a measurement of ATP), Cell migration inhibition ratio was calculated by the following calculating formula. The value of ICso was calculated from cell migration inhibition ratio of each concentration. The value was an average value (n=3).
As a result, the compounds of the present invention showed inhibitory activity against human MIP-1B-induced cell migration of human cultured PBMC with an ICs, value of 0.01uM or less. For example, the compound prepared in Example 7(29) showed an ICs value of 0.0012puM.
Cell migration inhibition ratio = (Ea - Ec)/(Eb - Ec) x 100
Ea: measured value when a test compound (0.01% in DMSO) is added
Eb: measured value when no test compound but only DMSO is added
Ec: measured value when no test compound but only DMSO is added with no added ligand to lower well
Biological Example 3 : Stability test in liver microsome of monkey
It was demonstrated that the compounds of the present invention have metabolic stability by the following experiments, for example.
To a solution of 100 mmol/L phosphate buffer (pH7.4, it was prepared from 100 mmol/L of aqueous solution of dipotassium hydrogen phosphate and 100 mmol/L of aqueous solution of potassium dihydrogen phosphate), liver microsome of monkey (final concentration: 1 mg/mL) and a test compound (final concentration: 5 pmol/L) was added and the mixture solution was pre-incubated for 5 minutes. The mixture solution was added by NADPH generating system (13 mmol/L B-NADP" (final concentration: 1.3 mmol/L), 33 mmol/L G-6-P (final concentration: 3.3 mmol/L), 10 U/mL G-6-P DH (from Yeast) (final concentration: 0.4 U/mL), and 33 mmol/L. magnesium chloride solution (final concentration: 3.3 mmol/L)). While the mixture was incubated at 37°C, 100 pL of the reaction solution was taken out 0 and 30 minutes after the start, and was added to acetonitrile (2 mL) to terminate the reaction (n=2). After internal standard solution was added thereto, the mixture solution was agitated, and then centrifuged at 3000 rpm for 5 minutes. 100 pL of the resulting supernatant was mixed with 100 pL of mobile phase A, and then was analyzed by LC/MS/MS.
The condition of LC/MS/MS for analysis is outlined below.
® ®
LC condition:
Column: XTerra RP8 3.5 um (2.1mmID x 50mm) (Waters
Corporation)
Temperature of column: 40°C
Mobile phase A: 5 mmol/L aqueous ammonium acetate solution / acetonitrile (80/20, V/V)
Mobile phase B: 5 mmol/L aqueous ammonium acetate solution / acetonitrile (20/80, V/V)
Temperature of sample: 4°C
Injection volume of sample: 5 uL
Time for analysis: 10 min
Composition of mobile phases, and Flow rate:
Table 1 ooo [so | eso | se wooo [so [eso | so
MS/MS condition:
Measuring equipment: API3000 (AB/MDS SCIEX)
Ionization method: Electrospray ionization (ESI, Positive)
The appropriate monitoring ion was selected for an each sample. For example, 647.5 (m/z) as parent ion and 277.0 (m/z) as daughter ion were selected for the compound prepared in Example 7(83).
The residual ratio of the unmetabolite (%) of the test compound in liver microsome of monkey was calculated by the following calculation formula.
The residual ratio of the unmetabolite (%) = (a concentration of the test compound at 30 minutes) /(a concentration of the test compound at 0 minute) x 100
® ®
As a result, it was proven that the compounds of the present invention are metabolic stable in liver microsome. For example, the residual ratio of the unmetabolite of the compound prepared in Example 7(83) was 88%.
Biological Example 4
Pharmacokinetics test in blood in monkey:
It was demonstrated that the compounds of the present invention have a good property of pharmacokinetics in blood by the following experiments, for example.
Each of five test compounds were weighed, and dissolved in Soltol (Trademark; BASF Takeda Vitamins Ltd.) / propylene glycol = 7/3 heated to 50°C to be 5 mg/mL solution thereof. Equal amount of each five samples were weighed, mixed, and then diluted with distilled water for injection by five times to make a solution for oral administration. The solution for oral administration (1 mg/kg) was forced intragastric administering to cynomolgus monkey (male, Hamri Co., Ltd) with sonde (n=3). The administering was done in the fasting state but they have freedom to drink water. Each 1 mL of blood samples were collected from superficial cephalic vein, using a heparinized syringe, 5, 15, 30 minutes, 1, 2, 4, 6, 8 and 24 hours after administration. Collected samples were stored into ice, centrifuged at 3000 rpm for 15 minutes to get plasma. The plasma was stored at -20°C. The plasma sample stored at -20°C was dissolved, then 100 pL of the resulting solution was added by internal standard solution and acetonitrile (2 mL), agitated, centrifuged at 3000 rpm for 10 minutes. The resulting supernatant was dried with a centrifuge concentrator. The residue was redissolved in 100 pL of mobile phase A, and then 40 pL of the resulting solution was analyzed by LC/MS/MS
The condition of LC/MS/MS for analysis is outlined below.
LC condition:
Measuring equipment: Waters 2790 (Waters)
Column: YMC-Pack MB-ODS 5 um (2. 1mmID x 50mm) (YMC)
Temperature of column: room temperature
Flow rate: 200 pL / minute
Mobile Phase: 20 mmol/L aqueous ammonium acetate solution {acetonitrile (1/1, V/V)
MS/MS condition:
Measuring equipment: QUATTRO Ultima (Micromass)
Ionization method: ES+
Capillary voltage: 3.20kV
Temperature of source: 150°C
® ®
Temperature of desolvation: 250°C
Multiplier: 650V
The appropriate monitoring ion was selected for an each sample. For example, 575.64 (m/z) as parent ion and 262.07 (m/z) as daughter ion for the compound prepared in Example 6(17), and 587.20 (m/z) as parent ion and 227.12 (m/z) as daughter ion for the compound prepared in Example 7(54) were selected, respectively.
Transition of plasma concentration of the test compound in monkey was analyzed with non-compartment analytic method using WinNonlin 4.0.1 (Pharsight), and
AUC was calculated.
As a result, it was proven that the compounds of the present invention have a good property of pharmacokinetics in blood. For example, the AUC of the compound prepared in Examples 6(17) and 7(54) were 226 ng-h/mL and 1150 ng-h/mL, respectively.
Biological Example 5
Measurement of bioavailability (BA):
It was demonstrated that the compounds of the present invention have good absorption of oral preparations by the following experiments, for example.
The test compound was weighed, and dissolved in 30%HP-B-CD (Trademark;
Mitsubishi Corporation) to make 1 mg/mL solution for intravenous administration. The test compound was weighed, and dissolved in Soltol (Trademark; BASF Takeda Vitamins
Ltd.) / propylene glycol = 7/3 heated to 50°C to be S mg/mL solution thereof. Equal amount of each five samples were weighed, mixed, and then diluted with distilled water for injection by five times to make a solution for oral administration. The solution for intravenous administration (1 mg/kg) was administered to cynomolgus monkey (male,
Hamri Co., Ltd) via superficial cephalic vein by single intravenous dose (n=3). The solution for oral administration (3 mg/kg) was forced intragastric administering to cynomolgus monkey (male, Hamn Co., Ltd) with sonde (n=3). The administering was done in the fasting state but they have freedom to drink water. Each 1 mL of blood samples were collected from superficial cephalic vein, using a heparinized syringe, 5, 15, 30 minutes, 1, 2, 4, 6, 8 and 24 hours after administration. Collected samples were stored into ice, centrifuged at 3000 rpm for 15 minutes to get plasma. The plasma was stored at -20°C. The plasma sample stored at -20°C was dissolved, then 100 uL of the resulting solution was added by internal standard solution and acetonitrile (2 mL), agitated, centrifuged at 3000 rpm for 10 minutes. The residue was redissolved in 100 pL of mobile phase A, and then 40 pL of the resulting solution was analyzed by LC/MS/MS
The condition of LC/MS/MS for analysis is outlined below.
_ ®
LC condition:
Measuring equipment: Waters 2790 (Waters)
Column: YMC-Pack MB-ODS 5 um (2. 1mmID x 50mm) (YMC)
Temperature of column: room temperature
Flow rate: 200 pL / minute
Mobile phase: 20 mmol/L aqueous ammonium acetate solution / acetonitrile (1/1)
MS/MS condition:
Measuring equipment: QUATTRO Ultima (Micromass)
Ionization method: ES+
Capillary voltage: 3.20kV
Temperature of source: 150°C
Temperature of desolvation: 250°C
Multiplier: 650 V
The appropriate monitoring ion was selected for an each sample. For example, 575.64 (m/z) as parent ion and 262.07 (m/z) as daughter ion (cone current: 35V, collision current: 34 eV) were selected for the compound prepared in Example 6(17).
Transition of plasma concentration of the test compound in monkey was analyzed with non-compartment analytic method using WinNonlin 4.0.1 (Pharsight), and
AUC was calculated.
BA was calculated by the following calculation formula.
BA (%) = (AUC,;.,. /Dose, , )/(AUC;,. /Dose;v) x 100
AUC,,: AUC when a test compound is orally administered
Dosey... amount of the compound administered orally
AUC;v: AUC when a test compound is intravenously administered
Doseiv: amount of the compound administered intravenously
As a result, it was proven that the compounds of the present invention have good absorption of oral preparations. For example, a BA of the compound prepared in
Example 6(17) was 42%.
_ ®
Biological Example 6
Model of renal allotransplantation in cynomolgus monkeys to evaluate immunosuppressive effect of the compound of the present invention:
Cynomolgus monkeys (body weight : 3-4.5 kg) that were ABO-compatible, major histocompatibility complex (MHC) -different, more specifically, MLR miss- matched donor (male) -recipient (either sex) combinations underwent bilateral nephrectomy with subsequent implantation of an allogenic kidney from a selected donor animal. A test substance (a compound of the present invention and/or an immunosuppressant agent) was administered daily starting on Day-1 (the day before transplantation) until the day before rejection was defined. The efficacy was assessed by comparing the length of the survival of the transplanted kidney.
The compound of the present invention was administered in combination with subtherapeutic immunosuppressant agent on the market (Cyclosporine, sirolimus, and/or tacrolimus). The efficacy was demonstrated by comparing with administration of immunosuppressant agent alone.
The compound of the present invention was administered, for example, per os (PO), twice a day at a dose level of 3, 10 or 30 mg/kg.
For example, the presence of rejection was suspected if the serum creatinine levels rise. In particular, rejection of transplanted kidney was defined as an increase in the serum creatinine levels to 8 mg/dL.
As a result, the compound of the present invention showed an immunosuppressive effect in the model of renal allotransplantation in cynomolgus monkeys.
Formulation Examples
Formulation Example 1
N'-(4-fluorophenyl)-N-[1-({6-[4-(methylsulfonyl)phenoxy]pyridin-3- yl}methyl)piperidin-4-yl]-N-phenylurea hydrochloride (10 g), calcium carboxymethyl cellulose (disintegrant, 2.0 g), magnesium stearate (lubricant, 1.0 g) and microcrystalline cellulose (87 g) are admixed in a conventional manner, punched them out to give 1000 tablets each containing 10 mg of active ingredient.
Formulation Example 2
N'-(4-fluorophenyl)-N-[1-({6-[4-(methylsulfonyl)phenoxy]pyridin-3- yljmethyl)piperidin-4-yl]-N-phenylurea hydrochloride (10 g), mannitol(200 g) and distilled water (5 L) are admixed in a conventional manner. Then the solution was filtered through a dustproofing filter, and then 5 ml aliquots were charged into ampoules, which were autoclaved to give 1000 ampoules each containing 10 mg of active ingredient.
®
The compounds of the present invention represented by formula (I) has the antagonistic activity against chemokine receptor, especially CCRS, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, efc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus- host disease, efc.), immunosuppression, psoriasis, multiple sclerosis, efc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, erc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchoplumonary aspergillosis, allergic eosinophilic gastroenteritis, efc.), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, efc.), acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.
Therefore, chemokine receptor antagonist, especially CCRS antagonist, is useful as medicament.
Claims (40)
1. A compound represented by formula (I) SONORCET X wherein R' represents (1) -N(R'*)SO,-R'®, (2) -SO,NR!°R'®| (3) -COOR'E, (4) ORY (5) -S(0)aR'C, (6) -CONR™RY | (7) -NR'®COR', or (8) cyano, wherein m is 0, 1 or 2; R' RB RIC R'P R'E RY RIC RM RY R'™™ and RY each independently represents a hydrogen atom, a hydrocarbon group which may have a substituent(s), or a 3- to 15-membered heterocyclic group which may have a substituent(s), and wherein R' and R'® or R'™ and RY may form a nitrogen-containing heterocyclic group which may have a substituent(s) together with a nitrogen atom to which they bind; X and Y each independently represents a bond or a spacer containing 1 to 3 atoms as a main chain; ring A and ring B, which are the same or different, each represents a 3- to 15- membered carbocyclic group or heterocyclic group which may have a substituent(s); ring D is a 3- to 15-membered nitrogen-containing heterocyclic group which may have a substituent(s); R? is (1) a hydrogen atom, (2) a hydrocarbon group which may have a substituent(s), (3) a cyano group, (4) a hydroxy group which may be protected, (5) an amino group which may have a substituent(s), (6) an oxo group, (7) a 3- to 15-membered heterocyclic group which may have a substituent(s) or (8) =N-OR®, wherein R® represents a hydrogen atom or C1-4 alkyl, a salt thereof, an N-oxide thereof or a solvate thereof] or a prodrug thereof.
2. The compound according to claim 1, wherein X and Y are each independently a bond or a divalent group comprising a combination of one or two unit(s) selected from (1) -CR'R®-, (2) -NR’-, (3) -CO-, (4) -O-, (5) -S-, (6) -SO-, (7) -SO,- and (8) -C(=N-OR'%)-, wherein R’ and R® each independently represents a hydrogen atom, C1-4 alkyl, -OR"! or phenyl, R’ represents a hydrogen atom, C1-4 alkyl, or phenyl; R'® and R"! each independently represents a hydrogen atom or C1-4 alkyl.
3. The compound according to claim 2, wherein X is a bond, -O- or -CH,-;
4. The compound according to claim 2, wherein Y is C1-2 alkylene.
5. The compound according to claim 1, wherein ring D is a 5- to 10-membered nitrogen-containing heterocyclic group which may have a substituent(s).
6. The compound according to claim 5, wherein ring D is a tropane, pyrrolidine, piperidine or azepane ring which may have a substituent(s).
7. The compound according to claim 6, wherein ring D is a piperidine ring which may have a substituent(s).
8. The compound according to claim 1, wherein ring A and ring B, which are the same or different, are each a S- or 6-membered aromatic ring group which may have a substituent(s).
9. The compound according to claim 1, wherein R? is 0] AEN _R N RST R52 wherein the arrow represents a binding position to ring D, R* R¥ and R* each independently represents (1) a hydrogen atom, (2) a hydrocarbon group which may have a substituent(s), (3) a 3- to 15-membered heterocyclic group which may have a substituent(s), (4) a C1-4 alkoxy group which may have a substituent(s), (5) a phenoxy group which may have a substituent(s) or (6) a benzyloxy group which may have a substituent(s).
10. The compound according to claim 1, wherein R? is 0) SN PY R54 RS! wherein the arrow represents a binding position to ring D, R*' and R** each independently represents (1) a hydrogen atom, (2) a hydrocarbon group which may have a substituent(s), (3) a 3- to 15-membered heterocyclic group which may have a substituent(s), (4) a C1-4 alkoxy group which may have a substituent(s), (5) a phenoxy group which may have a substituent(s) or (6) a benzyloxy group which may have a substituent(s).
11. The compound according to claim 1, which is represented by formula (Ib) —,O0 1 _R>* (Ib) ” NN R>? RY? wherein all symbols have the same meanings as those described in claim 1 or 9.
12. The compound according to claim 9, wherein the hydrocarbon group which may have a substituent(s) or the 3- to 15-membered heterocyclic group which may have a substituent(s) represented by R’' is an aromatic ring group which may have a substituent(s).
13. The compound according to claim 12, wherein the aromatic ring group which may have a substituent(s) is a benzene, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, or thiadiazole ring.
14. The compound according to claim 12, which is represented by formulae (Ie), (IH), (Ig), or (Ih)
SONONE x NRE Ce R56 R52 DLT 8 53 (If x Jr R56 RS? , 53 ( X N JR (lg) or R56 R52 wn). ) 0 X sa (Ih) vy R56 R52 wherein symbol “NN represents (-configuration and symbol “Ww. represents a- configuration, B-configuration or the mixture of them; R*® is aromatic ring group which may have a substituent(s); other symbols have the same meanings as those described in claim 1 or 9.
15. The compound according to claim 1, wherein the hydrocarbon group which may have a substituent(s) represented by R*! is C1-15 alkyl.
16. The compound according to claim 15, which is selected from the group consisting of (DH) 5-({[butyl(1-{4-[4-(methylsulfonyl)phenoxy]benzyl}-4- piperidinyl)amino]carbonyl }amino)-2,4-difluorobenzamide, 2) 5-[({butyl[1-({6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4- piperidinylJamino }carbonyl)amino]-2,4-difluorobenzamide, (3) 5-({[butyl(1-{[6-(4-{[(2-methoxyethyl)amino]carbonyl } phenoxy)-3- pyridinyl]methyl}-4-piperidinyl)amino]carbonyl }amino)-2,4-difluorobenzamide, ©) 5-{[(butyl{1-[(6-{4-[(ethylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl}amino)carbonyl]amino }-2,4-difluorobenzamide, 5) 5-{[(butyl{1-[(6-{2-methyl-4-[(methylsulfonyl)amino]phenoxy }-3- pyridinyl)methyl]-4-piperidinyl }amino)carbonyl]amino}-2-chloro-4-fluorobenzamide,
® ® 6) 2-(5-{[ (butyl {1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]- 4-piperidinyl }amino)carbonyl}amino }-2,4-difluorophenyl)acetamide, ©) 5-[({butyl[1-(4-{4-[(methylsulfonyl)amino]phenoxy }benzyl)-4- piperidinylJamino }carbonyl)amino]-2,4-difluoro-N-methylbenzamide, 8) 5-{[(butyl{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl}amino)carbony!]amino}-2,4-difluorobenzamide, and ©) 5-[({butyl[1-(4-{4-[(methylamino)sulfonyl]phenoxy }benzyl)-4- piperidinyl]amino }carbonyl)amino]-2,4-difluorobenzamide.
17. The compound according to claim 12, wherein the aromatic ring group represented by R*' is a mono- carbocyclic group or mono- heterocyclic group which have aromaticity.
18. The compound according to claim 17, which is selected from the group consisting of €)) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl}(phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy }-3-methoxyphenyl)methanesulfonamide, (2) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbony!}(phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide, 3) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl }(3-thienyl)amino]-1- piperidinyl } methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide, @)) N-[4-({5-[(4-{3-thienyl[(3-thienylamino)carbonyl]Jamino}-1- piperidinyl)methyl]-2-pyridinyl}oxy)phenyl]methanesulfonamide, (5) 2-fluoro-5-({[{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl } (phenyl)amino]carbonyl }amino)benzamide, (6) N-{4-[4-({4-[{{(4-fluorophenyl)amino]carbonyl }(phenyl)amino}-1- piperidinyl } methyl)-3,5-dimethyl- 1H-pyrazol-1-yl]phenyl } methanesulfonamide, ©) 4-[4-({4-[{[(4-fluorophenyl)amino]carbonyl}(phenyl)amino]-1- piperidinyl } methyl)-3,5-dimethyl-1H-pyrazol-1-yl}-N-[2-(4- morpholinyl)ethyl]benzenesulfonamide, (8) N-(4-{[5-({4-[{[(2,4-difluorophenyl)amino]carbonyl}(3-thienyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide, 9) 2-chloro-N-methyl-5-({[ {1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl }(phenyl)amino]carbonyl } amino)benzamide, (10) N-(4-{[5-({4-[({[4-chloro-3-(4- morpholinylcarbonyl)phenylJamino} carbonyl)(phenyl)amino]-1-piperidinyl } methyl)-2- pyridinyl]oxy} phenyl)methanesulfonamide,
PCT/JP2005/017209 (11) 2-fluoro-5-{[((3-fluorophenyl) { 1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl}-4-piperidinyl } amino)carbonyl]amino } benzamide, (12) N-(3-fluorophenyl)-N'-(6-methyl-3-pyridinyl)-N-[ 1-({6-[4- (methylsulfonyl)phenoxy]-3-pyridinyl } methyl)-4-piperidinyl]urea, (13) 2-[4-({4-[[({4-fluoro-3- [(methylsulfonyl)amino]phenyl}amino)carbonyl](phenyl)amino]-1- piperidinyl}methyl)phenoxy]-5-{(methylsulfonyl)amino]benzamide, (14) 2-fluoro-N-methyl-5-({[ {1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl } (phenyl)amino]carbonyl} amino )benzamide, (15) 2-fluoro-N-methyl-5-({[[ 1-({6-[4-(methylsulfonyl)phenoxy]-3- pyridinyl}methyl)-4-piperidinyl](phenyl)amino]carbonyl } amino)benzamide, (16) 2-[4-({4-[({[3-(acetylamino)-4-fluorophenyl]amino} carbonyl)(phenyl)amino]- 1-piperidinyl} methyl)phenoxy]-5-[(methylsulfonyl)amino]benzamide, (17) N-(4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino}carbonyl } (phenyl)amino]-1- piperidinyl}methyl)-2-pyridinyljoxy} phenyl)methanesulfonamide, (18) N-[2-fluoro-5-({[ {1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3- pynidinyl)methyl]-4-piperidinyl} (phenyl)amino]carbonyl}amino)phenyl]acetamide, (19) N-{4-[(5- {[4-((3-fluorophenyl) {[(6-methyl-3- pyridinyl)amino]carbonyl}amino)-1-piperidinyljmethyl}-2- pyridinyl)oxy]phenyl} methanesulfonamide, and (20) N'-(4-fluorophenyl)-N-[1-({6-[4-(methylsulfonyl)phenoxy]pyridin-3- yl}methyl)piperidin-4-yl]-N-phenylurea.
19. The compound according to claim 11, which is selected from a group the group consisting of: (1) 2-fluoro-5-({[ {1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidiny!} (phenyl)amino]carbonyl} amino)benzamide, 2) N-(4-{[5-({4-[{[(6-methyl-3-pyridinyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl }methyl)-2-pyridinylJoxy} phenyl)methanesulfonamide, 3 N-[2-fluoro-5-({[ {1-[(6- {4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl} (phenyl)amino]carbonyl}amino)phenyl]acetamide, and (4) N-{4-[(5-{[4-((3-fluoropheny!) {[(6-methyl-3- pyridinyl)amino]carbonyl}amino)-1-piperidinyljmethyl}-2- pyridinyl)oxy]phenyl} methanesulfonamide.
20. The compound according to claim 11, which is selected from the group consisting of: S142 AMENDED SHEET
® ® @)) 5-[({butyl[1-(4- {2-methyl-4-[(methylsulfonyl)amino phenoxy } benzyl)-4- piperidinylJamino}carbonyl)amino]-2,4-difluorobenzamide, 2) N-(4-{[5-({4-[{[(2,4-difluorophenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy }-3-methoxypheny!)methanesulfonamide, 3) N-(4-{[5-({4-[{[(4-methylphenyl)amino]carbony!} (phenyl)amino]-1- piperidinyl } methy!)-2-pyridinyl]oxy } phenyl)methanesulfonamide, C)) N-(4-{[5-({4-[{[(4-chlorophenyl)amino]carbonyl}(phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]Joxy } phenyl)methanesulfonamide, and (5) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl}(phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]oxy } phenyl)acetamide.
21. The compound according to claim 1, which is selected from the group consisting of’ (1) 2-fluoro-5-({[{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl }(phenyl)amino]carbonyl }amino)benzamide, 2) N-(4-{[5-({4-[{[(6-methy]-3-pyridinyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinylJoxy } phenyl)methanesulfonamide dihydrochloride, 3) N-[2-fluoro-5-({[{1-[(6-{4-[(methylsulfonyl)amino]phenoxy}-3- pyridinyl)methyl]-4-piperidinyl }(phenyl)amino]carbonyl }amino)phenylJacetamide hydrochloride, 4) N-{4-[(5-{[4-((3-fluorophenyl){[(6-methyl-3- pyridinyl)amino]carbonyl } amino)-1-piperidinyl]methyl}-2- pyridinyl)oxy]phenyl} methanesulfonamide dihydrochloride, (5) 5-[({butyl[1-(4-{2-methyl-4-[(methylsulfonyl)amino]phenoxy } benzyl)-4- piperidinyl]amino }carbonyl)amino]-2,4-difluorobenzamide hydrochloride, (6) N-(4-{[5-({4-[{[(2,4-difluorophenyl)amino]carbonyl }(phenyl)amino]-1- piperidinyl } methyl)-2-pyridinylJoxy}-3-methoxyphenyl)methanesulfonamide hydrochloride, (7 N-(4-{[5-({4-[{[(4-methylphenyl)amino]carbonyl} (phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide, 8) - N-(4-{[5-({4-[{[(4-chlorophenyl)amino]carbonyl}(phenyl)amino]-1- piperidinyl } methyl)-2-pyridinyl]oxy } phenyl)methanesulfonamide, and (9) N-(4-{[5-({4-[{[(4-fluorophenyl)amino]carbonyl } (phenyl)amino]-1- piperidinyl} methyl)-2-pyridinyl]oxy } phenyl)acetamide hydrochloride.
22. A pharmaceutical composition, which comprises the compound according to claim 1, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof.
23. The pharmaceutical composition according to claim 22, which is a chemokine receptor antagonist.
24. The pharmaceutical composition according to claim 23, which is a CCRS antagonist.
25. The pharmaceutical composition according to claim 24, which is an agent for treatment and/or prevention for a CCR5-related disease.
26. The pharmaceutical composition according to claim 25, wherein the CCR5-related disease is infectious diseases, immunological diseases, inflammatory diseases and/or cardiovascular diseases.
27. The pharmaceutical composition according to claim 26, wherein the CCR5-related disease is infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with Respiratory Syncytial Virus, rejection in organ transplantation, multiple sclerosis, inflammatory bowel disease, and/or asthma.
28. The pharmaceutical composition according to claim 26, wherein the immunological diseases is rejection in organ transplantation.
29. The pharmaceutical composition according to claim 22, which is an agent for prevention and/or treatment for infectious diseases, immunological diseases, inflammatory diseases and/or cardiovascular diseases.
30. A medicament comprising a combination of the compound represented by formula (I) according to claim 1, a salt thereof, an N-oxide thereof, a solvate thereof. or a prodrug thereof, and one or more agent(s) selected from a reverse transcriptase inhibitor, a protease inhibitor, an integrase inhibitor, a CCR2 antagonist, a CCR3 antagonist, a CCR4 antagonist, a CCRS antagonist, a CXCR3 antagonist, a CXCR4 antagonist, a fusion inhibitor, an antibody against a surface antigen of HIV, and a vaccine of HIV.
31. A medicament comprising a combination of the compound represented by formula (I) according to claim 1, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof, and one or more agent(s) selected from an immunosuppressant agent, a nonsteroidal antiinflammatory drug, a disease modifying anti-rheumatic drug, steroids, an S144 -
PCT/JP2005/017209 antiinflammatory enzyme preparations, a chondroprotective agents, a T-cell inhibitor, a TNFa inhibitor, a prostaglandin synthase inhibitor, an IL-1 inhibitor, an IL-6 inhibitor, an interferon gamma agonist, prostaglandins, a phosphodiesterase inhibitor, and a metalloproteinase inhibitor.
32. Use of a compound represented by formula (I) according to claim 1, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof for the manufacture of an agent for prevention and/or treatment of a CCR5-related disease.
33. A compound of 5-{[(butyl{1-[(2-methyl-6- {4- [(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl } amino)carbonyl]amino}-2,4-difluorobenzamide, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof.
34. A compound of 5-{[(butyl{1-[(2-methyl-6- {4- [(methylsulfonyl)amino]phenoxy }-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl}amino}-2,4-difluorobenzamide hydrochloride.
35. A pharmaceutical composition, which comprises 5- {[(butyl { 1-[(2-methyl- 6- {4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl}amino)carbonyl]amino}-2,4-difluorobenzamide, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof.
36. A pharmaceutical composition, which comprises 5- {[(butyl {1-[(2-methyl- 6- {4-[(methylsulfonyl)amino]phenoxy}-3-pyridinyl)methyl]-4- piperidinyl }amino)carbonyl]amino}-2,4-difluorobenzamide hydrochloride.
37. A compound according to any one of claims 1 to 21, 33 or 34, substantially as herein described with reference to and as illustrated in any of the examples and the accompanying sequence listings.
38. A composition according to any one of claims 22 to 29, 35 or 36, substantially as herein described with reference to and as illustrated in any of the examples and the accompanying sequence listings.
39. A medicament according to claim 30 or claim 31, substantially as herein described with reference to and as illustrated in any of the examples and the accompanying sequence listings.
40. Use according to claim 32, substantially as herein described with reference to and as illustrated in any of the examples and the accompanying sequence listings. - 145 - AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004264855 | 2004-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200702100B true ZA200702100B (en) | 2008-05-28 |
Family
ID=38796124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200702100A ZA200702100B (en) | 2004-09-13 | 2007-03-12 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101056855B (en) |
ZA (1) | ZA200702100B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710411B (en) * | 2015-03-13 | 2017-04-26 | 安润医药科技(苏州)有限公司 | Synthesis method of avanafil |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0108099D0 (en) * | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
-
2005
- 2005-09-12 CN CN2005800389254A patent/CN101056855B/en not_active Expired - Fee Related
-
2007
- 2007-03-12 ZA ZA200702100A patent/ZA200702100B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101056855B (en) | 2011-06-15 |
CN101056855A (en) | 2007-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8604207B2 (en) | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | |
US8003642B2 (en) | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | |
JP4736043B2 (en) | Nitrogen-containing heterocyclic derivatives and drugs containing them as active ingredients | |
US20070043079A1 (en) | Heterocyclic compound containing nitrogen atom and use thereof | |
ZA200702100B (en) | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | |
ZA200507365B (en) | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |